



Australian Government
Department of Health and Ageing
Therapeutic Goods Administration

POISONS STANDARD 2009

The National Drugs and Poisons Schedule Committee, acting in accordance with its power under paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989* (the Act), prepares this new Poisons Standard under that Act, in substitution for the current Poisons Standard.

Signed
DR RUTH LOPERT
CHAIR
NATIONAL DRUGS AND POISONS SCHEDULE COMMITTEE

Dated this 3rd day of August 2009

1. Citation

This instrument is the *Poisons Standard 2009*.

2. Commencement

This instrument commences on 14 August 2009.

3. The New Poisons Standard

For the purposes of paragraph 52(2)(b) of the Act the new Poisons Standard is the Poisons Standard 2009, prepared by the National Drugs and Poisons Schedule Committee, which consist of the Standard for the Uniform Scheduling of Drugs and Poisons No 24, published by the Committee in 2009 as set out in Schedule 1.

**Schedule 1-Standard for the
Uniform Scheduling of Drugs
and Poisons No. 23 published
by the National Drugs and
Poisons Scheduling Committee
in 2009**

**STANDARD FOR THE UNIFORM SCHEDULING OF
DRUGS AND POISONS
No. 24**

June 2009

© Commonwealth of Australia 2009

ISBN 1-74186-911-0

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the:

Commonwealth Copyright Administration
Attorney-General's Department
Robert Garran Offices
National Circuit
BARTON ACT 2600

or posted at <http://www.ag.gov.au/cca>

Published by the Australian Government under the *Therapeutic Goods Act 1989*.

Publication approval number: P3-5403



Australian Government

Department of Health and Ageing

This publication is a consolidation of the amendments resulting from decisions made at meetings of the National Drugs and Poisons Schedule Committee (NDPSC) up to and including the October 2008 meeting. The basis of these amendments can be found in the 'Record of the Reasons', which can be accessed from the NDPSC website:

www.tga.gov.au/ndpsc/records.htm

Further inquiries should be directed to:

The Secretary
National Drugs and Poisons Schedule Committee
GPO Box 9848
CANBERRA ACT 2601

Or by email: NDPSC@health.gov.au

Media Liaison Unit
Australian Government Department of Health and Ageing

CONTENTS

PREFACE	v
INTRODUCTION	vii
PRINCIPLES OF SCHEDULING	ix
PART 1 INTERPRETATION	1
PART 2 LABELS AND CONTAINERS	11
LABELS	11
General requirements	11
Immediate wrapper	11
Primary packs and immediate containers	12
Statements of quantity, proportion or strength	19
Exemptions	21
Selected containers and measure packs	21
Ampoules, pre-filled syringes and injection vials	21
Transport containers and wrappings	22
Dispensary, industrial, laboratory and manufacturing poisons	22
Dispensed medicines	23
Gas cylinders	23
Paints	23
Camphor and naphthalene	24
Prohibitions	24
CONTAINERS	25
Containers for poisons other than Schedule 5 poisons	25
Containers for Schedule 5 poisons	26
Approved containers	26
Child-resistant closures	27
Schedule 8 poisons	29
Exemptions	30
Camphor and naphthalene	30
Prohibitions	31
PART 3 MISCELLANEOUS REGULATIONS	32
Advertising	32
Sale or Supply	32
Schedule 2 poisons	32
Schedule 3 poisons	32
Schedule 4 poisons	33
Schedule 7 poisons	33
Prohibitions on sale, prescribing and possession	34
Storage	34
Dispensed Medicines	34

PART 4	THE SCHEDULES	36	
	Schedule 1	37	
	Schedule 2	38	
	Schedule 3	58	
	Schedule 4	66	
	Schedule 5	156	
	Schedule 6	192	
	Schedule 7	238	
	Schedule 8	250	
	Schedule 9	254	
PART 5	APPENDICES	260	
	Appendix A	General Exemptions	261
	Appendix B	Substances considered not to require control by scheduling	265
	Appendix C	Substances, other than those included in Schedule 9, of such danger to health as to warrant prohibition of sale, supply and use	275
	Appendix D	Additional Controls on possession or supply of poisons included in Schedule 4 or 8	279
	Appendix E	First Aid instructions for poisons	282
	Appendix F	Warning Statements and general safety directions for poisons	301
	Appendix G	Dilute Preparations	332
	Appendix H	Schedule 3 poisons permitted to be advertised	334
	Appendix I	Uniform Paint Standard	335
	Appendix J	Conditions for availability and use of Schedule 7 poisons	337
	Appendix K	Drugs required to be labelled with a sedation warning	342
INDEX		345	

PREFACE

The *Standard for the Uniform Scheduling of Drugs and Poisons* is the decisions of the National Drugs and Poisons Schedule Committee, regarding classification of drugs and poisons into Schedules for inclusion in the relevant legislation of the States and Territories. It also includes model provisions about containers and labels, and recommendations about other controls on drugs and poisons.

This document is presented with a view to promoting uniform scheduling of substances and uniform labelling and packaging requirements throughout Australia.

INTRODUCTION

CLASSIFICATION

Drugs and poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with the relevant State or Territory Authority.

Schedule 1. [This Schedule is intentionally blank.]

Schedule 2. Pharmacy Medicine – Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person.

Schedule 3. Pharmacist Only Medicine – Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription.

Schedule 4. Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.

Schedule 5. Caution – Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label.

Schedule 6. Poison – Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label.

Schedule 7. Dangerous Poison – Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply.

Schedule 8. Controlled Drug – Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence.

Schedule 9. Prohibited Substance – Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

Availability of drugs and poisons

The purpose of classification is to group drugs and poisons into Schedules that require similar regulatory controls over their availability.

These Schedules have been developed over a long period and contain drugs and poisons that may be obsolete for various reasons. Also as part of the move to harmonise the Australian and New Zealand classifications many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.

Inclusion of a drug or poison in a Schedule indicates the degree of control required if it is marketed. It does not indicate:

- that the drug or poison is available; nor
- that it has been approved or is efficacious for any use that may be specified in a Schedule,

nor does it negate any obligation for registration of a therapeutic good or an agricultural or veterinary chemical containing that drug or poison.

Preparations containing poisons listed in two or more schedules.

If a preparation contains two or more poisons, the provisions relating to each of the Schedules in which those poisons are included apply.

Where it is not possible to comply both with a provision relating to one of those Schedules and with a provision relating to another of those Schedules, the provision of the more restrictive Schedule applies, unless a contrary intention is indicated in the Schedules or relevant legislation.

The Schedules listed in order of greatest to least restriction are 9, 8, 4, 7, 3, 2, 6, 5. Schedule 1 is not currently in use.

PRINCIPLES OF SCHEDULING

PRINCIPLES OF SCHEDULING

Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.

This Standard now lists poisons in nine Schedules according to the degree of control recommended to be exercised over their availability to the public.

Poisons for therapeutic use (drugs) are included in Schedules 2, 3, 4 and 8 with progression through these schedules signifying increasingly strict controls.

For agricultural, domestic and industrial poisons Schedules 5, 6 and 7 represent increasingly strict container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7.

Schedule 9 contains substances that should be available only for medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State/Territory Health Authorities. Although appearing as a Schedule in this Standard the method by which it is implemented in the States/Territories may vary.

Substances in products which have been considered for scheduling but have been exempted from this standard may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).

Appendix C contains a list of substances or preparations, the sale, supply or use of which should be prohibited because of their known dangerous properties. It is recommended that provisions of this appendix be put into effect through inclusion of the substances in appropriate State and Territory legislation.

READING THE SCHEDULES

Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.

Firstly, poisons are now scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned overleaf. Older group entries are being revised and replaced by individual entries as time permits although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.

Secondly, schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the two different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.

Where exceptions are included in an entry these have been emphasised by printing the word “except” in bold type.

Where the schedule entries for a poison make a specific exclusion or exemption, the requirements of this Standard do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation such as pesticide registration may apply.

Where a schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (‘reverse scheduling’), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.

Where a poison has been included in more than one Schedule the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.

It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise. (See Interpretation PART 1 [paragraph 1(2)]).

It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a Scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, toxicologically) to a Scheduled poison or is readily converted (either physically or chemically) to a Scheduled poison. However, a substance is only considered a derivative of a Scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a Scheduled poison, the same scheduling requirements as the Scheduled poison, including limits on access, supply and availability, will apply.

Finally, when using the Standard to determine the scheduling status of a poison it may be necessary to search each relevant Schedule as well as Appendices A, B and C and the Index. In this process if the poison is not found under its “approved name” it may be shown under a group term such as:

Group	Example
the parent acid of salts	“oxalic acid” to find sodium oxalate
the radical of a salt	“chromates” to find potassium chromate
the element	“arsenic” to find arsenic trioxide
a chemical group with similar toxicological or pharmacological activity	“hydrocarbons, liquid” to find kerosene
a pharmacological group	“anabolic steroidal agents” to find “androsterone”

PART 1 INTERPRETATION

1. (1) In this Standard, unless the contrary intention appears —

“Animal feed premix” means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.

“Appropriate authority” means:

- (a) in the Australian Capital Territory, ACT Health;
- (b) in New South Wales, the Director-General of New South Wales Health;
- (c) in the Northern Territory, the Chief Health Officer of the Department of Health & Families;
- (d) in Queensland, the Chief Executive of Queensland Health;
- (e) in South Australia, the Chief Executive of the Department of Health;
- (f) in Tasmania, the Secretary of the Department of Health and Human Services;
- (g) in Victoria, the Secretary to the Department of Human Services;
- (h) in Western Australia, the Chief Executive Officer of the Department of Health.

“Approved name” means:

- (a) in relation to a poison that is for therapeutic use —
 - (i) the Australian Approved Name for the poison, not including synonyms, as listed in the publication entitled “Therapeutic Goods Administration Approved Terminology for Medicines”, July 1999, or its successor, published by the Therapeutic Goods Administration, Canberra; or, if the poison is not listed in that publication,
 - (ii) the international non-proprietary name recommended for the poison by the World Health Organisation; or, if no such name is recommended,

- (iii) the English name, not including synonyms, by which the poison is described in the British Pharmacopoeia, the British Pharmaceutical Codex, the Australian Pharmaceutical Formulary and Handbook or the British Pharmacopoeia (Veterinary); or, if the poison is not described in any of those publications,
 - (iv) the approved name given to the poison by the Medicines Commission of Great Britain; or, if no such name is given,
 - (v) the accepted scientific name or the name descriptive of the true nature and origin of the poison;
- (b) in relation to a poison that is not for therapeutic use —
- (i) the English name recommended by the Standards Association of Australia as the common name for the poison; or, if no such name is recommended,
 - (ii) the English name given to the poison by the International Organisation for Standardisation; or, if no such name is given,
 - (iii) the English name given to the poison by the British Standards Institution; or, if no such name is given,
 - (iv) the Australian Approved Name for the poison, not including synonyms, as listed in the publication entitled “Therapeutic Goods Administration Approved Terminology for Drugs”, January 1993 (ISBN 0 644 28628 8), or its successor, published by the Australian Government Publishing Service; or, if the poison is not listed in that publication,
 - (v) the English name, not including synonyms, by which the poison is described in the British Pharmacopoeia, the British Pharmaceutical Codex, the Australian Pharmaceutical Formulary and Handbook or the British Pharmacopoeia (Veterinary); or, if the poison is not described in any of those publications,
 - (vi) the approved name given to the poison by the Medicines Commission of Great Britain; or, if no such name is given,
 - (vii) the international non-proprietary name recommended for the poison by the World Health Organisation; or, if no such name is recommended,
 - (viii) the accepted scientific name or the name descriptive of the true nature and origin of the poison.

“Australian Code for the Transport of Dangerous Goods by Road and Rail” means the seventh edition of the document of that name.

“Blood” means whole blood extracted from human donors.

“Blood components” means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.

“Child-resistant closure” means:

- (a) a closure that complies with the requirements for a child-resistant closure in the Australian Standard AS 1928-2007 entitled *Child-resistant packaging – Requirements and testing procedures for reclosable packages* (ISO 8317:2003, MOD);
- (b) a closure approved by an order made under section 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or
- (c) in the case of a can fitted with a press-on lid, a lid of the design known as “double tight” or “triple tight”.

“Child-resistant packaging” means packaging that:

- (a) complies with the requirements of the Australian Standard AS 1928-2007 entitled *Child-resistant packaging – Requirements and testing procedures for reclosable packages* (ISO 8317:2003, MOD);
- (b) is reclosable and complies with the requirements of at least one of the following Standards:
 - (i) the International Organization for Standardization Standard ISO 8317:2003 entitled *Child-resistant packaging – Requirements and testing procedures for reclosable packages*;
 - (ii) the British Standards Institution Standard BS EN ISO 8317:2004 entitled *Child-resistant packaging - Requirements and testing procedures for reclosable packages*;
 - (iii) the Canadian Standards Association Standard CSA Z76.1-06 entitled *Reclosable Child-Resistant Packages*;
 - (iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, entitled *Poison prevention packaging standards* and Section 1700.20, entitled *Testing procedure for special packaging*;

(c) is approved as child-resistant by any order made under section 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(d) is in the form of blister or strip packaging in which a unit of use is individually protected until the time of release and that complies with Section 3 (Requirements for non-reclosable packages) of Australian Standard AS 1928-2001 entitled *Child-resistant packages*.

“Compounded” in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.

“Debitterised neem seed oil” means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.

“Dermal use” means application to the skin primarily for localised effect.

“Designated solvent” means the following:

acetone
 dimethylformamide
 N-(N-dodecyl)-2-pyrrolidone
 hydrocarbons, liquid
 methanol when included in Schedule 5
 methyl ethyl ketone
 methyl isoamyl ketone
 methyl isobutyl ketone
 N-methyl-2-pyrrolidone
 N-(N-octyl)-2- pyrrolidone
 phenyl methyl ketone
 styrene
 tetrachloroethylene
 1,1,1-trichloroethane

“Distributor” means a person who imports, sells or otherwise supplies a poison.

“Divided preparation” means a preparation manufactured and packed as discrete pre-measured dosage units prior to sale or supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.

“Dosage unit” means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.

“Drug” means a poison intended for human or animal therapeutic use.

“Essential oils” means products obtained from natural raw materials either by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation. For scheduling purposes it also means:

- (a) oils of equivalent composition derived through synthetic means; or
- (b) prepared mixtures of oils of equivalent composition comprising a mixture of synthetic and natural components.

“External” in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.

“First Schedule Paint” means a paint containing the specified proportion of any substance in the First Schedule to Appendix I of this Standard.

“Graphic material” means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.

“Height” in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.

“Hemp seed oil” means the oil obtained by cold expression from the ripened fruits (seeds) of *Cannabis sativa*.

“Immediate container” includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.

“Immediate wrapper” means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.

“Internal use” means administration:

- (a) orally, except for topical effect in the mouth; or
- (b) for absorption and the production of a systemic effect,
 - (i) by way of a body orifice other than the mouth; or
 - (ii) parenterally, other than by application to unbroken skin.

“**Label**” means a statement in writing on a container of a poison.

“**Main label**” means, where there are two or more labels on a container or a label is divided into two or more portions:

- (a) that label or portion of the label on which the name of the product is most prominently shown and which is primarily designed to attract attention; or
- (b) where the name of the product is equally prominent on two or more labels or portions of a label, each of those labels or portions of the label on which the name of the product is equally prominent.

“**Manufacturer**” means a person who manufactures, produces, or packs a poison.

“**Measure pack**” means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.

“**Name and address**” means the name and address, in Australia, of the manufacturer or distributor of a poison but does not include a post office, cable, telegraphic or code address. Where such manufacturer or distributor is a company incorporated in accordance with the appropriate law of any State or Territory of the Commonwealth of Australia or a firm registered under the Business Names Act of any State or Territory, the inclusion in the label of the registered name of the corporation or firm or its branch or its division and the city or town in which a registered office is situated shall be deemed to comply with the requirements.

“**Non-access packaging**” is packaging that complies with the requirements of Australian Standard AS4710-2001 entitled *Packages for chemicals not intended for access or contact with their contents by humans*, in relation to products that are not intended for human therapeutic use.

“**Non-volatile content**” in relation to a paint or tinter means that portion of a paint or tinter determined to be the non-volatile content by Method 301.1 of Australian Standard AS 1580-301.1-2005 entitled *Paints and related materials – Methods of test – Non-volatile content by mass*.

“**Paint**”, without limiting the ordinary meaning, includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material.

“Pesticide” means any substance or mixture of substances used or intended to be used:

- (a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or
- (b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non-agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.

“Poison” means any substance or preparation included in a Schedule to this Standard.

“Primary pack” means the pack in which a poison and its immediate container or immediate wrapper or measure pack are presented for sale or supply.

“Required Advisory Statements for Medicine Labels” means the document of that name, as published by the Therapeutic Goods Administration in September 2008.

“Restricted flow insert” means a restriction fitted, or moulded, in the neck of a container which:

- (a) cannot readily be removed from the container by manual force; and
- (b) limits the delivery of the contents to drops each of which is not more than 200 microlitres.

“Second Schedule Paint” means a paint containing the specified proportion of any substance in the Second Schedule to Appendix I of this Standard.

“Selected container” means:

- (a) an injection vial having a nominal capacity of ten millilitres or less;
- (b) a single use syringe; or
- (c) any other container for substances for therapeutic use having a nominal capacity of ten millilitres or less.

“Solid” is considered to include “powder” for the purposes of scheduling.

“Therapeutic use” means use in or in connection with:

- (a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals;
- (b) influencing, inhibiting or modifying a physiological process in human beings or animals; or
- (c) testing the susceptibility of human beings or animals to a disease or ailment.

“Third Schedule Paint” means a paint containing the specified proportion of any substance in the Third Schedule to Appendix I of this Standard.

“Tinter” means any pigment or admixture of pigment with other substances, in powder, semi-solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.

“Topical use” means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.

“Toy” means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of fourteen years.

“Transdermal use” means application to the skin primarily for systemic effect.

“Writing” includes the visible representation or reproduction of words or figures in any form, and “to write” and “written” have corresponding meanings.

- (2) Unless the contrary intention appears a reference to a substance in a schedule or an appendix to this Standard includes:
 - (a) that substance prepared from natural sources or artificially; and
 - (b) where the substance is a plant (other than a plant included in Schedule 8 or 9), that plant or any part of that plant when packed or prepared for therapeutic use; and
 - (c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative; and
 - (d) every alkaloid of the substance and every salt of such an alkaloid; and

- (e) every stereoisomer of the substance and every salt of such a stereoisomer; and
 - (f) every recombinant form of the substance; and
 - (g) a preparation or admixture containing any proportion of the substance,
- but does not include:
- (h) a preparation or product included in Appendix A, or a substance and the reason for its entry in Appendix B; or
 - (i) a substance included in Appendix G at a concentration not exceeding the concentration specified in column 2 of that Appendix in respect of that substance; or
 - (j) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8; or
 - (k) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the *Standards for Active Constituents*, as published by the Australian Pesticides and Veterinary Medicines Authority.
- (3) Unless the contrary intention appears where a concentration, strength or quantity is specified in a schedule or an appendix to this Standard in respect of a substance:
- (a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance that is listed in the Schedule or Appendix; and
 - (b) the expression “one per cent” means:
 - (i) in the case of a liquid preparation, 1 gram of the substance per 100 millilitres of the preparation; or
 - (ii) in the case of a solid, semi-solid or pressurised spray aerosol preparation, 1 gram of the substance per 100 grams of the preparation; and
 - (iii) any expression of greater or lesser percentages shall have a corresponding meaning; and

- (c) in the case of codeine such concentration, strength or quantity is calculated as anhydrous codeine.
- (4) A reference to a boiling or distillation temperature in the schedules means that temperature at an atmospheric pressure of 101.325 kPa (760 millimetres of mercury).

PART 2

LABELS AND CONTAINERS

LABELS

2. A person must not sell or supply a poison unless it is labelled in accordance with paragraphs 3 to 19 of this Standard.

General requirements

3. Any word, expression or statement required by this Standard to be written on a label or container must be written:
 - (1) on the outside face of the label or container; and
 - (2) in the English language; and
 - (3) in durable characters; and
 - (4) in a colour or colours to provide a distinct contrast to the background colour; and
 - (5) in letters at least 1.5 millimetres in height.
4. Sub-paragraph 3(5) does not apply to a word, expression or statement on a container which has a capacity of 20 millilitres or less, or on the label of such a container if:
 - (1) an appropriate authority approves the use of smaller letters; and
 - (2) the letters are at least 1 millimetre in height.
5. The label must be printed on, or securely attached to:
 - (1) the outside of the immediate container; and
 - (2) if the immediate container is enclosed in a primary pack, the outside of that primary pack.

Immediate wrapper

6.
 - (1) A poison enclosed in an immediate wrapper must be contained in a primary pack labelled in accordance with paragraph 7 of this Standard; and
 - (2) the immediate wrapper must be conspicuously labelled with:
 - (a) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and

- (b) the approved name of the poison; and
- (c) a statement of the quantity or strength of the poison in accordance with paragraph 8.

Primary packs and immediate containers

7. (1) The primary pack and immediate container of a poison must be labelled as follows:

- (a) with the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the following table:

Schedule	Purpose	Signal words required
2	for any purpose	PHARMACY MEDICINE
3	for any purpose	PHARMACIST ONLY MEDICINE
4	for human use	PRESCRIPTION ONLY MEDICINE
4	for animal use	PRESCRIPTION ANIMAL REMEDY
5	for any purpose	CAUTION
6	for any purpose	POISON
7	for any purpose	DANGEROUS POISON
8	for any purpose	CONTROLLED DRUG

written:

- (i) on the first line or lines of the main label; and
- (ii) in bold-face sanserif capital letters of uniform thickness; and
- (iii) in letters at least half the height of the largest letter or numeral on the label but need not be larger than:
 - (A) 6 millimetres on labels for packages having a nominal capacity of 2 litres or less; or
 - (B) 15 millimetres on labels for packages having a nominal capacity of more than 2 litres; and

(iv) if the poison:

- (A) is a Schedule 5 poison, with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail* or a statement of the principal hazard of the poison, written on that line; or
- (B) is not a Schedule 5 poison, with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on that line;

(b) if the poison is a Schedule 8 poison, with the cautionary statement –

POSSESSION WITHOUT AUTHORITY ILLEGAL

written:

- (i) on a separate line or lines immediately below the signal words required by sub-paragraph 7(1)(a); and
- (ii) in bold-face sanserif capital letters of uniform thickness; and
- (iii) in letters at least four tenths the height of the letters used for the signal words; and
- (iv) with no other statement written on the same line;

(c) with the cautionary statement –

KEEP OUT OF REACH OF CHILDREN

written:

- (i) on a separate line or lines:
 - (A) immediately below the signal word or words required by sub-paragraph 7(1)(a); or
 - (B) where the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by sub-paragraph 7(1)(b), on the line immediately below that statement; and
- (ii) in bold-face sanserif capital letters of uniform thickness; and
- (iii) in letters at least four tenths the height of the letters used for the signal word or words; and

- (iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;
- (d) if the poison is a dry chlorinating compound containing more than 10 per cent of available chlorine, **except** for preparations certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances) as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, with the cautionary statement –

FIRE AND EXPLOSION HAZARD

written:

- (i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by sub-paragraph 7(1)(c); and
- (ii) in bold-face sanserif capital letters of uniform thickness; and
- (iii) in letters at least four tenths the height of the letters used for the signal word or words; and
- (iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;
- (e) if the poison is an alkaline salt in a dishwashing machine product, with the cautionary statement –

BURNS SKIN AND THROAT

written:

- (i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by sub-paragraph 7(1)(c); and
- (ii) in bold-face sanserif capital letters of uniform thickness; and
- (iii) in letters at least four tenths the height of the letters used for the signal word; and
- (iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line of the main label;

- (f) if the poison is an aqueous solution of paraquat, with the cautionary statements –

**CAN KILL IF SWALLOWED
DO NOT PUT IN DRINK BOTTLES
KEEP LOCKED UP**

written:

- (i) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by sub-paragraph 7(1)(c); and
 - (ii) in bold-face sanserif capital letters of uniform thickness; and
 - (iii) in letters at least four tenths the height of the letters used for the signal words; and
 - (iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same lines of the main label;
- (g) if safety directions are required on the label by sub-paragraph 7(1)(n), with the cautionary statement –

**READ SAFETY DIRECTIONS BEFORE OPENING
OR USING**

or with the cautionary statement –

READ SAFETY DIRECTIONS

written:

- (i) on a separate line or lines;
 - (A) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by sub-paragraph 7(1)(c); or
 - (B) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and
- (ii) in bold-face sanserif capital letters of uniform thickness; and

- (iii) in letters at least four tenths the height of the letters used for the signal word or words; and
 - (iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;
- (h) if the poison meets the criteria for a ‘flammable liquid’ in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, with the cautionary statement –

FLAMMABLE

written on the main label in bold-face sanserif capital letters of uniform thickness, unless already present in accordance with the requirements of the *Australian Code for the Transport of Dangerous Goods by Road and Rail*;

- (i) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written on the main label in bold-face sanserif capital letters of uniform thickness;

- (j) if the poison is a Schedule 5 poison intended for any purpose other than internal or pesticidal use, with the cautionary statement –

DO NOT SWALLOW

written in sanserif capital letters on the main label or as part of the directions for use;

- (k) with the approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with paragraph 8:
 - (i) if the poison is for human therapeutic use, written in accordance with orders made under section 10(3) of the Commonwealth *Therapeutic Goods Act, 1989*; or
 - (ii) if the poison is not for human therapeutic use, written in bold-face sanserif capital letters on the main label, unless:
 - (A) a list of approved names is required; and
 - (B) it is impractical to include the list on the main label; and

- (C) an appropriate authority has authorised its inclusion on another part of the label; or
- (iii) if the poison is a Schedule 5 poison referred to in column 1 of the following table the appropriate name opposite thereto in column 2 may be used as the approved name:

TABLE

Column 1	Column 2
Alkaline salts	Alkaline salts
Amines for use as curing agents for epoxy resins (unless separately specified in the Schedules)	Aliphatic amines or aromatic amines
Epoxy resins, liquid	Liquid epoxy resins
Hydrocarbons, liquid	Liquid hydrocarbons
Quaternary ammonium compounds	Quaternary ammonium compound(s)

- (iv) if a poison contains a mixture of designated solvents in excess of 25 per cent of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25 per cent, the approved names of those solvents may be expressed as follows:
- (A) where the designated solvent is a liquid hydrocarbon as “liquid hydrocarbons”; or
- (B) where the designated solvent is a ketone as “ketones”; or
- (C) in any other case as “solvents” or “other solvents”;
- (l) if the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, with the following expression written immediately below the approved name or the list of declared contents –

AN ANTICHOLINESTERASE COMPOUND

- (i) the requirements of sub-paragraph 7(1)(l) do not apply to:
 - (A) dazomet, mancozeb, metiram, propineb, thiram, tri-allate, zineb or ziram; or
 - (B) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or
 - (C) an organophosphorus compound or carbamate contained in a pressurised spray pack for household use;
- (m) if the poison is prepared, packed or sold for a specific purpose, with clear and adequate directions for use unless:
 - (i) the poison is included in Schedule 4 or Schedule 8; or
 - (ii) it is impractical to include such directions on the label and:
 - (A) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”; and
 - (B) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label; and
 - (C) the insert is enclosed in the primary pack;
- (n) if use of the poison may be harmful to the user, with appropriate safety directions (see Appendix F), grouped together as a distinct section of the label and prefaced by the words –

SAFETY DIRECTIONS

written in bold-face capital letters;

- (o) if any warning statement or statements are required for the poison (see Appendix F), with that warning statement or those statements grouped together:
 - (i) if safety directions are included on the label, immediately after the words “SAFETY DIRECTIONS”; or
 - (ii) if there are no safety directions, immediately preceding the directions for use;

(p) if the poison is not for human internal use and is not a Schedule 3, Schedule 4 or Schedule 8 poison, with appropriate first aid instructions (see Appendix E):

(i) grouped together and prefaced by the words –

FIRST AID

written in bold-face capital letters; or

(ii) if a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:

(A) written on each immediate container as specified in sub-paragraph 7(1)(p)(i); and

(B) replaced on the primary pack with the statement –

FIRST AID: See inner packs;

(q) with the name and address of the manufacturer or distributor.

(2) For the purposes of sub-paragraph 7(1)(a)(iii) the term “largest letter or numeral” does not include:

(a) a single letter or numeral which is larger than other lettering on the label; or

(b) an affix forming part of the trade name; or

(c) in the case of a poison for therapeutic use, numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.

Statements of quantity, proportion or strength

8. The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:

(1) if the poison is for human therapeutic use, in the manner prescribed by orders made under section 10(3) of the Commonwealth *Therapeutic Goods Act 1989*;

- (2) if the poison is for a purpose or purposes other than human therapeutic use and:
- (a) if the poison is in a pressurised spray aerosol preparation, as the mass of the poison per stated mass of the preparation;
 - (b) if the poison is a liquid in a liquid preparation, as the mass or volume of the poison per stated volume of the preparation;
 - (c) if the poison is a liquid in a solid or semi-solid preparation, as the mass or volume of the poison per stated mass of the preparation;
 - (d) if the poison is a solid or semi-solid in a liquid preparation, as the mass of the poison per stated volume of the preparation;
 - (e) if the poison is a solid or semi-solid in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;
 - (f) if the poison is a gas in a liquid preparation, as the mass of the poison per stated volume of the preparation;
 - (g) if the poison is a gas in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;
 - (h) if the poison is a gas in a gaseous preparation, as the mass of the poison per stated mass of the preparation;
- (3) if the poison is a solution of a mineral acid, the proportion of the acid may be expressed as the mass of the acid per stated mass of the preparation;
- (4) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:
- contains not more than 10 per cent (*name of the metal*); or
 - contains not more than 30 per cent (*name of the metal*); or
 - contains more than 30 per cent of (*name of the metal*);
- (5) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5 per cent of the product;
- (6) if the poison is a lead-based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non-volatile content of the paint;

- (7) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.
- (8) For the purposes of sub-paragraph 8(7) “derivative” includes alkaloid.

Exemptions

Selected containers and measure packs

9. The requirements of paragraph 7 do not apply to an immediate container that is a measure pack or a selected container (other than an ampoule, a pre-filled syringe or an injection vial to which paragraphs 10 or 11 apply) when:
 - (1) packed in a primary pack labelled in accordance with paragraph 7; and
 - (2) labelled with:
 - (a) the signal word or words, relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the table to sub-paragraph 7(1)(a); and
 - (b) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with paragraph 8; and
 - (c) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and
 - (d) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written in sanserif capital letters.

Ampoules, pre-filled syringes and injection vials

10. The requirements of paragraph 7 do not apply to a selected container, or an ampoule (other than an ampoule to which paragraph 11 applies) when:
 - (1) packed in a primary pack labelled in accordance with paragraph 7; and
 - (2) labelled with:
 - (a) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with paragraph 8; and

- (b) with the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and
- (c) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written in sanserif capital letters.

- 11.** The requirements of paragraph 7 do not apply to a selected container that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:
- (1) packed in a primary pack labelled in accordance with paragraph 7; and
 - (2) the strip is labelled in accordance with paragraph 10; and
 - (3) the ampoule is labelled with:
 - (a) the approved name of the poison or the trade name of the product; and
 - (b) the quantity, proportion or strength of the poison in accordance with paragraph 8.

Transport containers and wrappings

- 12.** The labelling requirements of this Standard do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.

Dispensary, industrial, laboratory and manufacturing poisons

- 13.** The labelling requirements of this Standard do not apply to a poison that:
- (1) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and
 - (2) is labelled in accordance with the *National Occupational Health and Safety Commission's National Code of Practice for the Labelling of Workplace Substances* [NOHSC: 2012 (1994)].

Dispensed medicines

14. Unless otherwise specified by regulation, the labelling requirements of this Standard do not apply to a poison for therapeutic use that:

- (1) is supplied by a medical, dental or veterinary practitioner in the ordinary course of their professional practice; or
- (2) is supplied on and in accordance with a prescription written by a medical, dental or veterinary practitioner or any other person authorised to prescribe drugs and poisons; or
- (3) is prepared and supplied by a pharmacist for an individual patient.

Gas cylinders

15. The requirements of sub-paragraphs 7(1)(a)(iv), 7(1)(c)(iv), and 7(1)(g)(iv) do not apply to a cylinder containing a poison that is a compressed gas.

Paints

16. The requirements of paragraph 7 do not apply to:

- (1) paint (other than a paint for therapeutic or cosmetic use) which:
 - (a) contains only Schedule 5 poisons; or
 - (b) is a First Schedule or Second Schedule paint that is labelled with:
 - (i) the word “WARNING”, written in bold-face sanserif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and
 - (ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-face sanserif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and
 - (iii) the appropriate warnings specified for the paint in Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and
 - (iv) the name and proportion of the First Schedule or Second Schedule poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non-volatile content” or “in the dried film” of the paint; or

- (2) a tinter which contains:
 - (a) only Schedule 5 poisons; or
 - (b) a poison included in the First Schedule or Second Schedule to Appendix I, provided that it is labelled with the name and proportion of that poison, and where the poison is a metal or metal salt, the proportion is expressed as the metallic element present as “calculated on the non-volatile content” or “in the dried film”.

Camphor and naphthalene

17. The labelling requirements of sub-paragraph 3(4) and paragraph 7 do not apply to a device that contains camphor or naphthalene in block, ball, disc or pellet form if the device:
 - (1) complies with paragraph 28; and
 - (2) is sold or supplied in a primary pack labelled in accordance with paragraphs 3 and 7.

Prohibitions

18. A label used in connection with any poison must not include:
 - (1) any reference to this Standard, or any comment on, reference to, or explanation of any expression required by this Standard that directly or by implication contradicts, qualifies or modifies such expression; or
 - (2) any expression or device suggesting or implying that the poison is safe, harmless, non-toxic, non-poisonous, or is recommended or approved by the Government or any government authority unless required by legislation; or
 - (3) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or
 - (4) any trade name or description that:
 - (a) represents any single constituent of a compound preparation; or
 - (b) misrepresents the composition or any property or quality of the poison; or
 - (c) gives any false or misleading indication of origin or place of manufacture of the poison.

- 19.** A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure:
- (1) any expression required by this Standard to be written or embossed on the container or pack; or
 - (2) any of the ribs or embossed or printed words required by paragraph 21, 22 or 23 as appropriate.

CONTAINERS

- 20.** A person must not sell or supply a poison unless the immediate container complies with the requirements of paragraphs 21 to 28 of this Standard.

Containers for poisons other than Schedule 5 poisons

- 21.** If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of 2 litres or less, the container must comply with Australian Standard AS 2216-1997, entitled *Packaging for poisonous substances*.
- 21a.** Notwithstanding subparagraph 21, a poison which is in Schedule 6 and is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216-1997, entitled *Packaging for poisonous substances*, if:
- (1) the other safety factors are not diminished; and
 - (2) the container has a restricted flow insert and a child-resistant closure.
- 22.** If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of more than 2 litres, the container must:
- (1) comply with sub-section 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances*; and
 - (2) have the word "POISON":
 - (a) in sanserif capital letters the height of which is at least one thirty second part of the length, height or width of the container, whichever is the greatest:
 - (i) embossed; or
 - (ii) indelibly written in a colour in distinct contrast to the background colour;
 - (b) on the side or shoulder of the container.

Containers for Schedule 5 poisons

23. (1) The container in which any Schedule 5 poison is sold or supplied must:
- (a) comply with the container requirements of paragraph 21 or paragraph 22; or
 - (b) be readily distinguishable from a container in which food, wine or other beverage is sold; and
 - (i) comply with sub-section 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances*, excluding paragraph 1.4.3;
 - (ii) be securely closed and, except when containing a preparation for use on one occasion only, be capable of being re-closed to prevent spillage of its contents; and
 - (iii) have the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” embossed or indelibly written thereon, or printed on a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.
- (2) Notwithstanding sub-paragraph 23(1), the following Schedule 5 poisons namely:
- (a) methylated spirit(s);
 - (b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;
 - (c) petrol;
 - (d) toluene; or
 - (e) xylene,

must not be sold or supplied in a bottle or jar having a nominal capacity of 2 litres or less, unless the immediate container complies with the container requirements specified in paragraph 21.

Approved containers

24. Notwithstanding sub-paragraphs 21, 22 and 23 a poison may be packed in a container that does not comply with the tactile identification requirements of

Australian Standard AS2216-1997 entitled *Packaging for poisonous substances* or the requirements of paragraphs 22(2) or 23(1)(iii) if:

- (1) the other safety factors are not diminished;
- (2) the container is for a specific purpose; and
- (3) an appropriate authority has approved the use of the container for that purpose.

Child-resistant closures

25. (1) If a poison listed in column 1 of the following table is sold or supplied in a container having a nominal capacity specified for that poison in column 2 it must be closed with a child-resistant closure.

TABLE	
Column 1 Name of the poison	Column 2 Nominal capacity
Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine tablets.	All sizes
Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine liquids, solids or gels.	5 litres / kilograms or less
Alkaline salts included in Schedule 5, when packed and labelled as a food additive.	2.5 litres or less
Anise oil when included in Schedule 5.	200 millilitres or less
Basil oil when included in Schedule 5.	200 millilitres or less
Bay oil when included in Schedule 6.	200 millilitres or less
Cajuput oil when included in Schedule 6.	200 millilitres or less
Cassia oil when included in Schedule 5.	200 millilitres or less
Cineole when included in Schedule 6.	2 litres or less
Cinnamon bark oil when included in Schedule 5.	200 millilitres or less

TABLE

Column 1 Name of the poison	Column 2 Nominal capacity
Cinnamon leaf oil when included in Schedule 6.	200 millilitres or less
Clove oil when included in Schedule 6.	200 millilitres or less
Essential oils when included in Schedule 6 because of their natural camphor component.	200 millilitres or less
Ethylene glycol when included in Schedule 6.	5 litres or less
Ethylene glycol when included in Schedule 5 in preparations containing more than 50 per cent of ethylene glycol.	5 litres or less
Eucalyptus oil when included in Schedule 6.	2 litres or less
Eugenol when included in Schedule 6.	200 millilitres or less
Hydrocarbons, liquid, when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid.	5 litres or less
Hydrochloric acid when included in Schedule 6.	5 litres or less
Marjoram oil when included in Schedule 5.	200 millilitres or less
Melaleuca oil (tea-tree oil) when included in Schedule 6.	200 millilitres or less
Methylated spirit excluding preparations or admixtures.	5 litres or less
Methyl salicylate and preparations containing more than 50 per cent of methyl salicylate.	200 millilitres or less
Nutmeg oil when included in Schedule 5.	200 millilitres or less

TABLE (continued)

Column 1 Name of the poison	Column 2 Nominal capacity
Oil of turpentine.	5 litres or less
Pennyroyal oil when included in Schedule 6.	200 millilitres or less
Potassium hydroxide as such.	2.5 litres or less
Potassium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs.	5 litres or less
d-Pulegone when included in Schedule 6.	200 millilitres or less
Sage oil (Dalmatian) when included in Schedule 6.	200 millilitres or less
Sodium hydroxide as such.	2.5 litres or less
Sodium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs.	5 litres or less
Thujone when included in Schedule 6.	200 millilitres or less
Thyme oil when included in Schedule 5.	200 millilitres or less

- (2) The manufacturer or packer of a poison must ensure that the child-resistant closure is appropriate for the container and the poison and that it retains its child-resistant properties for the expected life of the poison.

Schedule 8 poisons

- 25A.** (1) A person who supplies any Schedule 8 poison must ensure that the Schedule 8 poison is packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.

- (2) This paragraph does not apply to the supply of a Schedule 8 poison by a:
- (a) medical practitioner, dentist or veterinary surgeon in the practice of his or her profession;
 - (b) pharmacist on the prescription of a medical practitioner, dentist or veterinary surgeon;
 - (c) pharmacist employed at a hospital, on the written requisition of a medical practitioner, a dentist or the nurse in charge of the ward in which the Schedule 8 poison is to be used or stored; or
 - (d) nurse on the direction in writing of a medical practitioner or dentist.

Exemptions

26. (1) Paragraphs 21, 22 and 23 do not apply to the immediate container of a poison prepared, packed and sold:
- (a) for human internal or animal internal use; or
 - (b) as a solid or semi-solid preparation for human external or animal external use; or
 - (c) as a paint, other than a paint for therapeutic or cosmetic use; or
 - (d) in containers having a nominal capacity of 15 millilitres or less; or
 - (e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or
 - (f) solely for dispensary, industrial, laboratory or manufacturing purposes.
- (2) Paragraph 25 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.
27. The tactile identification or embossing required by paragraphs 21, 22 or 23 of this Standard or Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances* do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.

Camphor and naphthalene

28. The container requirements of paragraph 21 do not apply to a device that contains only camphor or naphthalene in block, ball, disc or pellet form for domestic use, if the device:

- (1) in normal use, prevents removal or ingestion of its contents; and
- (2) is incapable of reacting with the poison; and
- (3) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and
- (4) has the word "POISON" and the approved name of the poison embossed or indelibly printed on it.

Prohibitions

29. A person must not sell or supply camphor or naphthalene in ball, block, disc or pellet form for domestic use unless the balls, blocks, discs or pellets are enclosed in a device which prevents removal or ingestion of its contents.
30. A person must not sell or supply a poison in a container which has the name of another poison embossed or indelibly marked thereon.
31. A person must not sell any poison, drug or medicine which is for internal use or any food, drink or condiment in a container prescribed by paragraphs 21, 22 or 23 of this Standard.

PART 3 MISCELLANEOUS REGULATIONS

(It is recommended that the States and Territories implement regulations which provide controls similar to those included in this Part of the Standard.)

ADVERTISING

32. A person must not include any reference to a poison included in:

- (a) Schedule 3 unless included in Appendix H; or
- (b) Schedule 4 or Schedule 8,

of this Standard in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.

33. A person must not include any reference to a substance included in Schedule 9 of this Standard in any advertisement.

SALE OR SUPPLY

Schedule 2 poisons

34. A person, other than a pharmacist (or an assistant under the direction of a pharmacist) or a medical, dental or veterinary practitioner in the lawful practice of their professions, must not sell or supply a Schedule 2 poison unless licensed to do so.

35. A person is not eligible to be granted a licence to sell a Schedule 2 poison by way of retail sale unless:

- (1) he or she is carrying on the business of selling goods by retail; and
- (2) the premises from which the poison will be sold is more than 25 kilometres by the shortest practical route from the nearest pharmacy; and
- (3) he or she produces such evidence, as may be required, that he or she is a fit and proper person to be so licensed.

Schedule 3 poisons

36. A person, other than a pharmacist, or a medical, dental or veterinary practitioner, in the lawful practice of his or her profession, must not sell or supply a Schedule 3 poison.

37. The person who sells or supplies a Schedule 3 poison must:

- (1) provide adequate instructions for use, either written or verbal, at the time of supply or sale; and
- (2) label the container with his or her name or the name of the pharmacy and the address from which it was sold or supplied; and
- (3) if required by regulation, make a record of the transaction in a prescription book or other approved recording system.

Schedule 4 poisons

38. A person, other than a medical, dental or veterinary practitioner in the ordinary course of their professions or a pharmacist dispensing a legal prescription must not sell or supply a Schedule 4 poison.

39. Paragraph 38 does not apply to a pharmacist who sells or supplies a Schedule 4 poison, other than a poison excepted by regulation from this provision, without a prescription if:

- (1) the patient is under medical treatment with the poison and continuation of medication is essential; and
- (2) the quantity sold or supplied does not exceed 3 days medication; and
- (3) the pharmacist is satisfied that an emergency exists.

40. Paragraphs 34, 36, 37 and 38 do not apply to sale by way of wholesale dealing to a pharmacist, medical practitioner, veterinary practitioner, dentist or a person licensed or otherwise authorised to possess, sell or supply such poisons.

Schedule 7 poisons

41. (1) A person must not possess or use a Schedule 7 poison for domestic or domestic garden purposes.

(2) A person must not sell or supply:

- (a) a Schedule 7 poison for domestic or domestic garden purposes; or
- (b) a Schedule 7 poison being a liquid preparation containing paraquat unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell; or
- (c) a Schedule 7 poison for which an authorisation to possess or use is required by sub-paragraph (3) unless the purchaser produces his or her authorisation.

- (3) A person must not possess or use any of the following Schedule 7 poisons unless he or she is authorised to do so by the appropriate authority:

Arsenic
 Cyanides
 Fluoroacetic acid
 Fluoroacetamide
 Hydrocyanic acid
 Strychnine
 Thallium.

- (4) The appropriate authority may exempt a person or a class of persons from the requirement to hold an authorisation under sub-paragraph (3) and may vary or revoke the exemption by notice in writing.

Prohibitions on sale, prescribing and possession

42. A person must not:

- (1) knowingly have in his or her possession or sell, supply or use a substance listed in Appendix C of this Standard for the purpose or purposes indicated in relation to that poison in Appendix C; or
- (2) sell or supply, other than by way of wholesale dealing, or prescribe a poison listed in Appendix D paragraphs 1, 2, 3 or 4 except in accordance with the provisions indicated for that poison in Appendix D; or
- (3) knowingly have in his or her possession a poison listed in Appendix D paragraph 5 without authority.

STORAGE

- 43.** A person who sells or supplies Schedule 2 poisons must keep those poisons in such a way that public access to advice from a pharmacist is available if required.
- 44.** A person who sells or supplies Schedule 3, Schedule 4 or Schedule 7 poisons must keep those poisons in a part of the premises to which the public does not have access.

DISPENSED MEDICINES

45. A person must not supply a dispensed medicine for human use containing:

- (1) a poison for internal use listed in Appendix K unless it is clearly labelled with warning statement 39, 40 or 90 as specified in Appendix F, Part 1; or
- (2) levocabastine, unless it is clearly labelled with warning statement 62 in Appendix F, Part 1; or

- (3) acitretin, adapalene, bexarotene, etretinate, isotretinoin, lenalidomide, thalidomide or tretinoin:
 - (i) for oral use unless it is clearly labelled with warning statements 7, 62 and 76 in Appendix F, Part 1;
 - (ii) for topical use unless it is clearly labelled with warning statements 62 and 77 in Appendix F, Part 1; or
- (4) leflunomide unless it is clearly labelled with warning statements 7, 62 and 87 in Appendix F, Part 1; or
- (5) misoprostol unless it is clearly labelled with warning statement 53 in Appendix F, Part 1; or
- (6) dienestrol unless it is clearly labelled with warning statement 67 in Appendix F, Part 1.

PART 4
THE SCHEDULES

SCHEDULE 1

This Schedule is intentionally blank.

SCHEDULE 2

(Substances marked † are listed in Appendix C)

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH₃COOH) for therapeutic use.

ACETYLCYSTEINE in preparations for oral use **except** when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACONITUM spp. for therapeutic use in adults:

- (a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids; or
- (b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids.

ALOXIPRIN.

AMETHOCAINE in preparations for topical use other than eye drops, containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMOROLFINE for topical use in preparations containing 0.25 per cent or less of amorolfine **except** in preparations for the treatment of tinea pedis.

ANTAZOLINE in eye drops.

ASPIRIN **except**:

- (a) when included in Schedule 4, 5 or 6;
- (b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:
 - (i) enclosed in a primary pack that contains 12 or less such powders or sachets of granules; and
 - (ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
 - (i) packed in blister or strip packaging or in a container with a child-resistant closure;

SCHEDULE 2—continued

- (ii) in a primary pack of not more than 25 tablets or capsules, each containing 325 mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; and
 - (iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (d) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
- (i) packed in blister or strip packaging or in a container with a child-resistant closure;
 - (ii) in a primary pack containing 100 or less tablets or capsules, each containing 100 mg or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and
 - (iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

ATROPA BELLADONNA (belladonna):

- (a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
- (b) for oral use:
 - (i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
 - (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ATROPINE (excluding atropine methonitrate) for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

SCHEDULE 2—continued

- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

AZELAIC ACID in dermal preparations.

AZELASTINE in preparations for nasal use.

BECLOMETHASONE in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BENZOCAINE in preparations for topical use other than eye drops:

- (a) containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
- (b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per cent or less of benzoyl peroxide **except** in preparations containing 5 per cent or less of benzoyl peroxide.

BENZYDAMINE in preparations for topical use, **except** in preparations for dermal use.

BEPHENIUM SALTS.

BIFONAZOLE in preparations for dermal use **except**:

- (a) in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp; or
- (b) in preparations for the treatment of tinea pedis.

BROMHEXINE.

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

SCHEDULE 2—continued

- (b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

BUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

CARBETAPENTANE **except** in preparations containing 0.5 per cent or less of carbetapentane.

CARBOCISTEINE.

CETIRIZINE in preparations for oral use.

CHLOPHEDIANOL.

CHLORBUTOL for human use in topical preparations containing 5 per cent or less of chlorbutol **except** in preparations containing 0.5 per cent or less of chlorbutol.

CHLOROFORM in preparations for therapeutic use **except**:

- (a) when included in Schedule 4; or
(b) in preparations containing 0.5 per cent or less of chloroform.

CHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day-night pack containing chlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

CICLOPIROX in preparations for dermal use and for application to the nails containing 2 per cent or less of ciclopirox **except** in preparations for the treatment of tinea pedis.

SCHEDULE 2—continued

CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or less of total local anaesthetic substances.

CINNAMEDRINE.

CLOTRIMAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

CODEINE when:

- (a) compounded:
 - (i) with a single non-opiate analgesic substance in tablets or capsules each containing 10 mg or less of codeine when:
 - (A) packed in blister or strip packaging or in a container with a child-resistant closure; and
 - (B) in a primary package containing 25 or less dosage units; or
 - (ii) with a single non-opiate analgesic substance in individually wrapped powders containing 10 mg or less of codeine when in a primary pack containing 25 or less dosage units; or
 - (iii) with one or more other therapeutically active substances:
 - (A) in divided preparations each containing 10 mg or less of codeine; or
 - (B) in undivided preparations containing 0.25 per cent or less of codeine; and
- (b) labelled with a recommended daily dose not exceeding 60 mg of codeine.

CREOSOTE derived from wood other than beechwood for human therapeutic use, **except** in preparations containing 10 per cent or less of creosote derived from wood other than beechwood.

DATURA spp. for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or

SCHEDULE 2—continued

- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

except when separately specified in these Schedules.

DATURA STRAMONIUM (stramonium) for oral use when:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

except for smoking or burning.

DATURA TATULA (stramonium) for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

except for smoking or burning.

DELPHINIUM STAPHISAGRIA **except** in preparations containing 0.2 per cent or less of *Delphinium staphisagria*.

DESLORATADINE in preparations for oral use.

DEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing dexchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

SCHEDULE 2—continued

DEXTROMETHORPHAN(excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.

DIBROMOPROPAMIDINE for ophthalmic use.

DICLOFENAC in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac.

DIHYDROCODEINE when compounded with aspirin and no other therapeutically active substance in divided preparations:

- (a) containing 5 mg or less of dihydrocodeine per dosage unit;
- (b) packed in blister or strip packaging or in a container with a child-resistant closure;
- (c) enclosed in primary packs containing 25 or less dosage units; and
- (d) labelled with a recommended dose not exceeding 10 mg of dihydrocodeine.

DIMENHYDRINATE in primary packs of 10 doses or less, for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

DIPHENHYDRAMINE in oral preparations:

- (a) in a primary pack containing ten dosage units or less, for the prevention or treatment of motion sickness; or
- (b) when combined with one or more other therapeutically active substances when:
 - (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 - (ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

SCHEDULE 2—continued

- (b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

DUBOISIA LEICHHARDTII for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DUBOISIA MYOPOROIDES for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ECONAZOLE for human use in dermal preparations **except** in preparations for the treatment of tinea pedis.

ETAFEDRINE.

ETHER for therapeutic use **except**:

- (a) when included in Schedule 4; or
- (b) in preparations containing 10 per cent or less of ether.

ETHYLMORPHINE when:

- (a) compounded with one or more other therapeutically active substances:
- (i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or

SCHEDULE 2—continued

- (ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine; and

(b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.

ETOFENAMATE in preparations for external use.

FAMOTIDINE when sold in the manufacturer's original pack containing not more than 14 days supply.

FELBINAC in preparations for external use.

FEXOFENADINE in preparations for oral use.

FLUORIDES for human use:

- (a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or

- (b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure:

- (i) for therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels* **except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

- (ii) for non-therapeutic use when labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less,

except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less,

SCHEDULE 2—continued

except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.

FLURBIPROFEN in divided preparations for topical oral use containing 10 mg or less of flurbiprofen per dosage unit.

FLUTICASONE in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

FOLIC ACID for human therapeutic use **except**:

- (a) when included in Schedule 4; or
- (b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

FOLINIC ACID for human therapeutic use **except**:

- (a) when included in Schedule 4; or
- (b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

† FORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

- (a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
- (b) in other preparations containing 0.2 per cent or less of free formaldehyde.

GELSEMIUM SEMPERVIRENS.

GLUTARALDEHYDE for human therapeutic use.

HEXACHLOROPHANE in preparations for human use containing 3 per cent or less of hexachlorophane **except**:

- (a) in preparations containing 0.75 per cent or less of hexachlorophane; or
- (b) in preparations for use on infants, as specified in Schedule 4.

SCHEDULE 2—continued

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 0.5 per cent or less of hydrocortisone:

- (a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
- (b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:
 - (i) in undivided preparations in packs of 35 g or less; or
 - (ii) in packs containing 12 or less suppositories.

HYDROQUINONE (excluding monobenzone and other alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per cent or less of hydroquinone **except** hair preparations containing 1 per cent or less of hydroquinone.

8-HYDROXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, **except** in preparations for external use containing 1 per cent or less of such substances.

HYOSCINE (excluding hyoscine butylbromide):

- (a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or
- (b) for oral use:
 - (i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
 - (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.

SCHEDULE 2—continued

HYOSCYAMINE:

- (a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
- (b) for oral use:
 - (i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
 - (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.

HYOSCYAMUS NIGER for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

except in a pack containing 0.03 mg or less of total solanaceous alkaloids.

IBUPROFEN in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen:

- (a) in liquid preparations when sold in the manufacturer's original pack containing 4 grams or less of ibuprofen; or
- (b) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units **except** when:
 - (i) as the only therapeutically active constituent other than an effervescent agent;
 - (ii) packed in blister or strip packaging or in a container with a child-resistant closure;

SCHEDULE 2—continued

- (iii) in a primary pack containing not more than 25 dosage units;
- (iv) not labelled for the treatment of children 6 years of age or less; and
- (v) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

INDANAZOLINE.

INDOMETHACIN in preparations for external use containing 1 per cent or less of indomethacin.

IODINE:

- (a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or
- (b) in preparations for human external therapeutic use containing more than 2.5 per cent of available iodine (excluding salts, derivatives or iodophors).

IPRATROPIUM in preparations for nasal use.

IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use **except**:

- (a) when included in Schedule 4; or
- (b) when labelled with a recommended daily dose of 24 mg or less of iron:
 - (i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or
 - (ii) in divided preparations:
 - (A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or
 - (B) containing 5 mg or less of iron per dosage unit.

ISOCONAZOLE for human use in dermal preparations.

ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.

SCHEDULE 2—continued

KETOCONAZOLE in preparations for dermal use **except**:

- (a) in preparations containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
- (b) in preparations for the treatment of tinea pedis.

KETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen.

LEVOCABASTINE in topical eye or nasal preparations.

LIGNOCAINE in preparations for topical use other than eye drops:

- (a) containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
- (b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

LINDANE in preparations for human external therapeutic use containing 2 per cent or less of lindane.

LITHIUM in preparations for dermal use containing 1 per cent or less of lithium **except**:

- (a) when present as an excipient at 0.25 per cent or less of lithium; or
- (b) in preparations containing 0.01 per cent or less of lithium.

LOBELIA INFLATA **except** for smoking or burning.

LOBELINE **except** in preparations for smoking or burning.

LODOXAMIDE in preparations for ophthalmic use.

LOPERAMIDE in preparations for oral use in packs of 20 dosage units or less.

LORATADINE in preparations for oral use.

MEBENDAZOLE for human therapeutic use.

MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

SCHEDULE 2—continued

MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.

MEPYRAMINE for dermal use.

MERCURY for external use in preparations containing 0.5 per cent or less of mercury.

METHOXAMINE in preparations for external use **except** in preparations containing 1 per cent or less of methoxamine.

METHOXYPHENAMINE.

METHYLEPHEDRINE.

MICONAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.

MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.

NAPHAZOLINE.

NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

NICLOSAMIDE for human therapeutic use.

NICOTINE for use as an aid in withdrawal from tobacco smoking in preparations for inhalation.

NIZATIDINE when sold in the manufacturer's original pack containing not more than 14 days supply.

NOSCAPINE.

NYSTATIN in dermal preparations.

OXETACAINE (oxethazaine) in preparations for internal use.

OXICONAZOLE for dermal use **except** in preparations for the treatment of tinea pedis.

OXYMETAZOLINE.

PAPAVERINE **except** when included in Schedule 4.

SCHEDULE 2—continued

PARACETAMOL for therapeutic use **except**:

- (a) when included in Schedule 4;
- (b) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine or when combined with effervescent agents) when:
 - (i) enclosed in a primary pack that contains not more than 12 such powders or sachets of granules;
 - (ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
 - (iii) not labelled for the treatment of children 6 years of age or less; and
 - (iv) not labelled for the treatment of children under 12 years of age when combined with phenylephrine; or
- (c) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine or when combined with effervescent agents) when:
 - (i) packed in blister or strip packaging or in a container with a child-resistant closure;
 - (ii) in a primary pack containing not more than 25 tablets or capsules;
 - (iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
 - (iv) not labelled for the treatment of children 6 years of age or less; and
 - (v) not labelled for the treatment of children under 12 years of age when combined with phenylephrine.

† PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

- (a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde;
or
- (b) in other preparations containing 0.2 per cent or less of free formaldehyde.

SCHEDULE 2—continued

PENCICLOVIR for external use for the treatment of *Herpes labialis*.

PHEDRAZINE.

PHENAZONE for human external use.

PHENIRAMINE:

- (a) in eye drops; or
- (b) when combined with one or more other therapeutically active substances in oral preparations when:
 - (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 - (ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

PHENOL, or any homologue boiling below 220°C, for human therapeutic use **except**:

- (a) when included in Schedule 4; or
- (b) in preparations for external use containing 3 per cent or less of such substances.

PHENYLEPHRINE **except**:

- (a) when included in Schedule 4;
- (b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or
- (c) in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.

PHOLCODINE:

- (a) in liquid preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or
- (b) when compounded with one or more other therapeutically active substances, in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.

SCHEDULE 2—continued

PIPERAZINE for human therapeutic use.

PODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

POTASSIUM CHLORATE for therapeutic use **except** in preparations containing 10 per cent or less of potassium chlorate.

PRILOCAINE in preparations for dermal use containing 10 per cent or less of total local anaesthetic substances.

PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.

PROMETHAZINE in oral preparations:

- (a) in a primary pack containing ten dosage units or less, for the prevention or treatment of motion sickness; or
- (b) when combined with one or more other therapeutically active substances when:
 - (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 - (ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

PROPAMIDINE for ophthalmic use.

PYRANTEL for human therapeutic use.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.

SCHEDULE 2—continued

PYRITHIONE ZINC for human therapeutic use, **except** in preparations for the treatment of the scalp containing 2 per cent or less of pyriithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

RANITIDINE in preparations supplied in the manufacturer's original pack containing not more than 14 days supply **except** in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer's original pack containing not more than 14 dosage units.

SALICYLAMIDE **except** when included in Schedule 4.

SELENIUM in preparations for human therapeutic use **except**:

- (a) for topical use containing 3.5 per cent or less of selenium sulfide;
- (b) when included in Schedule 4; or
- (c) for oral use with a recommended daily dose of 150 micrograms or less.

SILVER for therapeutic use **except**:

- (a) in solutions for human oral use containing 0.3 per cent or less of silver when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (b) in other preparations containing 1 per cent or less of silver.

SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.

SODIUM NITRITE for therapeutic use (excluding when present as an excipient).

SQUILL **except** in preparations containing 1 per cent or less of squill.

SULCONAZOLE in preparations for dermal use.

TERBINAFINE for dermal use **except** in preparations for the treatment of tinea pedis.

TETRACHLOROETHYLENE for human therapeutic use.

TETRAHYDROZOLINE.

THIABENDAZOLE for human therapeutic use.

TIOCONAZOLE in preparations for dermal use **except** in preparations for the treatment of tinea pedis.

SCHEDULE 2—continued

TRAMAZOLINE.

TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

TRIMEPRAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing trimeprazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing triprolidine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

TUAMINOHEPTANE.

TYMAZOLINE.

XYLOMETAZOLINE.

ZINC CHLORIDE for human dermal use **except** in preparations containing 5 per cent or less of zinc chloride.

SCHEDULE 3

ADRENALINE in preparations containing 1 per cent or less of adrenaline **except** in preparations containing 0.02 per cent or less of adrenaline.

ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of alclometasone in packs containing 30 g or less of the preparation.

AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.

AMOROLFINE for topical use **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for the treatment of tinea pedis.

AZATADINE in oral preparations.

AZELASTINE in topical eye preparations containing 0.05 per cent or less of azelastine.

BROMPHENIRAMINE in oral preparations **except**:

- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.

BUCLIZINE in oral preparations.

BUTOCONAZOLE in preparations for vaginal use.

CHLORBUTOL in preparations for human use **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 0.5 per cent or less of chlorbutol.

CHLORPHENIRAMINE in oral preparations **except**:

- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.

CICLOPIROX in preparations for dermal use and for application to the nails **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for the treatment of tinea pedis.

SCHEDULE 3—continued

CIMETIDINE in a primary pack containing not more than 14 days supply.

CLEMASTINE in preparations for oral use.

CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing 30 g or less of the preparation.

CLOTRIMAZOLE in preparations for vaginal use.

CODEINE when compounded with:

- (a) a single non-opiate analgesic substance in divided preparations containing 10 mg or less of codeine per dosage unit and with a recommended daily dose not exceeding 60 mg of codeine; or
- (b) paracetamol in divided preparations containing 12 mg or less of codeine per dosage unit and with a recommended daily dose greater than 60 mg but not exceeding 100 mg of codeine when:
 - (i) packed in blister or strip packaging or in a container with a child-resistant closure; and
 - (ii) in a primary pack containing 12 or less dosage units,

except when included in Schedule 2.

CYCLIZINE in preparations for oral use.

CYPROHEPTADINE in oral preparations.

DEXCHLORPHENIRAMINE in oral preparations **except**:

- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units **except** when included in Schedule 2.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

- (a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or

SCHEDULE 3—continued

- (b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine,

except when included in Schedule 2.

DI-iodohydroxyquinoline (iodoquinol) for vaginal use.

DIMENHYDRINATE in oral preparations **except** when included in Schedule 2.

DIMETHINDENE in oral preparations.

DIPHENHYDRAMINE in oral preparations **except**:

- (a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age.

DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate.

DITHRANOL for therapeutic use.

DOXYLAMINE in oral preparations **except**:

- (a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age.

ECONAZOLE in preparations for vaginal use.

ERYTHRITYL TETRANITRATE for therapeutic use.

FLAVOXATE.

FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.

FLUORIDES for human topical use:

- (a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure **except** when included in or expressly excluded from Schedule 2; or

SCHEDULE 3—continued

- (b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion **except**:
- (i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
 - (ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:
 - (A) Do not swallow; and
 - (B) Do not use [this product/name of product] in children six years of age or less; or
 - (iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.

GLUCAGON.

GLYCERYL TRINITRATE:

- (a) in preparations for oral use; or
- (b) in preparations for rectal use.

GLYCOPYRRONIUM **except** when included in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1 per cent or less of hydrocortisone:

- (a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
- (b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:
 - (i) in undivided preparations, in packs of 35 g or less; or
 - (ii) in packs containing 12 or less suppositories,

except when included in Schedule 2.

SCHEDULE 3—continued

IBUPROFEN in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units when labelled:

- (a) with a recommended daily dose of 1200 mg or less of ibuprofen; and
 - (b) not for the treatment of children under 12 years of age,
- except** when included in or expressly excluded from Schedule 2.

INOSITOL NICOTINATE.

ISOCONAZOLE in preparations for vaginal use.

ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.

KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

LEVONORGESTREL for emergency post-coital contraception.

MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.

MALATHION in preparations for human external use **except** in preparations containing 2 per cent or less of malathion.

MANNITYL HEXANITRATE for therapeutic use.

MEPYRAMINE in oral preparations.

METHDILAZINE in oral preparations.

METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

MICONAZOLE for human use in topical preparations:

- (a) for the treatment of oral candidiasis; or
- (b) for vaginal use.

SCHEDULE 3—continued

NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit **except**:

- (a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
- (b) nicotinamide.

NICOTINYL ALCOHOL **except** in preparations containing 100 mg or less of nicotiny alcohol per dosage unit.

NYSTATIN in preparations for topical use **except** when included in Schedule 2.

ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.

OXICONAZOLE in preparations for vaginal use.

PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days of supply.

PHENIRAMINE in oral preparations **except**:

- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.

PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.

PROMETHAZINE in oral preparations **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for the treatment of children under 2 years of age.

PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack:

- (a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or
- (b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).

SALBUTAMOL as the only therapeutically active substance:

- (a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
- (b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.

SALICYLIC ACID in preparations for dermal use **except** in preparations containing 40 per cent or less of salicylic acid.

SANTONIN.

SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.

SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.

SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of sulfacetamide.

TERBUTALINE as the only therapeutically active substance:

- (a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or
- (b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.

THEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline.

TIOCONAZOLE in preparations for vaginal use.

TRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of triamcinolone in a pack of 5 g or less.

SCHEDULE 3—continued

TRIMEPRAZINE:

- (a) in solid oral preparations **except** when included in Schedule 2; or
- (b) in liquid oral preparations containing 10 mg or less of trimeprazine per 5 mL, **except** in preparations for the treatment of children under 2 years of age.

TRIPROLIDINE in oral preparations **except**:

- (a) when included in Schedule 2; or
- (b) for the treatment of children under 2 years of age.

SCHEDULE 4

(Substances marked † are listed in Appendix C)

(Substances marked # are listed in Appendix D)

ABACAVIR.

ABATACEPT.

ABCIXIMAB.

ACAMPROSATE CALCIUM.

ACARBOSE.

ACEBUTOLOL.

ACEPROMAZINE.

ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.

ACETARSOL.

ACETAZOLAMIDE.

ACETOHEXAMIDE.

ACETYLCARBROMAL.

ACETYLCHOLINE.

ACETYLCYSTEINE **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACETYLDIGITOXIN.

ACETYL ISOVALERYLTYSIN.

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.

ACETYLSTROPHANTHIDIN.

ACICLOVIR **except** in preparations containing 5 per cent or less of aciclovir for the treatment of *Herpes labialis* in packs containing 10 g or less.

SCHEDULE 4—continued

ACIPIMOX.

ACITRETIN.

ACOKANTHERA OUABAIO.

ACOKANTHERA SCHIMPERI.

ACONITUM spp. **except**:

- (a) when included in Schedule 2;
- (b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or
- (c) in preparations for dermal use in adults containing 0.02 per cent or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.

ACRIVASTINE.

ADALIMUMAB.

ADAPALENE.

ADEFOVIR.

ADENOSINE for human therapeutic use in preparations for injection.

ADIPHENINE.

ADONIS VERNALIS.

ADRAFINIL.

ADRENALINE **except**:

- (a) when included in Schedule 3; or
- (b) in preparations containing 0.02 per cent or less of adrenaline.

ADRENOCORTICAL HORMONES **except** when separately specified in these Schedules.

AGALSIDASE.

AGLEPRISTONE.

AGOMELATINE.

SCHEDULE 4—continued

ALATROFLOXACIN MESYLATE.

ALBENDAZOLE **except**:

- (a) when included in Schedule 5 or 6; or
- (b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.

ALCLOFENAC.

ALCLOMETASONE **except** when included in Schedule 3.

ALCURONIUM.

ALDESLEUKIN.

ALDOSTERONE.

ALEFACEPT.

ALEMTUZUMAB.

ALENDRONIC ACID.

ALFACALCIDOL.

ALFUZOSIN.

ALGLUCERASE.

ALGLUCOSIDASE.

ALISKIREN.

ALLERGENS.

ALLOPURINOL.

ALLYLOESTRENOL.

ALOSETRON.

ALPHADOLONE.

ALPHAXALONE.

ALPRAZOLAM.

SCHEDULE 4—continued

ALPRENOLOL.

ALPROSTADIL.

ALSEROXYLON.

ALTEPLASE.

ALTRENOGEST.

ALTRETAMINE (hexamethylmelamine).

AMANTADINE.

AMBENONIUM CHLORIDE.

AMBUCETAMIDE.

AMBUTONIUM BROMIDE.

AMCINONIDE.

AMETHOCAINE **except**:

- (a) when included in Schedule 2; or
- (b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMIFOSTINE.

AMIKACIN.

AMILORIDE.

AMINOCAPROIC ACID.

AMINOGLUTETHIMIDE.

AMINOMETRADINE.

† AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.

AMINOPHYLLINE **except** when included in Schedule 3.

AMINOPTERIN.

4-AMINOPYRIDINE for therapeutic use.

SCHEDULE 4—continued

AMINOREX.

AMINOSALICYLIC ACID.

AMIODARONE.

AMIPHENAZOLE.

AMISOMETRADINE.

AMISULPRIDE.

AMITRIPTYLINE.

AMLODIPINE.

AMMI VISNAGA.

AMMONIUM BROMIDE for therapeutic use.

AMODIAQUINE.

AMOROLFINE **except:**

- (a) when included in Schedule 2 or 3; or
- (b) in preparations for the treatment of tinea pedis.

AMOXAPINE.

AMOXYCILLIN.

AMPHOMYCIN.

AMPHOTERICIN.

AMPICILLIN.

AMPRENAVIR.

AMRINONE.

AMSACRINE.

AMYL NITRITE.

SCHEDULE 4—continued

AMYLOBARBITONE when packed and labelled for injection.

AMYLOCAINE.

ANABOLIC STEROIDAL AGENTS.

ANAGRELIDE.

ANAKINRA.

ANASTROZOLE.

ANCESTIM.

ANCROD and its immunoglobulin antidote.

ANECORTAVE.

ANDROGENIC STEROIDAL AGENTS.

ANDROISOXAZOLE.

ANDROSTANOLONE.

ANDROSTENEDIOL.

ANDROSTENEDIONE.

ANGIOTENSIN AMIDE.

ANIDULAFUNGIN.

ANISTREPLASE.

ANTAZOLINE **except** when included in Schedule 2.

ANTIBIOTIC SUBSTANCES **except**:

- (a) when separately specified in these Schedules; or
- (b) nisin.

ANTIGENS for human therapeutic use **except** when separately specified in this Schedule.

ANTI-HISTAMINES **except**:

- (a) when included in Schedule 2 or 3; or

SCHEDULE 4—continued

(b) when separately specified in this Schedule.

ANTIMONY for therapeutic use **except** when separately specified in these Schedules.

ANTISERA (immunosera) for human use by injection **except** when separately specified in these Schedules.

APOCYNUM spp.

APOMORPHINE.

APRACLONIDINE.

APRAMYCIN.

APREPITANT.

APRONAL.

APROTININ.

ARECOLINE.

ARIPIRAZOLE.

ARSENIC for human therapeutic use **except** when separately specified in these Schedules.

ARTEMETHER.

ARTICAINE.

ASPIRIN:

(a) when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or

(b) for injection.

ASTEMIZOLE.

ATAMESTANE.

ATAZANAVIR.

ATENOLOL.

ATIPAMEZOLE.

ATOMOXETINE.

ATORVASTATIN.

ATOSIBAN.

SCHEDULE 4—continued

ATOVAQUONE.

ATRACURIUM BESYLATE.

ATROPA BELLADONNA (belladonna) **except** when included in Schedule 2.

ATROPINE **except** when included in Schedule 2.

ATROPINE METHONITRATE.

AURANOFIN.

AUROTHIOMALATE SODIUM.

AVILAMYCIN **except**:

- (a) in animal feed premixes containing 15 per cent or less of avilamycin activity; or
- (b) in animal feeds containing 50 mg/kg or less of avilamycin activity.

AVIPTADIL.

AVOPARCIN.

AZACITIDINE.

AZACYCLONOL.

AZAPERONE.

AZAPROPAZONE.

AZARIBINE.

AZATADINE **except** when included in Schedule 3.

AZATHIOPRINE.

AZELAIC ACID **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 1 per cent or less of azelaic acid for non-human use.

SCHEDULE 4—continued

AZELASTINE **except** when included in Schedule 2 or 3.

AZITHROMYCIN.

AZLOCILLIN.

AZTREONAM.

BACAMPICILLIN.

BACITRACIN.

BACLOFEN.

BALSALAZIDE.

BAMBERMYCIN (flavophospholipol) **except**:

- (a) when included in Schedule 6; or
- (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

BAMBUTEROL.

BAMETHAN.

BAMIPINE.

BARBITURATES **except** when separately specified in these Schedules.

BASILIXIMAB.

BECAPLERMIN.

BECLAMIDE.

BECLOMETHASONE **except** when included in Schedule 2.

BEMEGRIDE.

BENACTYZINE.

BENZAEPRIIL.

SCHEDULE 4—continued

BENDROFLUAZIDE.

BENETHAMINE PENICILLIN.

BENORYLATE.

BENOXAPROFEN.

BENPERIDOL.

BENSERAZIDE.

BENZATHINE PENICILLIN.

BENZHEXOL.

BENZILONIUM.

BENZOCAINE **except:**

- (a) when included in Schedule 2;
- (b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
- (c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZODIAZEPINE derivatives **except** when separately specified in these Schedules.

BENZOYL PEROXIDE in preparations for human therapeutic use **except:**

- (a) when included in Schedule 2; or
- (b) in preparations for external use containing 5 per cent or less of benzoyl peroxide.

BENZPHETAMINE.

BENZTHIAZIDE.

BENZTROPINE (benzatropine).

BENZYDAMINE **except:**

- (a) when included in Schedule 2; or
- (b) in preparations for dermal use.

SCHEDULE 4—continued

BENZYLPENICILLIN.

BEPRIDIL.

BERACTANT.

BETAHISTINE.

BETAMETHASONE.

BETAXOLOL.

BETHANECHOL CHLORIDE.

BETHANIDINE.

BEVACIZUMAB.

BEVANTOLOL.

BEXAROTENE.

BEZAFIBRATE.

BICALUTAMIDE.

BIFONAZOLE **except**:

- (a) when included in Schedule 2;
- (b) in preparations for dermal use containing 1 per cent or less of bifonazole for the treatment of the scalp; or
- (c) in preparations for dermal use for the treatment of tinea pedis.

BIMATOPROST.

BIPERIDEN.

BISMUTH COMPOUNDS for cosmetic use, **except**:

- (a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per cent or less; or
- (b) bismuth oxychloride.

BISMUTH COMPOUNDS for human therapeutic use, **except** bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.

SCHEDULE 4—continued

BISOPROLOL.

BIVALIRUDIN.

BLEOMYCIN.

BOLANDIOL.

BOLASTERONE.

BOLAZINE.

BOLDENONE (dehydrotestosterone).

BOLENOL.

BOLMANTALATE.

BORON, including boric acid and borax, for human therapeutic use **except**:

- (a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose;
- (b) in preparations for dermal use containing 0.35 per cent or less of boron, which are not for paediatric or antifungal use; or
- (c) when present as an excipient.

BORTEZOMIB.

BOSENTAN.

BOTULINUM TOXINS for human use **except** when separately specified in these Schedules.

BRETYLIUM TOSYLATE.

BRIMONIDINE.

BRINZOLAMIDE.

BROMAZEPAM.

BROMIDES, inorganic, for therapeutic use **except** when separately specified in these Schedules.

BROMOCRIPTINE.

SCHEDULE 4—continued

BROMOFORM for therapeutic use.

BROMPHENIRAMINE **except** when included in Schedule 2 or 3.

BROMVALETONE.

BRUGMANSIA spp.

BUCLIZINE **except** when included in Schedule 3.

BUDESONIDE **except** when included in Schedule 2.

BUFEXAMAC **except**:

- (a) in preparations for dermal use containing 5 per cent or less of bufexamac; or
- (b) in suppositories.

BUMETANIDE.

BUPHENINE.

BUPIVACAINE.

BUPROPION.

BUSERELIN.

BUSPIRONE.

BUSULPHAN.

BUTACAINE.

BUTOCONAZOLE **except** when included in Schedule 3.

BUTRACONAZOLE.

BUTYL AMINOBENZOATE **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

BUTYLCHLORAL HYDRATE.

BUTYL NITRITE.

CABERGOLINE.

SCHEDULE 4—continued

CADMIUM COMPOUNDS for human therapeutic use.

CALCIPOTRIOL.

CALCITONIN.

CALCITRIOL.

CALCIUM CARBIMIDE for therapeutic use.

CALCIUM POLYSTYRENE SULPHONATE.

CALOTROPIS GIGANTEA.

CALOTROPIS PROCERA.

CALUSTERONE.

CAMPHORATED OIL for therapeutic use.

CAMPHOTAMIDE.

CANDESARTAN CILEXETIL.

CANDICIDIN.

CANINE TICK ANTI-SERUM.

CANTHARIDIN.

CAPECITABINE.

CAPREOMYCIN.

CAPTODIAME.

CAPTOPRIL.

CAPURIDE.

CARAMIPHEN.

CARBACHOL.

CARBAMAZEPINE.

CARBARYL for human therapeutic use.

SCHEDULE 4—continued

CARBAZOCHROME.

CARBENICILLIN.

CARBENOXOLONE for internal use.

CARBETOCIN.

CARBIDOPA.

CARBIMAZOLE.

CARBOCROMEN.

CARBOPLATIN.

CARBOPROST.

CARBROMAL.

CARBUTAMIDE.

CARBUTEROL.

CARINDACILLIN.

CARISOPRODOL.

CARMUSTINE.

CARNIDAZOLE.

CARPROFEN.

CARVEDILOL.

CASPOFUNGIN.

CATHINE.

CEFACETRILE.

CEFACLOR.

CEFADROXIL.

CEFALORIDINE.

SCHEDULE 4—continued

CEFAMANDOLE.

CEFAPIRIN.

CEFAZOLIN.

CEFEPIME.

CEFETAMET.

CEFIXIME.

CEFODIZIME.

CEFONICID.

CEFOPERAZONE.

CEFOTAXIME.

CEFOTETAN.

CEFOTIAM.

CEFOVECIN for veterinary use.

CEFOXITIN.

CEFPIROME.

CEFPODOXIME.

CEFSULODIN.

CEFTAZIDIME.

CEFTIBUTEN.

CEFTIOFUR.

CEFTRIAZONE.

CEFUROXIME.

CELECOXIB.

CELIPROLOL.

SCHEDULE 4—continued

CEPHAELIS ACUMINATA (ipecacuanha) **except** in preparations containing 0.2 per cent or less of emetine.

CEPHAELIS IPECACUANHA **except** in preparations containing 0.2 per cent or less of emetine.

CEPHALEXIN.

CEPHALONIUM.

CEPHALOTHIN.

CEPHRADINE.

CERIVASTATIN.

CERULETIDE.

CETIRIZINE **except** when included in Schedule 2.

CETRORELIX.

CETUXIMAB.

CHENODEOXYCHOLIC ACID.

CHLORAL FORMAMIDE.

CHLORAL HYDRATE **except** in preparations for topical use containing 2 per cent or less of chloral hydrate.

CHLORALOSE **except** when included in Schedule 6.

CHLORAMBUCIL.

CHLORAMPHENICOL.

CHLORANDROSTENOLONE.

CHLORAZANIL.

CHLORCYCLIZINE.

CHLORDIAZEPOXIDE.

CHLORMERODRIN.

SCHEDULE 4—continued

CHLORMETHIAZOLE.

CHLORMEZANONE.

CHLOROFORM for use in anaesthesia.

4-CHLOROMETHANDIENONE.

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.

CHLOROQUINE.

CHLOROTHIAZIDE.

CHLOROTRIANISENE.

CHLOROXYDIENONE.

CHLORPHENIRAMINE **except** when included in Schedule 2 or 3.

CHLORPHENTERMINE.

CHLORPROMAZINE.

CHLORPROPAMIDE.

CHLORPROTHIXENE.

CHLORQUINALDOL for human topical use.

CHLORTETRACYCLINE **except** when included in Schedule 5.

CHLORTHALIDONE.

CHLORZOXAZONE.

CHOLERA VACCINE.

CHOLESTYRAMINE (colestyramine) for human therapeutic use.

CHYMOPAPAIN for human therapeutic use.

CICLACILLIN.

CICLESONIDE.

CICLOPIROX **except** when included in Schedule 2 or 3.

SCHEDULE 4—continued

CIDOFOVIR.

CILASTATIN.

CILAZAPRIL.

CIMETIDINE **except** when included in Schedule 3.

CINACALCET.

CINCHOCAINE **except** when included in Schedule 2.

CINOXACIN.

CIPROFLOXACIN.

CISAPRIDE.

CISATRACURIUM BESYLATE.

CISPLATIN.

CITALOPRAM.

CLADRIBINE.

CLANOBUTIN.

CLARITHROMYCIN.

CLAVULANIC ACID.

CLEMASTINE **except** when included in Schedule 3.

CLEMIZOLE.

CLENBUTEROL.

CLIDINIUM BROMIDE.

CLINDAMYCIN.

† CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human topical use **except** when separately specified in this Schedule.

CLOBAZAM.

SCHEDULE 4—continued

CLOBETASOL.

CLOBETASONE (clobetasone-17-butyrate) **except** when included in Schedule 3.

CLOCORTOLONE.

CLODRONIC ACID (includes sodium clodronate).

CLOFAZIMINE.

CLOFENAMIDE.

CLOFIBRATE.

CLOMIPHENE.

CLOMIPRAMINE.

CLOMOCYCLINE.

CLONAZEPAM.

CLONIDINE.

CLOPAMIDE.

CLOPIDOGREL.

CLOPROSTENOL.

CLORAZEPATE.

CLOREXOLONE.

CLORPRENALINE.

CLOSTEBOL (4-chlorotestosterone).

CLOTRIMAZOLE **except**:

- (a) when included in Schedule 2, 3 or 6; or
- (b) in preparations for dermal use for the treatment of tinea pedis.

CLOXACILLIN.

CLOZAPINE.

SCHEDULE 4—continued

COBALT for human therapeutic use **except** as dicobalt edetate in preparations for the treatment of cyanide poisoning.

CODEINE when compounded with one or more other therapeutically active substances:

- (a) in divided preparations containing 30 mg or less of codeine per dosage unit; or
- (b) in undivided preparations containing 1 per cent or less of codeine,
except when included in Schedule 2 or 3.

CO-DERGOCRINE.

COLASPASE.

COLCHICINE.

COLCHICUM AUTUMNALE.

COLESTIPOL.

COLFOSCERIL PALMITATE for human therapeutic use.

COLISTIN.

COLLAGEN in preparations for injection or implantation:

- (a) for tissue augmentation; or
- (b) for cosmetic use.

CONVALLARIA KEISKI.

CONVALLARIA MAJALIS.

COPPER COMPOUNDS for human use **except**:

- (a) when separately specified in these Schedules;
- (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or
- (c) in other preparations containing 5 per cent or less of copper compounds.

CORONILLA spp.

SCHEDULE 4—continued

CORTICOSTERONE.

CORTICOTROPHIN.

CORTISONE.

CO-TRIMOXAZOLE.

COUMARIN for therapeutic use (excluding when present as an excipient).

CRYSTAL VIOLET for human use **except** when used as a dermal marker.

CUPRIMYXIN.

CURARE.

CYCLANDELATE.

CYCLIZINE **except** when included in Schedule 3.

CYCLOBENZAPRINE.

CYCLOFENIL.

CYCLOHEXIMIDE.

CYCLOPENTHIAZIDE.

CYCLOPENTOLATE.

CYCLOPHOSPHAMIDE.

CYCLOPROPANE for therapeutic use.

CYCLOSERINE.

CYCLOSPORIN.

CYCLOTHIAZIDE.

CYCRIMINE.

CYMARIN.

CYPROHEPTADINE **except** when included in Schedule 3.

CYPROTERONE.

SCHEDULE 4—continued

CYSTEAMINE for human therapeutic use.

CYTARABINE.

DABIGATRAN.

DACARBAZINE.

DACLIZUMAB.

DACTINOMYCIN.

DALFOPRISTIN.

DALTEPARIN (includes dalteparin sodium).

DANAPAROID (includes danaparoid sodium).

DANAZOL.

DANTHRON for human use.

DANTROLENE.

DAPSONE.

DAPTOMYCIN.

DARBEPOETIN.

DARIFENACIN.

DARUNAVIR.

DATURA spp. **except:**

- (a) when included in Schedule 2; or
- (b) when separately specified in this Schedule.

DASATINIB.

DATURA STRAMONIUM (stramonium) **except:**

- (a) when included in Schedule 2; or
- (b) for smoking or burning.

SCHEDULE 4—continued

DATURA TATULA (stramonium) **except**:

- (a) when included in Schedule 2; or
- (b) for smoking or burning.

DAUNORUBICIN.

DEANOL.

DEBRISOQUINE.

DECAMETHONIUM.

DEFERASIROX.

DEFERIPRONE.

DEFLAZACORT.

DEHYDROCHLOROMETHYLTESTOSTERONE.

DEHYDROCORTICOSTERONE.

DELAVIRDINE (includes delavirdine mesylate).

DEMBREXINE **except** when included in Schedule 5.

DEMECARIUM.

DEMECLOCYCLINE.

DEOXYCORTONE.

DEOXYRIBONUCLEASE **except**:

- (a) when separately specified in this Schedule; or
- (b) for external use.

DERACOXIB.

DEFERRIOXAMINE.

DESFLURANE.

DESIPRAMINE.

SCHEDULE 4—continued

DESIRUDIN.

DESLANOSIDE.

DESLORATADINE **except** when included in Schedule 2.

DESLORELIN.

DESMOPRESSIN (D.D.A.V.P.).

DESOGESTREL.

DESONIDE.

DESOXYMETHASONE.

DESVENLAFAXINE.

DETOMIDINE.

DEXAMETHASONE.

DEXCHLORPHENIRAMINE **except** when included in Schedule 2 or 3.

DEXFENFLURAMINE.

DEXMEDETOMIDINE.

DEXTROMETHORPHAN (excluding its stereoisomers) **except** when included in Schedule 2.

DEXTROPROPOXYPHENE:

- (a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or
- (b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.

DEXTRORPHAN (excluding its stereoisomers).

DIAMTHAZOLE.

DIAVERIDINE.

DIAZEPAM.

DIAZOXIDE.

SCHEDULE 4—continued

DIBENZEPIN.

DIBOTERMIN.

DIBROMOPROPAMIDINE for therapeutic use **except** when included in Schedule 2.

DICHLORALPHENAZONE.

DICHLOROPHEN for human therapeutic use.

DICHLORPHENAMIDE.

DICLOFENAC **except**:

- (a) when included in Schedule 2 or 3; or
- (b) in preparations for dermal use.

DICLOXACILLIN.

DICYCLOMINE.

DIDANOSINE.

DIENESTROL.

DIENOGEST.

DIETHAZINE.

DIETHYLCARBAMAZINE for human therapeutic use.

DIETHYLPROPION.

DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5 per cent of the dose of difenoxin.

DIFLORASONE.

DIFLOXACIN.

DIFLUCORTOLONE.

DIFLUNISAL.

DIGITALIS LANATA.

SCHEDULE 4—continued

DIGITALIS PURPUREA.

DIGITOXIN.

DIGOXIN.

DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).

DIHYDRALAZINE.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

- (a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
- (b) in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine,

except when included in Schedule 2 or 3.

DIHYDROERGOTOXINE.

DIHYDROLONE.

DIHYDROSTREPTOMYCIN.

DIHYDROTACHYSTEROL.

† DI-iodohydroxyquinoline (iodoquinol) **except**:

- (a) when included in Schedule 3; or
- (b) for human internal use.

DIISOPROPYLAMINE DICHLOROACETATE.

DILTIAZEM.

DIMENHYDRINATE **except** when included in Schedule 2 or 3.

DIMERCAPROL.

DIMETHANDROSTANOLONE.

DIMETHAZINE.

SCHEDULE 4—continued

DIMETHINDENE **except** when included in Schedule 3.

DIMETHOTHIAZINE.

DIMETHOXANATE.

DIMETHYL SULFOXIDE for therapeutic use **except**:

- (a) when included in Schedule 6; or
- (b) in in-vitro test kits.

DIMETRIDAZOLE.

2,4-DINITROCHLOROBENZENE for therapeutic use.

DINITROCRESOLS for therapeutic use **except** when separately specified in these Schedules.

DINITRONAPHTHOLS for therapeutic use **except** when separately specified in these Schedules.

DINITROPHENOLS for therapeutic use.

DINITROTHYMOLS for therapeutic use **except** when separately specified in these Schedules.

DINOPROST.

DINOPROSTONE.

DIPERODON.

DIPHEMANIL **except** in preparations for dermal use.

DIPHENHYDRAMINE **except** when included in Schedule 2 or 3.

DIPHENIDOL.

DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate **except** when included in Schedule 3.

DIPHENYLPYRALINE.

DIPHThERIA TOXOID.

SCHEDULE 4—continued

DIPIVEFRIN.

DIPYRIDAMOLE.

DIRITHROMYCIN.

DIRLOTAPIDE.

DISOPHENOL.

DISOPYRAMIDE.

DISTIGMINE.

DISULFIRAM for therapeutic use.

DISULPHAMIDE.

DITHIAZANINE **except** when included in Schedule 6.

DITIOCARB.

DOBUTAMINE.

DOCETAXEL.

DOFETILIDE.

DOLASETRON.

DOMPERIDONE.

DONEPEZIL.

DOPAMINE.

DOPEXAMINE.

DORNASE.

DORZOLAMIDE.

DOTHIEPIN.

DOXANTRAZOLE.

DOXAPRAM.

SCHEDULE 4—continued

DOXAZOSIN.

DOXEPIN.

DOXORUBICIN.

DOXYCYCLINE.

DOXYLAMINE **except** when included in Schedule 2 or 3.

DROPERIDOL.

DROSPIRENONE.

DROSTANOLONE.

DROTRECOGIN.

DUBOISIA LEICHHARDTII **except** when included in Schedule 2.

DUBOISIA MYOPOROIDES **except** when included in Schedule 2.

DULOXETINE.

DUTASTERIDE.

DYDROGESTERONE.

ECONAZOLE **except**:

- (a) when included in Schedule 2, 3 or 6; or
- (b) in preparations for dermal use for the treatment of tinea pedis.

ECOTHIOPATE (includes ecothiopate iodide).

ECTYLUREA.

EDETIC ACID for human therapeutic use **except**:

- (a) in preparations containing 0.25 per cent or less of edetic acid;
- (b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or
- (c) in contact lens preparations.

EDOXUDINE.

SCHEDULE 4—continued

EDROPHONIUM.

EFALIZUMAB.

EFAVIRENZ.

EFLORNITHINE.

ELETRIPTAN.

ELTENAC.

EMEPRONIUM.

EMETINE **except** in preparations containing 0.2 per cent or less of emetine.

EMTRICITABINE.

ENALAPRIL.

ENESTEBOL.

ENFLURANE for therapeutic use.

ENFUVIRTIDE.

ENOXACIN.

ENOXAPARIN.

ENOXIMONE.

ENPROSTIL.

ENROFLOXACIN.

ENTACAPONE.

ENTECAVIR.

EPHEDRA spp. **except** in preparations containing 0.001 per cent or less of ephedrine.

EPHEDRINE.

EPICILLIN.

EPINASTINE.

SCHEDULE 4—continued

EPIRUBICIN.

EPITIOSTANOL.

EPLERENONE.

EPOETINS.

EPOPROSTENOL.

EPROSARTAN.

EPTIFIBATIDE.

ERGOMETRINE.

ERGOT.

ERGOTAMINE.

ERGOTOXINE.

ERLOTINIB.

ERTAPENEM.

ERYSIMUM spp.

ERYTHROMYCIN.

ERYTHROPOIETIN.

ERYTHROPOIETINS **except** when separately specified in these Schedules.

ESCITALOPRAM.

ESMOLOL.

ESOMEPRAZOLE.

ESTRAMUSTINE.

ESTROPIPATE (piperazine oestrone sulfate).

ETANERCEPT.

ETHACRYNIC ACID.

SCHEDULE 4—continued

ETHAMBUTOL.

ETHAMIVAN.

ETHANOLAMINE in preparations for injection.

ETHCHLORVYNOL.

ETHER for use in anaesthesia.

ETHINAMATE.

ETHINYLOESTRADIOL.

ETHIONAMIDE.

ETHISTERONE.

ETHOGLUCID.

ETHOHEPTAZINE.

ETHOPROPAZINE.

ETHOSUXIMIDE.

ETHOTOIN.

ETHOXZOLAMIDE.

ETHYL CHLORIDE for human therapeutic use.

ETHYLDIENOLONE.

† ETHYLHEXANEDIOL for animal use.

ETHYLMORPHINE when compounded with one or more other therapeutically active substances:

- (a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
- (b) in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine,

except when included in Schedule 2.

SCHEDULE 4—continued

ETHYLOESTRENOL.

ETHYNODIOL.

ETIDOCAINE.

ETIDRONIC ACID (includes disodium etidronate):

- (a) for internal use; or
- (b) in topical preparations **except** in preparations containing 1 per cent or less of etidronic acid.

ETILEFRIN.

ETIPROSTON.

ETODOLAC.

ETOFENAMATE **except** when included in Schedule 2.

ETONOGESTREL.

ETOPOSIDE.

ETORICOXIB.

ETRETINATE.

EVEROLIMUS.

EXEMESTANE.

EXENATIDE.

EZETIMIBE.

FAMCICLOVIR.

FAMOTIDINE **except** when included in Schedule 2.

FELBINAC **except** when included in Schedule 2.

FELODIPINE.

FELYPRESSIN.

SCHEDULE 4—continued

FENBUFEN.

FENCAMFAMIN.

FENCLOFENAC.

FENFLURAMINE.

FENOFIBRATE.

FENOLDOPAM.

FENOPROFEN.

FENOTEROL.

FENPIPRAMIDE.

FENPIPRANE.

FENPROPOREX.

FENPROSTALENE.

FEXOFENADINE **except** when included in Schedule 2.

FIBRINOLYSIN **except** for external use.

FILGRASTIM.

FINASTERIDE.

FIROCOXIB.

FLECAINIDE.

FLEROXACIN.

FLOCTAFENINE.

FLORFENICOL.

FLUANISONE.

FLUCLOROLONE.

FLUCLOXACILLIN.

SCHEDULE 4—continued

FLUCONAZOLE **except** when included in Schedule 3.

FLUCYTOSINE.

FLUDARABINE.

FLUDROCORTISONE.

FLUFENAMIC ACID.

FLUMAZENIL.

FLUMETHASONE.

FLUMETHIAZIDE.

FLUNISOLIDE.

FLUNIXIN MEGLUMINE.

FLUOCINOLONE.

FLUOCINONIDE.

FLUOCORTIN.

FLUOCORTOLONE.

FLUORESCEIN in preparations for injection.

FLUORIDES in preparations for human use **except** when included in or expressly excluded from Schedule 2 or 3.

FLUOROMETHOLONE.

FLUOROURACIL.

FLUOXETINE.

FLUOXYMESTERONE.

FLUPENTHIXOL.

FLUPHENAZINE.

FLUPROSTENOL.

FLURANDRENOLONE.

SCHEDULE 4—continued

FLURAZEPAM.

FLURBIPROFEN **except** when included in Schedule 2.

FLUROXENE for human therapeutic use.

FLUSPIRILENE.

FLUTAMIDE.

FLUTICASONE **except** when included in Schedule 2.

FLUVASTATIN.

FLUVOXAMINE.

FOLIC ACID in preparations for human use for injection.

FOLINIC ACID in preparations for human use for injection.

FOLLICLE-STIMULATING HORMONE **except** when separately specified in this Schedule.

FOLLITROPIN ALPHA.

FOLLITROPIN BETA.

FOMIVIRSEN.

FONDAPARINUX.

FORMEBOLONE.

FORMESTANE.

FORMOTEROL.

FOSAMPRENAVIR.

FOSAPREPITANT.

FOSCARNET.

FOSFESTROL (diethylstilboestrol diphosphate).

FOSINOPRIL.

SCHEDULE 4—continued

FOSPHENYTOIN.

FOTEMUSTINE.

FRAMYCETIN.

FULVESTRANT.

FURALTADONE.

FURAZABOL.

FURAZOLIDONE.

FUROSEMIDE (frusemide).

FUSIDIC ACID.

GABAPENTIN.

GALANTAMINE.

GALANTHUS spp.

GALLAMINE.

GALSULFASE.

GANCICLOVIR.

GANIRELIX.

GATIFLOXACIN.

GEFITINIB.

GEMCITABINE.

GEMEPROST.

GEMFIBROZIL.

GEMIFLOXACIN.

GENTAMICIN.

GESTODENE.

SCHEDULE 4—continued

GESTONORONE.

GESTRINONE.

GHRH INJECTABLE PLASMID.

GITALIN.

GLATIRAMER ACETATE.

GLIBENCLAMIDE.

GLIBORNURIDE.

GLICLAZIDE.

GLIMEPIRIDE.

GLIPIZIDE.

GLISOXEPIDE.

GLUTATHIONE for parenteral use.

GLUTETHIMIDE.

GLYCERYL TRINITRATE **except** when included in Schedule 3.

GLYCOPYRRONIUM in preparations for injection.

GLYMIDINE.

GnRH VACCINE.

GONADORELIN.

GONADOTROPHIC HORMONES **except** when separately specified in this Schedule.

GOSERELIN.

GRAMICIDIN.

GRANISETRON.

GREPAFLOXACIN.

SCHEDULE 4—continued

GRISEOFULVIN.

GUAIPHENESIN for human therapeutic use **except**:

- (a) in oral liquid preparations containing 2 per cent or less of guaiphenesin; or
- (b) in divided preparations containing 200 mg or less of guaiphenesin per dosage unit.

GUANABENZ.

GUANACLINE.

GUANETHIDINE.

GUANIDINE.

HACHIMYCIN.

HAEMATIN.

HAEMOPHILUS INFLUENZAE VACCINE.

HALCINONIDE.

HALOFANTRINE.

HALOFENATE.

HALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the treatment of animals.

HALOPERIDOL.

HALOTHANE for therapeutic use.

HEMEROCALLIS (Hemerocallis flava).

HEPARINS for internal use **except** when separately specified in this Schedule.

HEPATITIS A VACCINE.

HEPATITIS B VACCINE.

HETACILLIN.

SCHEDULE 4—continued

HEXACHLOROPHANE:

- (a) in preparations for use on infants; or
- (b) in other preparations **except**:
 - (i) when included in Schedule 2 or 6; or
 - (ii) in preparations containing 0.75 per cent or less of hexachlorophane.

HEXAMETHONIUM.

HEXETIDINE for human internal use.

HEXOBENDINE.

HEXOCYCLIUM.

HEXOPRENALINE.

HISTAMINE for therapeutic use **except** in preparations containing 0.5 per cent or less of histamine.

HOMATROPINE.

HUMAN CHORIONIC GONADATROPHIN **except** in pregnancy test kits.

HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation:

- (a) for tissue augmentation;
- (b) for cosmetic use; or
- (c) for the treatment of animals.

HYDRALAZINE.

HYDRARGAPHEN.

HYDROCHLOROTHIAZIDE.

HYDROCORTISONE:

- (a) for human use **except** when included in Schedule 2 or 3; or
- (b) for the treatment of animals.

SCHEDULE 4—continued

HYDROCYANIC ACID for therapeutic use.

HYDROFLUMETHIAZIDE.

HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use **except**:

- (a) when included in Schedule 2; or
- (b) in hair preparations containing 1 per cent or less of hydroquinone.

HYDROXYCHLOROQUINE.

HYDROXYEPHEDRINE.

HYDROXYPHENAMATE.

HYDROXYPROGESTERONE.

HYDROXYSTENOZOL.

HYDROXYUREA.

HYDROXYZINE.

HYGROMYCIN.

HYOSCINE **except** when included in Schedule 2.

HYOSCYAMINE **except** when included in Schedule 2.

HYOSCYAMUS NIGER **except**:

- (a) when included in Schedule 2; or
- (b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.

HYPOTHALAMIC RELEASING FACTORS **except** when separately specified in this Schedule.

HYPROMELLOSE in preparations for injection.

IBAFLOXACIN for veterinary use.

IBANDRONIC ACID.

IBRITUMOMAB.

SCHEDULE 4—continued

IBUFENAC.

IBUPROFEN **except**:

- (a) when included in or expressly excluded from Schedule 2 or 3; or
- (b) in preparations for dermal use.

IBUTEROL.

IBUTILIDE.

IDARUBICIN.

IDOXURIDINE **except** in preparations containing 0.5 per cent or less of idoxuridine for dermal use.

IDURSULFASE.

IFOSFAMIDE.

ILOPROST.

IMATINIB.

IMIDAPRIL.

IMIGLUCERASE.

IMIPENEM.

IMIPRAMINE.

IMIQUIMOD.

IMMUNOGLOBULINS for human parenteral use **except** when separately specified in these Schedules.

INDAPAMIDE.

INDINAVIR.

INDOMETHACIN **except** when included in Schedule 2.

INDOPROFEN.

INDORAMIN.

SCHEDULE 4—continued

INFLIXIMAB.

INFLUENZA AND CORYZA VACCINES:

- (a) for parenteral use; or
- (b) for nasal administration.

INSULIN-LIKE GROWTH FACTOR I.

INSULIN-LIKE GROWTH FACTORS **except** when separately specified in this Schedule.

INSULINS.

INTERFERONS.

INTERLEUKINS **except** when separately specified in these Schedules.

IODOTHIOURACIL.

IPRATROPIUM **except** when included in Schedule 2.

IPRIFLAVONE.

IPRINDOLE.

IPRONIAZID.

IRBESARTAN.

IRINOTECAN.

IRON COMPOUNDS in injectable preparations for human use.

ISOAMINILE.

ISOAMYL NITRITE.

ISOBUTYL NITRITE.

ISOCARBOXAZID.

ISOCONAZOLE **except** when included in Schedule 2, 3 or 6.

ISOETARINE.

SCHEDULE 4—continued

ISOFLURANE for therapeutic use.

ISOMETHEPTENE.

ISONIAZID.

ISOPRENALINE.

ISOPRINOSINE.

ISOPROPAMIDE **except** when included in Schedule 2.

ISOSORBIDE DINITRATE **except** when included in Schedule 3.

ISOSORBIDE MONONITRATE.

ISOTRETINOIN.

ISOXICAM.

ISOXSUPRINE.

ISRADIPINE.

ITRACONAZOLE.

IVABRADINE.

IVERMECTIN:

- (a) for human use; or
- (b) for the treatment of mange in dogs.

IXABEPILONE.

KANAMYCIN.

KETANSERIN **except** in topical veterinary preparations containing 0.5 per cent or less of ketanserin.

KETAZOLAM.

SCHEDULE 4—continued

KETOCONAZOLE except:

- (a) when included in Schedule 2;
- (b) in preparations for dermal use containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
- (c) in preparations for dermal use for the treatment of tinea pedis.

KETOPROFEN except:

- (a) in preparations for dermal use; or
- (b) when included in Schedule 3.

KETOROLAC (includes ketoralac trometamol).

KETOTIFEN **except** when included in Schedule 2.

KHELLIN.

KITASAMYCIN except:

- (a) when included in Schedule 5 ; or
- (b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.

LABETALOL.

LACIDIPINE.

LAMIVUDINE.

LAMOTRIGINE.

LANATOSIDES.

LANREOTIDE.

LANSOPRAZOLE.

LANTHANUM for therapeutic use.

LAPATINIB.

SCHEDULE 4—continued

LARONIDASE.

LAROPIPRANT.

LATAMOXEF.

LATANOPROST.

LAUDEXIUM.

LAUROMACROGOLS in preparations for injection **except**:

- (a) when present as an excipient; or
- (b) when separately specified in these Schedules.

† LEAD for human therapeutic use.

LEFETAMINE.

LEFLUNOMIDE.

LENALIDOMIDE.

LENOGRASTIM.

LEPIRUDIN.

LEPTAZOL.

LERCANIDIPINE.

LETROZOLE.

LEUPRORELIN.

LEVALLORPHAN.

LEVAMISOLE:

- (a) for human therapeutic use; or
- (b) in preparations for the prevention or treatment of heartworm in dogs.

LEVETIRACETAM.

LEVOBUNOLOL.

SCHEDULE 4—continued

LEVOBUPIVACAINE.

LEVOCABASTINE **except** when included in Schedule 2.

LEVODOPA.

LEVOMEPRMAZINE.

LEVONORGESTREL **except** when included in Schedule 3.

LEVOSIMENDAN.

LIDOFLAZINE.

LIGNOCAINE **except**:

- (a) when included in Schedule 2;
- (b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
- (c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

LINCOMYCIN.

LINDANE for human therapeutic use **except** when included in Schedule 2.

LINEZOLID.

LIOTHYRONINE.

LISINOPRIL.

LISURIDE.

LITHIUM for therapeutic use **except**:

- (a) when included in Schedule 2;
- (b) when present as an excipient in preparations for dermal use containing 0.25 per cent or less of lithium; or
- (c) in preparations containing 0.01 per cent or less of lithium.

LODOXAMIDE **except** when included in Schedule 2.

SCHEDULE 4—continued

LOFEXIDINE.

LOGIPARIN for internal use.

LOMEFLOXACIN.

LOMUSTINE.

LOPERAMIDE **except** when included in Schedule 2.

LOPINAVIR.

LOPRAZOLAM.

LORACARBEF.

LORATADINE **except** when included in Schedule 2.

LORAZEPAM.

LORMETAZEPAM.

LOSARTAN.

LOXAPINE.

LUMEFANTRINE.

LUMIRACOXIB.

LUTEINISING HORMONE **except** in ovulation test kits.

LYMECYCLINE.

MAFENIDE **except** when included in Schedule 6.

MANDRAGORA OFFICINARUM.

MANNOMUSTINE.

MAPROTILINE.

MARAVIROC.

MARBOFLOXACIN.

MAROPITANT.

SCHEDULE 4—continued

MAZINDOL.

MEASLES VACCINE.

MEBANAZINE.

MEBEVERINE.

MEBHYDROLIN.

MEBOLAZINE.

MEBUTAMATE.

MECAMYLAMINE.

MECASERMIN.

MECILLINAM.

MECLOCYCLINE.

MECLOFENAMATE.

MECLOFENOXATE.

MECLOZINE **except** when included in Schedule 2.

MEDAZEPAM.

MEDETOMIDINE.

MEDIGOXIN (methylidigoxin).

MEDROXYPROGESTERONE.

MEDRYSONE.

MEFENAMIC ACID **except** when included in Schedule 2.

MEFENOREX.

MEFLOQUINE.

MEFRUSIDE.

MEGESTROL.

SCHEDULE 4—continued

MELAGATRAN.

MELATONIN for human use.

MELENGESTROL **except** when included in Schedule 6.

MELOXICAM.

MELPHALAN.

MEMANTINE.

MENINGOCOCCAL VACCINE.

MENOTROPHIN.

MEPACRINE.

MEPENZOLATE.

MEPHENESIN.

MEPHENTERMINE.

MEPINDOLOL.

MEPITIOSTANE.

MEPIVACAINE.

MEPROBAMATE.

MEPTAZINOL.

MEPYRAMINE **except** when included in Schedule 2 or 3.

MEQUITAZINE.

MERCAPTOMERIN.

MERCAPTOPURINE.

MERCURY for cosmetic or therapeutic use **except**:

- (a) when separately specified in these Schedules; or
- (b) in a sealed device which prevents access to the mercury.

SCHEDULE 4—continued

MEROPENEM.

MERSALYL.

MESABOLONE.

MESALAZINE.

MESNA.

MESTANOLONE (androstalone).

MESTEROLONE.

MESTRANOL.

METANDIENONE.

METARAMINOL.

METENOLONE.

METERGOLINE.

METFORMIN.

METHACHOLINE.

METHACYCLINE.

METHALLENOESTRIL.

METHANDRIOL.

METHANTHELINIUM.

METHAZOLAMIDE.

METHDILAZINE **except** when included in Schedule 3.

METHENOLONE.

METHICILLIN.

METHIMAZOLE.

METHISAZONE.

SCHEDULE 4—continued

METHIXENE.

METHOCARBAMOL.

METHOHEXITONE.

METHOIN.

METHOTREXATE.

METHOXAMINE **except:**

- (a) when included in Schedule 2; or
- (b) in preparations for external use containing 1 per cent or less of methoxamine.

METHOXSALEN.

METHOXYFLURANE.

METHSUXIMIDE.

METHYCLOTHIAZIDE.

METHYL AMINOLEVULINATE.

#METHYLANDROSTANOLONE.

METHYLCLOSTEBOL.

METHYLDOPA.

METHYLENE BLUE in preparations for injection.

METHYLERGOMETRINE.

METHYL MERCURY for therapeutic use.

METHYLPENTYNOL.

METHYLPHENOBARBITONE.

METHYLPREDNISOLONE.

METHYL SALICYLATE in preparations for internal therapeutic use.

METHYLTESTOSTERONE.

SCHEDULE 4—continued

METHYLTHIOURACIL.

METHYLTRIENOLONE.

METHYPRYLONE.

METHYSERGIDE.

METOCLOPRAMIDE **except** when included in Schedule 3.

METOLAZONE.

METOPROLOL.

METRIBOLONE.

METRIFONATE (trichlorfon) for human therapeutic use.

METRONIDAZOLE.

METYRAPONE.

MEXILETINE.

MEZLOCILLIN.

MIANSERIN.

MIBEFRADIL.

MIBOLERONE.

MICONAZOLE **except:**

- (a) when included in Schedule 2, 3 or 6; or
- (b) in preparations for dermal use for the treatment of tinea pedis.

MIDAZOLAM.

MIDODRINE.

MIGLITOL.

MIGLUSTAT.

MILBEMYCIN OXIME **except** when included in Schedule 5.

SCHEDULE 4—continued

MILRINONE.

MINOCYCLINE.

MINOXIDIL **except** when included in Schedule 2.

MIRTAZAPINE.

MISOPROSTOL.

MITOBRONITOL.

MITOMYCIN.

MITOTANE.

MITOXANTRONE.

MITRATAPIDE.

MIVACURIUM CHLORIDE.

MOCLOBEMIDE.

MODAFINIL.

MOLGRAMOSTIM.

MOLINDONE.

MOMETASONE **except** when included in Schedule 2.

MONENSIN **except:**

- (a) when included in Schedule 5 or 6; or
- (b) in animal feeds containing 360 mg/kg or less of antibiotic substances.

MONOBENZONE and other alkyl ethers of hydroquinone for human therapeutic use or cosmetic use.

MONOCLONAL ANTIBODIES for therapeutic use **except:**

- (a) in diagnostic test kits; or
- (b) when separately specified in these Schedules.

SCHEDULE 4—continued

MONTELUKAST.

MOPERONE.

MORAZONE.

MORICIZINE.

MOTRAZEPAM.

MOTRETINIDE.

MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin **except** when included in Schedule 5.

MOXIFLOXACIN.

MOXONIDINE.

MUMPS VACCINE.

MUPIROCIN.

MURAGLITAZAR.

MUROMONAB.

MUSTINE (nitrogen mustard).

MYCOPHENOLIC ACID (includes mycophenolate mofetil).

NABUMETONE.

NADOLOL.

NADROPARIN.

NAFARELIN.

NAFTIDROFURYL.

NALBUPHINE.

NALIDIXIC ACID.

NALORPHINE.

SCHEDULE 4—continued

NALOXONE.

NALTREXONE.

NANDROLONE.

NAPROXEN **except** when included in Schedule 2.

NARASIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 100 mg/kg or less of antibiotic substances.

NARATRIPTAN.

NATALIZUMAB.

NATAMYCIN.

NATEGLINIDE.

NEBACUMAB.

NEDOCROMIL.

NEFAZODONE.

NEFOPAM.

NELFINAVIR (includes nelfinavir mesylate).

NEOMYCIN.

NEOSTIGMINE.

NEPAFENAC.

NERIUM OLEANDER.

NESIRITIDE.

NETILMICIN.

NEVIRAPINE.

NIALAMIDE.

SCHEDULE 4—continued

NICARDIPINE.

NICERGOLINE.

NICOFURANOSE.

NICORANDIL.

NICOTINE in preparations for human therapeutic use **except**:

- (a) when included in Schedule 2; or
- (b) for use as an aid in withdrawal from tobacco smoking in chewing gum, lozenges, or preparations for sublingual or transdermal use.

NICOTINIC ACID for human therapeutic use **except**:

- (a) when contained in other Schedules;
- (b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
- (c) nicotinamide.

NICOUMALONE.

NIFEDIPINE.

NIFENAZONE.

NIKETHAMIDE.

NILOTINIB.

NILUTAMIDE.

NIMESULIDE.

NIMODIPINE.

NIMORAZOLE.

NIRIDAZOLE.

NISOLDIPINE.

NITRAZEPAM.

SCHEDULE 4—continued

NITRENDIPINE.

NITRIC OXIDE for human therapeutic use.

NITROFURANTOIN.

NITROFURAZONE.

NITROUS OXIDE for therapeutic use.

NITROXOLINE.

NIZATIDINE **except** when included in Schedule 2.

NOMIFENSINE.

NORADRENALINE.

19-NORANDROSTENEDIOL.

19-NORANDROSTENEDIONE.

NORANDROSTENOLONE.

NORBOLETHONE.

NORCLOSTEBOL.

NORELGESTROMIN.

NORETHANDROLONE.

NORETHISTERONE.

NORFLOXACIN.

NORGESTREL.

NORMETHANDRONE.

NORTRIPTYLINE.

NOVOBIOCIN.

NOXIPTYLINE.

NYSTATIN **except** when included in Schedule 2 or 3.

SCHEDULE 4—continued

OCTAMYLAMINE.

OCTATROPINE.

OCTREOTIDE.

OCTYL NITRITE.

OESTRADIOL **except** when included in Schedule 5.

OESTRIOL.

OESTROGENS **except** when separately specified in these Schedules.

OESTRONE.

OFLOXACIN.

OLANZAPINE.

OLEANDOMYCIN **except**:

- (a) when included in Schedule 5; or
- (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

OLEANDRIN.

OLMESARTAN.

OLOPATADINE.

OLSALAZINE.

OMALIZUMAB.

OMEPRAZOLE.

ONDANSETRON.

OPIPRAMOL.

ORBIFLOXACIN.

ORCIPRENALINE.

SCHEDULE 4—continued

ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use **except**:

- (a) when separately specified in these Schedules; or
- (b) in preparations containing 2 per cent or less of malathion for external use.

ORLISTAT **except** when included in Schedule 3.

ORNIDAZOLE.

ORNIPRESSIN.

ORPHENADRINE.

ORTHOPTERIN.

OSELTAMIVIR.

OUABAIN.

OVANDROTONE.

OXABOLONE.

OXACILLIN.

OXALIPLATIN.

OXANDROLONE.

OXAPROZIN.

OXAZEPAM.

OXCARBAZEPINE.

OXEDRINE for human internal use **except** in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.

OXETACAINE (oxethazaine) **except** when included in Schedule 2.

OXICONAZOLE **except**:

- (a) when included in Schedule 2 or 3; or
- (b) in preparations for the treatment of tinea pedis.

SCHEDULE 4—continued

OXITROPIUM.

OXOLAMINE.

OXOLINIC ACID.

XPENTIFYLLINE (pentoxifylline).

XPRENOLOL.

OXYBUPROCAINE.

OXYBUTYNIN.

OXYMESTERONE.

OXYMETHOLONE.

OXYPHENBUTAZONE.

OXYPHENCYCLIMINE.

OXYPHENONIUM.

OXYTETRACYCLINE **except** when included in Schedule 5.

OXYTOCIN.

PACLITAXEL.

PALIFERMIN.

PALIPERIDONE.

PALIVIZUMAB.

PALONOSETRON.

PAMAQUIN.

PAMIDRONIC ACID (includes disodium pamidronate).

PANCREATIC ENZYMES **except**:

- (a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or
- (b) when separately specified in these Schedules.

SCHEDULE 4—continued

PANCURONIUM.

PANITUMUMAB.

PANTOPRAZOLE **except** when included in Schedule 3.

PAPAVERINE in preparations for injection.

PARACETAMOL:

- (a) when combined with aspirin or salicylamide or any derivative of these substances **except** when separately specified in these Schedules;
- (b) in slow release tablets or capsules containing more than 665 mg of paracetamol;
- (c) in non-slow release tablets or capsules containing more than 500 mg of paracetamol;
- (d) in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol; or
- (e) for injection.

PARALDEHYDE.

PARAMETHADIONE.

PARAMETHASONE.

PARECOXIB.

PARICALCITOL.

PAROMOMYCIN.

PAROXETINE.

PECAZINE.

PEFLOXACIN.

PEGAPTANIB.

PEGFILGRASTIM.

PEGINTERFERON.

SCHEDULE 4—continued

PEGVISOMANT.

PEMETREXED.

PEMOLINE.

PENPIDINE.

PENBUTOLOL.

PENCICLOVIR **except** when included in Schedule 2.

PENETHAMATE.

PENICILLAMINE.

PENTAERYTHRITYL TETRANITRATE.

PENTAGASTRIN.

PENTAMETHONIUM.

PENTAMIDINE (includes pentamidine isethionate).

PENTHIENATE.

PENTOBARBITONE when packed and labelled for injection.

PENTOLINIUM.

PENTOSAN POLYSULFATE SODIUM.

PERGOLIDE.

PERHEXILINE.

PERICYAZINE.

PERINDOPRIL.

PERMETHRIN for human therapeutic use **except** in preparations containing 5 per cent or less of permethrin.

PERPHENAZINE.

PERTUSSIS ANTIGEN.

SCHEDULE 4—continued

PHENACEMIDE.

PHENACETIN for therapeutic use (excluding when present as an excipient).

PHENAGLYCODOL.

PHENAZONE **except** when included in Schedule 2 or 5.

PHENAZOPYRIDINE.

PHENELZINE.

PHENETICILLIN.

PHENFORMIN.

PHENGLUTARIMIDE.

PHENINDIONE.

PHENIRAMINE **except** when included in Schedule 2 or 3.

PHENISATIN.

PHENOBARBITONE.

PHENOL in preparations for injection.

PHENOLPHTHALEIN for human therapeutic use.

PHENOXYBENZAMINE.

PHENOXYMETHYLPENICILLIN.

PHENSUXIMIDE.

PHENTERMINE.

PHENTHIMENTONIUM.

PHENTOLAMINE.

PHENYLBUTAZONE.

SCHEDULE 4—continued

PHENYLEPHRINE:

- (a) in preparations for injection; or
- (b) in preparations for human ophthalmic use containing 5 per cent or more of phenylephrine.

PHENYLPROPANOLAMINE.

PHENYLTOLOXAMINE.

PHENYTOIN.

PHOLCODINE:

- (a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or
- (b) in undivided preparations containing 2.5 per cent or less of pholcodine, **except** when included in Schedule 2.

PHTHALYLSULFATHIAZOLE.

PHYSOSTIGMINE.

PICROTOXIN.

PILOCARPINE **except** in preparations containing 0.025 per cent or less of pilocarpine.

PIMECROLIMUS.

PIMOBENDAN.

PIMOZIDE.

PINACIDIL.

PINDOLOL.

PIOGLITAZONE.

PIPECURONIUM.

PIPEMIDIC ACID.

SCHEDULE 4—continued

PIPENZOLATE.

PIPER METHYSTICUM (kava) in preparations for human use **except** when included on the Australian Register of Therapeutic Goods in preparations:

- (a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:
 - (i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or
 - (ii) the amount of dried whole or peeled rhizome in the teabag does not exceed 3 g;

and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

- (b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome; or
- (c) in dermal preparations.

PIPERACILLIN.

PIPERIDINE.

PIPERIDOLATE.

PIPOBROMAN.

PIPOTHIAZINE.

PIPRADROL.

PIRACETAM.

PIRBUTEROL.

PIRENOXINE (catalin).

PIRENZEPINE.

PIRETANIDE.

SCHEDULE 4—continued

PIROXICAM **except** in preparations for dermal use.

PIRPROFEN.

PITUITARY HORMONES **except** when separately specified in these Schedules.

PIVAMPICILLIN.

PIZOTIFEN.

PLICAMYCIN.

PNEUMOCOCCAL VACCINE.

PODOPHYLLOTOXIN for human use:

- (a) internally;
- (b) in preparations for the treatment of anogenital warts; or
- (c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM EMODI (podophyllin) for human use:

- (a) internally;
- (b) in preparations for the treatment of anogenital warts; or
- (c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM PELTATUM (podophyllin) for human use:

- (a) internally;
- (b) in preparations for the treatment of anogenital warts; or
- (c) in other preparations **except** when included in Schedule 2 or 3.

POLIDEXIDE.

POLIOMYELITIS VACCINE.

POLYACRYLAMIDE in preparations for injection or implantation:

- (a) for tissue augmentation; or
- (b) for cosmetic use.

SCHEDULE 4—continued

POLYESTRADIOL.

POLYLACTIC ACID in preparations for injection or implantation:

- (a) for tissue augmentation; or
- (b) for cosmetic use.

POLYMYXIN.

POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, **except** when separately specified in these Schedules.

POLYTHIAZIDE.

PORACTANT.

POSACONAZOLE.

POTASSIUM BROMIDE for therapeutic use.

POTASSIUM CHLORIDE in oral preparations for human therapeutic use **except**:

- (a) when containing less than 550 mg of potassium chloride per dosage unit;
- (b) in preparations for oral rehydration therapy;
- (c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or
- (d) in preparations for enteral feeding.

POTASSIUM PERCHLORATE for therapeutic use.

PRACTOLOL.

PRALIDOXIME.

PRAMIPEXOLE.

PRAMOCAINE.

PRAMPINE.

PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).

PRAVASTATIN.

SCHEDULE 4—continued

PRAZEPAM.

PRAZIQUANTEL for human therapeutic use.

PRAZOSIN.

PREDNISOLONE.

PREDNISON.

PREGABALIN.

PREGNENOLONE.

PRENALTEROL.

PRENYLAMINE.

PRILOCAINE **except** when included in Schedule 2.

PRIMAQUINE.

PRIMIDONE.

PROBENECID.

PROBUCOL.

PROCAINAMIDE.

PROCAINE.

PROCAINE PENICILLIN.

PROCARBAZINE.

PROCHLORPERAZINE **except** when included in Schedule 3.

PROCYCLIDINE **except** when included in Schedule 2.

PROGESTERONE **except** when included in Schedule 5.

PROGESTOGENS **except** when separately specified in these Schedules.

PROGLUMIDE.

PROGUANIL.

SCHEDULE 4—continued

PROLINTANE.

PROMAZINE.

PROMETHAZINE **except** when included in Schedule 2 or 3.

PROMOXOLANE.

PROPAFENONE.

PROPAMIDINE for therapeutic use **except** when included in Schedule 2.

PROPANIDID.

PROPANTHELINE.

PROPENTOFYLLINE.

PROPETANDROL.

PROPIONIBACTERIUM ACNES for therapeutic use.

PROPOFOL.

PROPRANOLOL.

PROPYLHEXEDRINE.

PROPYLTHIOURACIL.

PROPYPHENAZONE.

PROQUAZONE.

PROSCILLARIDIN.

PROSTAGLANDINS **except** when separately specified in this Schedule.

PROSTIANOL.

PROTAMINE.

PROTHIONAMIDE.

PROTHIPENDYL.

PROTIRELIN.

SCHEDULE 4—continued

PROTOVERATRINES.

PROTRIPTYLINE.

PROXYMETACAINE.

PSEUDOEPHEDRINE **except** when included in Schedule 3.

PYRAZINAMIDE.

PYRIDINOLCARBAMATE.

PYRIDOSTIGMINE.

PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use **except**:

- (a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.

PYRIMETHAMINE.

PYROVALERONE.

PYRVINIUM.

QUAZEPAM.

QUETIAPINE.

QUINAGOLIDE.

QUINAPRIL.

QUINBOLONE.

QUINETHAZONE.

QUINIDINE.

QUININE for human therapeutic use **except** when the maximum recommended daily dose is 50 mg or less of quinine.

SCHEDULE 4—continued

QUINISOCAINE (dimethisoquin).

QUINUPRISTIN.

RABEPRAZOLE.

RABIES VACCINE.

RACTOPAMINE **except** when included in Schedule 5.

RALOXIFENE.

RALTEGRAVIR.

RALTITREXED.

RAMIPRIL.

RANIBIZUMAB.

RANITIDINE **except**:

- (a) when included in Schedule 2; or
- (b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer's original pack containing not more than 14 dosage units.

RAPACURONIUM.

RASAGILINE.

RASBURICASE.

RAUWOLFIA SERPENTINA.

RAUWOLFIA VOMITORIA.

RAZOXANE.

REBOXETINE.

REMOXIPRIDE.

REPAGLINIDE.

RESERPINE.

SCHEDULE 4—continued

RETEPLASE.

RIBAVIRIN.

RIFABUTIN.

RIFAMPICIN.

RIFAMYCIN.

RIFAPENTINE.

RILUZOLE.

RIMEXOLONE.

RIMITEROL.

RIMONABANT.

RISEDRONIC ACID.

RISPERIDONE.

RITODRINE.

RITONAVIR.

RITUXIMAB.

RIVASTIGMINE.

RIZATRIPTAN.

ROCURONIUM.

ROFECOXIB.

ROLITETRACYCLINE.

ROMIFIDINE.

ROMIPLOSTIM.

RONIDAZOLE.

SCHEDULE 4—continued

ROPINIROLE.

ROPIVACAINE.

ROSIGLITAZONE.

ROSOXACIN.

ROSUVASTATIN.

ROTIGOTINE.

ROXIBOLONE.

ROXITHROMYCIN.

RUBELLA VACCINE.

RUBOXISTAURIN.

SALBUTAMOL **except** when included in Schedule 3.

SALCATONIN.

SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.

SALINOMYCIN **except**:

- (a) when included in Schedule 6; or
- (b) in animal feeds containing 60 mg/kg or less of antibiotic substances.

SALMETEROL.

SAQUINAVIR.

SCHOENOCAULON OFFICINALE (sabadilla) **except** in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of *Schoenocaulon officinale*.

SCOPOLIA CARNIOLICA for therapeutic use.

SELEGILINE.

SCHEDULE 4—continued

SELENIUM:

- (a) for human oral use with a recommended daily dose of more than 300 micrograms; or
- (b) for the treatment of animals **except**:
 - (i) when included in Schedule 6 or 7;
 - (ii) in solid, slow release bolus preparations each weighing 100 g or more and containing 300 mg or less of selenium per dosage unit;
 - (iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit;
 - (iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or
 - (v) in feeds containing 1 g/tonne or less of selenium

SERMORELIN.

SERTINDOLE.

SERTRALINE.

SEVELAMER.

SEVOFLURANE.

SEX HORMONES and all substances having sex hormonal activity **except** when separately specified in these Schedules.

SIBUTRAMINE.

SILANDRONE.

SILDENAFIL.

SILICONES for intra-ocular use.

SILVER SULFADIAZINE.

SIMVASTATIN.

SIROLIMUS.

SCHEDULE 4—continued

SISOMICIN (sisomycin).

SITAGLIPTIN.

SITAXENTAN.

SODIUM BROMIDE for therapeutic use.

SODIUM CELLULOSE PHOSPHATE for human internal use.

SODIUM CROMOGLYCATE **except** when included in Schedule 2.

SODIUM MORRHUATE in preparations for injection.

SODIUM NITROPRUSSIDE for human therapeutic use.

SODIUM PHOSPHATE in preparations for oral laxative use.

SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.

SODIUM SALICYLATE in preparations for injection for the treatment of animals.

SODIUM TETRADECYLSULFATE in preparations for injection.

SOLASODINE.

SOLIFENACIN.

SOMATOSTATIN.

SOMATOTROPIN EQUINE.

SOMATROPIN (human growth hormone).

SONTOQUINE.

SORAFENIB.

SOTALOL.

SPARFLOXACIN.

SPARTEINE.

SPECTINOMYCIN.

SPIRAMYCIN.

SCHEDULE 4—continued

SPIRAPRIL.

SPIRONOLACTONE.

STANOLONE.

STANOZOLOL.

STAVUDINE.

STENBOLONE.

STEROID HORMONES **except** when separately specified in these Schedules.

STILBOESTROL (diethylstilboestrol).

STREPTODORNASE.

STREPTOKINASE.

STREPTOMYCIN.

STRONTIUM RANELATE.

STROPHANTHINS.

STROPHANTHUS spp.

STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of animals.

STRYCHNOS spp. **except** in preparations containing 1 mg or less per litre or per kilogram of strychnine.

STYRAMATE.

SULBACTAM.

SULCONAZOLE **except** when included in Schedule 2.

SULFACETAMIDE **except** when included in Schedule 3 or 5.

SULFADIAZINE **except** when included in Schedule 5.

SULFADIMETHOXINE.

SULFADIMIDINE **except** when included in Schedule 5.

SCHEDULE 4—continued

SULFADOXINE.

SULFAFURAZOLE.

SULFAGUANIDINE.

SULFAMERAZINE **except** when included in Schedule 5.

SULFAMETHIZOLE.

SULFAMETHOXAZOLE.

SULFAMETHOXYDIAZINE.

SULFAMETHOXYPYRIDAZINE.

SULFAMETROLE.

SULFAMONOMETHOXINE.

SULFAMOXOLE.

SULFAPHENAZOLE.

SULFAPYRIDINE.

SULFAQUINOXALINE.

SULFASALAZINE.

SULFATHIAZOLE **except** when included in Schedule 5.

SULFATROXAZOLE.

SULFINPYRAZONE.

SULFOMYXIN.

SULFONAMIDES **except**:

- (a) when separately specified in this Schedule; or
- (b) when included in Schedule 3, 5 or 6.

SULFONMETHANE (sulfonal) and alkyl sulfonals.

SULINDAC.

SCHEDULE 4—continued

SULTAMICILLIN.

SULTHIAME.

SUMATRIPTAN.

SUNITINIB.

SUPROFEN.

SUTILAINS.

SUXAMETHONIUM.

SUXETHONIUM.

TACRINE.

TACROLIMUS.

TADALAFIL.

TAMOXIFEN.

TAMSULOSIN.

TANACETUM VULGARE **except** in preparations containing 0.8 per cent or less of oil of tansy.

TASONERMIN.

TAZAROTENE.

TAZOBACTAM.

T-CELL RECEPTOR ANTIBODY.

TEGAFUR.

TEGASEROD.

TELITHROMYCIN.

TEICoplanin.

TELbivudine.

SCHEDULE 4—continued

TELMISARTAN.

TEMAZEPAM.

TEMOZOLOMIDE.

TEMSIROLIMUS.

TENECTEPLASE.

TENIPOSIDE.

TENOFOVIR.

TENOXICAM.

TEPOXALIN.

TERAZOSIN.

TERBINAFINE **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for dermal use for the treatment of tinea pedis.

TERBUTALINE **except** when included in Schedule 3.

TERFENADINE.

TERIPARATIDE.

TERLIPRESSIN.

TERODILINE.

TEROPTERIN.

TESTOLACTONE.

TESTOSTERONE **except** when included in Schedule 6.

TETANUS ANTITOXIN **except** when used for short-term protection or treatment of tetanus in animals.

TETANUS TOXOID for human use.

SCHEDULE 4—continued

TETRABENAZINE.

TETRACOSACTRIN.

TETRACYCLINE **except** when included in Schedule 5.

TETRAETHYLAMMONIUM.

TETROXOPRIM.

THALIDOMIDE.

THENYLDIAMINE.

THEOPHYLLINE **except** when included in Schedule 3.

THEVETIA PERUVIANA.

THEVETIN.

THIACETARSAMIDE in preparations for the prevention or treatment of heart worm in dogs.

THIAMBUTOSINE.

THIAZOSULFONE.

THIETHYLPERAZINE.

THIOACETAZONE.

THIOCARLIDE.

THIOGUANINE.

THIOMESTERONE (tiomesterone).

THIOPENTONE.

THIOPROPAZATE.

THIOPROPERAZINE.

THIORIDAZINE.

THIOSTREPTON.

SCHEDULE 4—continued

THIOTEPA.

THIOTHIXENE.

THIOURACIL.

THIOUREA for therapeutic use **except** in preparations containing 0.1 per cent or less of thiourea.

THYMOXAMINE (includes thymoxamine hydrochloride).

THYROID **except** when separately specified in this Schedule.

THYROTROPHIN.

THYROXINE (includes thyroxine sodium).

TIAGABINE.

TIAMULIN.

TIAPROFENIC ACID.

TIARAMIDE.

TIBOLONE.

TICARCILLIN.

TICLOPIDINE.

TIEMONIUM.

TIENILIC ACID.

TIGECYCLINE.

TIGLOIDINE.

TILETAMINE.

TILMICOSIN.

TILUDRONIC ACID (includes disodium tiludronate).

TIMOLOL.

SCHEDULE 4—continued

TINIDAZOLE.

TINZAPARIN (includes tinzaparin sodium).

TIOCONAZOLE **except:**

- (a) when included in Schedule 2 or 3; or
- (b) in preparations for dermal use for the treatment of tinea pedis.

TIOTROPIUM.

TIPEPIDINE.

TIPRANAVIR.

TIRILAZAD.

TIROFIBAN.

TOBRAMYCIN.

TOCAINIDE.

TOLAZAMIDE.

TOLAZOLINE.

TOLBUTAMIDE.

TOLCAPONE.

TOLFENAMIC ACID.

TOLMETIN.

TOLONIUM.

TOLPROPAMINE.

TOLRESTAT.

TOLTERODINE.

TOPIRAMATE.

TOPOTECAN.

SCHEDULE 4—continued

TORASEMIDE.

TOREMIFENE.

TOXOIDS for human parenteral use **except** when separately specified in these Schedules.

TRAMADOL.

TRANDOLAPRIL.

TRANEXAMIC ACID.

TRANYLCPROMINE.

TRASTUZUMAB.

TRAVOPROST.

TRAZODONE.

TRENBOLONE (trienbolone, trienolone) **except** when included in Schedule 5.

TREOSULPHAN.

TREPROSTINIL.

TRESTOLONE.

TRETAMINE.

TRETINOIN.

TRIACETYLOLEANDOMYCIN.

TRIAMCINOLONE **except** when included in Schedule 2 or 3.

TRIAMTERENE.

TRIAZQUONE.

TRIAZOLAM.

TRICHLORMETHIAZIDE.

TRICHLOROACETIC ACID for human dermal use **except** when in preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

SCHEDULE 4—continued

TRICHLOROETHYLENE for therapeutic use.

TRICLOFOS.

TRICYCLAMOL.

TRIDIHEXETHYL.

TRIFLUOPERAZINE.

TRIFLUPERIDOL.

TRIFLUPROMAZINE.

TRILOSTANE.

TRIMEPRAZINE **except** when included in Schedule 2 or 3.

TRIMETAPHAN.

TRIMETHOPRIM.

TRIMIPRAMINE.

TRIMUSTINE.

TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.

TRIOXYSALEN.

TRIPLENNAMINE.

TRIPLE ANTIGEN VACCINE.

TRIPROLIDINE **except** when included in Schedule 2 or 3.

TRIPTORELIN.

TROGLITAZONE.

TROMETAMOL in preparations for injection **except** in preparations containing
3 per cent or less of trometamol.

TROPICAMIDE.

TROPISETRON.

SCHEDULE 4—continued

TROVAFLOXACIN.

TROXIDONE.

TRYPTOPHAN for human therapeutic use **except** in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.

TUBOCURARINE.

TULATHROMYCIN.

TULOBUTEROL.

TYLOSIN **except**:

- (a) when included in Schedule 5;
- (b) in animal feeds containing 50 mg/kg or less of antibiotic substances:
 - (i) for growth promotion;
 - (ii) for the prevention of liver abscesses in cattle; or
 - (iii) for the prevention of ileitis in pigs; or
- (c) in milk replacers for calves, or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.

TYPHOID VACCINE.

UNOPROSTONE.

URACIL.

URAPIDIL.

URETHANE (excluding its derivatives) for therapeutic use.

UROFOLLITROPIN.

UROKINASE.

URSODEOXYCHOLIC ACID.

VACCINES for human therapeutic use **except** when separately specified in this Schedule.

SCHEDULE 4—continued

VACCINES, veterinary live virus **except**:

- (a) poultry vaccines;
- (b) pigeon pox vaccine; or
- (c) scabby mouth vaccine.

VALACICLOVIR.

VALDECOXIB.

VALGANCICLOVIR.

VALNOCTAMIDE.

VALPROIC ACID.

VALSARTAN.

VANCOMYCIN.

VARDENAFIL.

VARENICLINE.

VARICELLA VACCINE.

VASOPRESSIN.

VECURONIUM.

VEDAPROFEN.

VENLAFAXINE.

VERAPAMIL.

VERATRUM spp. **except** when separately specified in this Schedule.

VERTEPORFIN.

VIDARABINE.

VIGABATRIN.

SCHEDULE 4—continued

VILDAGLIPTIN.

VILOXAZINE.

VINBLASTINE.

VINCAMINE.

VINCRISTINE.

VINDESINE.

VINORELBINE.

VINYL ETHER for therapeutic use.

VIRGINIAMYCIN **except** when included in Schedule 5.

VISNADINE.

VITAMIN A for human therapeutic or cosmetic use **except**:

- (a) in preparations for topical use containing 1 per cent or less of vitamin A;
- (b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of vitamin A per daily dose; or
- (c) in preparations for parenteral nutrition replacement.

VITAMIN D for human internal therapeutic use **except** in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.

VORICONAZOLE.

WARFARIN for therapeutic use.

XAMOTEROL.

XANTHINOL NICOTINATE.

XIMELAGATRAN.

XIPAMIDE.

XYLAZINE.

SCHEDULE 4—continued

YOHIMBINE.

ZAFIRLUKAST.

ZALCITABINE.

ZALEPLON.

ZANAMIVIR.

ZERANOL **except** when included in Schedule 6.

ZIDOVUDINE.

ZILPATEROL.

ZIMELDINE.

ZINC COMPOUNDS for human internal use **except**:

- (a) in preparations with a recommended daily dose of 25 mg or less of zinc; or
- (b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

ZIPRASIDONE.

ZOLAZEPAM.

ZOLEDRONIC ACID.

ZOLMITRIPTAN.

ZOLPIDEM.

ZONISAMIDE.

ZOPICLONE.

ZOXAZOLAMINE.

ZUCLOPENTHIXOL.

SCHEDULE 5

(Substances marked † are listed in Appendix C)

ABAMECTIN in preparations, for internal use for the treatment of animals, containing 1 per cent or less of abamectin.

ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid (CH_3COOH) **except**:

- (a) when included in Schedule 2 or 6; or
- (b) for therapeutic use.

ACETONE **except** in preparations containing 25 per cent or less of designated solvents.

ACRIFLAVINE in preparations for veterinary use containing 2.5 per cent or less of acriflavine.

AKLOMIDE.

ALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less of albendazole **except** in intraruminal implants each containing 3.85 g or less of albendazole.

† ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:

- (a) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is more than 11.5;
- (b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5;
- (c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
- (d) in liquid or semi-solid preparations the pH of which is more than 11.5,

except when separately specified in these Schedules.

ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50 per cent or less of alkoxyated fatty alkylamine polymer **except** in preparations containing 20 per cent or less of alkoxyated fatty alkylamine polymer.

SCHEDULE 5—continued

ALLETHRIN in preparations containing 10 per cent or less of allethrin **except**:

- (a) in insecticidal mats; or
- (b) in other preparations containing 1 per cent or less of allethrin.

ALLOXYDIM.

ALPHA-CYPERMETHRIN:

- (a) in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or
- (b) in other preparations containing 1.5 per cent or less of alpha-cypermethrin.

AMETRYN.

AMINACRINE in preparations for veterinary use containing 2.5 per cent or less of aminacrine.

AMINES for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

AMITROLE.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5 per cent or less of ammonia **except**:

- (a) in preparations for human internal therapeutic use;
- (b) in preparations for inhalation when absorbed in an inert solid material; or
- (c) in preparations containing 0.5 per cent or less of free ammonia.

AMMONIUM THIOCYANATE **except** in preparations containing 10 per cent or less of ammonium thiocyanate.

ANHYDRIDES, ORGANIC ACID, for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

ANISE OIL **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

SCHEDULE 5—continued

- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

- (c) in preparations containing 50 per cent or less of anise oil.

ASPIRIN for the treatment of animals, in divided preparations when packed in blister or strip packaging or in a container with a child-resistant closure.

ATRAZINE.

† AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, for agricultural use.

AZOXYSTROBIN.

BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed *Pseudomonas fluorescens*.

BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq.cm.

BASIL OIL **except:**

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

- (c) in preparations containing 5 per cent or less of methyl chavicol.

BEAUVERIA BASSIANA in preparations containing 1×10^8 Colony Forming Units (CFU)/mL or less of *Beauveria bassiana*.

BENALAXYL.

BENDIOCARB in preparations containing 2 per cent or less of bendiocarb.

SCHEDULE 5—continued

BENTAZONE.

BENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkonium chloride **except** in preparations containing 5 per cent or less of benzalkonium chloride.

BENZOFENAP.

BENZOYL PEROXIDE **except**:

- (a) when included in Schedule 2 or 4; or
- (b) in preparations containing 5 per cent or less of benzoyl peroxide.

BERGAMOT OIL **except**:

- (a) when steam distilled or rectified;
- (b) in preparations for internal use;
- (c) in preparations containing 0.4 per cent or less of bergamot oil;
- (d) in soaps or bath or shower gels that are washed off the skin;
- (e) in medicines for human therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (f) in other preparations when packed in containers labelled with the statement:
Application to the skin may increase sensitivity to sunlight.

BETACYFLUTHRIN:

- (a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin; or
- (b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.

BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 0.3 per cent or less of total bifluorides.

BIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin **except** in preparations containing 1 per cent or less of bioallethrin.

BIORESMETHRIN **except** in preparations containing 10 per cent or less of bioresmethrin.

SCHEDULE 5—continued

BORIC ACID (excluding its salts) and BORAX **except**:

- (a) when included in Schedule 4;
- (b) in preparations, other than insect baits, containing 1 per cent or less of boron; or
- (c) in hand cleaning preparations.

BORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron trifluoride (BF₃).

BROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole.

BUPROFEZIN **except** in preparations containing 40 per cent or less of buprofezin.

BUTHIDAZOLE.

BUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.

BUTRALIN.

BUTROXYDIM.

CAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor **except**:

- (a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

- (c) in rosemary oil, sage oil (Spanish), or lavandin oils; or
- (d) in preparations containing 2.5 per cent or less of camphor.

CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide peroxide **except** in preparations containing 9 per cent or less of carbamide peroxide.

SCHEDULE 5—continued

CARBARYL:

- (a) in preparations containing 10 per cent or less of carbaryl **except** when included in Schedule 4; or
- (b) when impregnated into plastic resin material containing 20 per cent or less of carbaryl.

CASSIA OIL **except**:

- (a) in food additives; or
- (b) in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia oil; or
- (c) in other preparations containing 2 per cent or less of cassia oil.

CHLORFENAC.

CHLORFENSON.

CHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine **except**:

- (a) in preparations containing 1 per cent or less of chlorhexidine; or
- (b) when in solid preparations.

CHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, **except**:

- (a) when separately specified in these Schedules;
- (b) sodium hypochlorite preparations with a pH of less than 11.5;
- (c) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

- (d) liquid preparations containing less than 2 per cent of available chlorine; or
- (e) other preparations containing 4 per cent or less of available chlorine.

CHLORNIDINE.

SCHEDULE 5—continued

CHLOROCRESOL **except** in preparations containing 3 per cent or less of chlorocresol.

CHLORPROPHAM.

CHLORPYRIFOS:

- (a) in aqueous preparations containing 20 per cent or less of microencapsulated chlorpyrifos;
- (b) in controlled release granular preparations containing 10 per cent or less of chlorpyrifos; or
- (c) in other preparations containing 5 per cent or less of chlorpyrifos,

except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORSULFURON.

CHLORTETRACYCLINE in preparations:

- (a) for topical application to animals for ocular use only; or
- (b) containing 40 per cent or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

CHLORTHAL-DIMETHYL.

CINMETHYLIN.

CINNAMON BARK OIL **except**:

- (a) in food additives; or
- (b) in preparations containing 2 per cent or less of cinnamon bark oil.

CLETHODIM.

CLIMBAZOLE in preparations containing 40 per cent or less of climbazole **except** in preparations containing 2 per cent or less of climbazole.

CLOFENTEZINE.

CLOPYRALID.

SCHEDULE 5—continued

CLOQUINTOCET-MEXYL.

CLORSULON.

CLOTHIANIDIN in preparations containing 20 per cent or less of clothianidin.

CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil **except** in preparations containing 25 per cent or less of clove oil.

COPPER ACETATE in preparations containing 20 per cent or less of copper acetate **except** in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS in animal feed additives containing 5 per cent or less of copper **except** in preparations containing 1 per cent or less of copper.

COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide **except** in preparations containing 12.5 per cent or less of copper hydroxide.

COPPER OXIDES in preparations containing 25 per cent or less of copper oxides **except**:

- (a) in preparations for internal use;
- (b) in marine paints; or
- (c) in other preparations containing 5 per cent or less of copper oxides.

COPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper oxychloride **except** in preparations containing 12.5 per cent or less of copper oxychloride.

COPPER SULFATE in preparations containing 15 per cent or less of copper sulfate **except**:

- (a) in preparations for internal use; or
- (b) in other preparations containing 5 per cent or less of copper sulfate.

COUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl.

4-CPA.

CYANATRYN.

SCHEDULE 5—continued

CYANOACRYLATE ESTERS in contact adhesives **except**:

- (a) when labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or

- (b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:

- (i) labelled with the approved name or trade name of the poison, the quantity and the warning:

Can cause eye injury. Instantly bonds skin; and

- (ii) enclosed in a primary pack labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.

CYANURIC ACID (excluding its salts and derivatives).

CYCLOHEXANONE PEROXIDE.

CYCLOPROTHRIN **except** in preparations containing 10 per cent or less of cycloprothrin.

CYCLOXYDIM.

CYFLUTHRIN:

- (a) in wettable powders containing 10 per cent or less of cyfluthrin;
 (b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or
 (c) in emulsions containing 5 per cent or less of cyfluthrin.

CYHALOFOP-BUTYL.

CYMIAZOLE.

SCHEDULE 5—continued

CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin.

CYPHENOTHHRIN in preparations containing 10 per cent or less of cyphenothrin.

CYPROCONAZOLE **except** in preparations containing 10 per cent or less of cyproconazole.

CYPRODINIL.

CYSTEAMINE in cosmetic preparations containing 6 per cent or less of cysteamine **except** in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE for the treatment of animals:

- (a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or
- (b) in undivided preparations containing 5 per cent or less of cythioate.

2,4-D in preparations containing 20 per cent or less of 2,4-D.

DAMINOZIDE.

2,4-DB.

DELTAMETHRIN:

- (a) in aqueous preparations containing 5 per cent or less of deltamethrin when no organic solvent other than a glycol is present;
- (b) in wetttable granular preparations containing 25 per cent or less of deltamethrin when packed in child-resistant packaging each containing 3 g or less of the formulation;
- (c) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or
- (d) in other preparations containing 0.5 per cent or less of deltamethrin.

DEMBREXINE in oral preparations for the treatment of animals.

2,4-DES.

DIAFENTHIURON.

N,N-DIALLYLDICHLOROACETAMIDE **except** in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide.

SCHEDULE 5–continued

DIAZINON in dust preparations containing 2 per cent or less of diazinon.

DICAMBA (including its salts and derivatives) in preparations containing 20 per cent or less of dicamba.

DICHLONE.

para-DICHLOROBENZENE.

DICHLOROISOCYANURIC ACID containing 40 per cent or less of available chlorine, **except** in:

- (a) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

- (b) liquid preparations containing less than 2 per cent of available chlorine; or
- (c) other preparations containing 4 per cent or less of available chlorine.

DICHLOROMETHANE (methylene chloride) **except**:

- (a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10 per cent or less of dichloromethane;
- (b) in other preparations in pressurised spray packs; or
- (c) in paints and tinters containing 5 per cent or less of dichloromethane.

DICHLOROPHEN for the treatment of animals.

DICHLORVOS:

- (a) when impregnated in plastic resin strip material containing 20 per cent or less of dichlorvos;
- (b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals; or
- (c) in pressurised spray packs containing 10 grams or less of dichlorvos.

DICLOBUTRAZOL.

DICLORAN.

SCHEDULE 5—continued

DICOFOL.

DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of diethanolamine **except** in preparations containing 5 per cent or less of diethanolamine.

DIETHYLENE GLYCOL MONOBUTYL ETHER **except** in preparations containing 10 per cent or less of diethylene glycol monobutyl ether.

DIETHYLTOLUAMIDE (DEET) **except**:

- (a) in medicines for human therapeutic use containing 20 per cent or less of diethyltoluamide, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations for human use, other than medicines, containing 20 per cent or less of diethyltoluamide, when labelled with the warning statement:

WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or

- (c) in preparations other than for human use containing 20 per cent or less of diethyltoluamide.

DIFENOCONAZOLE.

DIFLUBENZURON.

DIMETHICODIETHYLBENZALMALONATE **except** when included in preparations containing 10 per cent or less of dimethicodiethylbenzalmalonate.

DIMETHIRIMOL.

DIMETHOMORPH **except** in preparations containing 10 per cent or less of dimethomorph.

DIMETHYLACETAMIDE in preparations containing 20 per cent or less of dimethylacetamide.

DIMETHYLFORMAMIDE in preparations containing 10 per cent or less of dimethylformamide **except** in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DINICONAZOLE.

SCHEDULE 5—continued

DI-N-PROPYL ISOCINCHOMERONATE **except** in preparations containing 25 per cent or less of di-N-propyl isocinchomeronate.

DIPHENAMID.

DITHIOPYR.

N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-dodecyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-octyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

DORAMECTIN for internal use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

EMAMECTIN in preparations containing 2 per cent or less of emamectin.

EMODEPSIDE in preparations containing 2.5 per cent or less of emodepside for external treatment of animals.

ENILCONAZOLE.

EPOXICONAZOLE.

EPOXY RESINS, LIQUID.

EPRINOMECTIN in preparations containing 0.5 per cent or less of eprinomectin.

ESBIOTHRIN in preparations containing 10 per cent or less of esbiothrin **except** in pressurised spray packs containing 1 per cent or less of esbiothrin.

ESFENVALERATE in preparations containing 0.1 per cent or less of esfenvalerate.

1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE.

ETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of ethanolamine **except**:

- (a) when included in Schedule 4; or
- (b) in preparations containing 5 per cent or less of ethanolamine.

ETHER in preparations containing more than 10 per cent of ether for use in internal combustion engines.

ETHOFUMESATE.

SCHEDULE 5—continued

ETHOXYQUIN **except** in preparations containing 10 per cent or less of ethoxyquin.

ETHOXYSULFURON.

ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except**:

- (a) in paints or paint tinters; or
- (b) in other preparations containing 2.5 per cent or less of ethylene glycol.

ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use **except** in preparations containing 1 per cent or less of ethyl methacrylate as residual monomer in a polymer.

ETRIDIAZOLE.

EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol **except** in preparations containing 25 per cent or less of eugenol.

EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (*Corymbia citriodora*), **except** in preparations containing 40 per cent or less of extract of lemon eucalyptus.

FENARIMOL.

FENBENDAZOLE for the treatment of animals.

FENBUCONAZOLE.

FENCHLORAZOLE-ETHYL.

FENOPROP.

FENOXAPROP-ETHYL.

FENOXAPROP-P-ETHYL.

FENSON.

FENTHION:

- (a) in preparations containing 25 per cent or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or
- (b) in preparations containing 10 per cent or less of fenthion.

SCHEDULE 5—continued

FIPRONIL in preparations containing 10 per cent or less of fipronil **except** in preparations containing 0.05 per cent or less of fipronil.

FLAMPROP-METHYL.

FLAMPROP-M-METHYL.

FLORASULAM.

FLUAZURON.

FLUBENDAZOLE for the treatment of animals.

FLUBENDIAMIDE.

FLUCHLORALIN.

FLUDIOXONIL **except** in preparations containing 10 per cent or less of fludioxonil.

FLUMETHRIN:

- (a) when impregnated in plastic resin strip material containing 3 per cent or less of flumethrin; or
- (b) in oil based preparations containing 1 per cent or less of flumethrin.

FLUMICLORAC PENTYL.

FLUORIDES in preparations containing 3 per cent or less of fluoride ion **except** in preparations:

- (a) for human use; or
- (b) containing 15 mg/kg or less of fluoride ion.

FLUVALINATE in aqueous preparations containing 25 per cent or less of fluvalinate.

FORMIC ACID (excluding its salts and derivatives) **except** in preparations containing 0.5 per cent or less of formic acid.

FOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of fospirate.

FURALAXYL.

FURATHIOCARB in microencapsulated suspensions containing 50 per cent or less of furathiocarb.

SCHEDULE 5—continued

GAMMA-CYHALOTHRIN in aqueous preparations containing 15 per cent or less of microencapsulated gamma-cyhalothrin.

GLUFOSINATE-AMMONIUM.

GLUTARALDEHYDE in preparations containing 5 per cent or less of glutaraldehyde **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYPHOSATE.

HALOSULFURON-METHYL.

HEXACONAZOLE **except** in preparations containing 5 per cent or less of hexaconazole.

HEXAZINONE in preparations containing 25 per cent or less of hexazinone.

HYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in welded plastic labyrinths.

HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), **except**:

- (a) toluene and xylene when included in Schedule 6;
- (b) benzene and liquid aromatic hydrocarbons when included in Schedule 7;
- (c) food grade and pharmaceutical grade white mineral oils;
- (d) in solid or semi-solid preparations;
- (e) in preparations containing 25 per cent or less of designated solvents;
- (f) in preparations packed in pressurised spray packs;
- (g) in adhesives packed in containers each containing 50 grams or less of adhesive;

SCHEDULE 5—continued

- (h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or
- (i) in other preparations when packed in containers with a capacity of 2 mL or less.

HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HCl) **except**:

- (a) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl); or
- (b) for therapeutic use.

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1 per cent or less of hydrogen fluoride.

HYDROGEN PEROXIDE (excluding its salts and derivatives):

- (a) in hair dye preparations containing 12 per cent or less of hydrogen peroxide **except** in hair dyes containing 6 per cent or less of hydrogen peroxide; or
- (b) in other preparations containing 6 per cent (20 volume) or less of hydrogen peroxide **except** in preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1 per cent or less of hydrosilicofluoric acid (H₂SiF₆).

IMAZALIL.

IMAZAMOX **except** in preparations containing 25 per cent or less of imazamox.

IMAZAPIC **except** in preparations containing 25 per cent or less of imazapic.

IMAZAPYR **except** in preparations containing 25 per cent or less of imazapyr.

IMAZETHAPYR **except** in preparations containing 25 per cent or less of imazethapyr.

IMIDACLOPRID in preparations containing 20 per cent or less of imidacloprid **except** in preparations containing 5 per cent or less of imidacloprid.

SCHEDULE 5—continued

IMIPROTHRIN in preparations containing 50 per cent or less of imiprothrin **except** in preparations containing 10 per cent or less of imiprothrin.

INDOXACARB (Includes the R and S enantiomers) in preparations containing 1 per cent or less of indoxacarb.

3-iodo-2-propynyl butyl carbamate (Iodocarb) in preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate **except** in aqueous preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IODOSULFURON-METHYL-SODIUM.

IRON COMPOUNDS:

- (a) for the treatment of animals (excluding up to 1 per cent of iron oxides when present as an excipient):
 - (i) in preparations for injection containing 20 per cent or less of iron **except** in preparations containing 0.1 per cent or less of iron; or
 - (ii) in other preparations containing 4 per cent or less of iron **except**:
 - (A) in liquid or gel preparations containing 0.1 per cent or less of iron; or
 - (B) in animal feeds or feed premixes; or
- (b) in garden preparations **except** in preparations containing 4 per cent or less of iron.

ISOEUGENOL in preparations containing 25 per cent or less of isoeugenol **except** in preparations containing 10 per cent or less of isoeugenol.

ISOPHORONE.

ISOXABEN.

ISOXAFLUTOLE.

IVERMECTIN for use in animals:

- (a) in preparations for the prophylaxis of heartworm in cats and dogs;
- (b) in intraruminal implants containing 160 mg or less of ivermectin;

SCHEDULE 5—continued

- (c) in preparations containing 3.5 per cent or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or
- (d) in other preparations containing 2 per cent or less of ivermectin.

KITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

LAMBDA-CYHALOTHRIN:

- (a) in aqueous preparations containing 1 per cent or less of lambda- cyhalothrin; or
- (b) in aqueous preparations containing 2.5 per cent or less of microencapsulated lambda-cyhalothrin.

† LEAD COMPOUNDS in preparations for use as hair cosmetics.

LEMON OIL **except**:

- (a) when steam distilled or rectified;
- (b) in preparations for internal use;
- (c) in preparations containing 0.05 per cent or less of lemon oil;
- (d) in soaps or bath or shower gels that are washed off the skin;
- (e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals **except**:

- (a) when included in Schedule 4; or
- (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

SCHEDULE 5—continued

LIME OIL **except**:

- (a) when steam distilled or rectified;
- (b) in preparations for internal use;
- (c) in preparations containing 0.5 per cent or less of lime oil;
- (d) in soaps or bath or shower gels that are washed off the skin;
- (e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LINDANE in preparations containing 10 per cent or less of lindane **except** when included in Schedule 2 or 4.

LUFENURON **except**:

- (a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or
- (b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.

MADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic substances.

MAGNESIUM CHLORATE **except** in preparations containing 10 per cent or less of magnesium chlorate.

MALACHITE GREEN in preparations for veterinary use containing 10 per cent or less of malachite green.

MALATHION in preparations containing 10 per cent or less of malathion **except**:

- (a) for human therapeutic use; or
- (b) in dust preparations containing 2 per cent or less of malathion.

MANCOZEB.

SCHEDULE 5—continued**MARJORAM OIL except:**

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

- (c) in preparations containing 50 per cent or less of marjoram oil.

MCPA

- (a) in preparations containing 25 per cent or less of MCPA (acid); or
- (b) in preparations containing 50 per cent or less of the salts and esters of MCPA.

MCPB.**MEBENDAZOLE for the treatment of animals:**

- (a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or
- (b) in undivided preparations containing 25 per cent or less of mebendazole.

MECLOFENAMIC ACID for the treatment of animals.**MECOPROP in preparations containing 2 per cent or less of mecoprop.****MEFENPYR-DIETHYL.****MEPIQUAT.****METAFLUMIZONE.****METALAXYL in preparations containing 35 per cent or less of metalaxyl.****METALDEHYDE in preparations containing 2 per cent or less of metaldehyde.****METHABENZTHIAZURON.**

SCHEDULE 5—continued

METHANOL (excluding its derivatives) in preparations containing 10 per cent or less of methanol **except** in preparations containing 2 per cent or less of methanol.

METHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb.

METHOXYCHLOR.

METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) **except**:

- (a) when included in preparations or admixtures; or
- (b) when packed in containers having a capacity of more than 5 litres.

METHYLENE BLUE in preparations for veterinary use containing 50 per cent or less of methylene blue.

METHYL ETHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ETHYL KETONE PEROXIDE.

METHYL ISOAMYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ISOBUTYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

N-METHYL-2-PYRROLIDONE:

- (a) when packed in single use containers having a capacity of 2 mL or less; or
- (b) in preparations containing 50 per cent or less of N-methyl-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

METHYL SALICYLATE in preparations containing 25 per cent or less of methyl salicylate **except**:

- (a) in preparations for therapeutic use; or
- (b) in preparations containing 5 per cent or less of methyl salicylate.

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5-TRIAZINE.

SCHEDULE 5—continued

METIRAM.

METOLACHLOR.

MILBEMECTIN in preparations containing 1 per cent or less of milbemectin.

MILBEMYCIN OXIME for the prophylaxis of heartworm in dogs and cats.

MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.

MORANTEL in preparations containing 25 per cent or less of morantel **except** in preparations containing 10 per cent or less of morantel.

MOXIDECTIN:

- (a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5 per cent or less of moxidectin;
- (b) in preparations for external use for the treatment of cats and dogs, containing 2.5 per cent or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or
- (c) for internal use for the treatment of animals:
 - (i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or
 - (ii) in other preparations containing 2 per cent or less of moxidectin.

MYCLOBUTANIL.

NAA **except** in preparations containing 25 per cent or less of NAA.

NALED when impregnated in plastic resin strip material containing 20 per cent or less of naled.

NAPTALAM.

NETOBIMIN for the treatment of animals, in preparations containing 12.5 per cent or less of netobimin.

NITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid (HNO₃) **except** in preparations containing 0.5 per cent or less of nitric acid.

SCHEDULE 5—continued

NITROSCANATE for the treatment of animals.

NONOXINOL 9 in preparations containing 25 per cent or less of nonoxinol 9 **except**:

- (a) when labelled with the statements:
 IRRITANT; and
 Avoid contact with eyes;
- (b) in preparations containing 12.5 per cent or less of nonoxinol 9; or
- (c) in preparations for human use.

NORBORMIDE.

NUTMEG OIL **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
 KEEP OUT OF REACH OF CHILDREN; or
- (c) in preparations containing 50 per cent or less of nutmeg oil.

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE **except** in preparations containing 10 per cent or less of N-octyl bicycloheptene dicarboximide.

N-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-octyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

OESTRADIOL in implant preparations for growth promotion in animals.

OLEANDOMYCIN in animal feed premixes for growth promotion.

OMETHOATE in pressurised spray packs containing 0.2 per cent or less of omethoate.

SCHEDULE 5—continued

ORANGE OIL (BITTER) **except:**

- (a) when steam distilled or rectified;
- (b) in preparations for internal use;
- (c) in preparations containing 1.4 per cent or less of orange oil (bitter);
- (d) in soaps or bath or shower gels that are washed off the skin;
- (e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

OXADIARGYL.

OXADIXYL.

OXANTEL EMBONATE for the treatment of animals.

OXFENDAZOLE for the treatment of animals.

OXIBENDAZOLE for the treatment of animals.

OXYCARBOXIN.

OXYTETRACYCLINE in preparations:

- (a) for topical application to animals for ocular use only; or
- (b) containing 40 per cent or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

OXYTHIOQUINOX.

PACLOBUTRAZOL.

PENCONAZOLE.

PENDIMETHALIN.

PERACETIC ACID in concentrations of 10 per cent or less of peracetic acid.

SCHEDULE 5—continued

PERMETHRIN (excluding preparations for human therapeutic use):

- (a) in preparations containing 25 per cent or less of permethrin; or
- (b) in preparations for external use, for the treatment of dogs, containing 50 per cent or less of permethrin when packed in single use containers having a capacity of 4 mL or less,

except in preparations containing 2 per cent or less of permethrin.

PETROL **except** preparations containing 25 per cent or less of petrol.

PHENAZONE for the external treatment of animals.

PHENISOPHAM.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15 per cent or less of such substances, **except** in preparations containing 3 per cent or less of such substances.

PHENYL METHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

ortho-PHENYLPHENOL **except** in preparations containing 5 per cent or less of o-phenylphenol.

PHOSPHONIC ACID (excluding its salts and derivatives) **except** in preparations containing 10 per cent or less of phosphonic acid (H_3PO_3).

PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35 per cent or less of phosphoric acid (H_3PO_4) **except**:

- (a) in preparations containing 15 per cent or less of phosphoric acid (H_3PO_4);
- (b) in solid or semi-solid preparations; or
- (c) in professional dental kits.

ortho-PHTHALALDEHYDE in preparations containing 1 per cent or less of ortho-phthalaldehyde.

PICARIDIN **except** in preparations containing 20 per cent or less of picaridin.

PINE OILS in preparations containing 25 per cent or less of pine oils when packed and labelled as a herbicide.

SCHEDULE 5—continued

PINOXADEN in preparations containing 10 per cent or less of pinoxaden.

PIPERAZINE for animal use.

PIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb.

POLIHEXANIDE **except** in preparations containing 5 percent or less of polihexanide.

POLIXETONIUM SALTS in preparations containing 60 per cent or less of polixetonium salts
except in preparations containing 1 per cent or less of polixetonium salts.

POLYETHANOXY (15) TALLOW AMINE.

POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- ω -
HYDROXY-, MONO-C₁₃₋₁₅-ALKYL ETHERS.

POTASSIUM CHLORATE **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 10 per cent or less of potassium chlorate.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide being:

- (a) solid preparations the pH of which in a 10 g/L aqueous solution is more than 11.5; or
- (b) liquid or semi-solid preparations the pH of which is more than 11.5.

POTASSIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of potassium metabisulphite.

POTASSIUM NITRITE in preparations containing 1 per cent or less of potassium nitrite
except:

- (a) in preparations containing 0.5 per cent or less of potassium nitrite;
- (b) when present as an excipient in preparations for therapeutic use; or
- (c) in aerosols.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:

- (a) solid preparations the pH of which in a 10 g/L aqueous solution is less than 2.5;
or
- (b) liquid or semi-solid preparations the pH of which is less than 2.5.

SCHEDULE 5—continued

POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.

PRALLETHRIN (cis:trans=20:80) in preparations containing 10 per cent or less of prallethrin **except** in insecticidal mats containing 1 per cent or less of prallethrin.

PROFOXYDIM **except** in preparations containing 20 per cent or less of profoxydim.

PROGESTERONE:

- (a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or
- (b) in implant preparations for growth promotion in cattle.

PROHEXADIONE CALCIUM.

PROMETRYN.

PROPAMOCARB.

PROPANIL.

PROPAQUIZAFOP.

PROPICONAZOLE in preparations containing 20 per cent or less of propiconazole.

PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent or less of propionic acid, **except**:

- (a) in preparations containing 30 per cent or less of propionic acid; or
- (b) for therapeutic use.

PROPOXUR:

- (a) when impregnated in plastic resin strip material containing 10 per cent or less of propoxur;
- (b) in dust preparations containing 3 per cent or less of propoxur;
- (c) in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark colouring agent and a separate bittering agent;
- (d) in pressurised spray packs containing 10 g or less of propoxur; or
- (e) in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

SCHEDULE 5—continued

PROPYZAMIDE.

PYMETROZINE.

PYRACLOSTROBIN.

PYRAFLUFEN-ETHYL.

PYRASULFOTOLE.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids **except**:

- (a) in preparations for human therapeutic use; or
- (b) in preparations containing 10 per cent or less of such substances.

PYRIDABEN in preparations containing 25 per cent or less of pyridaben.

PYRIFENOX.

PYRITHIOBAC SODIUM.

PYRITHIONE ZINC in paints containing 0.5 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint **except** in paints containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint.

QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20 per cent or less of quaternary ammonium compounds **except**:

- (a) when separately specified in these Schedules;
- (b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
- (c) in preparations containing 5 per cent or less of such quaternary ammonium compounds.

QUINCLORAC.

QUININE in preparations for veterinary use containing 1 per cent or less of quinine.

QUINTOZENE.

QUIZALOFOP-P-ETHYL in aqueous preparations containing 40 per cent or less of quizalofop-p-ethyl.

SCHEDULE 5—continued

RACTOPAMINE in animal feed premixes containing 10 per cent or less of ractopamine.

RESMETHRIN in preparations containing 10 per cent or less of resmethrin.

RIMSULFURON.

ROBENIDINE **except** in preparations containing 20 per cent or less of robenidine.

SALICYLANILIDE.

SELAMECTIN **except** in preparations containing 12 per cent or less of selamectin.

SETHOXYDIM.

SIDURON.

SILICOFLUORIDES in preparations containing 3 per cent or less of fluoride ion **except**:

- (a) barium silicofluoride when separately specified in this Schedule; or
- (b) in preparations containing 15 mg/kg or less of fluoride ion.

SINBIOALLETHRIN in preparations containing 10 per cent or less of sinbioallethrin **except** in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM CHLORATE **except** in preparations containing 10 per cent or less of sodium chlorate.

SODIUM DIACETATE **except** in preparations containing 60 per cent or less of sodium diacetate.

SODIUM DODECYLBENZENE SULFONATE **except** in preparations containing 30 per cent or less of sodium dodecylbenzene sulfonate.

SODIUM HYDROGEN SULFATE **except** in preparations containing 10 per cent or less of sodium hydrogen sulfate.

SODIUM HYDROSULFITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium hydrosulfite.

SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide being:

- (a) solid preparations the pH of which in a 10 g/L aqueous solution is more than 11.5; or
- (b) liquid or semi-solid preparations the pH of which is more than 11.5.

SCHEDULE 5—continued

SODIUM LAURETH-6 CARBOXYLATE **except** in preparations containing 1 per cent or less of sodium laureth-6 carboxylate.

SODIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium metabisulphite.

SODIUM NITRITE in preparations containing 1 per cent or less of sodium nitrite **except**:

- (a) in preparations containing 0.5 per cent or less of sodium nitrite;
- (b) when present as an excipient in preparations for therapeutic use; or
- (c) in aerosols.

SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35 per cent or less of sodium percarbonate **except** in preparations containing 15 per cent or less of sodium percarbonate.

SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use **except** in preparations containing 10 per cent or less of sodium polystyrene sulphonate.

SODIUM STANNATE **except** in preparations for cosmetic use containing 1 per cent or less of sodium stannate.

SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.

SPINETORAM.

SPINOSAD **except** in aqueous suspensions containing 25 per cent or less of spinosad.

STAR ANISE OIL **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

- (c) in preparations containing 50 per cent or less of star anise oil.

SCHEDULE 5—continued

STYRENE (excluding its derivatives).

SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFADIMIDINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMERAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of sulfamic acid ($\text{H}_3\text{NO}_3\text{S}$).

SULFATHIAZOLE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFOMETURON-METHYL.

† SYMPHYTUM spp. (Comfrey) for dermal use.

2,3,6-TBA.

TDE (1,1-dichloro-2,2-bis [4-chlorophenyl] ethane) in preparations containing 10 per cent or less of TDE.

TEBUCONAZOLE.

TEBUFENOZIDE.

TEFLUTHRIN in preparations containing 2 per cent or less of tefluthrin.

TEMEPHOS:

- (a) in liquid preparations containing 10 per cent or less of temephos;
- (b) in powders containing 2 per cent or less of temephos; or
- (c) in preparations containing 40 per cent or less of temephos when packed in single use containers having a capacity of 2 mL or less.

TEPRALOXYDIM.

TERBUTRYN.

SCHEDULE 5—continued

TETRACHLOROETHYLENE in preparations containing 5 per cent or less of tetrachloroethylene **except**:

- (a) when included in Schedule 2;
- (b) in preparations for the treatment of animals; or
- (c) when absorbed into an inert solid.

TETRACHLORVINPHOS **except** in animal feeds containing 0.2 per cent or less of tetrachlorvinphos.

TETRACONAZOLE in preparations containing 20 per cent or less of tetraconazole.

TETRACYCLINE in preparations:

- (a) for topical application to animals for ocular use only; or
- (b) containing 40 per cent or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

TETRAMETHRIN [(R, cis): (R, trans) = 20:80] **except** in pressurised spray packs.

THIABENDAZOLE:

- (a) for the treatment of animals; or
- (b) when packed and labelled for use as a fungicide **except** in preparations containing 50 per cent or less of thiabendazole.

THIAMETHOXAM in preparations containing 60 per cent or less of thiamethoxam.

THIAZOPYR.

THIFENSULFURON.

THIOBENCARB.

THIODICARB in pelleted preparations containing 1.5 per cent or less of thiodicarb.

THYME OIL **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

SCHEDULE 5—continued

- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

- (c) in preparations containing 50 per cent or less of thyme oil.

TIOCARBAZIL.

TOLCLOFOS-METHYL.

TOLTRAZURIL.

TRALKOXYDIM.

TRENBOLONE in implant preparations for growth promotion in animals.

TRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon.

TRIADIMENOL.

TRI-ALLATE.

TRIBENURON-METHYL.

TRICHLOROACETIC ACID, alkali salts of.

† 1,1,1-TRICHLOROETHANE **except:**

- (a) in preparations packed in pressurised spray packs;
- (b) in preparations containing 25 per cent or less of designated solvents;
- (c) in preparations, other than writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less; or
- (d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:
- (i) the word “Trichloroethane” written in letters not less than 1 mm in height and in distinct contrast to the background; and

SCHEDULE 5—continued

(ii) the expression:

WARNING - DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;

written in bold face sans-serif capital letters not less than 1 mm in height and in distinct contrast to the background.

TRIDIPHANE.

TRIETAZINE.

TRIETHANOLAMINE (excluding its salts and derivatives) **except** in preparations containing 5 per cent or less of triethanolamine.

TRIFLOXYSTROBIN.

TRIFLUMIZOLE.

TRIFLUMURON.

TRIIISOPROPANOLAMINE LAURYL ETHER SULFATE **except** in preparations containing 30 per cent or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:

Avoid contact with eyes and skin; and

Wash hands after handling.

TRINEXAPAC-ETHYL **except**:

- (a) when packed in a sealed water-soluble measure pack; or
- (b) in solid preparations containing 25 per cent or less of trinexapac-ethyl in packs of 50 g or less.

3,6,9-TRIOXAUNDECANEDIOIC ACID **except** in preparations containing 5 per cent or less of 3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.

TRITICONAZOLE.

TURPENTINE OIL **except** in preparations containing 25 per cent or less of turpentine oil.

SCHEDULE 5—continued

TYLOSIN in animal feed premixes containing 5 per cent or less of antibiotic substances:

- (a) for growth promotion;
- (b) for the prevention of liver abscesses in cattle; or
- (c) for the prevention of ileitis in pigs.

VIRGINIAMYCIN in animal feed additives containing 1 per cent or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.

VERNOLATE.

WARFARIN in rodent baits containing 0.1 per cent or less of warfarin.

ZINEB.

SCHEDULE 6

(Substances marked † are listed in Appendix C)

ABAMECTIN:

- (a) in preparations for pesticidal use containing 2 per cent or less of abamectin **except** when included in Schedule 5; or
- (b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.

ACEPHATE.

ACETAMIPRID **except** in preparations containing 1 per cent or less of acetamiprid.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH_3COOH) **except** when included in Schedule 2.

ACETIC ANHYDRIDE excluding its derivatives.

ACIFLUORFEN.

ACINITRAZOLE **except** in preparations containing 20 per cent or less of acinitrazole.

ALBENDAZOLE for the treatment of animals **except:**

- (a) when included in Schedule 5; or
- (b) in intraruminal implants each containing 3.85 g or less of albendazole.

ALDRIN.

† ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:

- (a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
- (b) in liquid or semi-solid automatic dishwashing preparations the pH of which is more than 12.5.

ALKOXYLATED FATTY ALKYLAMINE POLYMER **except:**

- (a) when included in Schedule 5; or
- (b) in preparations containing 20 per cent or less of alkoxyLATED fatty alkylamine polymer.

SCHEDULE 6—continued

ALLETHRIN **except**:

- (a) when included in Schedule 5;
- (b) in insecticidal mats containing 20 per cent or less of allethrin; or
- (c) in other preparations containing 1 per cent or less of allethrin.

ALPHA-CYPERMETHRIN:

- (a) in aqueous preparations containing 25 per cent or less of alpha-cypermethrin; or
- (b) in other preparations containing 10 per cent or less of alpha-cypermethrin,
except when included in Schedule 5.

AMICARBAZONE.

AMIDITHION.

AMINOCARB in preparations containing 25 per cent or less of aminocarb.

AMINOETHOXYVINYLGLYCINE **except** in preparations containing 15 per cent or less of aminoethoxyvinylglycine.

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.

AMINOPYRALID.

AMITRAZ.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide)
except:

- (a) when included in Schedule 5;
- (b) in preparations for human internal therapeutic use;
- (c) in preparations for inhalation when absorbed in an inert solid material; or
- (d) in preparations containing 0.5 per cent or less of ammonia.

AMMONIUM PERSULFATE in hair preparations.

ANILINE (excluding its salts and derivatives) **except** in preparations containing 1 per cent or less of aniline.

SCHEDULE 6—continuedANTIMONY COMPOUNDS **except**:

- (a) when included in Schedule 4;
- (b) antimony chloride in polishes;
- (c) antimony titanate pigments in paint; or
- (d) in paints or tinters containing 5 per cent or less of antimony calculated on the non-volatile content of the paint or tinter.

ARSENIC:

- (a) in ant poisons containing 0.4 per cent or less of arsenic;
- (b) in animal feed premixes containing 4 per cent or less of arsenic; or
- (c) in preparations for the treatment of animals **except** thiacetarsamide when included in Schedule 4,

except when separately specified in this Schedule.

ASPIRIN for the treatment of animals **except** when included in Schedule 4 or 5.

AZACONAZOLE **except** in preparations containing 1 per cent or less of azaconazole.

† AZADIRACHTA INDICA (Neem) including its extracts and derivatives **except**:

- (a) when included in Schedule 5;
- (b) in preparations for human internal use;
- (c) debitterised neem seed oil;
- (d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (e) in preparations for dermal use containing 1 per cent or less of cold pressed neem seed oil.

AZAMETHIPHOS.

AZOBENZENE.

SCHEDULE 6—continued

BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

BARIUM SALTS **except:**

- (a) when included in Schedule 5;
- (b) barium sulfate; or
- (c) in paints or tinters containing 5 per cent or less of barium calculated on the non-volatile content of the paint or tinter.

† BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) **except:**

- (a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or
- (b) in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN;

If in eyes wash out immediately with water; and

WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height.

BAY OIL **except:**

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

SCHEDULE 6—continued

- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (e) in preparations containing 25 per cent or less of bay oil.

BEAUVERIA BASSIANA **except** when included in Schedule 5.

BENDIOCARB:

- (a) in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb;
- (b) in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation;
- (c) in insoluble granular preparations containing 5 per cent or less of bendiocarb; or
- (d) when impregnated in plastic resin strip material containing 10 per cent or less of bendiocarb,

except when included in Schedule 5.

BENQUINOX.

BENSULIDE.

BENZALKONIUM CHLORIDE **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 5 per cent or less of benzalkonium chloride.

SCHEDULE 6—continued

6-BENZYLADENINE **except** in preparations containing 2 per cent or less of 6-benzyladenine.

BERYLLIUM.

BETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin **except** when included in Schedule 5.

BETA-CYPERMETHRIN.

BHC (excluding lindane).

BIFENTHRIN in preparations containing 25 per cent or less of bifenthrin **except** in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3 per cent or less of total bifluorides **except** when included in Schedule 5.

BIOALLETHRIN **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 1 per cent or less of bioallethrin.

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine, or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;

Avoid contact with eyes;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.

SCHEDULE 6—continued

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;

Avoid contact with eyes;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.

† BITHIONOL for treatment of animals.

BORON TRIFLUORIDE in preparations containing 1 per cent or less of boron trifluoride (BF₃) **except** when included in Schedule 5.

BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.

BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.

BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.

BROMOFORM **except** when included in Schedule 4.

BROMOPHOS.

BROMOPHOS-ETHYL.

BROMOXYNIL.

BROMUCONAZOLE **except** when included in Schedule 5.

BROTIANIDE.

BUNAMIDINE.

BUTACARB.

BUTOXYCARBOXIM **except** when included in Schedule 5.

2-BUTOXYETHANOL and its ACETATES **except** in preparations containing 10 per cent or less of such substances.

SCHEDULE 6—continued

2-BUTOXY-2'-THIOCYANO-DIETHYL ETHER.

BUTYRIC ACID in preparations for use as insect lures.

CACODYLIC ACID:

- (a) in animal feed premixes containing 4 per cent or less of arsenic; or
- (b) in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.

CADMIUM COMPOUNDS **except**:

- (a) when included in Schedule 4; or
- (b) in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-volatile content of the paint or tint.

CADUSAFOS in aqueous preparations containing 20 per cent or less of microencapsulated cadusafos.

CAJUPUT OIL **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

SCHEDULE 6—continued

- (e) in preparations containing 25 per cent or less of cajuput oil; or
- (f) in oils containing 25 per cent or less of cajuput oil.

CALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol.

CAMBENDAZOLE.

CAMPBOR **except:**

- (a) when included in Schedule 4 or 5;
- (b) when enclosed in an inhaler device which prevents ingestion of its contents;
- (c) in solid or semi-solid preparations containing 12.5 per cent or less of camphor;
- (d) in liquid preparations containing 2.5 per cent or less of camphor;
- (e) in essential oils when the camphor is present as a natural component of the oil:
 - (i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
 - (ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
 - (iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

SCHEDULE 6—continued

- (iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.

CAPTAN.

CARBARYL **except** when included in Schedule 4 or 5.

CARBENDAZIM **except** in paints, jointing compounds and sealants containing 0.5 per cent or less of carbendazim.

CARBON DISULFIDE.

CARBAMIDE PEROXIDE **except**:

- (a) when included in Schedule 5; or
(b) in other preparations containing 9 per cent or less of carbamide peroxide.

CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use **except** in wash-off preparations containing 1 per cent or less of castor oil, monomaleate.

CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.

CHLORDANE.

CHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr.

CHLORFENETHOL.

CHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine **except**:

- (a) when included in Schedule 5;
(b) in preparations containing 1 per cent or less of chlorhexidine; or
(c) when in solid preparations.

SCHEDULE 6—continued**CHLORINATING COMPOUNDS except:**

- (a) when included in Schedule 5;
- (b) when separately specified in these Schedules;
- (c) sodium hypochlorite preparations with a pH of less than 11.5;
- (d) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

- (e) in liquid preparations containing less than 2 per cent of available chlorine; or
- (f) in other preparations containing 4 per cent or less of available chlorine.

CHLORMEQUAT.**CHLOROFORM except:**

- (a) when included in Schedule 2 or 4; or
- (b) in preparations containing 10 per cent or less of chloroform.

alpha-CHLOROHYDRIN.**CHLOROPHACINONE.**

(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL (uniconazole-p) **except** in preparations containing 5 per cent or less of (E)-(S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol.

CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.

CHLOROTHALONIL except in water-based paint containing 0.5 per cent or less of chlorothalonil.

CHLORPYRIFOS except:

- (a) when included in Schedule 5; or
- (b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

SCHEDULE 6—continued

CHLORPYRIFOS-METHYL.

CHLORTHIAMID.

CHROMATES (including dichromates) **except** in paints or tinters containing 5 per cent or less of chromium as the ammonium, barium, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter.

CHROMIUM TRIOXIDE (excluding its salts and derivatives).

CINEOLE **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (e) in preparations containing 25 per cent or less of cineole;
- (f) in oils containing 25 per cent or less of cineole; or
- (g) in rosemary oil or camphor oil (white).

SCHEDULE 6—continued**CINNAMON LEAF OIL except:**

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (e) in preparations containing 25 per cent or less of cinnamon leaf oil.

CLIMBAZOLE except:

- (a) when included in Schedule 5; or
- (b) in preparations containing 2 per cent or less of climbazole.

CLODINAFOP-PROPARGYL.

CLOMAZONE.

CLOSANTEL.

CLOTHIANIDIN **except** when included in Schedule 5.

CLOTRIMAZOLE for external treatment of animals.

SCHEDULE 6—continued**CLOVE OIL except:**

- (a) when included in Schedule 5;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (f) in preparations containing 25 per cent or less of clove oil.

N-COCO-1,3-DIAMINOPROPANE.**COPPER ACETATE except:**

- (a) when included in Schedule 5; or
- (b) in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS except:

- (a) when separately specified in these Schedules;
- (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose;

SCHEDULE 6—continued

- (c) pigments where the solubility of the copper compound(s) in water is 1 gram per litre or less;
- (d) in feed additives containing 1 per cent or less of copper; or
- (e) in other preparations containing 5 per cent or less of copper compounds.

COPPER HYDROXIDE except:

- (a) when included in Schedule 5; or
- (b) in preparations containing 12.5 per cent or less of copper hydroxide.

COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.

COPPER OXIDES except:

- (a) when included in Schedule 5;
- (b) in preparations for internal use;
- (c) in marine paints; or
- (d) in other preparations containing 5 per cent or less of copper oxides.

COPPER OXYCHLORIDE except:

- (a) when included in Schedule 5; or
- (b) in preparations containing 12.5 per cent or less of copper oxychloride.

COPPER SULFATE except:

- (a) when included in Schedule 5;
- (b) in preparations for internal use; or
- (c) in other preparations containing 5 per cent or less of copper sulfate.

COUMAPHOS

- (a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or
- (b) in other preparations containing 5 per cent or less of coumaphos.

SCHEDULE 6—continued

COUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl **except** when included in Schedule 5.

CREOSOTE derived from wood other than beechwood **except**:

- (a) when included in Schedule 2;
- (b) in preparations for human therapeutic use containing 10 per cent or less of creosote derived from wood other than beechwood; or
- (c) in other preparations containing 3 per cent or less of phenols and homologues of phenol boiling below 220°C.

CROTOXYPHOS.

CRUFOMATE.

CYANAMIDE.

CYANAZINE.

CYCLANILIDE.

N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM.

CYFLUTHRIN **except**:

- (a) when included in Schedule 5; or
- (b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.

CYOMETRINIL.

CYPERMETHRIN **except** when included in Schedule 5.

CYPHENOTHRIN **except** when included in Schedule 5.

CYSTEAMINE for cosmetic use **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE **except** when included in Schedule 5.

2,4-D **except** when included in Schedule 5.

DAZOMET.

SCHEDULE 6—continued

DELTAMETHRIN:

- (a) in aqueous preparations containing 25 per cent or less of deltamethrin, when no organic solvent, other than 10 per cent or less of a glycol, is present;
- (b) in wettable granular preparations containing 25 per cent or less of deltamethrin;
- (c) in water-dispersible tablets each containing 500 mg or less of deltamethrin;
- (d) in emulsifiable concentrates containing 11 per cent or less of deltamethrin in a solvent containing 40 per cent or less of acetophenone and 45 per cent or less of liquid hydrocarbons; or
- (e) in other preparations containing 3 per cent or less of deltamethrin,

except when included in Schedule 5.

DIAZINON **except** when included in Schedule 5.

DICAMBA (including its salts and derivatives) **except** when included in Schedule 5.

DICHOLOBENIL.

DICHLOFENTHION.

DICHOFLUANID.

ortho-DICHLOROBENZENE.

DICHLOROETHYL ETHER.

DICHLOROISOCYANURIC ACID **except**:

- (a) when included in Schedule 5;
- (b) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

- (c) in liquid preparations containing less than 2 per cent of available chlorine; or
- (d) in other preparations containing 4 per cent or less of available chlorine.

SCHEDULE 6—continued

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.

DICHLOROPHEN **except**:

- (a) when included in Schedules 4 or 5; or
- (b) in fabrics other than when:
 - (i) for human therapeutic use; or
 - (ii) as part of a registered pesticidal product.

1,2-DICHLOROPROPANE.

2,4-DICHLORPROP (including the R and S enantiomers).

DICHLORVOS in preparations containing 50 per cent or less of dichlorvos **except** when included in Schedule 5.

DICLOFOP-METHYL.

DICYCLANIL **except** in preparations containing 5 per cent or less of dicyclanil.

DIDECYLDIMETHYLAMMONIUM SALTS **except** in preparations containing 1 per cent or less of didecyldimethylammonium salts labelled with the statement:

Avoid contact with eyes.

DIELDRIN.

DIETHANOLAMINE (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 5 per cent or less of diethanolamine.

DIFENACOUM in preparations containing 0.25 per cent or less of difenacoum.

DIFENZOQUAT.

DIFETHIALONE in rodent baits containing 0.0025 per cent or less of difethialone.

† 5,6-DIHYDROXYINDOLINE.

DIMETHENAMID-P.

DIMETHIPIN.

DIMETHOATE.

SCHEDULE 6—continued

DIMETHYLACETAMIDE **except** when included in Schedule 5.

DIMETHYLFORMAMIDE **except**:

- (a) when included in Schedule 5; or
- (b) in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DIMETHYL SULFOXIDE:

- (a) when not for therapeutic use; or
- (b) for the treatment of animals:
 - (i) when combined with no other therapeutic substance(s);
 - (ii) in liquid preparations containing copper salicylate and 1 per cent or less of methyl salicylate as the only other therapeutic substances; or
 - (iii) in clay poultices containing 2 per cent or less of dimethyl sulfoxide.

DINITROCRESOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

- (a) when included in Schedule 4; or
- (b) when separately specified in this Schedule.

DINITROPHENOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

- (a) when included in Schedule 4; or
- (b) when separately specified in this Schedule.

DIOXACARB.

DIOXANE.

DIPHACINONE.

DIQUAT in preparations containing 20 per cent or less of diquat.

SCHEDULE 6—continued

DISULFIRAM **except** when included in Schedule 4.

DISULFOTON in granular preparations containing 5 per cent or less of disulfoton.

DITHIANON.

DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.

DIUREDOSAN.

N-(N-DODECYL)-2-PYRROLIDONE **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 25 per cent or less of designated solvents.

DODINE.

DORAMECTIN for external use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

DSMA in herbicide or defoliant preparations containing 10 per cent or less of DSMA.

ECONAZOLE for external treatment of animals.

EMAMECTIN in preparations containing 5 per cent or less of emamectin **except** when included in Schedule 5.

EMODEPSIDE for the treatment of animals **except** when included in Schedule 5.

ENDOSULFAN in aqueous preparations containing 33 per cent or less of microencapsulated endosulfan.

ENDOTHAL in preparations containing 20 per cent or less of endothal.

EPTC.

ESBIOTHRIN **except**:

- (a) when included in Schedule 5; or
- (b) in pressurised spray packs containing 1 per cent or less of esbiothrin.

ESFENVALERATE **except** when included in Schedule 5.

SCHEDULE 6—continued

ETHANOLAMINE (excluding its salts and derivatives) **except:**

- (a) when included in Schedule 4 or 5; or
- (b) in preparations containing 5 per cent or less of ethanolamine.

ETHEPHON (excluding its salts and derivatives).

ETHER **except:**

- (a) when included in Schedule 2, 4 or 5; or
- (b) in preparations containing 10 per cent or less of ether.

ETHIOFENCARB.

ETHOATE-METHYL.

ETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2 per cent of linseed oil.

ETHYL BROMIDE.

ETHYL FORMATE when packed and labelled for use as a fumigant.

ETHYLENE CHLOROXYDRIN.

ETHYLENE DICHLORIDE.

ETHYLENE GLYCOL (excluding its salts and derivatives) **except:**

- (a) when included in Schedule 5;
- (b) in paints or paint tinters; or
- (c) in preparations containing 2.5 per cent or less of ethylene glycol.

ETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES, **except:**

- (a) when separately specified in these Schedules; or
- (b) in preparations containing 10 per cent or less of such substances.

ETRIMFOS.

SCHEDULE 6—continued**EUCALYPTUS OIL except:**

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (e) in preparations containing 25 per cent or less of eucalyptus oil.

EUGENOL except:

- (a) when included in Schedule 5;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

SCHEDULE 6—continued

- (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (f) in preparations containing 25 per cent or less of eugenol.

FAMPHUR in preparations containing 20 per cent or less of famphur.

FEBANTEL **except:**

- (a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or
(b) in undivided preparations containing 10 per cent or less of febantel.

FENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos.

FENAZAFLOR.

FENBUTATIN OXIDE.

FENCHLORPHOS.

FENITROTHION.

FENOXACRIM in preparations for the treatment of carpets during manufacture.

FENPYROXIMATE.

FENTHION in preparations containing 60 per cent or less of fenthion **except** when included in Schedule 5.

FENVALERATE.

FIPRONIL **except:**

- (a) when included in Schedule 5; or
(b) in preparations containing 0.05 per cent or less of fipronil.

FLOCOUMAFEN in preparations containing 0.005 per cent or less of flocoumafen.

FLUAZIFOP-BUTYL.

SCHEDULE 6—continued

FLUAZIFOP-P-BUTYL.

FLUAZINAM.

FLUCOFURON in preparations for the treatment of carpets during manufacture.

FLUMETHRIN **except** when included in Schedule 5.

FLUORIDES **except**:

- (a) when included in Schedule 5;
- (b) in preparations for human use; or
- (c) in preparations containing 15 mg/kg or less of fluoride ion.

FLUPROPANATE.

FLUQUINCONAZOLE.

FLUSILAZOL.

FLUTRIAFOL **except** in fertilisers containing 0.5 per cent or less of flutriafol.

FLUVALINATE **except** when included in Schedule 5.

† FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde **except**:

- (a) for human therapeutic use;
- (b) in oral hygiene preparations;
- (c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;
- (d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL;
- (e) in all other cosmetic preparations; or
- (f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

SCHEDULE 6—continued

FORMOTHION.

FOSPIRATE **except** when included in Schedule 5.

FUMAGILLIN.

GLUTARALDEHYDE **except**:

- (a) when included in Schedule 2 or 5; or
- (b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYCERYL THIOGLYCOLLATE in hair waving preparations **except** when labelled with directions for use that include the statement:

Wear protective gloves when using. Keep out of eyes.

GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical **except**:

- (a) in cosmetic preparations for salon use only which are labelled in accordance with the *National Occupational Health and Safety Commission's National Code of Practice for the Labelling of Workplace Substances* [NOHSC:2012 (1994)];
- (b) in preparations containing 5 per cent or less of glycolic acid; or
- (c) in preparations containing 20 per cent or less of glycolic acid with a pH of 3.5 or greater.

GUAZATINE.

HALOXON.

HALOXYFOP.

HEPTACHLOR.

HEXACHLOROPHANE in preparations for the treatment of animals.

HEXAZINONE **except** when included in Schedule 5.

SCHEDULE 6—continued

HYDRAMETHYLNON **except** when included in Schedule 5.

HYDRAZINE.

HYDROCHLORIC ACID (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5;
- (b) in preparations for therapeutic use; or
- (c) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl).

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1 per cent or less of hydrogen fluoride **except** when included in Schedule 5.

HYDROGEN PEROXIDE (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5;
- (b) in hair dye preparations containing 6 per cent (20 volume) or less of hydrogen peroxide; or
- (c) in other preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROQUINONE **except**:

- (a) when included in Schedule 2 or 4; or
- (b) in preparations containing 10 per cent or less of hydroquinone.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1 per cent or less of hydrosilicofluoric acid (H_2SiF_6) **except** when included in Schedule 5.

IMIDACLOPRID **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 5 per cent or less of imidacloprid.

IMIDOCARB.

IMINOCTADINE TRIALBESILATE.

SCHEDULE 6—continued

IMIPROTHRIN **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 10 per cent or less of imiprothrin.

INDOXACARB (Includes the R and S enantiomers) **except** when included in Schedule 5.

IODINE (excluding its salts, derivatives and iodophors) **except**:

- (a) when included in Schedule 2; or
- (b) in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.

IODOPHORS **except** in preparations containing 1.5 per cent or less of available iodine.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) **except**:

- (a) when included in Schedule 5; or
- (b) in aqueous preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IOXYNIL.

IRON COMPOUNDS (excluding up to 1 per cent of iron oxides when present as an excipient) for the treatment of animals **except**:

- (a) when included in Schedule 5;
- (b) in liquid or gel preparations containing 0.1 per cent or less of iron; or
- (c) in animal feeds or feed premixes.

ISOCONAZOLE for external treatment of animals.

ISOCYANATES, free organic, boiling below 300° C, **except** in:

- (a) viscous polyurethane adhesives; or
- (b) viscous polyurethane sealants;

containing not more than 0.7 per cent of free organic isocyanates boiling below 300°C.

SCHEDULE 6—continued**ISOEUGENOL except:**

- (a) when included in Schedule 5; or
- (b) in preparations containing 10 per cent or less of isoeugenol.

LAMBDA-CYHALOTHRIN:

- (a) in aqueous preparations containing 25 per cent or less of microencapsulated lambda-cyhalothrin; or
- (b) in other preparations containing 1 per cent or less of lambda-cyhalothrin,
except when included in Schedule 5.

LASALOCID except in animal feeds containing 100 mg/kg or less of antibiotic substances.

LAURYLISOQUINOLINIUM BROMIDE.**† LEAD COMPOUNDS except:**

- (a) when included in Schedule 4 or 5;
- (b) in paints, tinters, inks or ink additives;
- (c) in preparations for cosmetic use containing 100 mg/kg or less of lead;
- (d) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or
- (e) in ceramic glazes when labelled with the warning statement:

CAUTION - Harmful if swallowed. Do not use on surfaces which contact food or drink.

written in letters not less than 1.5 mm in height.

LEVAMISOLE for the treatment of animals except:

- (a) when included in Schedule 4 or 5; or
- (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LINDANE except when included in Schedule 2, 4 or 5.

SCHEDULE 6—continued

MAFENIDE when packed and labelled for the treatment of ornamental fish only.

MALATHION **except**:

- (a) when included in Schedule 5;
- (b) for human therapeutic use; or
- (c) in dust preparations containing 2 per cent or less of malathion.

MCPA **except** when included in Schedule 5.

MEBENDAZOLE for the treatment of animals **except** when included in Schedule 5.

MECOPROP **except** when included in Schedule 5.

MECOPROP-P.

MEFLUIDIDE.

MELALEUCA OIL (tea tree oil) **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (e) in preparations containing 25 per cent or less of melaleuca oil.

SCHEDULE 6—continued

MELENGESTROL ACETATE when used as an animal feed additive.

MENAZON.

2-MERCAPTOETHANOL in preparations for use as insect lures.

MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.

MERCUROCHROME for the treatment of animals, in preparations for topical use.

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION
PRODUCT for the treatment of animals.

METALAXYL **except** when included in Schedule 5.

METALDEHYDE **except** when included in Schedule 5.

METHACRIFOS in preparations containing 60 per cent or less of methacrifos.

METHAM.

METHANOL (excluding its derivatives) **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 2 per cent or less of methanol.

METHIOCARB in preparations containing 20 per cent or less of methiocarb **except** when included in Schedule 5.

METHOMYL in fly-baits containing 1 per cent or less of methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent.

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10 per cent or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure.

METHYLENE BISTHIOCYANATE **except** in preparations containing 1 per cent or less of methylene bithiocyanate.

METHYLEUGENOL **except** in preparations containing 1 per cent or less of methyleugenol.

METHYL ISOTHIOCYANATE.

SCHEDULE 6—continued

† METHYL METHACRYLATE (excluding its derivatives) **except**:

- (a) for cosmetic use; or
- (b) in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

METHYL NEODECANAMIDE **except** in liquid preparations containing 2 per cent or less of methyl neodecanamide.

METHYLNORBORNANYLPYRIDINE.

N-METHYL-2-PYRROLIDONE **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 25 per cent or less of designated solvents.

METHYL SALICYLATE **except**:

- (a) when included in Schedule 5;
- (b) in preparations for therapeutic use; or
- (c) in preparations containing 5 per cent or less of methyl salicylate.

METOSULAM.

METRIBUZIN.

MICONAZOLE for the external treatment of animals.

MILBEMECTIN **except** when included in Schedule 5.

MONENSIN:

- (a) in animal feed premixes containing 12.5 per cent or less of antibiotic substances;
or
- (b) in stockfeed supplements, blocks or licks containing 0.75 per cent or less of antibiotic substances.

MORANTEL **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 10 per cent or less of morantel.

SCHEDULE 6—continued

MOXIDECTIN for external use:

- (a) in preparations containing 2.5 per cent or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or
- (b) in preparations containing 2 per cent or less of moxidectin for the treatment of animals,

except when included in Schedule 5.

MSMA in herbicide or defoliant preparations containing 10 per cent or less of MSMA.

NALED **except** when included in Schedule 5.

NAPHTHALENE (excluding its derivatives).

NAPHTHALOPHOS in preparations containing 80 per cent or less of naphthalophos.

NARASIN in animal feed premixes containing 12 per cent or less of narasin.

NETOBIMIN for the treatment of animals **except** when included in Schedule 5.

NICKEL SULFATE.

NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.

NIMIDANE in preparations containing 25 per cent or less of nimidane.

NITENPYRAM **except** in divided preparations containing 100 mg or less of nitenpyram.

NITRIC ACID (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 0.5 per cent or less of nitric acid (HNO₃).

NITROBENZENE **except**:

- (a) in solid or semi-solid polishes;
- (b) in soaps containing 1 per cent or less of nitrobenzene; or
- (c) in other preparations containing 0.1 per cent or less of nitrobenzene.

SCHEDULE 6—continued

NITROPHENOLS, ortho, meta and para, **except** when separately specified in these Schedules.

NITROPRUSSIDES in preparations containing 2.5 per cent or less of nitroprussides **except** when included in Schedule 4.

NITROXYNIL.

NONOXINOL 9 **except**:

- (a) when included in Schedule 5;
- (b) in preparations containing 25 per cent or less of nonoxinol 9 when labelled with the statements:

IRRITANT; and

Avoid contact with eyes;

- (c) in preparations containing 12.5 per cent or less of nonoxinol 9; or
- (d) in preparations for human use.

1-OCTEN-3-OL **except** in preparations containing 5 per cent or less of 1-octen-3-ol.

OCTHILINONE **except** in paints, jointing compounds and sealants containing 1 per cent or less of octhilineone calculated on the non-volatile content.

N-(N-OCTYL)-2-PYRROLIDONE **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 25 per cent or less of designated solvents.

OLAQUINDOX **except** in preparations containing 10 per cent or less of olaquinox.

N-OLEYL-1,3-DIAMINOPROPANE.

OMETHOATE in preparations containing 30 per cent or less of omethoate **except** when included in Schedule 5.

OXADIAZON.

OXALIC ACID **except** its derivatives and insoluble salts.

OXYCLOZANIDE.

SCHEDULE 6—continued

PAECILOMYCES LILACINUS STRAIN 251.

† PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde **except:**

- (a) for human therapeutic use;
- (b) in oral hygiene preparations;
- (c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;
- (d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL;

- (e) in all other cosmetic preparations; or
- (f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PARATHION-METHYL in aqueous preparations containing 45 per cent or less of microencapsulated parathion-methyl.

PARBENDAZOLE.

PEBULATE.

PENNYROYAL OIL **except:**

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

- (c) in preparations containing 4 per cent or less of d-pulegone.

SCHEDULE 6—continued

PENTACHLOROPHENOL in preparations containing 1.5 per cent or less of pentachlorophenol.

PERACETIC ACID **except** when included in Schedule 5.

PERFLUIDONE.

PERMANGANATES **except** potassium permanganate in aqueous solutions containing 1 per cent or less of potassium permanganate.

PERMETHRIN **except**:

- (a) when included in Schedule 4 or 5;
- (b) in preparations for human therapeutic use containing 5 per cent or less of permethrin; or
- (c) in preparations containing 2 per cent or less of permethrin.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, **except**:

- (a) when separately specified in these Schedules;
- (b) when included in Schedule 5; or
- (c) in preparations containing 3 per cent or less of such substances.

PHENOTHIAZINE (excluding its derivatives) **except** in preparations containing 10 per cent or less of phenothiazine.

† PHENYLENEDIAMINES and alkylated phenylenediamines not elsewhere specified in these Schedules:

- (a) in preparations packed and labelled for photographic purposes;
- (b) in preparations packed and labelled for testing water **except** tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”;
- (c) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN, and

SCHEDULE 6—continued

WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height; or

- (d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING - This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

PHOSALONE.

PHOSMET.

PHOSPHORIC ACID (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5;
- (b) in preparations containing 15 per cent or less of phosphoric acid (H_3PO_4);
- (c) in solid or semi-solid preparations; or
- (d) in professional dental kits.

PHOXIM.

ortho-PHTHALALDEHYDE **except** when included in Schedule 5.

PINDONE.

PINE OILs when packed and labelled as a herbicide **except** when included in Schedule 5.

PINOXADEN **except** when included in Schedule 5.

PIPEROPHOS.

PIRIMICARB **except** when included in Schedule 5.

SCHEDULE 6—continued

PIRIMIPHOS-ETHYL.

PIRIMIPHOS-METHYL.

POLIXETONIUM SALTS **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 1 per cent or less of polixetonium salts.

POTASSIUM AZELOYL DIGLYCINATE **except** in preparations for cosmetic use containing 1 per cent or less of potassium azeloyl diglycinate.

POTASSIUM BROMATE **except** in preparations containing 0.5 per cent or less of potassium bromate.

POTASSIUM CYANATE.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5; or
- (b) preparations containing 5 per cent or less of potassium hydroxide being:
 - (i) solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
 - (ii) liquid or semi-solid preparations the pH of which is 11.5 or less.

POTASSIUM NITRITE in preparations containing 40 per cent or less of potassium nitrite **except**:

- (a) when included in Schedule 5;
- (b) in preparations containing 0.5 per cent or less of potassium nitrite;
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2 per cent or less of potassium nitrite.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT **except**:

- (a) when included in Schedule 5;
- (b) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is 2.5 or more, but not more than 11.5; or

SCHEDULE 6—continued

- (c) in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:
- (i) solid preparations the pH of which in a 10 g/L aqueous solution is 2.5 or more; or
 - (ii) liquid or semi-solid preparations the pH of which is 2.5 or more.

POTASSIUM PERSULFATE in hair preparations.

PRALLETHRIN (cis:trans=20:80) **except**:

- (a) when included in Schedule 5; or
- (b) in insecticidal mats containing 1 per cent or less of prallethrin.

PROCHLORAZ.

PROFENOFOS.

PROMACYL.

PROPACHLOR.

PROPARGITE.

PROPETAMPHOS.

PROPICONAZOLE **except** when included in Schedule 5.

PROPINEB.

PROPIONIC ACID (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5;
- (b) in preparations containing 30 per cent or less of propionic acid; or
- (c) for therapeutic use.

PROPOXUR **except** when included in Schedule 5.

PROSULFOCARB.

PROTHIOFOS.

d-PULEGONE **except** in preparations containing 4 per cent or less of d-pulegone.

SCHEDULE 6—continued

PYRACLOFOS.

PYRAZOPHOS.

PYRIDABEN **except** when included in Schedule 5.

PYRIDALYL.

PYRIDATE.

PYRIPROLE.

PYRITHIONE COPPER.

PYRITHIONE ZINC **except**:

- (a) when included in Schedule 2 or 5;
- (b) for human use in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in semi-solid hair preparations for animal use;
- (d) in shampoos for animal use containing 2 per cent or less of pyrithione zinc when labelled with the statement “Keep out of eyes” and “If in eyes rinse well with water”;
- (e) when immobilised in solid preparations containing 0.5 per cent or less of pyrithione zinc; or
- (f) in paints, jointing materials or sealants containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content.

PYROXSULAM.

QUATERNARY AMMONIUM COMPOUNDS **except**:

- (a) when separately specified in these Schedules;
- (b) when included in Schedule 5;
- (c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
- (d) in preparations containing 5 per cent or less of such quaternary ammonium compounds.

SCHEDULE 6—continued

QUIZALOFOP ETHYL.

QUIZALOFOP-P-ETHYL **except** when included in Schedule 5.

QUIZALOFOP-P-TEFURYL.

RESMETHRIN **except** when included in Schedule 5.

ROTENONE **except** in solid or semi-solid preparations containing 2 per cent or less of rotenone.

† SAFROLE **except**:

- (a) for internal use; or
- (b) in other preparations containing 1 per cent or less of safrole.

SAGE OIL (Dalmatian) **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
- (c) in preparations containing 4 per cent or less of thujone.

SALINOMYCIN in animal feed premixes containing 12 per cent or less of antibiotic substances.

SASSAFRAS OIL **except**:

- (a) for internal use; or
- (b) in other preparations containing 1 per cent or less of safrole.

SCHEDULE 6—continued**SELENIUM:**

- (a) in preparations containing 2.5 per cent or less of selenium when packed and labelled:
 - (i) for the blueing of gun barrels;
 - (ii) for photographic purposes; or
 - (iii) for the colouring of lead or lead alloys;
- (b) in coated granules containing 1 per cent or less of selenium for application to pasture **except** in fertilisers containing 200 g/tonne or less of selenium; or
- (c) for the treatment of animals:
 - (i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5 per cent or less of selenium;
 - (ii) in animal feed premixes containing 2 per cent or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium;
 - (iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or
 - (iv) as barium selenate in preparations for injection containing 5 per cent or less of selenium.

SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5 per cent or less of antibiotic substances.

SILICOFLUORIDES except:

- (a) when included in Schedule 5; or
- (b) in preparations containing 15 mg/kg or less of fluoride ion.

SILVER NITRATE except:

- (a) when included in or expressly excluded from Schedule 2; or
- (b) in preparations containing 1 per cent or less of silver.

SCHEDULE 6—continued

SINBIOALLETHRIN **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM ALUMINATE (excluding its salts and derivatives) **except**:

- (a) in solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
- (b) in liquid preparations the pH of which is 11.5 or less.

SODIUM BROMATE **except** in preparations containing 0.5 per cent or less of sodium bromate.

SODIUM HYDROXIDE (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5; or
- (b) preparations containing 5 per cent or less of sodium hydroxide being:
 - (i) solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
 - (ii) liquid or semi-solid preparations the pH of which is 11.5 or less.

SODIUM NITRITE in preparations containing 40 per cent or less of sodium nitrite **except**:

- (a) when included in Schedule 2 or 5;
- (b) in preparations containing 0.5 per cent or less of sodium nitrite;
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2 per cent or less of sodium nitrite.

SODIUM PERCARBONATE (CAS No. 15630-89-4) **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 15 per cent or less of sodium percarbonate.

SODIUM PERSULFATE

- (a) in hair preparations; or
- (b) in products for the treatment of water for swimming pools and spas.

SCHEDULE 6—continued

SODIUM SULFIDE in preparations for use as insect lures.

SPIROTETRAMAT.

SPIROXAMINE.

SULCOFURON in preparations for the treatment of carpets during manufacture.

SULFAMIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5.

SULFLURAMID.

SULFURIC ACID (excluding its salts and derivatives) **except**:

- (a) in fire extinguishers; or
- (b) in preparations containing 0.5 per cent or less of sulfuric acid (H₂SO₄).

SULFURYL FLUORIDE.

SULPROFOS.

2,4,5-T.

N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.

TAR ACIDS distilling within the range 230 -290°C inclusive.

TCMTB (2-[thiocyanomethylthio]benzothiazole).

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) **except** when included in Schedule 5.

TEBUFENPYRAD.

TEBUTHIURON.

TEMEPHOS **except** when in Schedule 5.

TERBUTHYLAZINE **except** in preparations containing 5 per cent or less of terbuthylazine.

TERPENES, CHLORINATED.

TESTOSTERONE in implant preparations for use in animals.

SCHEDULE 6—continued

TETRACHLOROETHYLENE **except**:

- (a) when included in Schedule 2 or 5;
- (b) in preparations containing 6 per cent or less of tetrachloroethylene when absorbed into an inert solid; or
- (c) in preparations for the treatment of animals.

TETRACONAZOLE **except** when included in Schedule 5.

TETRADIFON.

2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2 per cent or less of 2,2',6,6'-tetrakispropyl-diphenyl-carbodiimide.

TETRAMISOLE in preparations for the treatment of animals.

THIACLOPRID.

THIAMETHOXAM **except** when included in Schedule 5.

THIAZAFLURON.

THIODICARB **except** when included in Schedule 5.

THIOMETON.

THIOUREA and ALKYL THIOUREAS **except**:

- (a) when separately specified in these Schedules; or
- (b) for therapeutic use.

THIRAM **except** in paint containing 0.5 per cent or less of thiram.

THUJONE **except** in preparations containing 4 per cent or less of thujone.

TOLUENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of toluene or toluene and xylene.

†TOLUENEDIAMINE not elsewhere specified in these Schedules:

- (a) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN, and

SCHEDULE 6—continued

WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height; or

- (b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING - This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

TOLYLFLUANID.

TRANSFLUTHRIN **except**:

- (a) in preparations containing 1 per cent or less of transfluthrin; or
- (b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.

TRIADIMEFON **except**:

- (a) when included in Schedule 5; or
- (b) in fertilisers containing 5 g/kg or less of triadimefon.

TRICHLORFON **except** metrifonate included in Schedule 4.

TRICHLOROACETIC ACID **except**:

- (a) when included in Schedule 4 or 5; or
- (b) in human dermal preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE **except** when included in Schedule 4.

TRICHLOROPHENOL.

TRICLABENDAZOLE **except** in preparations containing 20 per cent or less of triclabendazole.

SCHEDULE 6—continued

TRICLOPYR.

TRIDEMORPH.

TRIETHYL PHOSPHATE.

TRIFLUOROMETHANESULFONIC ACID.

TRINITROPHENOL (excluding its derivatives) **except**:

- (a) in preparations for human therapeutic use; or
- (b) in preparations containing 5 per cent or less of trinitrophenol.

TRISODIUM NITRILOTRIACETATE **except** in preparations containing 20 per cent or less of trisodium nitrilotriacetate.

VAMIDOTHION.

WARFARIN **except** when included in Schedule 4 or 5.

XYLENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of xylene or xylene and toluene.

ZERANOL in ear implants for use as a growth promotant in steer cattle.

ZETA-CYPERMETHRIN in preparations containing 10 per cent or less of zeta-cypermethrin.

ZINC CHLORIDE **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 5 per cent or less of zinc chloride.

ZINC para-PHENOLSULFONATE **except** in preparations containing 5 per cent or less of zinc para-phenolsulfonate.

ZINC SULFATE **except**:

- (a) when included in or expressly excluded from Schedule 4; or
- (b) in other preparations containing 5 per cent or less of zinc sulfate.

ZIRAM in granular preparations.

SCHEDULE 7

ABAMECTIN **except** when included in Schedule 5 or 6.

ACIBENZOLAR-S-METHYL.

ACRIFLAVINE for veterinary use **except** when in Schedule 5.

ACROLEIN.

ACRYLONITRILE.

ALACHLOR.

ALDICARB.

ALDOXYCARB.

ALLYL ALCOHOL.

ALPHA-CYPERMETHRIN **except** when included in Schedule 5 or 6.

AMINACRINE for veterinary use **except** when included in Schedule 5.

AMINOCARB **except** when included in Schedule 6.

4-AMINOPYRIDINE **except** when included in Schedule 4.

AMITON.

ARPRINOCID.

ARSENIC **except**:

- (a) when separately specified in this Schedule;
- (b) when included in Schedule 4 or 6;
- (c) as selenium arsenide in photocopier drums;
- (d) as 10,10'-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic;
- (e) as 10,10'-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles:
 - (i) in contact with food stuffs, animal feeds or potable water;
 - (ii) of clothing and footwear in contact with the skin;

SCHEDULE 7—continued

- (iii) used as infant wear; or
- (iv) intended for use as packaging materials;
- (f) in animal feeds containing 75 g/tonne or less of arsenic; or
- (g) in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile content of the paint.

AZAFENIDIN.

AZINPHOS-ETHYL.

AZINPHOS-METHYL.

AZOCYCLOTIN.

BENDIOCARB **except** when included in Schedule 5 or 6.

BENOMYL **except** in paints containing 0.5 per cent or less of benomyl.

BENZENE (excluding its derivatives) **except**:

- (a) preparations containing 15 mL/L or less of benzene; or
- (b) petrol containing 50 mL/L or less of benzene.

BETACYFLUTHRIN **except** when included in Schedule 5 or 6.

BIFENTHRIN **except**:

- (a) when included in Schedule 6; or
- (b) in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) **except** when included in Schedule 5 or 6.

BORON TRIFLUORIDE **except** when included in Schedule 5 or 6.

BRODIFACOU **except** when included in Schedule 6.

BROMADIOLONE **except** when included in Schedule 6.

BROMETHALIN **except** when included in Schedule 6.

BROMINE (excluding its salts and derivatives).

SCHEDULE 7—continued

BRUCINE **except** in alcohol containing 0.02 per cent or less of brucine as a denaturant.

CACODYLIC ACID **except**:

- (a) when included in Schedule 6; or
- (b) in animal feeds containing 75 g/tonne or less of arsenic.

CADUSAFOS **except** when included in Schedule 6.

CALCIFEROL for use as a rodenticide **except** when included in Schedule 6.

CAPTAFOL.

CARBADOX.

CARBOFURAN.

CARBON TETRACHLORIDE **except** in chlorinated rubber based paint containing 1 per cent or less of carbon tetrachloride.

CARBOPHENOTHION.

CARBOSULFAN.

CHLORDECONE.

CHLORDIMEFORM.

CHLORFENAPYR **except** when included in Schedule 6.

CHLORFENVINPHOS.

CHLORINE (excluding its salts and derivatives).

CHLORHEXIDINE **except**:

- (a) when included in Schedule 5 or 6;
- (b) in preparations containing 1 per cent or less of chlorhexidine; or
- (c) when in solid preparations.

CHLOROMETHIURON.

5-CHLORO-3-METHYL-4-NITROPYRAZOLE.

SCHEDULE 7—continued

4-CHLORO-o-TOLUIDINE.

CHLOROPICRIN **except** when included in Schedule 6.

CHLORTHIOPHOS.

COLECALCIFEROL for use as a rodenticide.

COUMAPHOS **except** when included in Schedule 6.

COUMATETRALYL **except** when included in Schedule 5 or 6.

CREOSOTE derived from coal.

CREOSOTE derived from beechwood.

CYANIDES, metallic **except**:

- (a) ferricyanides;
- (b) ferrocyanides; or
- (c) when separately specified in these Schedules.

CYANOGEN.

CYHALOTHRIN (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.

CYHEXATIN.

DELTAMETHRIN **except** when included in Schedule 5 or 6.

DEMETON.

DEMETON-O-METHYL.

DEMETON-S-METHYL.

DIALIFOS.

4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).

1,2-DIBROMO-3-CHLOROPROPANE.

1,3-DICHLOROPROPENE.

DICHLORVOS **except** when included in Schedule 5 or 6.

SCHEDULE 7—continued

DICROTOPHOS.

DIFENACOUM **except** when included in Schedule 6.

DIFETHIALONE **except** when included in Schedule 6.

DIMEFOX.

4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine).

DIMETHYL SULFATE.

DIMETILAN.

DINITROCRESOLS **except** when included in Schedule 4 or 6.

DINITROPHENOLS **except** when included in Schedule 4 or 6.

DINOCAP.

DINOSEB.

DIQUAT **except** when included in Schedule 6.

DISULFOTON **except** when included in Schedule 6.

DORAMECTIN **except** when included in Schedule 5 or 6.

DSMA **except** when included in Schedule 6.

EMAMECTIN **except** when included in Schedule 5 or 6.

ENDOSULFAN **except** when included in Schedule 6.

ENDOTHAL **except** when included in Schedule 6.

ENDRIN.

EPICHLOROHYDRIN.

EPIDERMAL GROWTH FACTOR **except** in preparations for human therapeutic use.

EPRINOMECTIN **except** when included in Schedule 5.

ETACONAZOLE.

ETHION.

SCHEDULE 7—continued

ETHOPROPHOS **except** when included in Schedule 6.

ETHYLENE DIBROMIDE.

ETHYLENE OXIDE.

FAMPHUR **except** when included in Schedule 6.

FENAMIPHOS **except** when included in Schedule 6.

FENOXACRIM **except**:

- (a) when included in Schedule 6; or
- (b) in treated carpets.

FENSULFOTHION.

FENTHION **except** when included in Schedule 5 or 6.

FENTHION-ETHYL.

FLOCOUMAFEN **except** when included in Schedule 6.

FLUCOFURON **except**:

- (a) when included in Schedule 6; or
- (b) in treated carpets.

FLUCYTHRINATE.

FLUMIOXAZIN.

FLUROACETAMIDE.

FLUROACETIC ACID.

FOLPET.

FORMETANATE.

FURATHIOCARB **except** when included in Schedule 5.

GAMMA-CYHALOTHRIN **except** when included in Schedule 5.

HALOFUGINONE **except** when included in Schedule 4.

SCHEDULE 7—continued

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.

HCB.

HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C **except**:

- (a) when in solid polymers;
- (b) when containing 1 per cent or less of total polycyclic aromatic compounds as measured by IP 346; or
- (c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95.

HYDROCYANIC ACID **except**:

- (a) when included in Schedule 4; or
- (b) its salts and derivatives other than cyanides separately specified in this Schedule.

HYDROFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

HYDROGEN SULFIDE.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

IODOMETHANE.

ISOCARBOPHOS.

ISOFENPHOS.

ISOPROTURON.

IVERMECTIN **except** when included in Schedule 4 or 5.

LAMBDA-CYHALOTHRIN **except** when included in Schedule 5 or 6.

LEPTOPHOS.

LITHIUM PERFLUOROCTANE SULFONATE **except** in sealed bait stations containing 1 per cent or less of lithium perfluorooctane sulfonate.

SCHEDULE 7—continued

MADURAMICIN **except**:

- (a) when included in Schedule 5; or
- (b) in animal feeds containing 5 mg/kg or less of antibiotic substances.

MALACHITE GREEN for veterinary use **except** when included in Schedule 5.

MAZIDOX.

MECARBAM.

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.

MERCURY **except**:

- (a) when separately specified in this Schedule;
- (b) when included in Schedule 2, 4 or 6;
- (c) in preparations containing 0.01 per cent or less of mercury in organic form as a preservative;
- (d) mercury (metallic) in scientific instruments;
- (e) dental amalgams; or
- (f) in a sealed device, for therapeutic use, which prevents access to the mercury.

METHACRIFOS **except** when included in Schedule 6.

METHAMIDOPHOS.

METHAPYRILENE.

METHAZOLE.

METHIDATHION.

METHIOCARB **except** when included in Schedule 5 or 6.

METHOMYL **except** when included in Schedule 6.

METHOXYETHYLMERCURIC ACETATE.

SCHEDULE 7—continued

METHOXYETHYLMERCURIC CHLORIDE.

METHYL BROMIDE.

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL **except**:

- (a) when included in Schedule 6;
- (b) when used in laboratory analysis; or
- (c) when packed for industrial use in containers with a nominal capacity of 100 L or more.

4,4'-METHYLENEBIS[2-CHLOROANILINE] (MOCA).

METHYLENE BLUE for veterinary use **except** when included in Schedules 4 or 5.

MEVINPHOS.

MIPAFOX.

MIREX.

MOLINATE.

MONOCROTOPHOS.

MOXIDECTIN **except** when included in Schedule 4, 5 or 6.

MSMA **except** when included in Schedule 6.

NAPHTHALOPHOS **except** when included in Schedule 6.

NICOTINE **except**:

- (a) when included in Schedule 6;
- (b) in preparations for human therapeutic use; or
- (c) in tobacco prepared and packed for smoking.

NIMIDANE **except** when included in Schedule 6.

NITROFEN.

NITROPRUSSIDES **except** when included in Schedule 4 or 6.

SCHEDULE 7—continued

OMETHOATE **except** when included in Schedule 5 or 6.

OXAMYL.

OXYDEMETON METHYL.

PARAQUAT.

PARATHION.

PARATHION-METHYL **except** when included in Schedule 6.

PENTACHLOROPHENOL **except** when included in Schedule 6.

PHENYLMERCURIC ACETATE **except** in preparations containing 0.01 per cent or less of mercury as a preservative.

PHORATE.

PHOSFOLAN.

PHOSPHIDES, METALLIC.

PHOSPHINE.

PHOSPHORUS, YELLOW (excluding its salts and derivatives).

POTASSIUM NITRITE **except**:

- (a) when included in Schedule 5 or 6;
- (b) in preparations containing 0.5 per cent or less of potassium nitrite;
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2 per cent or less of potassium nitrite.

PROCYMIDONE.

PROPYLENE OXIDE.

PYRINURON.

QUININE for veterinary use **except** when included in Schedule 5.

SCHRADAN.

SCHEDULE 7—continued**SELENIUM except:**

- (a) when included in Schedule 6;
- (b) as selenium arsenide in photocopier drums;
- (c) in preparations for therapeutic use other than:
 - (i) drench concentrates containing 2.5 per cent or less of selenium; or
 - (ii) pour-on preparations containing 0.5 per cent or less of selenium;
- (d) in paints or tinters containing 0.1 per cent or less of selenium calculated on the non-volatile content of the paint or tinter; or
- (e) in fertilisers containing 200 g/tonne or less of selenium.

SEMDURAMICIN except:

- (a) when included in Schedule 6; or
- (b) in animal feeds containing 25 mg/kg or less of antibiotic substances.

SODIUM NITRITE except:

- (a) when included in Schedule 2, 5 or 6;
- (b) in preparations containing 0.5 per cent or less of sodium nitrite;
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2 per cent or less of sodium nitrite.

STRYCHNINE except when included in Schedule 4.

SULCOFURON except:

- (a) when included in Schedule 6; or
- (b) in treated carpets.

SULFENTRAZONE.

SULFOTEP.

TEFLUTHRIN except when included in Schedule 5.

SCHEDULE 7—continued

TEPP.

TERBUFOS.

TETRACHLOROETHANE.

2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE **except** when included in Schedule 6.

THALLIUM.

THIOFANOX.

TIN ORGANIC COMPOUNDS, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl **except**:

- (a) when separately specified in this Schedule;
- (b) in plastics;
- (c) in semi-solid sealants, adhesives or elastomers containing 1 per cent or less of the dialkyl, trialkyl or triphenyl tin component; or
- (d) in paint containing 1 per cent or less of such compounds calculated as tin in the non-volatile content of the paint.

ortho-TOLIDINE **except** in solid-state diagnostic therapeutic reagents.

TRIAMIPHOS.

TRIAZBUTIL.

TRIBUFOS (S,S,S-tributylphosphorotrithioate).

VINCLOZOLIN.

VINYL CHLORIDE.

ZETA-CYPERMETHRIN **except** when included in Schedule 6.

ZIRAM **except** when included in Schedule 6.

SCHEDULE 8

(Substances marked # are subject to additional controls - see Appendix D)

ACETYLDIHYDROCODEINE.

ACETYLMETHADOL.

ACETYLMORPHINES.

ALFENTANIL.

ALPHACETYLMETHADOL.

ALPHAPRODINE.

AMPHETAMINE.

AMYLOBARBITONE **except** when included in Schedule 4.

ANILERIDINE.

BENZYL MORPHINE.

BEZITRAMIDE.

BUPRENORPHINE.

BUTOBARBITONE.

BUTORPHANOL.

CARFENTANYL.

COCAINE.

CODEINE **except** when included in Schedule 2, 3 or 4.

CODEINE-N-OXIDE.

CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).

CYCLOBARBITONE.

SCHEDULE 8—continued

DEXAMPHETAMINE.

DEXTROMORAMIDE.

DEXTROPROPOXYPHENE **except** when included in Schedule 4.

DIFENOXIN **except** when included in Schedule 4.

DIHYDROCODEINE **except** when included in Schedule 2, 3 or 4.

DIHYDROMORPHINE.

DIPHENOXYLATE **except** when included in Schedule 3 or 4.

DIPIPANONE.

DRONABINOL (*delta*-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.

DROTEBANOL.

ETHYLAMPHETAMINE.

ETHYLMORPHINE **except** when included in Schedule 2 or 4.

FENTANYL.

FLUNITRAZEPAM.

HYDROCODONE.

HYDROMORPHINOL.

HYDROMORPHONE.

KETAMINE.

LEVAMPHETAMINE.

LEVOMETHAMPHETAMINE.

LEVOMORAMIDE.

LEVORPHANOL (excluding its stereoisomers).

METHADONE.

SCHEDULE 8—continued

METHYLAMPHETAMINE.

METHYLDIHYDROMORPHINE.

METHYLPHENIDATE.

1-METHYL-4-PHENYLPYPERIDINE-4-CARBOXYLIC ACID
(Pethidine intermediate C).

MORPHINE.

MORPHINE METHOBROMIDE.

MORPHINE-N-OXIDE.

NABILONE.

NORCODEINE.

NORMETHADONE.

OPIUM **except** the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.

OXYCODONE.

OXYMORPHONE.

PENTAZOCINE.

PENTOBARBITONE **except** when included in Schedule 4.

PETHIDINE.

PHENDIMETRAZINE.

PHENMETRAZINE.

PHENOPERIDINE.

4-PHENYLPYPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER
(Pethidine intermediate B).

PHOLCODINE **except** when included in Schedule 2 or 4.

PIRITRAMIDE.

SCHEDULE 8—continued

PROPIRAM.

QUINALBARBITONE.

RACEMORAMIDE.

REMIFENTANIL.

SECBUTOBARBITONE.

SUFENTANIL.

THEBACON.

THEBAINE.

TILIDINE.

SCHEDULE 9

(Trivial or unofficial names are marked *)

ACETORPHINE.

ACETYL-ALPHA-METHYLFENTANYL.

ALKOXYAMPHETAMINES and substituted alkoxyamphetamines **except** when separately specified in these Schedules.

ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines **except** when separately specified in these Schedules.

ALKYLTHIOAMPHETAMINES and substituted alkylthioamphetamines **except** when separately specified in these Schedules.

ALLYLPRODINE.

ALPHAMEPRODINE.

ALPHA-METHYLFENTANYL.

ALPHA-METHYLTHIOFENTANYL.

ALPHAMETHADOL.

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE *(STP or DOM).

5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans **except** when separately specified in these Schedules.

BENZETHIDINE.

BENZYLPIPERAZINE *(BZP).

BETACETYLMETHADOL.

BETA-HYDROXYFENTANYL.

BETA-HYDROXY-3-METHYLFENTANYL.

BETAMEPRODINE.

BETAMETHADOL.

BETAPRODINE.

SCHEDULE 9—continued

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA).

BUFOTENINE.

CANNABIS **except:**

- (a) when separately specified in these Schedules; or
- (b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinol and products manufactured from such fibre.

CATHINONE.

CLONITAZENE.

COCA LEAF.

CODOXIME.

4-CYANO-2-DIMETHYLAMINO-4,4'-DIPHENYLBUTANE.

DESOMORPHINE.

DIAMPROMIDE.

DIETHYLTHIAMBUTENE.

N,N-DIETHYLTRYPTAMINE *(DET).

DIMENOXADOL.

DIMEPHEPTANOL.

2,5-DIMETHOXYAMPHETAMINE *(DMA).

2,5-DIMETHOXY-4-BROMOAMPHETAMINE *(DOB).

2,5-DIMETHOXY-4-ETHYL- α -AMPHETAMINE *(DOET).

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2).

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I).

2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7).

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).

SCHEDULE 9—continued

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(DMHP).

N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA).

N,N-DIMETHYLAMPHETAMINE (Dimetamfetamine).

DIMETHYLTHIAMBUTENE.

N,N-DIMETHYLTRYPTAMINE *(DMT).

DIOXAPHETYL BUTYRATE.

ECGONINE.

N-ETHYL- α -METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE *(N-ETHYL MDA).

ETHYLMETHYLTHIAMBUTENE.

ETICYCLIDINE *(PCE).

ETONITAZENE.

ETORPHINE.

ETOXERIDINE.

FENETYLLINE.

FURETHIDINE.

HARMALA ALKALOIDS **except** in herbs, or preparations, for therapeutic use:

- (a) containing 0.1 per cent or less of harmala alkaloids; or
- (b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.

HEROIN.

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(PARAHEXYL).

4-HYDROXYBUTANOIC ACID and its salts.

HYDROXYPETHIDINE.

SCHEDULE 9—continued

ISOMETHADONE.

KETOBEMIDONE.

LEVOMETHORPHAN (excluding its stereoisomers).

LEVOPHENACYLMORPHAN.

LYSERGIC ACID.

LYSERGIDE.

MECLOQUALONE.

METAZOCINE.

METHAQUALONE.

METHCATHINONE.

5-METHOXY- α -METHYLTRYPTAMINE *(5-MeO-AMT).

5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE *(MMDA).

4-METHOXY- α -METHYLPHENYLETHYLAMINE *(PMA).

METHYL (2*S*, 4*aR*, 6*aR*, 7*R*, 9*S*, 10*aS*, 10*bR*)-9-ACETOXY-6*a*,10*b*-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2*H*-NAPHTHO[2,1-*c*]PYRAN-7-CARBOXYLATE *(SALVINORIN A).

4-METHYLAMINOREX.

METHYLDESORPHINE.

3,4-METHYLENEDIOXYAMPHETAMINE *(MDA).

3-METHYLFENTANYL.

N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE
*(N-HYDROXY MDA).

N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE *(MBDB).

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID
(Moramide intermediate).

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP).

SCHEDULE 9—continued

4-METHYLTHIOAMPHETAMINE.

3-METHYLTHIOFENTANYL.

METOPON.

MITRAGYNA SPECIOSA.

MITRAGYNINE.

MORPHERIDINE.

MUSCIMOL.

MYROPHINE.

NICOCODINE.

NICODICODINE.

NICOMORPHINE.

NORACYMETHADOL.

NORLEVORPHANOL.

NORMORPHINE.

NORPIPANONE.

PARA-FLUOROFENTANYL.

PHENADOXONE.

PHENAMPROMIDE.

PHENAZOCINE.

PHENCYCLIDINE *(PCP).

PHENOMORPHAN.

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP).

PIMINODINE.

PROHEPTAZINE.

SCHEDULE 9—continued

PROPERIDINE.

PSILOCYBINE.

RACEMETHORPHAN.

RACEMORPHAN.

ROLICYCLIDINE *(PHP or PCPY).

SALVIA DIVINORUM.

TENOCYCLIDINE *(TCP).

TETRAHYDROCANNABINOLS and their alkyl homologues **except**:

- (a) when separately specified in this Schedule;
- (b) when included in Schedule 8;
- (c) in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with a warning statement:
 Not for internal use; or
 Not to be taken; or
- (d) in products for purposes other than internal human use containing 50 mg/kg or less of tetrahydrocannabinols.

THIOFENTANYL.

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).

TRIMEPERIDINE.

3,4,5-TRIMETHOXY- α -METHYLPHENYLETHYLAMINE *(TMA).

3,4,5-TRIMETHOXYPHENETHYLAMINE (MESCALINE) and other substances structurally derived from methoxy-phenylethylamine **except**:

- (a) methoxyphenamine; or
- (b) where separately specified in this Schedule.

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBTANE.

PART 5 - APPENDICES

APPENDIX A**GENERAL EXEMPTIONS**

This Standard does not apply to a poison in any of the following products:

ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that do not fit the definition of an agvet chemical product.

BACTERIAL CULTURE MEDIA containing antibiotics.

CERAMICS.

CHEMISTRY SETS:

- (a) toy, when complying with the requirements of Australian Standard AS 8124.4-2003 *Safety of toys - Part 4: Experimental sets for chemistry and related activities*; or
- (b) for educational use, containing Schedule 5 or 6 poisons I containers of 3 mL or less of each liquid preparation or 5 g or less of each solid preparation in a discrete unit.

COPPER COMPOUNDS in paints.

DEXTRANS, GELATIN - SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/blood volume expanders.

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS.

ELECTRONIC COMPONENTS.

ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging.

EXPLOSIVES.

FOOD **except**:

- (a) food additives before incorporation into food; or
- (b) when used as a means of administering a poison for therapeutic use.

FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non-migratory component of glassy solid flakes or granules.

GLASS (including CRYSTAL WARE).

GLAZED POTTERY.

APPENDIX A—continued

HUMAN BLOOD PRODUCTS including:

- (a) whole blood;
- (b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and
- (c) the following plasma-derived therapeutic proteins and their equivalent recombinant alternatives:
 - (i) albumin;
 - (ii) anticoagulation complex;
 - (iii) clotting factors;
 - (iv) fibrinogen;
 - (v) protein C;
 - (vi) prothrombin complex concentrate (PCC); and
 - (vii) thrombin.

IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001 per cent or less of a poison included in Schedules 1 to 8.

INTRAOCULAR VISCOELASTIC PRODUCTS.

LUBRICANTS **except** soluble oils and solvent-deposited lubricating agents.

MATCHES.

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS.

MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the *Therapeutic Goods (Medical Devices) Regulation 2002*, as in force from time to time, **except**:

- (a) injectable tissue reconstructive, augmentation and restoration materials, including collagen;
- (b) medical devices which include anticoagulants;
- (c) artificial tears;

APPENDIX A—continued

- (d) urinary catheters; or
- (e) intra-articular fluids.

MOTOR, HEATING or FURNACE FUELS **except:**

- (a) when the contrary intention appears in any Schedule;
- (b) when containing methanol;
- (c) toy or hobby fuels; or
- (d) petrol or kerosene when packed in containers having a capacity of 20 litres or less.

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION.

PAPER **except:**

- (a) when prepared for pesticidal use; or
- (b) when containing a poison included in Schedule 8 or 9.

PHOTOGRAPHIC PAPER or FILM.

PIGMENTS when immobilised in a polymer.

PORCELAIN.

PRINTING INKS or INK ADDITIVES **except:**

- (a) when containing a pesticide; or
- (b) preparations containing more than 0.1 per cent of lead calculated on the non-volatile content of the ink or ink additive.

RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use.

RADIOISOTOPES for therapeutic use.

SEEDS treated with seed protectants.

SINGLE-USE TUBES for the estimation of alcohol content of breath.

APPENDIX A—continued

TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting.

TIMBER or WALLBOARD.

VITREOUS ENAMELS.

WRITING CORRECTION pens which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5.

APPENDIX B

SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL BY SCHEDULING

[This appendix should be read in conjunction with Appendix A]

INTRODUCTION

At various times, the NDPSC has considered substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary or not the most appropriate means of controlling the risk to public health.

Listing in Appendix B indicates that a decision has been taken not to list substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list i.e. there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non-hazardous, but have not been considered in relation to the need for scheduling.

Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:

- The toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;
- The use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or
- The public access was limited such that scheduling was inappropriate or unnecessary.

The list has been developed from current scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns "Reason for Entry" and "Area of Use".

Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.

The NDPSC considers applications for scheduling. Applications for entry into Appendix B will not be accepted.

APPENDIX B—continued**PART 1****REASONS FOR ENTRY**

- a Low Toxicity.
- b Use pattern restricts hazard.
- c Presentation/packaging restricts hazard.
- d Industrial use only.

PART 2**AREAS OF USE**

- 1. Agricultural
 - 1.1 Herbicide
 - 1.2 Insecticide
 - 1.2.1 Insecticide for codling moth
 - 1.2.2 Termiticide
 - 1.3 Fungicide
 - 1.3.1 On seed fungicide
 - 1.4 Bird Repellent
 - 1.5 Fertiliser
 - 1.6 Plant Growth Regulator
 - 1.7 Insect Pheromone
 - 1.8 Mushroom Bactericide
 - 1.9 Acaricide
 - 1.10 Biological control agent
- 2. Veterinary
 - 2.1 For animal use
 - 2.2 Treatment of mastitis in cows
 - 2.3 Coccidiostat
 - 2.4 Feed additive
 - 2.5 Antiseptic
 - 2.6 Scabicide
 - 2.7 Anthelmintic
 - 2.8 Vitamin/Mineral
 - 2.9 Growth Promotant
 - 2.10 Ectoparasiticide

APPENDIX B, Part 2—continued

3. Domestic
 - 3.1 Aromatherapy
 - 3.2 Food additive
 - 3.3 Cosmetic
 - 3.4 Human use
 - 3.5 Miticide
4. Industrial
 - 4.1 Water Treatment
 - 4.2 Biological control agent
5. Environmental
 - 5.1 Mosquito control
6. Human therapeutic use
 - 6.1 Diagnostic agent
 - 6.2 Medical device
 - 6.3 Antiseptic
 - 6.4 Sunscreen
 - 6.5 External Use
 - 6.6 Laxative
 - 6.7 Antiseborrheic
 - 6.8 Cytoprotective
 - 6.9 Vitamin/Mineral
 - 6.10 Eye Drops
7. General
 - 7.1 Any use
 - 7.2 Excipient
 - 7.3 Synergist
 - 7.4 Flux
 - 7.5 Pesticide
 - 7.6 Insect Repellent
 - 7.7 Solvent
 - 7.8 Disinfectant
 - 7.9 Preservative
 - 7.10 Antioxidant
 - 7.11 Resin Activator/Accelerant
 - 7.12 Sweetener Artificial
 - 7.13 Food additive

APPENDIX B—continued

PART 3

SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL
BY SCHEDULING

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE	Feb 2005	b	1.7
AGROBACTERIUM RADIOBACTER	Nov 1989	a	1
ALCOHOL, DEHYDRATED	Aug 2000	b	6
ALUM	May 1997	a	7.1
ALUMINIUM AMMONIUM SULFATE	May 1997	a	7.1
ALUMINIUM POTASSIUM SULFATE	May 1997	a	7.1
ALUMINIUM SILICATE	Nov 1974	a	7.1
ALUMINIUM tris (ETHYLPHOSPHONATE)	Aug 1986	a	1
AMMONIUM PHOSPHATE	Nov 1974	a	7.1
AMMONIUM THIOSULPHATE	Nov 1974	a	7.1
AMPROLIUM	Jun 1969	a	2.3
AMYL ACETATE	Nov 1974	a	7.1
α -AMYLASE derived from <i>Aspergillus niger</i>	Feb 2005	a	2.4
ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT	Jun 2004	a	2.1
ASPARTIC ACID	-	a	6
ASULAM	May 1986	a	1
AZIMSULFURON	Jun 2003	a	1.1
BACILLUS SPHAERICUS STRAIN 2362	Feb 2003	a	5.1
BACILLUS THURINGIENSIS (excluding endotoxin)	May 1992 Jun 2003	a a	5.1 2.10
BACILLUS TOYOI	Aug 1980	a	2.9
BACULOVIRUS CYDIA POMONELLA	Jun 2006	a	1.2
BENFLURALIN	-	a	1.1
BENSULFURON-METHYL	Aug 1987	a	1
BENTONITE	Jun 2002	a	7.1
BENZYL BENZOATE	Aug 1989	a	1.3.4

APPENDIX B, Part 3—continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
BETAINE HYDROCHLORIDE	Nov 1974	a	7.1
BIFENAZATE	Oct 2002	a	1.9
BISMUTH SUBNITRATE	Nov 1999	b, c	2.1
BIURET	Nov 1974	a	2.4
BOSCALID	June 2003	a	1.3
BOVINE SOMATOTROPHIN	May 1992	a	2
BROMACIL	Aug 1987	a	1
BROMOPROPYLATE	Nov 1994	a	1
BUPIRIMATE	Nov 1990	a	1
BUTAFENACIL	May 2000	a	1
BUTOXYPOLYPROPYLENE GYLCOL	Nov 1974	a	7.7
n-BUTYL BUTYRATE	-	a	7.1
n-BUTYL LACTATE	-	a	7.1
CARBETAMIDE	Aug 1991	a	1
CARBOXIN	Aug 1987	a	1
CARFENTRAZONE-ETHYL	Aug 1998	a	1
CELLULASE derived from Aspergillus niger	Feb 2005	a	2.4
CETYL ALCOHOL	Nov 1974	a	7.1
CHAMOMILE OIL	Feb 2000	a	3.1
CHINA CLAY	Nov 1974	a	7.1
CHLORANTRANILIPROLE	Sep 2008	a	1.2
CHLORFLUAZURON	Oct 2005	a	1.2.2
CHLORFLURENOL	Feb 1974	a	1.6
CHLORIDAZON	May 1988	a	1
CHLOROXYLENOLS	Feb 1975	a	7.8
CITRONELLA OIL	Feb 2000	a	7.1
CLARY SAGE OIL	Feb 2000	a	7.1
CLOPIDOL	Nov 1974	d	2.3
COBALT NAPHTHENATE	-	d	7.1
COLOPHONY	Feb 1997	b	7.4
CROSPVIDONE	Aug 1996	a	2
CULICINOMYCES CLAVOSPORUS	Nov 1982	a	5.1
CYCLAMIC ACID	Nov 1971	a	7.1
CYCLOHEXANE	Nov 1974	a	7.7

APPENDIX B, Part 3—continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
CYCLOHEXANOL ACETATE	-	a	7.7
CYROMAZINE	Nov 1980	a	2
DICLAZURIL	Nov 2001	a	2.3
DIETHYL CARBONATE	-	a	7.1
DIFLUFENICAN	Feb 1987	a	1
DIKEGULAC-SODIUM	Mar 1980	a	1.6
DIMETHICONE		a	7.1
DIMETHYL ETHER	Nov 1988	d	4
DIPHENYLAMINE	Feb 1988	a	1
DIPROPYLENE GLYCOL MONOMETHYL ETHER	Nov 1987	a	4
DIURON	Nov 1987	a	1
DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE)	Feb 1970	a	7.1
2,2-DPA	Nov 1989	a	1
DROMETRIZOLE TRISILOXANE	Oct 2003	a	6.4
EPSIPRANTEL	Nov 1991	a	2
ETHAMETSULFURON-METHYL	Nov 2000	a	1.1
ETHOPABATE	Jun 1969	d	2.3
ETHYL ACETATE	Nov 1974	a	7.1
ETHYL ALCOHOL	Nov 1974	a	7.1
ETHYLBUTYLACETYL- AMINOPROPIONATE	Aug 2000	a	3.4
ETHYL BUTYRATE	-	a	7.1
ETHYL LACTATE	-	a	7.1
ETOXAZOLE	Oct 2003	a	1.2
FENFURAM	May 1977	a	1.3.1
FENHEXAMID	Feb 1999	a	1
FENOXYCARB	Feb 1988	a	1
FLUFENOXURON	Feb 1997	a	1
FLUMETSULAM	Feb 1992	a	1
FLUOMETURON	Aug 1989	a	1
FLUTOLANIL	Nov 2001	a	1.3
FLUROXYPYR	May 1986	a, c	1
FORCHLORFENURON	Feb 2005	a	1.6
FULLERS EARTH	Nov 1974	a	7.1

APPENDIX B, Part 3—continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
FUNGAL PROTEASE derived from Aspergillus niger	Feb 2005	a	2.4
GERANIUM OIL	Feb 2000	a	7.1
GIBBERELIC ACID	Nov 1974	a	1.6
β-GLUCANASE derived from Aspergillus niger	Feb 2005	a	2.4
HEXAFLURON	Nov 1988	a	1
HEXYL ACETATE	-	a	7.7
HEXYTHIAZOX	Feb 1988	a	1
HUMAN OSTEOGENIC PROTEIN-1 (OP-1)	Aug 2001	b	6.2
HYDROPRENE	Feb 1988	a	1
HYDROXYPROPYL CELLULOSE	Nov 1982	a	7.1
ICODEXTRIN	Nov 2000	b	6
INDOLE-3-ACETIC ACID	Feb 1985	b	1.6
ISOPRENE ALCOHOL	-	a	7.1
IPRODIONE	Feb 1997	a	1
ISOSTEARYL ALCOHOL ETHOXYLATE	Nov 1999	a	5.1
KAOLIN	Nov 1974	a	7.1
KRESOXIM-METHYL	Aug 1999	a	1
KUNZEA OIL	Feb 2000	a	7.1
LAURIC ACID	Oct 2005	a	7.1
LAURYL ALCOHOL (1-DODECANOL)	Nov 1974	a	7.1
LAVANDIN OIL	Feb 2000	a	7.1
LAVENDER OIL	Feb 2000	a	7.1
LEAD, METALLIC	-	a	7.1
LEMONGRASS OIL	Feb 2000	a	7.1
LEPIDOPTEROUS SEX PHEROMONES	Nov 1990	a	1
LIMONENE (DIPENTENE)	Jun 2002	a	7.1
LINOLEIC ACID	Oct 2005	a	7.1
LINSEED FATTY ACIDS	Aug 1990	a	2.1
LINURON	Feb 1990	a	1
LIQUORICE, DEGLYCYRRHISINISED	May 1999	a	7.1
MALEIC HYDRAZIDE	Nov 1992	a	1
MANGANESE DIOXIDE	May 1999	b	1
MESOLSULFURON-METHYL	Feb 2002	a	1.1
METARHIZIUM ANISOPLIAE	Feb 2000	b	4.2

APPENDIX B, Part 3—continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
METARHIZIUM ANISOPLIAE	Jun 2003	a	1.10
METHOPRENE	Aug 1987	a	1
METHOXYFENOZIDE	Nov 2000	a	1
METHYL ACETATE	-	a	7.7
METHYL BENZOQUATE	Nov 1974	d	2.3
1-METHYLCYCLOPROPENE	Jun 2003	a	1.6
METHYL p-HYDROXYBENZOATE	Nov 1974	a	7.9
METSULFURONMETHYL	Nov 1985	a	1.1
MYRISTIC ACID	Oct 2005	a	7.1
NAPROPAMIDE	Aug 1987	a	1
NAPHTHYL ACETAMIDE	Nov 1974	a	1.6
NEROLI OIL	Feb 2000	a	7.1
NICARBAZIN	Jun 1969	d	2.3
NISIN	Jun 2003	a	3.2
NORFLURAZON	Nov 1983	a	1.1
NOVALURON	Nov 2000	a	1
NUCLEAR POLYHEDROSIS VIRUS OF <i>HELICOVERPA</i> ARMIGERA OCCLUSION BODIES	Feb 2004	a	1.2
OCTYL ALCOHOLS	Nov 1974	a	7.1
OLEIC ACID	Oct 2005	a	7.1
ORANGE OIL, SWEET	Aug 2000	a	7.1
OXABETRINIL	Feb 1987	a	1
OXYFLUORFEN	May 2001	a	1
PALMAROSA OIL	Feb 2000	a	7.1
PALMITIC ACID	Oct 2005	a	7.1
PATCHOULI OIL	Feb 2000	a	7.1
PECTINASE derived from <i>Aspergillus niger</i>	Feb 2005	a	2.4
PENCYCURON	Aug 1994	a	1
PENTADECANOIC ACID	Oct 2005	a	7.1
PEPPERMINT OIL	Feb 2000	a	7.1
PHENMEDIPHAM	May 1989	a	1.1
d-PHENOTHHRIN	Feb 1982	a	7.5, 1.2
PHYTASE	Feb 1996	a	2.4
PICLORAM	Aug 1987	a	1

APPENDIX B, Part 3—continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
PICOLINAFEN	May 2000	a	1
PIMELIC ACID	Oct 2005	a	7.1
PIPERONYL BUTOXIDE	Aug 1991	a	7.5
POLOXALENE	Nov 1974	a	7.1
POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC)	Nov 1997	a	4.1
POLYHEDROSIS VIRUS OF HELICO ZEA OCCLUSION BODIES	Nov 1996	a	1
POLY (GNRF) OVALBUMIN	Feb 1990	a	2
POLYSORBATE 20	May 2001	a	1
PORCINE SOMATOTROPHIN	Nov 1991	c	2
POTASSIUM SORBATE	Oct 2004	a	1.3
POTASSIUM BICARBONATE	Jun 2004	a	1
PRAZIQUANTEL	Oct 2005	a	2.1
PROPYL ACETATES	-	a	7.1
PROPYLENE GLYCOL	Nov 1974	a	7.1
2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER	Nov 1987	a	4
PROTHIOCONAZOLE	June 2005	a	1.3.1
PSEUDOMONAS FLUORESCENS	May 1985	a	1.8
PYRIMETHANIL	Feb 1996	a	1
PYRIPROXYFEN	Aug 1994	a	1
QUASSIA	Nov 1974	d	6, 2.1
QUINOXYFEN	Nov 2001	a	1.3
ROSEMARY OIL	Feb 2000	a	7.1
SAGE OIL (Spanish)	Feb 2000	a	7.1
SANDALWOOD OIL	Feb 2000	a	7.1
SEAWEED & UNFRACTIONED SEAWEED EXTRACTS	Feb 1985	d	1.5
SIMAZINE	Nov 1987	a	1.1
SODIUM BICARBONATE	Jun 2004	a	1
SODIUM PROPIONATE	Oct 2004	a	1.3
STERIC ACID	Oct 2005	a	7.1
SUCRALFATE	Aug 1982	a	6.8
SULESOMAB	Jun 2002	b	6.1

APPENDIX B, Part 3—continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
SULFOSULFURON	Feb 1998	a	1
SULPHATED POLYSACCHARIDES	-	a	7.1
TANNIC ACID	Dec 1965	a	7.1
TANNIC ACID/BENZYL ALCOHOL PRODUCT	Nov 1993	a	7.1
TERBACIL	Aug 1987	a	1
THAUMATIN	Nov 1990	a	3.2
THIDIAZURON	Nov 1989	a	1
TRIASULFURON	Feb 1988	a	1
TRICHODERMA HARZIANUM	May 1996	a	1
(Z)-9-TRICOSENE	Aug 1991	a	1
TRIETHYLENE GLYCOL	Nov 1974	a	7.1
TRIFLOXYSULFURON	Feb 2002	a	1.1
TRIFLURALIN	Aug 1990	a	1
TRIFORINE	Aug 1987	a	1
ULOCLADIUM OUDEMANSII	Oct 2003	a	1.10
UREA	Nov 1974	a	7.1
¹³ C-UREA	May 2001	a	6.1
VETIVER OIL	Feb 2000	a	7.1
VINYL ETHER	Nov 1987	b	6
VITAMIN K	Jul 1963	a	6.9, 2.8
XANTHOPHYLL (lutein)	Nov 1974	a	7.1
XYLANASE derived from Aspergillus niger	Feb 2005	a	2.4
YLANG YLANG OIL	Feb 2000	a	7.1
ZINC NAPHTHENATE	-	a	1.3

APPENDIX C**SUBSTANCES, OTHER THAN THOSE INCLUDED
IN SCHEDULE 9, OF SUCH DANGER TO HEALTH
AS TO WARRANT PROHIBITION OF
SALE, SUPPLY AND USE**

ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.

ACORUS CALAMUS (calamus) for human therapeutic use.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:

- (a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
- (b) in liquid or semi-solid automatic dishwashing preparations the pH of which is more than 12.5.

ALLYLISOPROPYLACETYLUREA for therapeutic use.

AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.

AMYGDALIN for therapeutic use.

ANCHUSA OFFICINALIS for therapeutic use.

ARISTOLOCHIA spp. for therapeutic use.

ARISTOLOCHIC ACID(S) for human therapeutic use.

ASARUM spp. containing aristolochic acid(s) for human therapeutic use.

AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use **except** 'de-bitterised neem seed oil'.

BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.

BITHIONOL for human therapeutic use.

BORAGO OFFICINALIS (Borage) for therapeutic use **except** the fixed oil derived from the seeds of Borago officinalis.

BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.

APPENDIX C—continued

BUCLOSAMIDE for therapeutic use.

BUNIODYL SODIUM for therapeutic use.

1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use.

CACALIA spp. for therapeutic use.

CINCHOPHEN and its derivatives for therapeutic use.

CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human internal use **except** when being used solely for experimental purposes in humans and such use:

- (a) is in accordance with an approval granted under paragraph 19(1)(b), and the requirements of subsection 19(4A), of the *Therapeutic Goods Act 1989* (as amended from time to time) - otherwise known as the Clinical Trial Exemption (CTX) scheme; or
- (b) is in accordance with the requirements of subsection 18(1) of the *Therapeutic Goods Act 1989* and Regulation 12(1A) of the *Therapeutic Goods Regulations 1990* (as amended from time to time) - otherwise known as the Clinical Trial Notification (CTN) scheme.

COAL TAR for cosmetic use other than in therapeutic goods.

CONIUM MACULATUM (coniine) for therapeutic use.

COTARNINE for therapeutic use.

CROTALARIA spp. for therapeutic use.

CROTON TIGLIUM for therapeutic use.

CYNOGLOSSUM spp. for therapeutic use.

DICOPHANE (DDT) for therapeutic use.

DIETHYLENE GLYCOL for use in toothpastes or mouthwashes **except** in preparations containing 0.25 per cent or less of diethylene glycol.

DIETHYLPHTHALATE in sunscreens or personal insect repellents for human use **except** in preparations containing 0.5 per cent or less of diethylphthalate.

5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2 per cent of 5,6-dihydroxyindoline.

APPENDIX C—continued

DI-iodohydroxyquinoline (iodoquinol) for human internal use.

DIMETHYLPHthalate in sunscreens or personal insect repellents for human use **except** in preparations containing 0.5 per cent or less of dimethylphthalate.

DULCIN for therapeutic use.

ETHYLHEXANEDIOL for human use.

EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.

FARFUGIUM JAPONICUM for therapeutic use.

FORMALDEHYDE (excluding its derivatives):

- (a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
- (b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;
- (c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or
- (d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde **except** in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

HELIOTROPIUM spp. for therapeutic use.

JUNIPERUS SABINE [savin(e)] for therapeutic use.

LEAD COMPOUNDS in paints, tinters, inks or ink additives **except** in preparations containing 0.1 per cent or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive.

LIGULARIA DENTATA for therapeutic use.

MELIA AZEDARACH including its extracts and derivatives.

METHYL METHACRYLATE for cosmetic use **except** in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

OXYPHENISATIN for therapeutic use.

APPENDIX C—continued

PARAFORMALDEHYDE (excluding its derivatives):

- (a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
- (b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;
- (c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or
- (d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde **except** in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PETASITES spp. for therapeutic use.

PHENYLENEDIAMINES in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

PTERIDIUM spp. for therapeutic use.

PULMONARIA spp. for therapeutic use.

SAFROLE for internal therapeutic use **except** in preparations containing 0.1 per cent or less of safrole.

SENECIO spp. for therapeutic use.

SILICONES for injection or implantation **except** when included in Schedule 4.

SYMPHYTUM spp. (Comfrey) for therapeutic or cosmetic use **except** when included in Schedule 5.

TOLUENEDIAMINE in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.

TRICHODESMA AFRICANA for therapeutic use.

TRIPARANOL for therapeutic use.

TUSSILAGO FARFARA for therapeutic use.

APPENDIX D

ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY OF POISONS INCLUDED IN SCHEDULE 4 OR 8

(Note - The following controls apply for the substances shown only when included in Schedule 4 or Schedule 8.)

1. Poisons available only from or on the prescription or order of an authorised medical practitioner.

CLOMIPHENE for human use.

CLOZAPINE for human use.

CYCLOFENIL for human use.

DINOPROST for human use.

DINOPROSTONE for human use.

FOLLITROPIN ALPHA (recombinant human follicle-stimulating hormone) for human use.

FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use.

LUTEINISING HORMONE for human use.

TERIPARATIDE for human use.

UROFOLLITROPIN (human follicle-stimulating hormone) for human use.

2. Poisons available only from or on the prescription or order of a specialist physician or a dermatologist and for which the prescriber must, where the patient is a woman of child-bearing age,:

(1) **ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and**

(2) **if the drug is -**

(a) **acitretin or etretinate, advise the patient to avoid becoming pregnant during or for a period of 24 months after completion of treatment; or**

(b) **bexarotene, isotretinoin or thalidomide, advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.**

ACITRETIN for human use.

BEXAROTENE for human use.

ETRETINATE for human use.

ISOTRETINOIN for human oral use.

THALIDOMIDE for human use.

APPENDIX D—continued

- 3. Poisons available only from or on the prescription or order of a medical practitioner authorised by the Secretary of the Commonwealth Department of Health and Ageing under section 19 of the *Therapeutic Goods Act 1989*.**

DRONABINOL (delta-9-tetrahydrocannabinol).

- 4. Poisons available only from or on the order of a specialist physician and for which the prescriber must, where the patient is a woman of child bearing age:**

- (a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
- (b) advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

TRETINOIN for human oral use.

LENALIDOMIDE.

- 5. Poisons for which possession without authority is illegal (e.g. possession other than in accordance with a legal prescription).**

ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4.

ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4.

DARBEPOETIN.

DEXTROPROPOXYPHENE.

EPHEDRINE.

EPOETINS.

ERYTHROPOIETIN.

ERYTHROPOIETINS **except** when separately specified in this Appendix.

GLUTETHIMIDE.

INSULIN-LIKE GROWTH FACTORS.

PHENTERMINE.

SOMATROPIN (human growth hormone).

- 6. Poisons available only from or on the prescription or order of a specialist physician and for which the prescriber must, where the patient is a woman of child-bearing age:**

- (a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
- (b) advise the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.

APPENDIX D—continued

BOSENTAN for human use.

SITAXENTAN for human use.

7. Poisons available only from or on the prescription or order of a dermatologist.

ALEFACEPT for human use.

APPENDIX E

FIRST AID INSTRUCTIONS FOR POISONS

[other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority]

INTRODUCTION

Directions for First Aid Attention

Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. The following code has been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in this appendix may be varied provided that the intent is not changed.

The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.

These First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as "If in eyes rinse well with water" may be appropriate.

Modified First Aid Instruction on Primary Pack

Where a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:

- (a) each immediate container must be labelled with first aid instructions appropriate for its contents; and
- (b) the primary pack must be labelled with the statement:

FIRST AID: See inner packs.

Exempt Preparations

This Appendix applies only to scheduled poisons. The directions are for substances and their preparations at the concentrations at which the schedules apply. If it is thought desirable to show first aid instructions for a substance exempted from the schedules, it is the responsibility of the manufacturer to ensure they are appropriate.

APPENDIX E—continued**Poisons Information Centre Telephone Numbers**

Companies should use the Poisons Information Centre telephone number(s) (Australia 131 126; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:

1. The poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
2. Calls must be logged and submitted for incorporation into the official collection of poisoning data.

APPENDIX E—continued**PART 1****STANDARD STATEMENTS**

To be grouped together and prefaced with the words “FIRST AID” (see Sub-paragraph 7(p) of this Standard).

Basic

- A For advice, contact a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor (at once).
- Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor.

General

- G1 Urgent hospital treatment is likely to be needed.
(Note - the words ‘at once’ to be added to instruction A).
- G2 If swallowed, give activated charcoal if instructed.
(Note - the words ‘at once’ to be added to instruction A).
- G3 If swallowed, do NOT induce vomiting.
- G4 Immediately give a glass of water.
- G5 Avoid giving milk or oils.
- G6 If sprayed in mouth, rinse mouth with water.

Eyes

- E1 If in eyes wash out immediately with water.
- E2 If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.

APPENDIX E, Part 1—continued*Respiratory system*

- R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.
- R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area.

Skin

- S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.
- S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor.
- S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor.
- S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor.
- S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766).

Special Purpose

- SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 131 126; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.

APPENDIX E—continued**PART 2****FIRST AID INSTRUCTIONS**

Standard statements in this Appendix apply to poisons other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority. Labelling is not required at concentrations below scheduled levels (see the INTRODUCTION to this Appendix).

POISON	STANDARD STATEMENTS
Acetic acid	A,G3,E2,S1
Acetic anhydride	A,G3,E2,S1
Acetone	A,G3
Acrolein	A,G1,G2,G3,E2,R2,S2
Alkaline Salts	A,G3,E2,S1
Amines for use as curing agents for epoxy resins	A,G3,E1,S1
4-Aminopyridine	A,G1,G2,E1,S1
Ammonia	
• 5 per cent or less	A
• above 5 per cent	A,G3,E1,R1,S1
Ammonium persulfate	A,G3,E2
Ammonium thiocyanate	A
Anhydrides, organic acid, for use as curing agents for epoxy resins	A,G3,E1,S1
Aniline	A,E2,R1,S1
Anise oil	A,G3
Antimony chloride	A,E2,S2

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Antimony compounds, except antimony chloride	A
Azadirachta indica (neem) including its extracts and derivatives when included in Schedule 6.	A,E1
Barium salts, except barium sulfate	A
Basil oil	A,G3
Bay oil	A,G3
Benzalkonium chloride	
• when included in Schedule 5	A,G3,E2
• when included in Schedule 6	A,G3,E2,S1
Benzene	A,G3,E1,R1,S1
Benzoyl peroxide	
• above 20 per cent	A,E2,S1
• above 10 per cent up to 20 per cent	A,E1
• 10 per cent or less	A
Bergamot oil	A,G3
Bifluorides (including ammonium, potassium and sodium salts)	
• when included in Schedule 5	A
• when included in Schedule 6 or 7	A,G3,E2,S5
Borax	A
Boric Acid	A
Boron trifluoride	
• when included in Schedule 5	A
• when included in Schedule 6 or 7	A,G3,E2,S5

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Bromoform	A,G3,E2,R1,S2
Brucine	A,G1,G2,G3,R2
2-Butoxyethanol and its acetates	A,E2,S1
Cadmium compounds	A
Cajuput oil	A,G3
Camphor	A,G1,G3,G5
Carbamide peroxide	
• more than 9 per cent up to 60 per cent	A,G3,E2,S1
• more than 60 per cent	A,G1,G3,G4,E2,S1
Carbon disulfide	A,G3,E2,R1,S2
Carbon tetrachloride	A,G3,E1,R1,S1
Cassia oil	A,G3
Chlorinating compounds, except when separately specified, containing	
• above 4 per cent and below 10 per cent of available chlorine	A,G3,E1,S1
• 10 per cent or more of available chlorine	A,G3,E2,S1
Chlorine (gas)	A,E1,R1
Chlorocresol	A,G3,E2,S2
Chloroform	A,G3,E1,R1,S1
Chromates	A,G3,E2,S1
Chromium trioxide	A,G3,E2,S1
Cineole	A,G1,G3

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Cinnamon bark oil	A,G3
Cinnamon leaf oil	A,G3
Climbazole	A
Clove oil	A,G1,G3,E2
Copper sulfate	A,G3,E2,S1
Creosote	A,G3,E2,S1
Cresols	A,G3,E2,S3
Cresols in pressurised spray packs	A,G6,E1,S1
Cyanides	A,G1,E1,R2
Cyanoacrylic acid esters	A
Cyanuric acid	A
Cyclohexanone peroxide	A,G3,E2,S1
Cysteamine	E1
ortho-Dichlorobenzene	A,G3,E1,S1
para-Dichlorobenzene (PDB)	A
Dichloroethyl ether	A,G3,E1, R1,S1
Dichloroisocyanurates	A,G3,E1,S1
Dichloromethane (methylene chloride)	A,G3,G5,E1,R1,S1
• in pressurised spray packs	A,G6,S1
Dichromates	A,G1,G3,E2,S1
Didecyldimethylammonium salts	A,G3
Diesel (distillate)	A,G3

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Diethanolamine	
• when included in Schedule 5	A,G3
• when included in Schedule 6	A,G3,E2,S1
5,6-Dihydroxyindoline	E1
Dimethylformamide	
• less than 75 per cent	A
• 75 per cent or more	A,E1,R1,S1
Dimethyl sulfoxide	A,G3,E1,S1
Dinitroresols	A,G1,E1,S1
Dinitrophenols	A,G1,E1,S1
Dioxane	A,G3,E1,R1,S1
Distillate	A,G3
N-(N-Dodecyl)-2-pyrrolidone	
• when included in Schedule 5	A,G3,E1
• when included in Schedule 6	A,G3,E2,S1
Epoxy resins liquid	A,G3,E2,S1
Essential oils containing camphor as natural component unless otherwise specified.	A,G3
Ethanolamine	
• when included in Schedule 5	A,G3,E1
• when included in Schedule 6	A,G3,E2,S1
Ether	A,G3,E1,R1
Ethyl bromide	A,E2,S1,R1

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Ethylene glycol	A
Ethylene glycol monoalkyl ethers and their acetates, except when separately specified	A,G3,E2,S1
Ethylene oxide	A,E2,R1
Eucalyptus oil	A,G1,G3
Eugenol	A,G1,G3,E2
Fluorides except when separately specified	
• when included in Schedule 5	A
• when included in Schedule 6	A,G1,G3,E2,S1
Formaldehyde (see also paraformaldehyde)	A,G3,E2,R1,S1
Formic acid	A,G3,E2,S1
Glutaraldehyde	
• below 5 per cent	A,G3,E1
• 5 per cent or more	A,G3,E2,S1
Glycolic acid	A,G3,E2
Hexachlorophane when included in Schedule 6	A
Hydrazine	A,G1,G3,E2,R1,S1
Hydrocarbons, liquid	A,G3
Hydrochloric acid	A,G3,E2,S1
• when included in Schedule 5	A,G3
Hydrofluoric acid and admixtures that generate hydrofluoric acid	
• when included in Schedule 5	A
• when included in Schedule 6 or 7	A,G3,E2,S5

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Hydrogen peroxide	
• more than 3 per cent up to 20 per cent	A,G3,E2,S1
• more than 20 per cent	A,G1,G3,G4,E2,S1
Hydroquinone	
• when included in Schedule 2	A
• when included in Schedule 4 or 6	A,G2,G3,E2,R2,S1
Hydrosilicofluoric acid	
• when included in Schedule 5	A
• when included in Schedule 6 or 7	A,G3,E2,S5
Iodine (excluding salts, derivatives and iodophors)	
• 2.5 per cent or more for human external use	A,E2
• 2.5 per cent or more for other uses	A,E2,S1
• below 2.5 per cent	A
Iodophors	A
Isocyanates, free organic	A,E2,S1
Isophorone	A,G3,E2,S1
Kerosene	A,G3
Lauryl isoquinolinium bromide	A,E1
Lead compounds	
• in hair cosmetics	A
• in other preparations	A,S1
Lemon oil	A,G3

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Lime oil	A,G3
Magnesium chlorate	A
Malathion at 20 per cent or less	A
Marjoram oil	A,G3
Melaleuca oil	A,G1,G3
Mercuric chloride	
• for external therapeutic use	A
• for other uses	A,G1,G3,E2,R2,S1
Mercuric iodide	A,G1,G3,E2,R2,S1
Mercuric nitrate	A,G1,G3,E2,R2,S1
Mercuric oxide	A,G1,G3
Mercuric potassium iodide	A,G1,G3,E2,R2,S1
Mercuric thiocyanate	A,G1,G3,E2,R2,S1
Mercurochrome	A
Mercurous chloride	A
Mercury metallic	A
Mercury, organic compounds	A,S1
• in preparations for human external use	A
Metaldehyde	A,E1,S1
Methanol	
• above 10%	A,G3
• 10% or less	A
Methylated spirit	A,G3

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Methyl ethyl ketone	A,G3
Methyl ethyl ketone peroxide	A,G3,E2,S1
Methyleugenol	A
Methyl isoamyl ketone	A,G3
Methyl isobutyl ketone	A,G3
N-Methyl-2-pyrrolidone	
• when included in Schedule 5	A,G3,E1
• when included in Schedule 6	A,G3,E2
Methyl salicylate liquid when included in Schedule 5 or 6	A,G3,E1
Naphthalene	A,G1,G3
Nitric acid	A,G3,E2,S1
Nitrobenzene	A,G3,E1,S1
Nitrophenol	A,G3,E2,S1
Nitroprussides	
• In aerosols	A,G6,R1
• In other preparations	A,G3
Nonoxinol 9	A,E2
Nutmeg oil	A,G3
2-Octyl-4-isothiazolin-3-one (Ocithilinone)	A,G3,E2,S1
N-(N-Octyl)-2-pyrrolidone	
• when included in Schedule 5	A,G3,E1
• when included in Schedule 6	A,G3,E2

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Orange oil (bitter)	A,G3
Oxalic acid	A,G3,E2,S1
Paraformaldehyde	A,G3,E2,R1,S1
Pennyroyal oil	A,G3
Peracetic acid	
• when included in Schedule 5	A,G3,E1,S1
• when included in Schedule 6	A,G3,E2,S1
Permanganates	A,G3,E2,S1
Petrol	A,G3,R1
Phenols	
• 25 per cent and less	A,G3,E2,S3
• above 25 per cent	A,G3,E2,S4
Phenols in pressurised spray packs	A,E1
Phenylenediamines and alkylated phenylenediamines	
• in hair dyes	A,E1
• in other preparations	A,G1,G3,E1,S1
Phenyl methyl ketone	
• As such, or in preparations of similar viscosity	A,G3,E1
N,N-bis(phenylmethylene)-bicyclo- -(2.2.1)heptane-2,5-dimethanamine	A,E2,S1
N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,6-dimethanamine	A,E2,S1

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
ortho-Phenylphenol	A,G3,E2,S1
• in pressurised spray packs	A,G6,E2,S1
Phosphonic acid	A,G3,E2,S1
• neutralised to pH 6 (approx)	A
• in spray packs	A,E2,S1
Phosphoric acid	A,G3,E2,S1
horus, yellow	A,G1,G3,E2,R2,S2
ortho-Phthalaldehyde	
• when included in Schedule 5	A,E1
• when included in Schedule 6	A,G3,E2,S1
Picric acid	A,G1,G3,E2,R1,S1
Polyethanoxy (15) tallow amine	A,E2,S1
Poly(oxy-1,2-ethanediyl), α - [2-[(2-hydroxyethyl)amino]-2- oxoethyl]- ω -hydroxy-, mono-C ₁₃₋₁₅ -alkyl ethers	A,E1
Potassium bromate	A
Potassium chlorate	A
Potassium cyanate	A,E1,S1
Potassium hydroxide	A,G3,E2,S1
Potassium metabisulphite	A
Potassium nitrite	
• when included in Schedule 7	A,G1,G3
• when included in Schedule 5 or 6	A,G3

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Potassium peroxomonosulfate triple salt	
• when included in Schedule 5	A,G3,E1
• when included in Schedule 6	A,G3,E2,S1
Potassium persulfate	A,G3,E2
Potassium sulfide	A,G3,E2,S1
Propionic acid	A,G3,E1,S1
d-Pulegone	A,G3
Pyrithione zinc	A,E1
Quaternary ammonium compounds except when separately specified	
• above 20 per cent	A,G3,E2
• 20 per cent and below	A,E2
• in pressurised spray packs	A,E2,G6
Safrole	A,G1,G3
Sage oil (Dalmatian)	A,G3
Sassafras oil	A,G1,G3
Selenium compounds	A,G1,E1,S1
Silicofluorides	
• when included in Schedule 5	A
• when included in Schedule 6	A,G1,G3,E2,S1
Silver salts	A,E2
Sodium aluminate	A,G3,E2,S1
Sodium bromate	A,G1

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Sodium chlorate	A
Sodium diacetate	A,G3,E2,S1
Sodium dichloroisocyanurate	A,G3,E1,S1
Sodium dodecylbenzene sulfonate	A,G3,E2,S1
Sodium hydrogen sulfate	A,G3,E1,S1
Sodium hydrosulfite	A,G3,E2,S1
Sodium hydroxide	A,G3,E2,S1
Sodium laureth-6 carboxylate	A
Sodium metabisulphite	A, G3
Sodium nitrite	
• when included in Schedule 7	A,G1,G3
• when included in Schedule 5 or 6	A,G3
Sodium percarbonate	
• when included in Schedule 5	A,G3,S1
• when included in Schedule 6	A,G3,E2,S1
Sodium persulfate	A,G3,E2
Sodium stannate	A,E1
Sodium sulfide	A,G3,E2,S1
Sodium trichloroacetate	A
Strychnine	A,G1,G2,G3,R2
Styrene	A,G3,S1,E1
Sulcofuron	A

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Sulfamic acid	A,G3,E2,S1
Sulfuric acid	A,G3,E2,S1
Terpenes, chlorinated	A,G3
Tetrachloroethane	A,G3,E1,R1,S1
Tetrachloroethylene	A,G3,E2,R1,S1
Thiourea	A
Thujone	A,G3
Thyme oil	A,G3
ortho-Tolidine	A
Toluene	
• above 75 per cent	A,G3,E1,R1,S1
• 75 per cent and below	A,G3
• in pressurised spray packs	A
Toluenediamine	
• in hair dyes	A,E1
• in other preparations	A,G1,G3,E1,S1
Trichloroacetic acid	A,G3,E2,S1
Trichloroacetic acid alkali salts	A
1,1,1-Trichloroethane	A,G3,E1,R1,S1
Trichloroethylene	A,G3,E1,R1,S1
Trichloroisocyanuric acid	A,G3,E1,S1
Triethanolamine	A,G3,E1,S1
Triethyl phosphate	A,E1

APPENDIX E, Part 2—continued

POISON	STANDARD STATEMENTS
Trifluoromethane-sulphonic acid	A,G3,E2
Triisopropanolamine lauryl ether sulfate	A,E1,S1
Turpentine (mineral)	A,G3
Turpentine oil (vegetable)	A,G3,E2
White spirit	A,G3
Xylene	
• above 75 per cent	A,G3,E1,R1,S1
• 75 per cent and below	A,G3
• in pressurised spray packs	A,G6,E1,S1
Xylenols	A,G3,E2,S3
• in pressurised spray packs	A,E1
Zinc chloride	A,G3,E2,S1
Zinc sulfate	A,G3,E2,S1

APPENDIX F

WARNING STATEMENTS AND GENERAL SAFETY DIRECTIONS FOR POISONS

[other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority and medicines for human use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*]

INTRODUCTION

Warning Statements and Safety Directions

It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.

Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. The following code has been prepared as a guide for this purpose.

The wording of warning statements and safety directions specified in this appendix may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.

Poisons Information Centre Telephone Numbers

Companies should use the Poisons Information Centre telephone number(s) (Australia 131 126; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand in warning statement No. 99 in Part 1 of this Appendix must meet the following criteria:

1. The poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
2. Calls must be logged and submitted for incorporation into the official collection of poisoning data.

APPENDIX F—continued**PART 1****WARNING STATEMENTS**

1. Highly corrosive.
2. Corrosive.
3. Corrosive liquid.
4. Strongly alkaline.
5. Irritant.
6. May cause cancer.
7. WARNING - Causes Birth Defects.
8. WARNING - May be fatal to children.
9. Can be fatal to children if sucked or swallowed.
10. May produce severe burns.
11. WARNING - Vapour may be harmful.
12. Vapour is harmful to health on prolonged exposure.
13. May be fatal if inhaled, swallowed or absorbed through skin.
14. Dust will irritate and burn eyes, nose and skin.
15. Liquid will cause burns.
16. Forms dangerous gas near radiators or naked flames.
17. Contact with eyes even for short periods can cause blindness.
18. Product will irritate the eyes, nose, throat and skin.
19. WARNING - Skin contact may be dangerous. Take every precaution to avoid contact - wash off after spillage and after use.
20. May give off dangerous gas if mixed with other products.

APPENDIX F, Part 1–continued

21. **WARNING** - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
22. Highly reactive oxidising chlorine compound.
23. May cause fire or explosion.
24. For external washing only. Rinse skin thoroughly after use.
25. Do not use on broken skin. Wash hands thoroughly after use.
26. (Powder) (and) (concentrated solutions) are dangerous if swallowed.
27. Not for therapeutic use.
28. (Over) (Repeated) exposure may cause sensitisation.
29. If congestion persists, consult your doctor or pharmacist.
30. **WARNING** - Do not use on face or on anal or genital areas.
31. **WARNING** - Do not use on face or on anal or genital areas except on doctor's advice.
32. This preparation should be part of an overall treatment plan regularly assessed with your doctor.
33. Do not take for periods longer than four weeks except on medical advice.
34. **WARNING** - This medication may be dangerous when used in large amounts or for a long time (period).
35. **CAUTION** - This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.

or

CAUTION - This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.
36. For use under medical supervision only.

APPENDIX F, Part 1–continued

37. Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.
38. CAUTION - Do not use for children under 2 years old unless a doctor has told you to.
39. This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.
40. This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.
41. Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor's advice.
42. WARNING - Overuse may stain the skin or mouth.
43. Use of this product is not necessary in areas supplied with fluoridated water.
44. WARNING - May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.
45. WARNING - If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor's advice.
46. WARNING - Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).
47. WARNING - This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
48. WARNING - This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
49. WARNING - Do not mix with other medication except on veterinarian's advice.
50. Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.

APPENDIX F, Part 1–continued

51. Irritant to skin, eyes, mucous membranes and upper respiratory tract.
52. Breathing vapour or spray mist is harmful and may cause an asthma-like reaction.
53. CAUTION - (Name of substance) should not be used by pregnant women.
54. Seek medical advice before first course of treatment.
55. Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.
56. WARNING - Can cause elevated blood pressure and interact adversely with other medication.
57. Not to be applied to infants under 12 months of age unless on doctor's advice.
58. Highly reactive oxidising bromine and chlorine compound.
59. May cause allergy.
60. Do not mix with detergents or other chemicals.
61. WARNING - Can react with other medicines. Ask your doctor or pharmacist before taking.
62. Do not use if pregnant.
63. See a doctor if you are pregnant or diabetic.
64. See a doctor (or) (*dentist*) if no better after (Insert number of days as per approved Product Information) days.
65. If getting better, keep using for (Insert number of days as per approved Product Information) days.
66. See a doctor if problem returns.
67. Do not use if pregnant or likely to become pregnant.
68. If symptoms persist beyond 5 days consult a doctor (or) (*dentist*).
69. If symptoms recur within two weeks of completing the course, consult a doctor.
70. Use only under medical supervision if you are taking other medicines.
71. Do not use during the last three months of pregnancy.

APPENDIX F, Part 1–continued

72. Do not use in the eyes.
73. Do not use for acne.
74. Do not use under waterproof bandages unless a doctor has told you to.
75. Do not use for more than 7 days unless a doctor has told you to.
76. Do not become pregnant during use or within (*Insert number of months as per approved product information*) month(s) of stopping treatment.
77. WARNING - May Cause Birth Defects.
78. Attacks skin and eyes.
79. Will irritate eyes.
80. (Intentionally blank)
81. (Intentionally blank)
82. (Intentionally blank)
83. This paint is dangerous to health, even when dry.
For industrial use only.
Do not use on toys or furniture.
Do not use on, in or around the home.
84. Breathing the vapour is dangerous.
Provide adequate ventilation during application.
Do not use in the presence of a naked flame.
Do not smoke.
85. This paint contains lead and is dangerous to health, even when dry.
For industrial use only.
Do not use on toys or furniture.
Do not use for painting any building or fixed structure.
Do not use where contact with food or drinking water is possible.
86. This tinter contains lead.
Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.
87. (*Insert brand name*) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.

APPENDIX F, Part 1–continued

88. This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.
89. Application to skin may increase sensitivity to sunlight.
90. This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.
91. CAUTION - Total iodine intake may exceed recommended level when taking this preparation.
92. WARNING - Contains iodine - do not take when pregnant **except** on physician's advice.
93. Causes severe burns, which are not likely to be immediately painful or visible.
94. WARNING - Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.
95. CAUTION - Do not use for children under 12 years old unless a doctor has told you to.
96. CAUTION - This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.
97. *Adults:* Keep to the recommended dose. Don't take this medicine for longer than a few days at a time unless advised to by a doctor.
98. *Children and adolescents:* Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.
99. If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 131 126; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.
100. Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.
101. Don't use [this product / name of the product]:
If you have a stomach ulcer
In the last 3 months of pregnancy [*This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea*]
If you are allergic to (name of substance) or anti-inflammatory medicines.

APPENDIX F, Part 1—continued

102. Unless a doctor has told you to, don't use [*this product / name of the product*]:
For more than a few days at a time
With other medicines containing aspirin or other anti-inflammatory medicines
If you have asthma
In children under 12 years of age
In children 12-16 years of age with or recovering from chicken pox, influenza or fever
If you are pregnant.
103. See a doctor before taking [this product / name of the product] for thinning the blood or for your heart. [*This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.*]
104. Unless a doctor has told you to, don't use [this product / name of the product]:
For more than a few days at a time
With other medicines containing (name of substance) or other anti-inflammatory medicines
If you have asthma
If you are pregnant [*This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.*]
105. Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.
106. Contains formaldehyde.

APPENDIX F—continued**PART 2****SAFETY DIRECTIONS - GENERAL**

To be grouped together and prefaced with the words “SAFETY DIRECTIONS” - see Sub-paragraph 7(n) to this Standard.

1. Avoid contact with eyes.
2. Attacks eyes - protect eyes when using.
3. Wear eye protection when mixing or using.
4. Avoid contact with skin.
5. Wear protective gloves when mixing or using.
6. Wash hands after use.
7. Wash hands thoroughly after use.
8. Avoid breathing dust (or) vapour (or) spray mist.
9. Use only in well ventilated area.
10. Ensure adequate ventilation when using.
11. No smoking.
12. Do not allow product to come into contact with other chemicals, especially acids.
13. Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.
14. Do not allow to get damp.
15. Store under cover in a dry, clean, cool, well ventilated place away from sunlight.
16. Store and transport in an upright container.
17. Do not mix with other chemicals.
18. Do not mix with different types of chlorinating chemicals.
19. Use clean containers for dispensing.

APPENDIX F, Part 2–continued

20. Mix with water only.
21. Do not add water to product - add product to water, but in case of fire drench with water.
22. In case of spillage flush with large quantities of water.
23. Keep away from heat, sparks and naked flames.
24. Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.
25. Avoid contact with food.
26. Avoid contact with clothing.
27. Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed.
28. Do not mix with hot water.
29. Obtain a supply of calcium gluconate gel.
30. (Intentionally blank.)
31. Do not use on broken skin.
32. Do not use under occlusive dressing.
33. Mix strictly according to instructions.
34. May cause fire if it comes into contact with other chemicals, paper or other flammable materials.
35. Wash gloves thoroughly, immediately after use.
36. Protect cuticles with grease or oil.

APPENDIX F—continued**PART 3****POISONS (other than agricultural and veterinary chemicals)
TO BE LABELLED WITH WARNING STATEMENTS
OR SAFETY DIRECTIONS**

(Where more than one statement or direction is required they may be combined to form simple sentences where appropriate.)

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Acetic acid in concentrations of 80 per cent or more except when in Schedule 2.	2	1,4,8
Acetic anhydride	2	1,4,8
Acetone in concentrations greater than 75 per cent.		1,4,8
Acitretin	7,62,76	
Adapalene for topical use.	77,62	
Alclometasone when included in Schedule 3.	38,72,73, 74,75	
Alkaline salts	4	1,4
Amines used as curing agents for epoxy resins.		1,3,4,5,8
Ammonia/ammonium hydroxide in concentrations greater than 20 per cent ammonia except in smelling salts.	4	1,4,8
Ammonium persulfate	5,21,25	1,5,23,33,34
Anhydrides, organic acid, for use as curing agents for epoxy resins.		1,3,4,5,8
Aniline	13	1,4,8

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Antihistamines not separately specified in this Appendix except :	39 or 40	
(a) dermal, ocular, parenteral and paediatric preparations;		
(b) oral preparations of astemizole, desloratadine, fexofenadine, loratadine or terfenadine;		
(c) nasal preparations of azelastine; or		
(d) preparations for the treatment of animals.		
Aromatic extract oils		1,3,4,5,6
Aspirin		
(a) for inhibition of platelet aggregation.	36	
(b) in sustained release preparations containing 650mg or more of aspirin.	36	
(c) in other preparations	101,102,103	
Astemizole	61	
Azadirachta indica (neem) including its extracts and derivatives when included in Schedule 6.	67	
Azocyclotin	48	
Benomyl	46	
Benzene	12	1,4,9
Benzoyl peroxide when included in Schedule 2.	55	

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Benzoyl peroxide when included in Schedule 5.		1,4,8
Bergamot oil	89	
Beryllium		1,4,8
Bifluorides (including ammonium, potassium and sodium salts)		
(a) when included in Schedule 5.	2	1,4
(b) when included in Schedule 6 or 7.	1,17,93	1,3,4,5,8,29,35
Bithionol for the treatment of animals.		1,4,8
Bexarotene		
(a) for human use.	7,62,76	
(b) for topical use.	62,77	
Boron trifluoride (including mixtures that generate boron trifluoride)		
(a) when included in Schedule 5.	2	1,4
(b) when included in Schedule 6 or 7.	1,17,93	1,3,4,5,8,29,35
Bosentan	7,62,76	
Bromoform		1,4,8
2-Butoxy-2'-thiocyanodiethyl ether		1,4,8
2-Butoxyethanol and its acetates		1,4,8
Camphor		
(a) in block, ball, disc or pellet form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents;	9	
(b) in other forms.	9	1

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Carbamide peroxide		
(a)	more than 9 per cent up to 30 per cent	5 1
(b)	more than 30 per cent up to 60 per cent	5 2
(c)	more than 60 per cent	2 2,4
Carbon disulphide	12	1,4,8,9,23
Carbon tetrachloride	12	1,4,8,9
Cassia oil		4
Chlorinating compounds		
(a)	in household cleaning or bleaching preparations.	20
(b)	in preparations containing less than 10 per cent of available chlorine.	11 1,4,10
(c)	in liquid preparations containing 10 per cent or more of available chlorine.	3,18 1,4,6,8,10, 15,16,17,18, 19,20,22,26
(d)	in dry preparations containing 10 per cent or more of available chlorine.	10,18,22,23 1,4,8,12,13, 14,15,16,17, 18,19,20,21, 22,26
(e)	in dry preparations containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances).	10,18,22 1,4,8,12,13, 14,15,16,17, 18,19,20,21, 22,26
(f)	in compressed block or tablets containing 10 per cent or more of available chlorine except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid.	10,22,23 12,13,14,15, 17,18,19,21

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
(g) in other compressed blocks or tablets containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances), as specified in <i>the Australian Code for the Transport of Dangerous Goods by Road and Rail</i> except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid.	10,22	12,13,14,15, 17,18,19,21
Chloroform when included in Schedule 6.		1,4,8
alpha-Chlorohydrin	13,51	1,4,8,9
Chromates (including dichromates) of alkali metals or ammonia		1,4,8
Chromium trioxide	2,14,15,23	1,4,8,13
Cimetidine when included in Schedule 3.	70,96	
Cinnamon bark oil		4
Clobetasone when included in Schedule 3.	72,73,74,75,95	
Clotrimazole in vaginal preparations when included in Schedule 3.	54,63,64,66	
Clove oil		1
Cyanides when included in Schedule 7.	13	4,8
Cyanuric acid		1,4,8
Cyclohexanone peroxide		1,4,8
Cysteamine		1
4,4-Diaminodiphenylmethane (methylene dianiline)		1,4,8

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
ortho-Dichlorobenzene		1,4,8
para-Dichlorobenzene		1,4
Dichloroethylene		1,4,8
Dichloroethyl ether		1,4,8
Dichloroisocyanurates		
(a) in household cleaning or bleaching preparations.	20	
(b) in preparations containing less than 10 per cent of available chlorine.	11	1,4,10
(c) in liquid preparations containing 10 per cent or more of available chlorine.	3,18	1,4,6,8,10, 15,16,17,18, 19,20,22,26
(d) in dry preparations containing 10 per cent or more of available chlorine.	10,18,22,23	1,4,8,12,13,14, 15,16,17,18,19, 20,21,22,26
(e) in dry preparations containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances), as specified in <i>the Australian Code for the Transport of Dangerous Goods by Road and Rail</i> .	10,18,22	1,4,8,12,13,14, 15,16,17,18,19, 20,21,22,26
(f) in anti-bacterial tablets containing 2.5 g or less of sodium dichloroisocyanurate.	60	
(g) in other compressed blocks or tablets containing 10 per cent or more of available chlorine except in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only.	10,22,23	12,13,14,15, 17,18,19,21

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
(h) in other compressed blocks or tablets containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances), as specified in <i>the Australian Code for the Transport of Dangerous Goods by Road and Rail</i> except in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only.	10,22	12,13,14,15,17, 18,19,21
(i) in other compressed blocks or tablets containing 10 per cent or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only.		
(i) during storage	10,22,23 18,21	12,13,14,15,17,
(ii) during use	5	1,4,7,12
(j) in other compressed blocks or tablets containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances) as specified in <i>the Australian Code for the Transport of Dangerous Goods by Road and Rail</i> in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only.		
(i) during storage	10,22 18,21	12,13,14,15,17,
(ii) during use	5	1,4,7,12

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Dichloromethane (methylene chloride)		
(a) in paint or lacquer removers.	12,16	1,4,8,11
(b) other than in paint or lacquer removers.		1,4,8,25
Diclofenac	101,104	
Dienestrol	67	
Diethanolamine when included in Schedule 5.	5	1,4
Diethanolamine when included in Schedule 6.	2,11,18	1,4,8
Diethyltoluamide for human use.	44	
5,6-Dihydroxyindoline	21,28	
Dimethylformamide		1,4,8
Dimethyl sulfate	2	1,4,8
Dimethyl sulfoxide		
(a) when not packed and labelled for therapeutic use.	27	1,4,5,8
(b) when packed and labelled for treatment of animals.	49	1,4,5,8
Dinitrocresols (and their homologues) except when for therapeutic use.		1,4,8
Dinitrophenols (and their homologues) except when for therapeutic use.		1,4,8
Dinocap	47	
Dioxane		1,4,8
Diphenoxylate when included in Schedule 3.	39 or 40, 41	
Econazole in vaginal preparations when included in Schedule 3.	54,63,64,66	

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Ephedrine in nasal preparations for topical use.	29	
Epichlorohydrin	2	1,4,8
Epoxy resins, liquid.		1,3,4,5,8
Ethanolamine when included in Schedule 5.	5	1,4
Ethanolamine when included in Schedule 6.	2,11,18	1,4,8
Ether when included in Schedule 5 or 6.		1,4,8
Ethoxyethylmercuric chloride		1,4
Ethyl bromide		1,4,8
Ethylene chlorohydrin		1,4,8
Ethylene glycol monoalkyl ethers and their acetates except when separately specified.		1,4,8
Ethylene oxide		1,4,8
Ethylmercuric chloride		1,4
Ethyl methacrylate	28	4,9,23
Etretinate	7,62,76	
Eugenol		1
Famotidine when included in Schedule 2.	96	
Fenoterol in metered aerosols.	32	
Fluconazole in oral preparations when included in Schedule 3.	64	

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Fluorides (including silicofluorides) when included in Schedule 5 or 6 except when separately specified.		1,4
Formaldehyde		
(a) in nail hardener cosmetics.	106	1,4,8,36
(b) in other preparations.	106	1,4,8
Formic acid		1,4,8
Glazing preparations containing lead compounds.	50	
Glutaraldehyde except when in Schedule 2		
(a) 25 per cent or less.	5,59	1,4,5
(b) more than 25 per cent.	3,59	1,4,5,8
Glycolic acid	79	1,5,6,31
Hexachlorophane in preparations for skin cleansing purposes containing 3 per cent or less of hexachlorophane.	24	
Hydrazine		1,4,8
Hydrochloric acid		
(a) 30 per cent or less of HCl.		1,4
(b) more than 30 per cent of HCl.		1,4,8
Hydrocortisone		
(a) for dermal use when included in Schedule 2 or 3.	38,72,73,74,75	
(b) for topical rectal use when included in Schedule 2 or 3.	38,75	

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Hydrocyanic acid when included in Schedule 7.	13	4,8
Hydrofluoric acid (including mixtures that generate hydrofluoric acid)		
(a) when included in Schedule 5.	2	1,4
(b) when included in Schedule 6 or 7.	1,17,93	1,3,4,5,8,29,35
Hydrogen peroxide		
(a) more than 3 per cent up to 10 per cent.	5	1
(b) more than 10 per cent up to 20 per cent.	5	2
(c) more than 20 per cent.	2	2,4
Hydroquinone		
(a) when in Schedule 2.	45	
(b) except when in Schedule 2 or 4.		1,4
Hydrosilicofluoric acid (including mixtures that generate hydrosilicofluoric acid)		
(a) when included in Schedule 5.	2	1,4
(b) when included in Schedule 6 or 7.	1,17,93	1,3,4,5,8,29,35
8-Hydroxyquinoline (including salts and derivatives) when prepared for internal use.	33	
Ibuprofen	101,104	

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Iodine		
(a) more than 20 per cent.		1,4,8
(b) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose.	91,92	
Ipratropium bromide in metered aerosols.	32	
Isocyanates (free organic)		
(a) when in paint.	28,52	1,5,8,10,27
(b) other than in paint.	28,52	1,4,8
Isoprenaline in metered aerosols	32	
Isotretinoin		
(a) for human oral use.	7,62,76	
(b) for topical use.	62,77	
Lead compounds		
(a) in hair cosmetics.	25	
(b) when in Schedule 6.		1,4,8
Leflunomide	7,62,87	
Lemon oil	89	
Levocabastine		
(a) in eye or nasal preparations containing 0.5 mg/mL or less of levocabastine.	62	
(b) in other preparations.	62 and either 39 or 40	

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Lime oil	89	
Loperamide when in Schedule 2.	41	
Magnesium chlorate		1,4
Mefanamic acid	101,104	
Mercuric thiocyanate		1,4
Metacresolsulphonic acid and formaldehyde condensation product for the treatment of animals.		1,4
Methanol except in methylated spirit.		1,4,8
Methoxamine in nasal preparations for topical use.	29	
Methyl chloride		1,4,8
Methylene bithiocyanate		1,4
Methyl ethyl ketone	5	1,4,8
Methyl ethyl ketone peroxide	2	2,3,4,6
Methyleugenol		1,6
Methyl iso-amyl ketone		1,4,8
Methyl iso-butyl ketone		1,4,8
Methyl iso-thiocyanate	5,12	1,4,8
Methyl methacrylate	28	4,9,23
Methylnorbornylpyridine	59	
1-(beta-Methyl sulphonamidoethyl)- 2-amino-3-N,N-diethylaminobenzene		1,4,8
Miconazole in vaginal preparations when included in Schedule 3.	54,63,64,66	

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Misoprostol	53	
Naphazoline in nasal preparations for topical use.	29	
Naphthalene		
(a) in block, ball, disc or pellet form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents;	9,105	
(b) in other forms.	9,105	1
Naproxen	101,104	
Nicotine except when in tobacco or when included in Schedule 2.		1,4
Nitric acid		
(a) 75 per cent or less HNO ₃ .	2	1,4
(b) more than 75 per cent HNO ₃ .	2	1,4,8
Nitrobenzene		1,4,8
Nitrophenols		1,4
Nitroprussides in aerosols.	84	8
Nizatidine when included in Schedule 2.	96	
Noradrenaline in metered aerosols.	32	
Nystatin in vaginal preparations when included in Schedule 3.	54,63,64,65,66	
Orange oil (bitter)	89	
Orciprenaline in metered aerosols.	32	
Oxalates, metallic		4,8

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Oxalic acid	2	4,8
Oxymetazoline in nasal preparations for topical use.	29	
Paint		
(a) First Schedule paints.	83	
(b) Second Schedule paints.	84	
Paracetamol	97 and/or 98,99,100	
Pentachlorophenol		1,4,8
Peracetic acid	2	1,4,8
Permanganates	2	24
Phenol and any other homologue of phenol		1,4
Phenols		5
Phenylenediamines and alkylated phenylenediamines		
(a) in hair dyes.	21	
(b) in preparations other than hair dyes.		1,4,8
Phenylephrine in nasal preparations for topical use.	29	
N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,5-dimethanamine	5,28	1,4,5,10
N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,6-dimethanamine	5,28	1,4,5,10
ortho-Phenylphenol except when in antiseptics.		1,4
Phenylpropanolamine	56	

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Phenytoin in pastes for the treatment of horses.	9	
Phosphonic acid		1,4
Phosphoric acid		1,4
Phosphorus (yellow)	2	1,4
ortho-Phthalaldehyde		
• when included in Schedule 6.	51,52,59	2,4,5,8,10
• when included in Schedule 5.	51,52,59	1,4,5,8,10
Picric acid (more than 20 per cent).		1,4
Podophyllin		
(a) in preparations specifically for use on anal or genital area.	36	
(b) in other liquid preparations when included in Schedule 2 or Schedule 3.	31	
(c) in other solid or semi-solid preparations when included in Schedule 2.	30	
Podophyllotoxin		
(a) in preparations specifically for use on anal or genital area.	36	
(b) in other liquid preparations when included in Schedule 2 or Schedule 3.	31	
(c) in other solid or semi-solid preparations when included in Schedule 2.	30	
Polihexanide		1,4,8

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Polyethanoxy (15) tallow amine		1,4
Poly(oxy-1,2-ethanediyl), α -[2-[(2-hydroxyethyl)amino]-2-oxoethyl]- ω -hydroxy-, mono-C ₁₃₋₁₅ -alkyl ethers	5,88	1,5
Potassium hydroxide		
(a) in preparations containing 0.5 per cent or less of potassium hydroxide.	5	1,4,6
(b) in solid preparations containing more than 0.5 per cent of potassium hydroxide.	2,10,78	3,5,28
(c) in liquid preparations containing more than 0.5 per cent of potassium hydroxide.	2,10,78	3,5
Potassium metabisulphite	5,26	1,4
Potassium nitrite in pickling or curing salts	94	
Potassium persulfate	5,21,25	1,5,23,33,34
Potassium sulfide	2	1,4
Propionic acid when in Schedule 6.	2	1,4
Ranitidine when included in Schedule 2.	96	
Safrole		
(a) in preparations for therapeutic use.		1
(b) other than for therapeutic use.		1,4
Salbutamol in metered aerosols or in dry powder formulations.	32	
Salicylamide	34 or 35	

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Sassafras oil		
(a) in preparations for therapeutic use.		1
(b) other than for therapeutic use.		1,4
Selenium compounds except when for therapeutic use (human or animal).		1,4,8
Silver in smoking deterrents.	42	
Sodium aluminate	2	1,4
Sodium chlorate		1,4
Sodium dodecylbenzene sulfonate	79	1
Sodium fluoride in preparations for human ingestion when in Schedule 2.	43	
Sodium hydrogen sulfate		1,4,8
Sodium hydrosulfite (more than 50 per cent)	5,26	1,4,8
Sodium hydroxide		
(a) in preparations containing 0.5 per cent or less of sodium hydroxide.	5	1,4,6
(b) in solid preparations containing more than 0.5 per cent of sodium hydroxide.	2,10,78	3,5,28
(c) in liquid preparations containing more than 0.5 per cent of sodium hydroxide.	2,10,78	3,5
Sodium laureth-6 carboxylate	79	1
Sodium metabisulphite (more than 50 per cent)	5,26	1,4

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Sodium nitrite		
• in pickling or curing salts	94	
Sodium persulfate	5,21,25	1,5,23,33,34
Sodium sulfide	2	1,4
Styrene		1,4,8
Sulfamic acid	2	1,4
Sulfuric acid	2	1,4
Symphytum spp. (Comfrey) when included in Schedule 5.		31,32
Tazarotene for topical use.	77,62	
Terbutaline in metered aerosols or in dry powder formulations.	32	
Terfenadine		61
Terpenes, chlorinated		1,4,8
Tetrachloroethane	12	8
Tetrachloroethylene when in Schedule 5 or 6.	12,16	1,4,8,11
Tetrahydrozoline in nasal preparations for topical use.	29	
Thalidomide	7,62,76	
Thiourea		1,4
Toluene		1,4,8
Toluenediamine		
(a) in hair dyes.	21	
(b) in preparations other than hair dyes.		1,4,8

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Tramazoline in nasal preparations for topical use.	29	
Tretinoin		
(a) for human oral use.	7,62,76	
(b) for topical use.	62,77	
Triamcinolone when in topical preparations for the treatment of mouth ulcers.	64 or 68	
Trichloroacetic acid except when for therapeutic use.	2	1,4
1,1,1-trichloroethane		8,9
Trichloroethylene except when for therapeutic use.	12	1,4,5,8,9
Trichlorophenol		1,4,8
Triethanolamine	5	1,4
Triethyl phosphate		1,4,8
Trifluoromethanesulfonic acid		
(a) more than 10 per cent.	1,17	1,4,8
(b) 10 per cent or less.		1,4,8
Triisopropanolamine lauryl ether sulfate		1,4,6
3,6,9-Trioxaundecanedioic acid	5	1
Tymazoline in nasal preparations for topical use.	29	
Vinclozolin	46	
Xylene		1,4,8

APPENDIX F, Part 3—continued

POISON	WARNING STATEMENTS	SAFETY DIRECTION
Xylometazoline in nasal preparations for topical use.	29	
Zinc chloride		1,4
Zinc sulfate when in Schedule 6.		1,4

APPENDIX G**DILUTE PREPARATIONS**

The requirements of this Standard do not apply to a poison listed in Column 1 of this Appendix at a concentration not more than that specified in Column 2 in respect of that poison.

Column 1 Poison	Column 2 Concentration (quantity per litre or kilogram)
ACETYLCHOLINE	1 mg
ALDOSTERONE	10 micrograms
ANTIMONY COMPOUNDS	1 mg
APOMORPHINE	1 mg
ARSENIC	1 mg
ATROPA BELLADONNA (belladonna)	300 micrograms
ATROPINE	300 micrograms
CANTHARIDIN	10 micrograms
CHLORINE	5 mg
CROTON TIGLIUM (croton oil)	1 mg
DIOXANE	100 mg
ERYSIMUM spp.	1 mg
FOLLICLE-STIMULATING HORMONE	100 micrograms
GELSEMIUM SEMPERVIRENS	1 mg
GLUCAGON	100 micrograms
GLYCERYL TRINITRATE	100 micrograms
GROWTH HORMONE	10 micrograms
HALOPERIDOL	1 mg
HYDROCYANIC ACID	1 microgram
HYOSCINE	300 micrograms
HYOSCYAMINE	300 micrograms
HYOSCYAMUS NIGER	300 micrograms
HYPOTHALAMIC RELEASING FACTORS	10 micrograms
INDOMETHACIN	1 mg
MERCURY	1 mg
METHYLMERCURY	300 micrograms
NAPHTHALENE	1 mg
NERIUM OLEANDER	1 mg
OESTRADIOL	10 micrograms
OESTRONE	100 micrograms
OXYTOCIN	1 microgram
PHOSPHORUS	1 mg
PODOPHYLLUM RESIN (podophyllin)	1 mg
PROGESTERONE	1 mg
PROPRANOLOL	1 mg

APPENDIX G—continued

Column 1 Poison	Column 2 Concentration (quantity per litre or kilogram)
SELENIUM	100 micrograms
STROPHANTHUS spp.	1 mg
STRYCHNINE	1 mg
TESTOSTERONE	1 mg
THYROXINE	10 micrograms

APPENDIX H**SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED**

Amorolfine.
Azelastine.
Butoconazole.
Clotrimazole.
Diclofenac.
Dimenhydrinate for the prevention and relief of motion sickness.
Diphenoxylate.
Econazole.
Fluconazole.
Hydrocortisone.
Miconazole.
Nystatin.
Pseudoephedrine.

APPENDIX I

UNIFORM PAINT STANDARD

This Appendix provides regulations for adoption by the States and Territories.

1. A person must not manufacture, sell, supply or use a First Schedule Paint for application to:
 - (1) a roof or any surface to be used for the collection or storage of potable water; or
 - (2) furniture; or
 - (3) any fence, wall, post, gate or building (interior or exterior) other than a building which is used exclusively for industrial purposes or mining or any oil terminal; or
 - (4) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.
2. A person must not manufacture, sell, supply or use a Third Schedule paint.
3. A person must not manufacture, sell, supply or use a paint for application to toys unless the paint complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2003 entitled *Safety of toys Part 3: Migration of certain elements*.
4. A person must not manufacture, sell, supply, or use a paint containing a pesticide except a fungicide, algicide, bactericide or antifouling agent.

The First Schedule

The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.

Substance	Proportion
ANTIMONY or antimony compounds other than antimony titanate pigments	more than 5 per cent
BARIUM salts except barium sulfate or barium metaborate	more than 5 per cent
CADMIUM or cadmium compounds	more than 0.1 per cent
CHROMIUM as chromates of ammonia, barium, potassium, sodium, strontium or zinc	more than 5 per cent
SELENIUM or selenium compounds	more than 0.1 per cent

APPENDIX I—continued**The Second Schedule**

Substance	Proportion
DICHLOROMETHANE (methylene chloride)	more than 5 per cent by wt
ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates	more than 10 per cent by vol
TOLUENE	more than 50 per cent by vol
XYLENE	more than 50 per cent by vol

The Third Schedule

The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.

Substance	Proportion
LEAD or lead compounds	more than 0.1 per cent

APPENDIX J**CONDITIONS FOR AVAILABILITY AND USE OF
SCHEDULE 7 POISONS****PART 1****CONDITIONS FOR AVAILABILITY AND USE**

(NOTE - the following controls are recommended for poisons only when included in Schedule 7. These conditions for availability and use may be implemented through poisons controls or other State or Territory legislation.)

1. Not to be available except to authorised or licensed persons.
2. Not to be used in printing inks.
3. Not to be used except by or in accordance with the directions of accredited government vermin control officers.
4. Not to be used in industries which handle, process or store foods, animal feeds or packaging materials.

APPENDIX J–continued**PART 2**

A poison listed in this Appendix is to be available only in accordance with the conditions specified beside it in the “Conditions” column. The conditions apply only when the poison is included in Schedule 7.

POISON	CONDITIONS
Abamectin	1
Acibenzolar-s-methyl	1
Acrolein	1
Acrylonitrile	1
Alachlor	1
Allyl alcohol	1
4-Aminopyridine	1
Arprinocid	1
Arsenic	1
Azocyclotin	1
Benzene	1
Bifluorides (including ammonium, potassium and sodium salts)	1
Boron trifluoride	1
Brodifacoum	1
Bromadiolone	1
Bromine	1
Brucine	1
Calciferol	1
Captafol	1
Carbadox	1

APPENDIX J, Part 2—continued

POISON	CONDITIONS
Carbon tetrachloride	1
Chlordecone	1
Chlordimeform	1
Chlorine	1
Chloromethiuron	1
Chloropicrin	1
4-Chloro-oh-toluidine	1
Colecalciferol	1
Coumatetralyl	1
Cyanogen	1
Cyhexatin	1
4,4-Diaminodiphenylmethane (methylene dianiline)	1
1,2-Dibromo-3-chloropropane	1
1,3-Dichloropropene	1
Difenacoum	1
4-Dimethylaminoazobenzene	1
Dinitroresols	1
Dinitrophenols	1
Dinoseb	1
Epichlorohydrin	1
Epidermal growth factor	1
Etaconazole	1

APPENDIX J, Part 2—continued

POISON	CONDITIONS
Ethylene dibromide	1
Ethylene oxide	1
Fluoracetamide	3
Fluoroacetic acid	3
Folpet	1
Halofuginone	1
Halogenated dibenzodioxins and dibenzofurans	1
HCB	1
Hydrocyanic acid and cyanides	1
Hydrofluoric acid	1
Hydrosilicofluoric acid	1
Iodomethane	1
Maduramicin	1
Mercury	1
Methacrifos	1
Methoxyethylmercuric acetate	1
Methoxyethylmercuric chloride	1
Methyl bromide	1
4,4'-Methylenebis[2-chloroaniline]	1
Mirex	1
Molinate	1
Nicotine	1

APPENDIX J, Part 2—continued

POISON	CONDITIONS
Nitrofen	1
Phenylmercuric acetate	1
Phosphides, metallic	1
Phosphine	1
Propylene oxide	1
Pyrinuron	1
Rotigotine	
Strychnine	1
Sulcofuron	1
Tetrachloroethane	1
2,2',6,6'-Tetraisopropyl-diphenyl-carbodiimide	1
Thallium	3
ortho-Tolidine	1
Trichloroisocyanuric acid	1
Vinyl chloride	1

APPENDIX K**DRUGS REQUIRED TO BE LABELLED
WITH A SEDATION WARNING**

(See Part 3 Paragraph 45)

Alprazolam
Amisulpride
Amitriptyline
Amylobarbitone
Aripiprazole
Azatadine
Baclofen
Benztropine
Bromazepam
Brompheniramine
Buclizine
Buprenorphine
Butobarbitone
Cetirizine
Chloral Hydrate
Chlordiazepoxide
Chlormethiazole
Chlorpheniramine
Chlorpromazine
Clemastine
Clomipramine
Clonazepam
Clonidine
Clorazepate
Clozapine
Codeine **except** when included in Schedule 2 or 3.
Cyclizine
Cyclobarbitone
Cycloserine
Cyproheptadine
Cysteamine
Dantrolene
Desipramine
Dexchlorpheniramine
Dextromoramide
Dextropropoxyphene
Diazepam
Difenoxin
Dihydrocodeine
Dimenhydrinate
Dimethindene

APPENDIX K—continued

Diphenhydramine
Diphenoxylate
Diphenylpyraline
Dothiepin
Doxepin
Doxylamine
Dronabinol (*delta*-9-tetrahydrocannabinol)
Droperidol
Duloxetine
Ethylmorphine
Fenfluramine
Flunitrazepam
Flupenthixol
Fluphenazine
Flurazepam
Gabapentin
Gemcitabine
Glutethimide
Haloperidol
Hydrocodone
Hydromorphone
Hydroxyzine
Imipramine
Lamotrigine
Levetiracetam
Levocabastine
Lorazepam
Mazindol
Mebhydrolin
Meclozine
Medazepam
Meprobamate
Mepyramine
Methadone
Methdilazine
Methocarbamol
Methylphenobarbitone
Mianserin
Mirtazapine
Morphine
Nalbuphine
Nitrazepam
Normethadone
Nortriptyline
Olanzapine
Opium in any form **except** the alkaloids Noscapine and Papaverine.
Oxazepam

APPENDIX K—continued

Oxycodone
Paliperidone
Papaveretum
Pentazocine
Pentobarbitone
Pericyazine
Perphenazine
Pethidine
Phenelzine
Pheniramine
Phenobarbitone
Phenoperidine
Phenyltoloxamine
Pholcodine
Pimozide
Pizotifen
Prazepam
Pregabalin
Prochlorperazine
Promazine
Promethazine
Protriptyline
Quetiapine
Quinalbarbitone
Risperidone
Rotigotine
Secbutobarbitone
Temazepam
Thenyldiamine
Thiethylperazine
Thiopropazate
Thioridazine
Thiothixene
Tramadol
Tranlycypromine
Trifluoperazine
Trimeprazine
Trimipramine
Triprolidine
Ziprasidone
Zolpidem
Zonisamide
Zopiclone

INDEX

A

ABACAVIR	66
ABAMECTIN	156, 192, 238, 338
ABATACEPT	66
ABCIXIMAB	66
ABRUS PRECATORIUS.....	275
ACAMPROSATE CALCIUM	66
ACARBOSE.....	66
ACEBUTOLOL	66
ACEPHATE	192
ACEPROMAZINE.....	66
ACETAMIPRID.....	192
ACETANILIDE	66
ACETARSOL	66
ACETAZOLAMIDE.....	66
ACETIC ACID.....	38, 156, 192, 286, 311
ACETIC ANHYDRIDE.....	192, 286, 311
ACETOHEXAMIDE	66
ACETONE	4, 156, 286, 311
ACETORPHINE	254
ACETYL-ALPHA-METHYLFENTANYL.....	254
ACETYLCARBROMAL	66
ACETYLCHOLINE.....	66, 332
ACETYLCYSTEINE.....	38, 66
ACETYLDIGITOXIN	66
ACETYLDIHYDROCODEINE.....	250
ACETYL ISOVALERYLTYSIN	66
ACETYLMETHADOL.....	250
ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.....	66
ACETYLMORPHINES	250
4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE.....	268
ACETYLSTROPHANTHIDIN.....	66
ACIBENZOLAR-S-METHYL.....	238, 338
ACICLOVIR	66
ACIFLUORFEN	192
ACINITRAZOLE.....	192
ACIPIMOX	67
ACITRETIN.....	35, 67, 279, 311
ACOKANTHERA OUABAIO	67
ACOKANTHERA SCHIMPERI.....	67
ACONITUM	38, 67
ACORUS CALAMUS	275
ACRIFLAVINE	156, 238
ACRIVASTINE	67
ACROLEIN.....	238, 286, 338
ACRYLONITRILE	238, 338
ADALIMUMAB	67

ADAPALENE.....	35, 67, 311
ADEFOVIR.....	67
ADENOSINE.....	67
ADIPHENINE.....	67
ADONIS VERNALIS.....	67
ADRAFINIL.....	67
ADRENALINE.....	58, 67
ADRENOCORTICAL HORMONES.....	67
AGALSIDASE.....	67
AGLEPRISTONE.....	67
AGOMELATINE.....	67
AGROBACTERIUM RADIOBACTER.....	268
AKLOMIDE.....	156
ALACHLOR.....	238, 338
ALATROFLOXACIN MESYLATE.....	68
ALBENDAZOLE.....	68, 156, 192
ALCLOFENAC.....	68
ALCLOMETASONE.....	58, 68, 311
ALCOHOL, DEHYDRATED.....	268
ALCURONIUM.....	68
ALDESLEUKIN.....	68
ALDICARB.....	238
ALDOSTERONE.....	68, 332
ALDOXYCARB.....	238
ALDRIN.....	192
ALEFACEPT.....	68, 281
ALEMTUZUMAB.....	68
ALENDRONIC ACID.....	68
ALFACALCIDOL.....	68
ALFENTANIL.....	250
ALFUZOSIN.....	68
ALGICIDES.....	261
ALGLUCERASE.....	68
ALGLUCOSIDASE.....	68
ALISKIREN.....	68
ALKALINE SALT(S).....	14, 17, 27, 156, 192, 275, 286, 311
ALKOXYAMPHETAMINES.....	254
ALKOXYLATED FATTY ALKYLAMINE POLYMER.....	156, 192
ALKOXYPHENYLETHYLAMINES.....	254
ALKYL PHENYLENEDIAMINES.....	325
ALKYL SULFONALS.....	144
ALKYL TETRAHYDROCANNABINOLS	
<i>See</i> TETRAHYDROCANNABINOLS	
ALKYLTHIOAMPHETAMINES.....	254
ALKYL THIOUREAS.....	235
ALLERGENS.....	68
ALLETHRIN.....	157, 193
ALLOPURINOL.....	68
ALLOXYDIM.....	157
ALLYL ALCOHOL.....	238, 338

ALLYLISOPROPYLACETYLUREA.....	275
ALLYLOESTRENOL.....	68
ALLYLPRODINE.....	254
ALOSETRON.....	68
ALOXIPRIN.....	38
ALPHA-CHLOROHYDRIN.....	202, 315
ALPHA-CHLORALOSE	
<i>See</i> CHLORALOSE	
ALPHA-CYPERMETHRIN.....	157, 193, 238
ALPHA-METHYLFENTANYL.....	254
ALPHA-METHYLTHIOFENTANYL.....	254
ALPHACETYLMETHADOL.....	250
ALPHADOLONE.....	68
ALPHAMEPRODINE.....	254
ALPHAMETHADOL.....	254
ALPHAPRODINE.....	250
ALPHAXALONE.....	68
ALPRAZOLAM.....	68, 342
ALPRENOLOL.....	69
ALPROSTADIL.....	69
ALSEROXYLON.....	69
ALTEPLASE.....	69
ALTRENOGEST.....	69
ALTRETAMINE.....	69
ALUM.....	268
ALUMINIUM AMMONIUM SULFATE.....	268
ALUMINIUM PHOSPHIDE	
<i>See also</i> PHOSPHIDES, METALLIC	
ALUMINIUM POTASSIUM SULFATE.....	268
ALUMINIUM SILICATE.....	268
ALUMINIUM TRIS (ETHYLPHOSPHONATE).....	268
AMANTADINE.....	69
AMBENONIUM.....	69
AMBUCETAMIDE.....	69
AMBUTONIUM.....	69
AMCINONIDE.....	69
AMETHOCAINE.....	38, 69
AMETRYN.....	157
AMFEBUTAMONE	
<i>See</i> BUPROPION	
AMICARBAZONE.....	193
AMIDITHION.....	193
AMIDOPYRINE.....	69, 275
AMIFOSTINE.....	69
AMIKACIN.....	69
AMILORIDE.....	69
AMINACRINE.....	157, 238
AMINES.....	17, 157, 286, 311
AMINOCAPROIC ACID.....	69
AMINOCARB.....	193, 238

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE	254
AMINOETHOXYVINYLGLYCINE	193
AMINOGLUTETHIMIDE	69
1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE	193
AMINOMETRADINE	69
AMINOPHENAZONE	69, 275
AMINOPHYLLINE	58, 69
5-(2-AMINOPROPYL)INDAN	254
AMINOPTERIN	69
AMINOPYRALID	193
4-AMINOPYRIDINE	69, 238, 286, 338
AMINOREX	70
AMINOSALICYLIC ACID	70
para-AMINOSALICYLIC ACID	
<i>See</i> AMINOSALICYCLIC ACID	
AMIODARONE	70
AMIPHENAZOLE	70
AMISOMETRADINE	70
AMISULPRIDE	70, 342
AMITON	238
AMITRAZ	193, 235
AMITRIPTYLINE	70, 342
AMITROLE	157
AMLODIPINE	70
AMMI VISNAGA	70
AMMONIA	157, 193, 286, 311, 315
AMMONIUM BIFLUORIDE	
<i>See also</i> FLUORIDES	
AMMONIUM BROMIDE	70
AMMONIUM CHROMATE	315
AMMONIUM DICHROMATE	315
AMMONIUM HYDROXIDE	157, 193, 311
<i>See also</i> AMMONIA	
AMMONIUM PERSULFATE	193, 286, 311
AMMONIUM PHOSPHATE	268
AMMONIUM THIOCYANATE	157, 286
AMMONIUM THIOSULPHATE	268
AMODIAQUINE	70
AMOROLFINE	38, 58, 70, 334
AMOXAPINE	70
AMOXYCILLIN	70
AMPHETAMINE	250
AMPHOMYCIN	70
AMPHOTERICIN	70
AMPICILLIN	70
AMPRENAVIR	70
AMPROLIUM	268
AMRINONE	70
AMSACRINE	70

AMYGDALIN	275
AMYL ACETATE	268
AMYLASE	268
AMYL NITRITE	70
AMYLOBARBITONE	71, 250, 342
AMYLOCAINE	71
ANABOLIC STEROIDAL AGENTS	71, 280
ANAGRELIDE	71
ANAKINRA	71
ANALYTICAL PREPARATIONS	262
ANASTROZOLE	71
ANCESTIM	71
ANCHUSA OFFICINALIS	275
ANCROD	71
ANDROGENIC STEROIDAL AGENTS	71, 280
ANDROISOXAZOLE	71
ANDROSTALONE	117
ANDROSTANOLONE	71
ANDROSTENEDIOL	71
ANDROSTENEDIONE	71
ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT ...	268
ANDROSTERONE	xi
<i>See also</i> ANABOLIC STEROIDAL AGENTS	
ANECORTAVE	71
ANGIOTENSIN AMIDE	71
ANHYDRIDES	286, 311
ANHYDRIDES, ORGANIC ACID	157
ANIDULAFUNGIN	71
ANILERIDINE	250
ANILINE	193, 286, 311
ANIMAL FEED PREMIX	1
ANISE OIL	27, 157, 286
ANISTREPLASE	71
ANTAZOLINE	38, 71
ANTIBIOTIC SUBSTANCES	71
ANTIGENS	71
ANTI HISTAMINES	71, 312
ANTIMONY	72, 335
<i>See also</i> ANTIMONY COMPOUNDS	
ANTIMONY CHLORIDE	286
ANTIMONY COMPOUNDS	194, 287, 332, 335
ANTISERA	72
APOCYNUM	72
APOMORPHINE	72, 332
APPROPRIATE AUTHORITY	1
APPROVED NAME	1
APRACLONIDINE	72
APRAMYCIN	72
APREPITANT	72

APRONAL	72
APROTININ	72
ARECOLINE	72
ARIPIPRAZOLE	72, 342
ARISTOLOCHIA SPP	275
ARISTOLOCHIC ACID(S)	275
AROMATIC EXTRACT OIL	244, 312
<i>See also</i> HYDROCARBONS, LIQUID AROMATIC	
ARPRINOCID	238, 338
ARSENIC	34, 72, 194, 199, 238, 240, 332, 338
ARTEMETHER	72
ARTICAINE	72
ASARUM SPP	275
ASPARTIC ACID	268
ASPIDOSPERMA QUEBRACHO	
<i>See</i> YOHIMBINE	
ASPIRIN	38, 44, 72, 140, 158, 194, 312
ASTEMIZOLE	72, 312
ASULAM	268
ATAMESTANE	72
ATAZANAVIR	72
ATENOLOL	72
ATIPAMEZOLE	72
ATOMOXETINE	72
ATORVASTATIN	73
ATOSIBAN	73
ATOVAQUONE	73
ATRACURIUM BESYLATE	73
ATRAZINE	158
ATROPA BELLADONNA	39, 73, 332
ATROPINE	39, 73, 332
ATROPINE METHONITRATE	73
ATROPINE SULFATE	60, 91, 93
AURANOFIN	73
AUROTHIOMALATE SODIUM	73
AVILAMYCIN	73
AVIPTADIL	73
AVOPARCIN	73
AZACITIDINE	73
AZACONAZOLE	194
AZACYCLONOL	73
AZADIRACHTA INDICA	158, 194, 275, 287, 312
AZAFENIDIN	239
AZAMETHIPHOS	194
AZAPERONE	73
AZAPROPAZONE	73
AZARIBINE	73
AZATADINE	58, 73, 342

AZATHIOPRINE.....	73
AZELAIC ACID	40, 73
AZELASTINE.....	40, 58, 74, 334
AZIMSULFURON.....	268
AZINPHOS-ETHYL.....	239
AZINPHOS-METHYL	239
AZITHROMYCIN	74
AZLOCILLIN	74
AZO BENZENE.....	194
AZOCYCLOTIN.....	239, 312, 338
AZOXYSTROBIN.....	158
AZTREONAM.....	74

B

BACAMPICILLIN.....	74
BACILLUS SPHAERICUS STRAIN 2362	268
BACILLUS THURINGIENSIS	158, 268
BACILLUS TOYOI.....	268
BACITRACIN.....	74
BACLOFEN.....	74, 342
BACTERIAL CULTURE MEDIA	261
BACTERIOCIDES.....	261
BACULOVIRUS CYDIA POMONELLA	268
BALSALAZIDE	74
BAMBERMYCIN.....	74, 195
BAMBUTEROL	74
BAMETHAN	74
BAMIPINE.....	74
BARBITURATES.....	74
BARIUM.....	195, 287, 335
BARIUM SILICOFLUORIDE.....	158
BASIC ORANGE 31.....	195, 275
BASILIXIMAB.....	74
BASIL OIL.....	27, 158, 287
BATTERIES	261
BAY OIL.....	27, 195, 287
BDMPEA	
<i>See</i> 4-BROMO-2,5-DIMETHOXY-PHENYLETHYLAMINE	
BEAUVERIA BASSIANA	158, 196
BECAPLERMIN.....	74
BECLAMIDE.....	74
BECLOMETHASONE	40, 74
BELLADONNA.....	39
BEMEGRIDE.....	74
BENACTYZINE	74
BENALAXYL.....	158
BENZAEPRILOL.....	74
BENDIOCARB.....	158, 196, 239

BENDROFLUAZIDE	75
BENETHAMINE PENICILLIN	75
BENFLURALIN	268
BENOMYL	239, 312
BENORYLATE	75
BENOXAPROFEN	75
BENPERIDOL	75
BENQUINOX	196
BENSERAZIDE	75
BENSULFURON-METHYL	268
BENSULIDE	196
BENTAZONE	159
BENTONITE	268
BENZALKONIUM CHLORIDE	159, 196, 287
<i>See also</i> QUATERNARY AMMONIUM COMPOUNDS	
BENZATHINE PENICILLIN	75
BENZATROPINE	75
BENZENE	239, 287, 312, 338
BENZETHIDINE	254
BENZHEXOL	75
BENZILONIUM	75
BENZOCAINE	40, 75
BENZODIAZEPINE DERIVATIVES	75
BENZOFENAP	159
BENZOYL METRONIDAZOLE	
<i>See</i> METRONIDAZOLE BENZOATE	
BENZOYL PEROXIDE	40, 75, 159, 287, 312, 313
BENZPHETAMINE	75
BENZTHIAZIDE	75
BENZTROPINE	75, 342
BENZYDAMINE	40, 75
6-BENZYLADENINE	197
BENZYL BENZOATE	268
BENZYLMORPHINE	250
BENZYL PENICILLIN	76
BENZYLPIPERAZINE	254
BEPHENIUM SALTS	40
BEPRIDIL	76
BERACTANT	76
BERGAMOT OIL	159, 287, 313
BERYLLIUM	197, 313
BETA-CYPERMETHRIN	197
BETA-HYDROXYFENTANYL	254
BETA-HYDROXY-3-METHYLFENTANYL	254
BETACETYLMETHADOL	254
BETACYFLUTHRIN	159, 197, 239
BETAHISTINE	76
BETAINE HYDROCHLORIDE	269
BETAMEPRODINE	254

BETAMETHADOL	254
BETAMETHASONE	76
BETAPRODINE	254
BETAXOLOL	76
BETHANECHOL CHLORIDE	76
BETHANIDINE	76
BEVACIZUMAB	76
BEVANTOLOL	76
BEXAROTENE	35, 76, 279, 313
BEZAFIBRATE	76
BEZITRAMIDE	250
BHC	197
BICALUTAMIDE	76
BIFENAZATE	269
BIFENTHRIN	197, 239
BIFLUORIDES	159, 197, 239, 287, 313, 338
BIFONAZOLE	40, 76
BIMATOPROST	76
BIOALLETHRIN	159, 197
BIORESMETHRIN	159
BIPERIDEN	76
BISMUTH CITRATE	76
BISMUTH COMPOUNDS	76
BISMUTH OXYCHLORIDE	76
BISMUTH SUBNITRATE	269
BISOPROLOL	77
BIS(TRIBUTYL TIN OXIDE) <i>See</i> TRIBUTYL TIN OXIDE	
BITHIONOL	198, 275, 313
BIURET	269
BIVALIRUDIN	77
BLEACHES <i>See</i> CHLORINATING COMPOUNDS	
BLEOMYCIN	77
BLOOD	3
<i>See also</i> HUMAN BLOOD PRODUCTS	
BLOOD COMPONENTS	3
BOILING TEMPERATURE	10
BOLANDIOL	77
BOLASTERONE	77
BOLAZINE	77
BOLDENONE	77
BOLENOL	77
BOLMANTALATE	77
BORAGE	275
BORAGO OFFICINALIS	275
BORATES <i>See</i> BORON	
BORAX	77, 160, 287
<i>See also</i> BORON	

BORIC ACID	77, 160, 287
<i>See also</i> BORON	
BORON	77, 160
BORON COMPOUNDS	
<i>See</i> BORON	
BORON TRIFLUORIDE	160, 198, 239, 287, 313, 338
<i>See also</i> BORON	
BORTEZOMIB	77
BOSCALID	269
BOSENTAN	77, 281, 313
BOTULINUM TOXINS	77
BOVINE SOMATOTROPHIN	269
BRAGANTIA SPP	275
BRETYLIUM	77
BRIMONIDINE	77
BRINZOLAMIDE	77
BRODIFACOUM	198, 239, 338
BROMACIL	269
BROMADIOLONE	198, 239, 338
BROMAZEPAM	77, 342
BROMETHALIN	198, 239
BROMHEXINE	40
BROMIDES	77
BROMINE	239, 305, 338
BROMOCHLORODIMETHYLHYDANTOIN	313
<i>See also</i> CHLORINATING COMPOUNDS	
BROMOCRIPTINE	77
4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE	255
BROMOFORM	78, 198, 288, 313
BROMOPHOS	198
BROMOPHOS-ETHYL	198
BROMOPROPYLATE	269
BROMOXYNIL	198
BROMPHENIRAMINE	40, 58, 78, 342
BROMUCONAZOLE	160, 198
BROMVALETONE	78
BROTIANIDE	198
BRUCINE	240, 288, 338
BRUGMANSIA	78
BUCLIZINE	58, 78, 342
BUCLOSAMIDE	276
BUDESONIDE	41, 78
BUFEXAMAC	78
BUFOTENINE	255
BUMETANIDE	78
BUNAMIDINE	198
BUNIODYL SODIUM	276
BUPHENINE	78
BUPIRIMATE	269

BUPIVACAINE.....	78
BUPRENORPHINE.....	250, 342
BUPROFEZIN.....	160
BUPROPION.....	78
BUSERELIN.....	78
BUSPIRONE.....	78
BUSULPHAN.....	78
BUTACAINE.....	78
BUTACARB.....	198
BUTAFENACIL.....	269
1,4-BUTANEDIOL.....	276
BUTHIDAZOLE.....	160
BUTOBARBITONE.....	250, 342
BUTOCONAZOLE.....	58, 78, 334
BUTORPHANOL.....	250
BUTOXYCARBOXIM.....	160, 198
2-(2-BUTOXY)ETHANOL	
<i>See</i> DIETHYLENE GLYCOL MONOBUTYL ETHER	
2-BUTOXYETHANOL.....	198, 288, 313
BUTOXPOLYPROPYLENE GYLCOL.....	269
2-BUTOXY-2'-THIOCYANO-DIETHYL ETHER.....	199, 313
BUTRACONAZOLE.....	78
BUTRALIN.....	160
BUTROXYDIM.....	160
BUTYL AMINOBENZOATE.....	78
N-BUTYL BUTYRATE.....	269
BUTYLCHLORAL HYDRATE.....	78
N-BUTYL LACTATE.....	269
BUTYL NITRITE.....	78
BUTYRIC ACID.....	199
BUTYROPHENONES	
<i>See</i> HALOPERIDOL	
BZP.....	254
C	
CABERGOLINE.....	78
CACALIA.....	276
CACODYLIC ACID.....	199, 240
CADMIUM.....	335
<i>See also</i> CADMIUM COMPOUNDS	
CADMIUM ACETATE	
<i>See</i> CADMIUM COMPOUNDS	
CADMIUM CHLORIDE	
<i>See</i> CADMIUM COMPOUNDS	
CADMIUM COMPOUNDS.....	79, 199, 288
CADMIUM NITRATE	
<i>See</i> CADMIUM COMPOUNDS	
CADUSAFOS.....	199, 240
CAFFEINE.....	72, 140

CAJUPUT OIL.....	27, 199, 288
CALAMUS	
<i>See</i> ACORUS CALAMUS	
CALCIFEROL	200, 240, 338
CALCIPOTRIOL	79
CALCITONIN.....	79
CALCITRIOL	79
CALCIUM CARBIMIDE	79
CALCIUM FOLINATE	
<i>See</i> FOLINIC ACID	
CALCIUM HYPOCHLORITE	
<i>See</i> CHLORINATING COMPOUNDS	
CALCIUM POLYSTYRENE SULPHONATE	79
CALOMEL	
<i>See</i> MERCURIC CHLORIDE	
CALOTROPIS GIGANTEA	79
CALOTROPIS PROCERA	79
CALUSTERONE	79
CAMBENDAZOLE	200
CAMPBOR	24, 30, 160, 200, 288, 313
CAMPBOR BLOCKS	
<i>See</i> CAMPBOR	
CAMPBOR OIL (WHITE)	
<i>See</i> CINEOLE	
CAMPBORATED OIL	79
CAMPHOTAMIDE	79
CANDESARTAN CILEXETIL	79
CANDICIDIN	79
CANINE TICK ANTI-SERUM	79
CANNABIS	255
CANNABIS SATIVA	5
CANTHARIDIN	79, 332
CAPECITABINE	79
CAPREOMYCIN	79
CAPTAFOL	240, 338
CAPTAN	201
CAPTODIAME	79
CAPTOPRIL	79
CAPURIDE	79
CARAMIPHEN.....	79
CARBACHOL	79
CARBADOX	240, 338
CARBAMATE	17
CARBAMAZEPINE	79
CARBAMIDE PEROXIDE	160, 201, 288, 314
CARBARYL	79, 161, 201
CARBAZOCHROME	80
CARBENDAZIM.....	201
CARBENICILLIN	80
CARBENOXOLONE	80

CARBETAMIDE	269
CARBETAPENTANE	41
CARBETOCIN	80
CARBIDOPA	80
CARBIMAZOLE	80
CARBOCISTEINE	41
CARBOCROMEN	80
CARBOFURAN	240
CARBON DISULFIDE	201, 288, 314
CARBON TETRACHLORIDE	240, 288, 314, 339
CARBOPHENOTHION	240
CARBOPLATIN	80
CARBOPROST	80
CARBOSULFAN	240
CARBOXIN	269
CARBROMAL	80
CARBUTAMIDE	80
CARDIAC GLYCOSIDES	
<i>See</i> UNDER INDIVIDUAL ENTRIES	
CARBUTEROL	80
CARFENTANYL	250
CARFENTRAZONE-ETHYL	269
CARINDACILLIN	80
CARISOPRODOL	80
CARMUSTINE	80
CARNIDAZOLE	80
CARPROFEN	80
CARVEDILOL	80
CASPOFUNGIN	80
CASSIA OIL	27, 161, 288, 314
CASTOR OIL, MONOMALEATE	201
CATALIN	
<i>See</i> PIRENOXINE	
CATHINE	80
CATHINONE	255
CEFACETRILE	80
CEFACTOR	80
CEFADROXIL	80
CEFALORIDINE	80
CEFAMANDOLE	81
CEFAPIRIN	81
CEFAZOLIN	81
CEFEPIME	81
CEFETAMET	81
CEFIXIME	81
CEFODIZIME	81
CEFONICID	81
CEFOPERAZONE	81
CEFOTAXIME	81
CEFOTETAN	81

CEFOTIAM	81
CEFOVECIN	81
CEFOXITIN.....	81
CEFPIROME	81
CEFPODOXIME.....	81
CEFSULODIN	81
CEFTAZIDIME	81
CEFTIBUTEN.....	81
CEFTIOFUR.....	81
CEFTRIAZONE	81
CEFUROXIME	81
CELECOXIB	81
CELIPROLOL.....	81
CELLULASE.....	269
CEPHACETRILE	
<i>See</i> CEFACETRILE	
CEPHAELIS ACUMINATA	82
CEPHAELIS IPECACUANHA	82
CEPHALEXIN.....	82
CEPHALONIUM.....	82
CEPHALORIDINE	82
<i>See</i> CEFALORIDIN	
CEPHALOTHIN	82
CEPHAMANDOLE	
<i>See</i> CEFAMANDOLE	
CEPHAPIRIN	
<i>See</i> CEFAPIRIN	
CEPHAZOLIN	
<i>See</i> CEFAZOLIN	
CEPHRADINE.....	82
CERAMICS	261
CERIVASTATIN.....	82
CERULETIDE	82
CETIRIZINE.....	41, 82, 342
CETRORELIX	82
CETUXIMAB	82
CETYL ALCOHOL.....	269
CHAMOMILE OIL.....	269
CHEMISTRY SETS.....	261
CHENODEOXYCHOLIC ACID.....	82
CHILD-RESISTANT CLOSURE	3
CHILD-RESISTANT PACKAGING.....	3
CHINA CLAY	269
CHLOPHEDIANOL	41
CHLORAL FORMAMIDE.....	82
CHLORAL HYDRATE	82, 342
CHLORALOSE.....	82, 201
CHLORAMBUCIL	82
CHLORAMPHENICOL	82
CHLORANDROSTENOLONE.....	82

CHLORANTRANILIPROLE	269
CHLORAZANIL	82
CHLORBUTOL	41, 58
CHLORCYCLIZINE	82
CHLORDANE	201
CHLORDECONE	240, 339
CHLORDIAZEPOXIDE	82, 342
CHLORDIMEFORM	240, 339
CHLORFENAC	161
CHLORFENAPYR	201, 240
CHLORFENETHOL	201
CHLORFENSON	161
CHLORFENVINPHOS	240
CHLORFLUAZURON	269
CHLORFLURENOL	269
CHLORHEXIDINE	161, 201, 240
CHLORIDAZON	269
CHLORINATING COMPOUNDS	161, 202, 288, 314
CHLORINE	240, 314, 332, 339
CHLORINE (GAS)	288
CHLORMEQUAT	202
CHLORMERODRIN	82
CHLORMETHIAZOLE	83, 342
CHLORMEZANONE	83
CHLORNIDINE	161
CHLOROCRESOL	162, 288
CHLOROFORM	41, 83, 202, 288, 315
CHLOROMESTERONE	
<i>See</i> DEHYDROCHLOROMETHYLTESTOSTERONE	
4-CHLOROMETHANDIENONE	83
CHLOROMETHIURON	240, 339
5-CHLORO-3-METHYL-4-NITROPYRAZOLE	240
CHLOROPHACINONE	202
(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)	
PENT-1-EN-3-OL	202
2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOL	83
CHLOROPICRIN	202, 241, 339
CHLOROQUINE	83
4-CHLOROTESTOSTERONE	85
<i>See also</i> CLOSTEBOL	
CHLOROTHALONIL	202
CHLOROTHIAZIDE	83
4-CHLORO-O-TOLUIDINE	241
CHLOROTRIANISENE	83
CHLOROXYDIENONE	83
CHLOROXYLENOLS	269
CHLORPHENIRAMINE	41, 58, 83, 342
CHLORPHENTERMINE	83
CHLORPROMAZINE	83, 342
CHLORPROPAMIDE	83

CHLORPROPHAM	162
CHLORPROTHIXENE	83
CHLORPYRIFOS	162, 202
CHLORPYRIFOS-METHYL	203
CHLORQUINALDOL	83
<i>See also</i> CLIOQUINOL	
CHLORSULFURON	162
CHLORTETRACYCLINE	83, 162
CHLORTHAL-DIMETHYL	162
CHLORTHALIDONE	83
CHLORTHIAMID	203
CHLORTHIOPHOS	241
CHLORZOAZONE	83
CHOLECALCIFEROL	
<i>See</i> COLECALCIFEROL	
CHOLERA VACCINE	83
CHOLESTYRAMINE	83
CHOLINE SALICYLATE	
<i>See</i> SALICYLIC ACID	
CHROMATES	XI, 203, 288, 315
CHROMIC ACID	
<i>See</i> CHROMIUM TRIOXIDE	
CHROMIUM	335
<i>See also</i> CHROMATES	
CHROMIUM TRIOXIDE	203, 288, 315
CHRYSANTHEMIC ACID ESTERS	184
CHYMOPAPAIN	83
CICLACILLIN	83
CICLESONIDE	83
CICLOPIROX	41, 58, 83
CIDOFOVIR	84
CILASTATIN	84
CILAZAPRIL	84
CIMETIDINE	59, 84, 315
CINACALCET	84
CINCHOCAINE	42, 84
CINCHOPHEN	276
CINEOLE	27, 203, 288
CINEROLONE	184
CINMETHYLIN	162
CINNAMEDRINE	42
CINNAMON BARK OIL	27, 162, 289, 315
CINNAMON LEAF OIL	28, 204, 289
CINOXACIN	84
CIPROFLOXACIN	84
CISAPRIDE	84
CISATRACURIUM BESYLATE	84
CISPLATIN	84
CITALOPRAM	84

CITRONELLA OIL	269
CLADRIBINE.....	84
CLANOBUTIN.....	84
CLARITHROMYCIN.....	84
CLARY SAGE OIL	269
CLAVULANIC ACID	84
CLEMASTINE.....	59, 84, 342
CLEMIZOLE	84
CLENBUTEROL	84
CLETHODIM	162
CLIDINIUM.....	84
CLIMBAZOLE	162, 204, 289
CLINDAMYCIN.....	84
CLIOQUINOL	84, 276
CLOBAZAM	84
CLOBETASOL.....	85
CLOBETASONE	59, 85, 315
CLOCORTOLONE.....	85
CLODINAFOP-PROPARGYL.....	204
CLODRONIC ACID.....	85
CLOFAZIMINE.....	85
CLOFENAMIDE	85
CLOFENTEZINE	162
CLOFIBRATE	85
CLOMAZONE.....	204
CLOMIPHENE	85, 279
CLOMIPRAMINE.....	85, 342
CLOMOCYCLINE	85
CLONAZEPAM.....	85, 342
CLONIDINE	85, 342
CLONITAZENE	255
CLOPAMIDE.....	85
CLOPIDOGREL	85
CLOPIDOL	269
CLOPROSTENOL.....	85
CLOPYRALID.....	162
CLOQUINTOCET-MEXYL.....	163
CLORAZEPATE.....	85, 342
CLOREXOLONE	85
CLORPRENALINE	85
CLORSULON	163
CLOSANTEL.....	204
CLOSTEBOL.....	85
CLOTHIANIDIN	163, 204
CLOTRIMAZOLE.....	42, 59, 85, 204, 315, 334
CLOVE OIL.....	28, 163, 205, 289, 315
CLOXACILLIN	85
CLOZAPINE.....	85, 279, 342
CO-DERGOCRINE	86
CO-TRIMOXAZOLE	87

COAL TAR.....	276
COBALT.....	86
COBALT NAPHTHENATE.....	269
COCAINE.....	250
COCA LEAF.....	255
N-COCO-1,3-DIAMINOPROPANE.....	205
CODEINE.....	10, 42, 59, 86, 250, 342
CODEINE-N-OXIDE.....	250
CODOXIME.....	255
COLASPAS.....	86
COLCHICINE.....	86
COLCHICUM.....	86
COLECALCIFEROL.....	241, 339
<i>See also</i> VITAMIN D	
COLESTIPOL.....	86
COLFOSCERIL PALMITATE.....	86
COLISTIN.....	86
COLLAGEN.....	86
COLOPHONY.....	269
COLTSFOOT	
<i>See</i> TUSSILAGO	
COMFREY.....	187, 278, 329
<i>See also</i> SYMPHYTUM	
CONCENTRATE OF POPPY STRAW.....	250
CONIINE.....	276
CONIUM MACULATUM.....	276
CONTAINERS.....	25
CONVALLARIA KEISKI.....	86
CONVALLARIA MAJALIS.....	86
COPPER ACETATE.....	163, 205
COPPER CHLORIDE.....	206
COPPER-CHROME-ARSENIC	
<i>See</i> CHROMATES, AND ARSENIC COMPOUNDS	
COPPER COMPOUNDS.....	86, 163, 205, 261
COPPER HYDROXIDE.....	163, 206
COPPER NITRATE.....	206
COPPER OXIDES.....	163, 206
COPPER OXYCHLORIDE.....	163, 206
COPPER SULFATE.....	163, 206, 289
CORONILLA.....	86
CORROSIVE SUBLIMATE	
<i>See</i> MERCUROUS CHLORIDE	
CORTICOSTERONE.....	87
CORTICOTROPHIN.....	87
CORTISONE.....	87
COTARNINE.....	276
COUMAPHOS.....	206, 241
COUMARIN.....	87
COUMATETRALYL.....	163, 207, 241, 339
4-CPA.....	163

CREOSOTE	42, 207, 241, 289
CRESOLS	181, 226, 289
<i>See also</i> PHENOL	
CROSPROVIDONE	269
CROTALARIA	276
CROTON TIGLIUM.....	276, 332
CROTOXYPHOS	207
CRUFOMATE	207
CRYSTAL VIOLET	87
CRYSTAL WARE	261
CUBÉ	
<i>See</i> ROTENONE	
CULICINOMYCES CLAVOSPORUS.....	269
CUPRIMYXIN.....	87
CURARE.....	87
CURING AGENTS	
<i>See</i> EPOXY RESINS	
CYANAMIDE.....	207
CYANATRYN	163
CYANAZINE.....	207
CYANIDES.....	34, 241, 289, 315, 340
CYANOACRYLATE ESTERS	164
CYANOACRYLIC ACID ESTERS	289
4-CYANO-2-DIMETHYLAMINO-4,4-DIPHENYLBUTANE	255
CYANOGEN	241, 339
4-CYANO-1-METHYL-4-PHENYLPYPERIDINE.....	250
CYANURIC ACID	164, 289, 315
CYCLAMIC ACID	269
CYCLANDELATE	87
CYCLANILIDE	207
CYCLIZINE.....	59, 87, 342
CYCLOBARBITONE.....	250, 342
CYCLOBENZAPRINE.....	87
CYCLOFENIL	87, 279
CYCLOHEXANE	269
CYCLOHEXANOL ACETATE	270
CYCLOHEXANONE PEROXIDE.....	164, 289, 315
CYCLOHEXIMIDE.....	87
N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM	207
CYCLOPENTHIAZIDE	87
CYCLOPENTOLATE	87
CYCLOPHOSPHAMIDE	87
CYCLOPROPANE	87
CYCLOPROTHRIN.....	164
CYCLOSERINE	87, 342
CYCLOSPORIN	87
CYCLOTHIAZIDE.....	87
CYCLOXYDIM.....	164
CYCRIMINE	87
CYFLUTHRIN.....	164, 207

CYHALOFOP-BUTYL	164
CYHALOTHRIN	241
CYHEXATIN	241, 304, 339
CYMARIN	87
CYMIAZOLE	164
CYNOGLOSSUM	276
CYOMETRINIL	207
CYPERMETHRIN	165, 207
CYPHENOTHRIN	165, 207
CYPROCONAZOLE	165
CYPRODINIL	165
CYPROHEPTADINE	59, 87, 342
CYPROTERONE	87
CYROMAZINE	270
CYSTEAMINE	88, 165, 207, 289, 315, 342
CYTARABINE	88
CYTHIOATE	165, 207

D

2,4-D	165, 207
DABIGATRAN	88
DACARBAZINE	88
DACLIZUMAB	88
DACTINOMYCIN	88
DALFOPRISTIN	88
DALMATIAN	29, 297
DALTEPARIN	88
DAMINOZIDE	165
DANAPAROID	88
DANAZOL	88
DANTHRON	88
DANTROLENE	88, 342
DAPSONE	88
DAPTOMYCIN	88
DARBEPOETIN	88, 280
DARIFENACIN	88
DARUNAVIR	88
DASATINIB	88
DATURA	42, 88
DATURA STRAMONIUM	43, 88
DATURA TATULA	43, 89
DAUNORUBICIN	89
DAZOMET	18, 207
2,4-DB	165
DDAVP	
<i>See</i> DESMOPRESSIN	
DDT	
<i>See</i> DICOPHANE	

DEANOL	89
<i>See also</i> DIMETHYLETHANOLAMINE (DMAE)	
DEBITTERISED NEEM SEED OIL	4
DEBRISOQUINE	89
DECAMETHONIUM SALTS	89
DEET	
<i>See</i> DIETHYLTOLUAMIDE	
DEFERASIROX	89
DEFERIPRONE	89
DEFLAZACORT	89
DEHYDROCHLOROMETHYLTESTOSTERONE	89
DEHYDROCORTICOSTERONE	89
DEHYDROEPIANDROSTERONE	134
DEHYDROISOANDROSTERONE	134
DEHYDROTESTOSTERONE	77
DELAVIRDINE	89
DELAVIRDINE MESYLATE	89
DELPHINIUM STAPHISAGRIA	43
DELTAMETHRIN	165, 208, 241
DELTA-9-TETRAHYDROCANNABINOL	251, 280, 343
DEMBREXINE	89, 165
DEMECARIUM BROMIDE	89
DEMECLOCYCLINE	89
DEMETON	241
DEMETON-O-METHYL	241
DEMETON-S-METHYL	241
DENATONIUM BENZOATE	177
DEOXYCORTONE	89
DEOXYRIBONUCLEASE	89
DERACOXIB	89
DERMAL USE	4
DERRIS	
<i>See</i> ROTENONE	
2,4-DES	165
DEFERRIOXAMINE	89
DESFLURANE	89
DESIGNATED SOLVENT	4
DESIPRAMINE	89, 342
DESIRUDIN	90
DESLANOSIDE	90
DESLORATADINE	43, 90
DESLORELIN	90
DESMOPRESSIN	90
DESOGESTREL	90
DESOMORPHINE	255
DESONIDE	90
DESOXYMETHASONE	90
DESVENLAFAXINE	90
DET	
<i>See</i> N,N-DIETHYLTRYPTAMINE	

DETOMIDINE.....	90
DEXAMETHASONE	90
DEXAMPHETAMINE	251
DEXCHLORPHENIRAMINE.....	43, 59, 90, 342
DEXFENFLURAMINE.....	90
DEXMEDETOMIDINE.....	90
DEXTRANS.....	261
DEXTROMETHORPHAN	44, 90
DEXTROMORAMIDE.....	251, 342
DEXTROPROPOXYPHENE.....	90, 251, 280, 342
DEXTRORPHAN	90
DI-ALKYL TIN COMPOUNDS	249
DI-IODOHYDROXYQUINOLINE.....	60, 92, 277
DIAFENTHIURON	165
DIALIFOS.....	241
N,N-DIALLYLDICHLOROACETAMIDE.....	165
4,4-DIAMINODIPHENYLMETHANE.....	241, 315, 339
DIAMPROMIDE	255
DIAMTHAZOLE	90
DIAVERIDINE	90
DIAZEPAM	90, 342
DIAZINON	166, 208
DIAZOXIDE	90
DIBENZEPIN	91
DIBENZODIOXINS	
<i>See</i> HALOGENATED DIBENZODIOXINS	
DIBENZOFURANS	
<i>See</i> HALOGENATED DIBENZODIOXINS	
DIBOTERMIN.....	91
1,2-DIBROMO-3-CHLOROPROPANE.....	241, 339
DIBROMOPROPAMIDINE	44
DIBUTYL TIN COMPOUNDS/SALTS.....	249
DICAMBA	166, 208
DICHOLOBENIL	208
DICHLOFENTHION	208
DICHOFLUANID	208
DICHLONE	166
DICHLORALPHENAZONE	91
1,2-DICHLOROBENZENE	
<i>See</i> ortho-DICHLOROBENZENE	
ORTHO-DICHLOROBENZENE	208, 289, 316
PARA-DICHLOROBENZENE	166, 289, 316
1,1-DICHLORO-2,2-BIS(4-CHLOROPHENYL)ETHANE	
<i>See</i> TDE	
1,2-DICHLOROETHANE	
<i>See</i> ETHYLENE DICHLORIDE	
DICHLOROETHYLENE.....	316
DICHLOROETHYL ETHER.....	208, 289, 316
<i>See also</i> CHLORINATING COMPOUNDS	

DICHLOROISOCYANURATES	289, 316
DICHLOROISOCYANURIC ACID.....	166, 208
DICHLOROMETHANE	166, 289, 318, 336
N-(2,6-DICHLORO-3-METHYLPHENYL)-5,7-DIMETHOXY- [1,2,4]-TRIAZOLO-[1,5A]PYRIMIDINE-2-SULFONAMIDE <i>See</i> METOSULAM	
4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE	209
DICHLOROPHEN	91, 166, 209
4-(2,4-DICHLOROPHENOXY)BUTYRIC ACID <i>See</i> 2,4-DB	
1,2-DICHLOROPROPANE	209
1,3-DICHLOROPROPENE	241, 339
DICHLORPHENAMIDE	91
2,4-DICHLORPROP	209
DICHLORVOS	166, 209, 241
DICHROMATES	289, 315
<i>See also</i> CHROMATES	
DICLAZURIL	270
DICLOBUTRAZOL	166
DICLOFENAC.....	44, 59, 91, 318, 334
DICLOFOP-METHYL.....	209
DICLORAN	166
DICLOXACILLIN	91
DICOFOL.....	167
DICOPHANE.....	276
DICROTOPHOS	242
DICYCLANIL.....	209
DICYCLOMINE	91
DIDANOSINE	91
DIDECYLDIMETHYLAMMONIUM SALTS	209, 289
DIELDRIN	209
DIENESTROL	35, 318
DIENOGEST	91
DIESEL	289
DIETHANOLAMINE	167, 209, 290, 318
DIETHAZINE	91
DIETHYL CARBAMAZINE.....	91
DIETHYL CARBONATE	270
DIETHYLENE GLYCOL	276
DIETHYLENE GLYCOL MONOBUTYL ETHER.....	167
N,N-DIETHYL-M-TOLUAMIDE <i>See</i> DIETHYLTOLUAMIDE	
DIETHYLPHTHALATE	276
DIETHYLPROPION.....	91
DIETHYLSTILBOESTROL	143
DIETHYLTHIAMBUTENE	255
DIETHYLTOLUAMIDE	167, 318
N,N-DIETHYLTRYPTAMINE	255
DIFENACOUM	209, 242, 339

DIFENOCONAZOLE	167
DIFENOXIN	91, 251, 342
DIFENZOQUAT	209
DIFETHIALONE	209, 242
DIFLORASONE	91
DIFLOXACIN	91
DIFLUBENZURON	167
DIFLUCORTOLONE	91
DIFLUFENICAN	270
DIFLUNISAL	91
DIGITALIS	91, 92
DIGITOXIN	92
DIGOXIN	92
DIGOXIN-SPECIFIC ANTIBODY	92
DIHYDRALAZINE	92
DIHYDROCODEINE	44, 59, 92, 251, 342
DIHYDROERGOTOXINE	92
DIHYDROLONE	92
DIHYDROMORPHINE	251
DIHYDROSTREPTOMYCIN	92
DIHYDROTACHYSTEROL	92
5,6-DIHYDROXYINDOLINE	209, 290, 318
DI-IODOHYDROXYQUINOLINE	60, 92, 277
<i>See also</i> CLIOQUINOL	
DIISOPROPYLAMINE DICHLOROACETATE	92
DIKEGULAC-SODIUM	270
DILTIAZEM	92
DIMEFOX	242
DIMENHYDRINATE	44, 60, 92, 334, 342
DIMENOXADOL	255
DIMEPHEPTANOL	255
DIMERCAPROL	92
DIMETHANDROSTANOLONE	92
DIMETHAZINE	92
DIMETHENAMID-P	209
DIMETHICODIETHYLBENZALMALONATE	167
DIMETHICONE	270
DIMETHINDENE	60, 93, 342
DIMETHIPIN	209
DIMETHIRIMOL	167
DIMETHISOQUIN	138
DIMETHOATE	209
DIMETHOMORPH	167
DIMETHOTHIAZINE	93
DIMETHOXANATE	93
2,5-DIMETHOXYAMPHETAMINE	255
2,5-DIMETHOXY-4-BROMOAMPHETAMINE	255
2,5-DIMETHOXY-4-ETHYL-A-AMPHETAMINE	255
2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE	255

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE.....	255
2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE	255
DIMETHYLACETAMIDE.....	167, 210
4-DIMETHYLAMINOAZOBENZENE	242, 339
3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE.....	255
N,N-DIMETHYLAMPHETAMINE.....	256
DIMETHYLETHANOLAMINE (DMAE)	
<i>See</i> DEANOL	
DIMETHYL ETHER.....	270
DIMETHYLFORMAMIDE.....	4, 167, 210, 290, 318
3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO- 6,6,9-TRIMETMYL-6H-DIBENZO(B,D)PYRAN.....	256
N,A-DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE.....	256
N,N-DIMETHYL-4-(PHENYLAZO)-BENZENAMINE	242
<i>See also</i> DIMETHYLAMINOAZOBENZENE	
DIMETHYLPHTHALATE.....	277
DIMETHYL SULFATE.....	242, 318
DIMETHYL SULFOXIDE.....	93, 210, 290, 318
DIMETHYLTHIAMBUTENE.....	256
DIMETHYL TIN COMPOUNDS.....	249
DIMETHYL-TIN DICHLORIDE	
<i>See</i> TIN ORGANIC COMPOUNDS	
N,N-DIMETHYLTRYPTAMINE.....	256
DIMETILAN.....	242
DIMETRIDAZOLE	93
DINICONAZOLE.....	167
2,4-DINITROCHLOROBENZENE.....	93
DINITROCRESOLS.....	93, 210, 242, 290, 318, 339
DINITRONAPHTHOLS	93
DINITROPHENOLS.....	93, 210, 242, 290, 318, 339
DINITROTHYMOLS	93
DINOCAP	242, 318
DINOPROST	93, 279
DINOPROSTONE	93, 279
DINOSEB.....	242, 339
DIOCTYL SODIUM SULFOSUCCINATE	
<i>See</i> DOCUSATE SODIUM	
DIOXACARB	210
DIOXANE.....	210, 290, 318, 332
DIOXAPHETYL BUTYRATE.....	256
DIOXINS	340
<i>See also</i> HALOGENATED DIBENZODIOXINS	
DIPERODON.....	93
DIPHACINONE.....	210
DIPHEMANIL.....	93
DIPHENAMID.....	168
DIPHENHYDRAMINE.....	44, 60, 93, 343
DIPHENIDOL.....	93
DIPHENOXYLATE.....	60, 93, 251, 334, 343
DIPHENYLAMINE.....	270

DIPHENYLPYRALINE	60, 93, 343
DIPHTHERIA TOXOID	93
DIPIANONE	251
DIPIVEFRIN	94
DIPROPYLENE GLYCOL MONOMETHYL ETHER	270
DI-N-PROPYL ISOCINCHOMERONATE	168
DI-N-PROPYL ISOCINCHOMERONATE	168
DIPROPYL TIN COMPOUNDS	249
DIPYRIDAMOLE	94
DIQUAT	210, 242
DIRITHROMYCIN	94
DIRLOTAPIDE	94
DISODIUM ETIDRONATE	99
DISODIUM TILUDRONATE	148
DISOPHENOL	94
DISOPYRAMIDE	94
DISTIGMINE	94
DISTILLATE	290
<i>See also</i> HYDROCARBONS, LIQUID	
DISTILLATION TEMPERATURE	10
DISTRIBUTOR	4
DISULFIRAM	94, 211
DISULFOTON	211, 242
DISULPHAMIDE	94
DITHIANON	211
DITHIAZANINE	94, 211
DITHIOCARBAMATES	
<i>See</i> UNDER INDIVIDUAL ENTRIES	
DITHIOPYR	168
DITHRANOL	60
DITIOCARB	94
DIUREDOSAN	211
DIURON	270
DIVIDED PREPARATION	4
DMA	
<i>See</i> 2,5-DIMETHOXYAMPHETAMINE	
DMHP	
<i>See</i> 3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (B,D) PYRAN	
DMT	
<i>See</i> N,N-DIMETHYLTRYPTAMINE	
DOB	
<i>See</i> 2,5-DIMETHOXY-4-BROMOAMPHETAMINE	
DOBUTAMINE	94
DOCETAXEL	94
DOCUSATE SODIUM-(DIOCTYL SODIUM SULFOSUCCINATE)	270
N-(N-DODECYL)-2-PYRROLIDONE	4, 177, 179, 211, 290
DODINE	168, 211
DOET	
<i>See</i> 2,5-DIMETHOXY-4-ETHYL-A-AMPHETAMINE	

DOFETILIDE.....	94
DOLASETRON	94
DOM	
<i>See</i> 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE	
DOMPERIDONE.....	94
DONEPEZIL	94
DOPAMINE.....	94
DOPEXAMINE.....	94
DORAMECTIN	168, 211, 242
DORNASE	94
DORZOLAMIDE.....	94
DOSAGE UNIT	4
DOTHIEPIN.....	94, 343
DOXANTRAZOLE	94
DOXAPRAM	94
DOXAZOSIN.....	95
DOXEPIN	95, 343
DOXORUBICIN	95
DOXYCYCLINE	95
DOXYLAMINE.....	44, 60, 95, 343
2,2-DPA	270
DROMETRIZOLE TRISILOXANE.....	270
DRONABINOL.....	251, 280, 343
DROPERIDOL.....	95, 343
DROSPIRENONE.....	95
DROSTANOLONE.....	95
DROTEBANOL.....	251
DROTRECOGIN	95
DRUG	4
DRY CLEANING FLUID.....	26
DSMA	211, 242
DUBOISIA LEICHHARDTII	45, 95
DUBOISIA MYOPOROIDES	45, 95
DULCIN.....	277
DULOXETINE	95, 343
DUTASTERIDE	95
DYDROGESTERONE.....	95

E

ECGONINE	256
ECONAZOLE	45, 60, 95, 211, 318, 334
ECOTHIOPATE	95
ECTYLUREA	95
EDETTIC ACID.....	95
EDOXUDINE	95
EDROPHONIUM	96
EFALIZUMAB.....	96
EFAVIRENZ.....	96
EFLORNITHINE	96

ELECTRICAL ACCUMULATORS	261
ELECTRONIC COMPONENTS	261
ELETRIPTAN	96
ELTENAC	96
EMAMECTIN	168, 211, 242
EMEPRONIUM SALTS	96
EMETINE	96
EMODEPSIDE	168, 211
EMTRICITABINE	96
ENALAPRIL	96
ENAMELLING PREPARATIONS	261
ENDOSULFAN	211, 242
ENDOTHAL	211, 242
ENDOTOXIN	268
ENDRIN	242
ENESTEBOL	96
ENFLURANE	96
ENFUVIRTIDE	96
ENHANCING AGENTS	261
ENILCONAZOLE	168
ENOXACIN	96
ENOXAPARIN	96
ENOXIMONE	96
ENPROSTIL	96
ENROFLOXACIN	96
ENTACAPONE	96
ENTECAVIR	96
EPHEDRA	96
EPHEDRINE	96, 280, 319
EPICHLOROHYDRIN	242, 319, 339
EPICILLIN	96
EPIDERMAL GROWTH FACTOR	242, 339
EPINASTINE	96
EPIRUBICIN	97
EPITIOSTANOL	97
EPLERENONE	97
EPOETINS	97, 280
EPOPROSTENOL	97
EPOXICONAZOLE	168
EPOXY RESINS	17, 157, 168, 290, 319
EPRINOMECTIN	168, 242
EPROSARTAN	97
EPSIPRANTEL	270
EPTC	211
EPTIFIBATIDE	97
EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN	
<i>See</i> IMMUNOGLOBULINS	
ERGOCALCIFEROL	
<i>See</i> VITAMIN D	

ERGOMETRINE	97
ERGOT	97
ERGOTAMINE.....	97
ERGOTOXINE.....	97
ERLOTINIB.....	97
ERTAPENEM.....	97
ERYSIMUM	97, 332
ERYTHRITYL TETRANITRATE	60
ERYTHROMYCIN.....	97
ERYTHROPOIETIN.....	97, 280
ESBIOTHRIN	168, 211
ESCITALOPRAM	97
ESFENVALERATE.....	168, 211
ESMOLOL	97
ESOMEPRAZOLE.....	97
ESSENTIAL OILS.....	5, 28, 290
ESTRAMUSTINE.....	97
ESTROPIPATE.....	97
ETACONAZOLE.....	242, 339
ETAFEDRINE	45
ETANERCEPT	97
ETHACRYNIC ACID.....	97
ETHAMBUTOL	98
ETHAMETSULFURON-METHYL	270
ETHAMIVAN.....	98
1,2-ETHANEDIAMINE POLYMER.....	168
ETHANEDINITRILE	
<i>See</i> CYANOGEN	
ETHANOL	177
<i>See also</i> ETHYL ALCOHOL	
ETHANOLAMINE	98, 168, 212, 290, 319
ETHCHLORVYNOL.....	98
ETHEPHON.....	212
ETHER.....	45, 98, 168, 212, 290, 319
ETHINAMATE.....	98
ETHINYLOESTRADIOL.....	98
ETHIOFENCARB.....	212
ETHION	242
ETHIONAMIDE	98
ETHISTERONE.....	98
ETHOATE-METHYL.....	212
ETHOFUMESATE	168
ETHOGLUCID	98
ETHOHEPTAZINE	98
ETHOPABATE.....	270
ETHOPROPAZINE	98
ETHOPROPHOS	212, 243
ETHOSUXIMIDE.....	98
ETHOTOIN.....	98

ETHOXYETHYLMERCURIC CHLORIDE	319
<i>See also</i> MERCURY	
ETHOXYQUIN.....	169
<i>See also</i> MERCURY	
ETHOXYSULFURON.....	169
ETHOXZOLAMIDE.....	98
ETHYL.....	249
ETHYL ACETATE.....	270
ETHYL ALCOHOL.....	270
<i>See also</i> ETHANOL	
ETHYLAMPHETAMINE.....	251
ETHYL BROMIDE.....	212, 290, 319
ETHYLBUTYLACETYL-AMINOPROPIONATE	270
ETHYL BUTYRATE.....	270
ETHYL CHLORIDE.....	98
ETHYLDIENOLONE.....	98
ETHYLENE CHLOROHYDRIN	212, 319
ETHYLENE DIBROMIDE.....	243, 340
ETHYLENE DICHLORIDE.....	212
ETHYLENE GLYCOL.....	28, 169, 212, 291, 319
ETHYLENE GLYCOL MONOALKYL ETHER ACETATES.....	212
ETHYLENE GLYCOL MONOALKYL ETHERS.....	212, 291, 336
ETHYLENE OXIDE.....	243, 291, 319, 340
ETHYL FORMATE.....	212
ETHYLHEXANEDIOL.....	98, 277
ETHYL LACTATE.....	270
N-ETHYL MDA	
<i>See</i> N-ETHYL- α -METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE	
N-ETHYL- α -METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE.....	256
ETHYLMERCURIC CHLORIDE	319
ETHYL METHACRYLATE	169
ETHYLMETHYLTHIAMBUTENE.....	256
ETHYLMORPHINE.....	45, 46, 98, 251, 343
ETHYLOESTRENOL.....	99
ETHYNODIOL.....	99
ETICYCLIDINE	256
ETIDOCAINE.....	99
ETIDRONIC ACID.....	99
ETILEFRIN.....	99
ETIPROSTON.....	99
ETODOLAC	99
ETOFENAMATE	46, 99
ETONITAZENE	256
ETONOGESTREL.....	99
ETOPOSIDE	99
ETORICOXIB.....	99
ETORPHINE.....	256
ETOXAZOLE	270
ETOXERIDINE	256
ETRETINATE.....	35, 99, 279, 319

ETRIDIAZOLE.....	169
ETRIMFOS	212
EUCALYPTUS OIL	28, 213, 291
EUGENOL	28, 169, 213, 291, 319
EUPATORIUM CANNABINUM.....	277
EVEROLIMUS	99
EXEMESTANE	99
EXENATIDE	99
EXPLOSIVES	261
EXTERNAL.....	5
EXTRACT OF LEMON EUCALYPTUS	169
EZETIMIBE.....	99

F

FAMCICLOVIR	99
FAMOTIDINE	46, 99, 319
FAMPHUR.....	214, 243
FAMPRIDINE	
<i>See</i> 4-AMINOPYRIDINE	
FARFUGIUM	277
FEBANTEL	214
FELBINAC	46, 99
FELODIPINE.....	99
FELYPRESSIN	99
FENAMIPHOS	214, 243
FENARIMOL.....	169
FENAZAFLOR.....	214
FENBENDAZOLE.....	169
FENBUCONAZOLE	169
FENBUFEN	100
FENBUTATIN.....	214
<i>See also</i> TIN ORGANIC COMPOUNDS	
FENBUTATIN OXIDE.....	214
FENCAMFAMIN	100
FENCHLORAZOLE-ETHYL.....	169
FENCHLORPHOS.....	214
FENCLOFENAC	100
FENETYLLINE	256
FENFLURAMINE	100, 343
FENFURAM	270
FENHEXAMID.....	270
FENITROTHION.....	214
FENOFIBRATE	100
FENOLDOPAM.....	100
FENOPROFEN	100
FENOPROP	169
FENOTEROL.....	100, 319
FENOXACRIM.....	214, 243
FENOXAPROP-ETHYL.....	169

FENOXAPROP-P-ETHYL	169
FENOXYCARB	270
FENPIPRAMIDE	100
FENPIPRANE	100
FENPROPOREX	100
FENPROSTALENE	100
FENPYROXIMATE	214
FENSON	169
FENSULFOTHION	243
FENTANYL	251
FENTHION	169, 214, 243
FENTHION-ETHYL	243
FENVALERATE	214
FERRICYANIDES	241
FERROCYANIDES	241
FEXOFENADINE	46, 100
FIBRINOLYSIN	100
FILGRASTIM	100
FINASTERIDE	100
FIPRONIL	170, 214
FIROCOXIB	100
FIRST SCHEDULE PAINT	5, 335, 336
FLAMPROP-M-METHYL	170
FLAMPROP-METHYL	170
FLAVOPHOSPHOLIPOL	74, 195
FLAVOXATE	60
FLECAINIDE	100
FLEROXACIN	100
FLOCOUMAFEN	214, 243
FLOCTAFENINE	100
FLORASULAM	170
FLORFENICOL	100
FLUANISONE	100
FLUAZIFOP-BUTYL	214
FLUAZIFOP-P-BUTYL	215
FLUAZINAM	215
FLUAZURON	170
FLUBENDAZOLE	170
FLUBENDIAMIDE	170
FLUCHLORALIN	170
FLUCLOROLONE	100
FLUCLOXACILLIN	100
FLUCOFURON	215, 243
FLUCONAZOLE	60, 101, 319, 334
FLUCYTHRINATE	243
FLUCYTOSINE	101
FLUDARABINE	101
FLUDIOXONIL	170
FLUDROCORTISONE	101

FLUFENAMIC ACID.....	101
FLUFENOXURON.....	270
FLUMAZENIL.....	101
FLUMETHASONE.....	101
FLUMETHIAZIDE.....	101
FLUMETHRIN.....	170, 215
FLUMETSULAM.....	270
FLUMICLORAC PENTYL.....	170
FLUMIOXAZIN.....	243
FLUNISOLIDE.....	101
FLUNITRAZEPAM.....	251, 343
FLUNIXIN MEGLUMINE.....	101
FLUOCINOLONE.....	101
FLUOCINONIDE.....	101
FLUOCORTIN.....	101
FLUOCORTOLONE.....	101
FLUOMETURON.....	270
FLUORESCEIN.....	101, 177
FLUORIDES.....	46, 60, 101, 170, 215, 291, 320
FLUROACETAMIDE.....	34, 243, 340
FLUROACETIC ACID.....	34, 243, 340
FLUOROMETHOLONE.....	101
FLUOROSILICATES	
<i>See</i> SILICOFLUORIDES	
FLUOROSILICIC ACID	
<i>See</i> HYDROSILICOFLUORIC ACID	
FLUOROURACIL.....	101
FLUOXETINE.....	101
FLUOXYMESTERONE.....	101
FLUPENTHIXOL.....	101, 343
FLUPHENAZINE.....	101, 343
FLUPROPANATE.....	215
FLUPROSTENOL.....	101
FLUQUINCONAZOLE.....	215
FLURANDRENOLONE.....	101
FLURAZEPAM.....	102, 343
FLURBIPROFEN.....	47, 102
FLUROXENE.....	102
FLUROXYPYR.....	270
FLUSILAZOL.....	215
FLUSPIRILENE.....	102
FLUTAMIDE.....	102
FLUTICASONE.....	47, 102
FLUTOLANIL.....	270
FLUTRIAFOL.....	215
FLUVALINATE.....	170, 215
FLUVASTATIN.....	102
FLUVOXAMINE.....	102
FOLIC ACID.....	47, 102

FOLINIC ACID	47, 102
FOLLICLE-STIMULATING HORMONE.....	102, 332
FOLLITROPIN ALPHA	102, 279
FOLLITROPIN BETA.....	102, 279
FOLPET	243, 340
FOMIVIRSEN.....	102
FONDAPARINUX	102
FOOD.....	261
FOOD ADDITIVES.....	261
FORCHLORFENURON	270
FORMALDEHYDE	47, 215, 277, 291, 308, 320
FORMEBOLONE.....	102
FORMESTANE	102
FORMETANATE	243
FORMIC ACID.....	170, 291, 320
FORMOTEROL	102
FORMOTHION	216
FOSAMPRENAVIR	102
FOSAPREPITANT	102
FOSCARNET.....	102
FOSFESTROL	102
FOSINOPRIL.....	102
FOSPHENYTOIN.....	103
FOSPIRATE.....	170, 216
FOTEMUSTINE	103
FRAMYCETIN.....	103
FRITTED GLAZING.....	261
FRUSEMIDE	
<i>See</i> FUROSEMIDE	
FULLERS EARTH	270
FULVESTRANT.....	103
FUMAGILLIN	216
FUNGAL PROTEASE.....	271
FURALAXYL.....	170
FURALTADONE	103
FURATHIOCARB.....	170, 243
FURAZABOL	103
FURAZOLIDONE	103
FURETHIDINE.....	256
FUROSEMIDE	103
FUSIDIC ACID.....	103

G

GABAPENTIN	103, 343
GALANTAMINE	103
GALANTHUS.....	103
GALLAMINE	103
GAMMA-CYHALOTHRIN	171, 243
GAMMA HYDROXYBUTYRATE(GHB)	
<i>See</i> 4-HYDROXYBUTANOIC ACID	

GANCICLOVIR	103
GANIRELIX	103
GATIFLOXACIN	103
GEFITINIB	103
GELATIN.....	261
GELSEMIUM SEMPERVIRENS.....	47, 332
GEMCITABINE	103, 343
GEMEPROST	103
GEMFIBROZIL	103
GEMIFLOXACIN.....	103
GENTAMICIN.....	103
GENTIAN VIOLET	
<i>See</i> CRYSTAL VIOLET	
GERANIUM OIL	271
GESTODENE	103
GESTONORONE	104
GESTRINONE.....	104
GHRH INJECTABLE PLASMID.....	104
GIBBERELIC ACID	271
GITALIN.....	104
GLASS	261
GLATIRAMER ACETATE.....	104
GLAZED POTTERY	261
GLAZING PREPARATIONS.....	320
GLIBENCLAMIDE	104
GLIBORNURIDE	104
GLICLAZIDE	104
GLIMEPIRIDE	104
GLIPIZIDE.....	104
GLISOXEPIDE	104
GLUCAGON	61, 332
GLUCANASE.....	271
GLUFOSINATE-AMMONIUM.....	171
GLUTARALDEHYDE	47, 171, 216, 291, 320
GLUTATHIONE.....	104
GLUTETHIMIDE	104, 280, 343
GLYCERYL THIOGLYCOLLATE	216
GLYCERYL TRINITRATE	61, 104, 332
GLYCOLIC ACID.....	216, 291, 320
GLYCOPYRRONIUM	61, 104
GLYMIDINE	104
GLYPHOSATE.....	171
GNRH VACCINE	104
GONADORELIN.....	104
GONADOTROPHIC HORMONES.....	104
GOSERELIN.....	104
GRAMICIDIN.....	104
GRANISETRON.....	104
GRAPHIC MATERIAL.....	5
GREPAFLOXACIN.....	104

GRISEOFULVIN	105
GROWTH HORMONE	142, 332
GUAIPHENESIN	105
GUANABENZ	105
GUANACLINE	105
GUANETHIDINE	105
GUANIDINE	105
GUAZATINE	216

H

HACHIMYCIN	105
HAEMATIN	105
HAEMOPHILUS INFLUENZAE VACCINE	105
HALCINONIDE	105
HALOFANTRINE	105
HALOFENATE	105
HALOFUGINONE	105, 243, 340
HALOGENATED DIBENZODIOXINS	244, 340
HALOGENATED DIBENZOFURANS	244, 340
HALOPERIDOL	105, 332, 343
HALOSULFURON-METHYL	171
HALOTHANE	105
HALOXON	216
HALOXYFOP	216
HALQUINOL	
<i>See</i> CLIOQUINOL	
HARMALA ALKALOIDS	256
HCB	244, 340
HEIGHT	5
HELIOTROPIUM	277
HEMEROCALLIS	105
HEMP AGRIMONY	
<i>See</i> EUPATORIUM CANNABINUM	
HEMP SEED OIL	5
HEPARINS	105
HEPATITIS A VACCINE	105
HEPATITIS B VACCINE	105
HEPTACHLOR	216
HEROIN	256
HETACILLIN	105
HEXACHLOROBENZENE	
<i>See</i> HCB	
HEXACHLOROPHANE	47, 106, 216, 291, 320
HEXAACONAZOLE	171
HEXAFLUOROSILICATES	
<i>See</i> SILICOFLUORIDES	
HEXAFLUOROSILICIC ACID	
<i>See</i> HYDROSILICOFLUORIC ACID	
HEXAFLURON	271

HEXAMETHONIUM	106
HEXAMETHYLMELAMINE	
<i>See</i> ALTRETAMINE	
HEXAZINONE	171, 216
HEXETIDINE	106
HEXOBENDINE	106
HEXOCYCLIUM	106
HEXOPRENALINE	106
HEXYL ACETATE	271
3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H- DIBENZO (B,D) PYRAN	256
HEXYTHIAZOX	271
HISTAMINE	106
HOBBY FUELS	263
HOMATROPINE	106
H5N1 INFLUENZA VIRUS HAEMAGGLUTININ	
<i>See</i> INFLUENZA AND CORYZA VACCINES	
HUMAN BLOOD PRODUCTS	262
<i>See also</i> BLOOD	
HUMAN CHORIONIC GONADATROPHIN	106
HUMAN FOLLICLE-STIMULATING HORMONE	
<i>See</i> UROFOLLITROPHIN	
HUMAN OSTEOGENIC PROTEIN-1 (OP-1)	271
HYALURONIC ACID	106
HYDRALAZINE	106
HYDRAMETHYLNON	171, 217
HYDRARGAPHEN	106
HYDRAZINE	217, 291, 320
HYDROCARBONS	4, 17, 28, 291
HYDROCARBONS, LIQUID	XI, 26, 171, 244
HYDROCHLORIC ACID	28, 172, 217, 291, 320
HYDROCHLOROTHIAZIDE	106
HYDROCODONE	251, 343
HYDROCORTISONE	48, 61, 106, 320, 334
HYDROCORTISONE ACETATE	48, 61
HYDROCYANIC ACID	34, 107, 244, 321, 332
<i>See also</i> CYANIDES	
HYDROFLUMETHIAZIDE	107
HYDROFLUORIC ACID	172, 217, 244, 291, 321, 340
HYDROFLUOSILICIC ACID	
<i>See</i> HYDROSILICOFLUORIC ACID	
HYDROGEN FLUORIDE	172, 217
HYDROGEN PEROXIDE	172, 217, 292, 321
HYDROGEN SULFIDE	244
HYDROMORPHINOL	251
HYDROMORPHONE	251, 343
HYDROPRENE	271
HYDROQUINONE	48, 107, 120, 217, 292, 321
HYDROSILICOFLUORIC ACID	172, 217, 244, 292, 321, 340
4-HYDROXYBUTANOIC ACID	256

HYDROXYCHLOROQUINE	107
HYDROXYEPHEDRINE	107
N-HYDROXY MDA	
<i>See</i> N-[ALPHA-METHYL-3,4-(METHYLENEDIOXY)	
PHENETHYL]HYDROXYLAMINE	
HYDROXYPETHIDINE	256
HYDROXYPHENAMATE	107
HYDROXYPROGESTERONE	107
HYDROXYPROPYL CELLULOSE	271
8-HYDROXYQUINOLINE	48, 84, 321
HYDROXYSTENOZOL	107
HYDROXYUREA	107
HYDROXYZINE	107, 343
HYGROMYCIN	107
HYOSCINE	48, 107, 332
HYOSCINE BUTYLBROMIDE	48
HYOSCYAMINE	49, 107, 332
HYOSCYAMUS NIGER	49, 107, 332
HYPOTHALAMIC RELEASING FACTORS	107, 332
HYPROMELLOSE	107

I

IBAFLOXACIN	107
IBANDRONIC ACID	107
IBRITUMOMAB	107
IBUFENAC	108
IBUPROFEN	49, 62, 108, 321
IBUTEROL	108
IBUTILIDE	108
ICODEXTRIN	271
IDARUBICIN	108
IDOXURIDINE	108
IDURSULFASE	108
IFOSFAMIDE	108
ILOPROST	108
IMATINIB	108
IMAZALIL	172
IMAZAMOX	172
IMAZAPIC	172
IMAZAPYR	172
IMAZETHAPYR	172
IMIDACLOPRID	172, 217
IMIDAPRIL	108
IMIDOCARB	217
IMIGLUCERASE	108
IMINOCTADINE TRIALBESILATE	217
IMIPENEM	108
IMIPRAMINE	108, 343
IMIPROTHRIN	173, 218
IMIQUIMOD	108

IMMEDIATE CONTAINER	5
IMMEDIATE WRAPPER	5
IMMUNOGLOBULINS	108
IMMUNOSERA	72
INDANAZOLINE	50
INDAPAMIDE	108
INDINAVIR	108
INDOLE-3-ACETIC ACID	271
1H-INDOLE-5,6-DIOL,2,3-DIHYDRO <i>See</i> 5,6-DIHYDROXYINDOLINE	
INDOMETHACIN	50, 108, 332
INDOPROFEN	108
INDORAMIN	108
INDOXACARB	173, 218
INFLIXIMAB	109
INFLUENZA AND CORYZA VACCINES	109
INK ADDITIVES	263
INOSITOL NICOTINATE	62, 108
INSULIN-LIKE GROWTH FACTOR I	109
INSULIN-LIKE GROWTH FACTORS	109, 280
INSULINS	109
INTERFERONS	109
INTERLEUKINS	109
INTERNAL USE	5
INTRAOCULAR VISCOELASTIC PRODUCTS	262
IN VITRO DIAGNOSTIC PREPARATIONS	262
IODINE	50, 218, 292, 307, 322
IODOCARB	173, 218
IODOMETHANE	244, 340
IODOPHORS	50, 218, 292
3-iodo-2-propynyl butyl carbamate	173, 218
IDOQUINOL	60, 92, 277
<i>See also</i> CLIOQUINOL	
IODOSULFURON-METHYL-SODIUM	173
IODOTHIOURACIL	109
IOXYNIL	218
IPECACUANHA	82
<i>See also</i> CEPHAELIS ACUMINATA AND CEPHAELIS IPECACUANHA	
IPRATROPIUM	50, 109, 322
IPRIFLAVONE	109
IPRINDOLE	109
IPRODIONE	271
IPRONIAZID	109
IRBESARTAN	109
IRINOTECAN	109
IRON COMPOUNDS	50, 109, 173, 218
ISOAMINILE	109
ISOAMYL NITRITE	109
ISOBUTYL NITRITE	109
ISOCARBOPHOS	244

ISOCARBOXAZID	109
ISOCONAZOLE	50, 62, 109, 218
ISOCYANATES	292
ISOCYANATES, FREE ORGANIC.....	218, 322
ISOETARINE	109
ISOEUGENOL	173, 219
ISOFENPHOS	244
ISOFLURANE	110
ISOMETHADONE	257
ISOMETHEPTENE	110
ISONIAZID	110
ISOPHORONE.....	173, 292
ISOPRENALINE	110, 322
ISOPRENE ALCOHOL	271
ISOPRINOSINE	110
ISOPROPAMIDE	50, 110
ISOPROTURON	244
ISOSORBIDE DINITRATE	62, 110
ISOSORBIDE MONONITRATE	110
ISOSTEARYL ALCOHOL ETHOXYLATE	271
ISOTRETINOIN	35, 110, 279, 322
ISOXABEN.....	173
ISOXAFLUTOLE	173
ISOXICAM	110
ISOXSUPRINE	110
ISRADIPINE.....	110
ITRACONAZOLE	110
IVABRADINE	110
IVERMECTIN	110, 173, 244
IXABEPILONE.....	110

J

JASMOLONE	184
JEQUIRITY	
<i>See</i> ABRUS PRECATORIUS	
JUNIPERUS SABINE.....	277

K

KANAMYCIN	110
KAOLIN.....	271
KAVA	
<i>See</i> PIPER METHYSTICOM	
KEROSENE	XI, 26, 263, 292
KETAMINE	251
KETANSERIN	110
KETAZOLAM	110
KETOBEMIDONE	257
KETOCONAZOLE.....	51, 111
KETOPROFEN	62, 111

KETORALAC TROMETAMOL	111
KETOROLAC	111
KETOTIFEN	51, 111
K-HDO	
<i>See</i> N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM	
KHELLIN	111
KITASAMYCIN	111, 174
KRESOXIM-METHYL	271
KUNZEA OIL	271
L	
LABEL	6, 11
LABETALOL	111
LACIDIPINE	111
LAMBDA-CYHALOTHRIN	174, 219, 244
LAMIVUDINE	111
LAMOTRIGINE	111, 343
LAMP OIL	26
LAMPS	261
LANATOSIDES	111
LANREOTIDE	111
LANSOPRAZOLE	111
LANTHANUM	111
LAPATINIB	111
LARONIDASE	112
LAROPIPRANT	112
LASALOCID	219
LATAMOXEF	112
LATANOPROST	112
LAUDEXIUM	112
LAURETH-9	
<i>See</i> LAUROMACROGOLS	
LAURIC ACID	271
LAUROMACROGOLS	112
LAURYL ALCOHOL (1-DODECANOL)	271
LAURYLISOQUINOLINIUM BROMIDE	219, 292
LAVANDIN OIL	271
<i>See also</i> CAMPHOR	
LAVENDER OIL	271
LEAD	20, 112, 232, 336
LEAD, METALLIC	271
LEAD COMPOUNDS	174, 219, 292, 320, 322
LEFETAMINE	112
LEFLUNOMIDE	35, 112, 322
LEMONGRASS OIL	271
LEMON OIL	174, 292, 322
LENALIDOMIDE	35, 112, 280
LENOGRASTIM	112
LEPIDOPTEROUS SEX PHEROMONES	271

LEPIRUDIN.....	112
LEPTAZOL.....	112
LEPTOPHOS.....	244
LERCANIDIPINE.....	112
LETROZOLE.....	112
LEUPRORELIN.....	112
LEVALLOPHAN.....	112
LEVAMISOLE.....	112, 174, 219
LEVAMPHETAMINE.....	251
LEVETIRACETAM.....	112, 343
LEVOBUNOLOL.....	112
LEVOBUPIVACAINE.....	113
LEVOCABASTINE.....	34, 51, 113, 322, 343
LEVOCETIRIZINE	
<i>See</i> CETIRIZINE	
LEVODOPA.....	113
LEVOMEPRMAZINE.....	113
LEVOMETHAMPHETAMINE.....	251
LEVOMETHORPHAN.....	257
LEVOMORAMIDE.....	251
LEVONORGESTREL.....	62, 113
LEVOPHENACYLMORPHAN.....	257
LEVORPHANOL.....	251
LEVOSIMENDAN.....	113
LIDOFLAZINE.....	113
LIGHT MINERAL AND PARAFFIN OILS	
<i>See</i> HYDROCARBONS, LIQUID	
LIGNOCAINE.....	51, 113
LIGULARIA.....	277
LIME OIL.....	175, 293, 323
LIMONENE.....	271
LINCOMYCIN.....	113
LINDANE.....	51, 113, 175, 197, 219
LINEZOLID.....	113
LINOLEIC ACID.....	271
LINSEED FATTY ACIDS.....	271
LINURON.....	271
LIOTHYRONINE.....	113
LIQUID HYDROCARBONS	
<i>See</i> HYDROCARBONS, LIQUID	
LIQUORICE, DEGLYCYRRHISINISED.....	271
LISINAPRIL.....	113
LISURIDE.....	113
LITHIUM.....	51, 113
LITHIUM PERFLUOROOCCTANE SULFONATE.....	244
LOBELIA INFLATA.....	51
LOBELINE.....	51
LODOXAMIDE.....	51, 113
LOFEXIDINE.....	114
LOGIPARIN.....	114

LOMEFLOXACIN.....	114
LOMUSTINE.....	114
LOPERAMIDE.....	51, 114, 323
LOPINAVIR.....	114
LOPRAZOLAM.....	114
LORACARBEF.....	114
LORATADINE.....	51, 114
LORAZEPAM.....	114, 343
LORMETAZEPAM.....	114
LOSARTAN.....	114
LOXAPINE.....	114
LUBRICANTS.....	262
LUFENURON.....	175
LUMEFANTRINE.....	114
LUMIRACOXIB.....	114
LUTEINISING HORMONE.....	114, 279
LYE WATER	
<i>See</i> ALKALINE SALTS, SODIUM HYDROXIDE OR POTASSIUM HYDROXIDE	
LYMECYCLINE.....	114
LYSERGIC ACID.....	257
LYSERGIDE.....	257
M	
MACROGOL 3350.....	62
MADURAMICIN.....	175, 245, 340
MAFENIDE.....	114, 220
MAGNESIUM CHLORATE.....	175, 293, 323
MAGNESIUM FLUOSILICATE	
<i>See</i> FLUORIDES	
MAGNESIUM PHOSPHIDE	
<i>See</i> PHOSPHIDES, METALLIC	
MAIN LABEL.....	6
MALACHITE GREEN.....	175, 245
MALATHION.....	62, 175, 220, 293
MALDISON	
<i>See</i> MALATHION	
MALEIC HYDRAZIDE.....	271
MANCOZEB.....	18, 175
<i>See also</i> DITHIOCARBAMATES	
MANDRAGORA OFFICINARUM.....	114
MANGANESE DIOXIDE.....	271
MANNITYL HEXANITRATE.....	62
MANNOMUSTINE.....	114
MANUFACTURER.....	6
MAPROTILINE.....	114
MARAVIROC.....	114
MARBOFLOXACIN.....	114
MARJORAM OIL.....	28, 176, 293
MAROPITANT.....	114
MATCHES.....	262

MAZIDOX	245
MAZINDOL	115, 343
MBDB	
<i>See</i> METHYLENEDIOXYBUTYLAMINE	
MCPA	176, 220
MCPB	176
MDA	
<i>See</i> 3,4-METHYLENEDIOXYAMPHETAMINE	
MDMA	
<i>See</i> N,ALPHA-DIMETHYL-3,4-(METHYLENEDIOXY) PHENYLETHYLAMINE	
MEASLES VACCINE	115
MEASURE PACK	6
MEBANAZINE	115
MEBENDAZOLE	51, 176, 220
MEBEVERINE	115
MEBHYDROLIN	115, 343
MEBOLAZINE	115
MEBUTAMATE	115
MECAMYLAMINE	115
MECARBAM	245
MECASERMIN	115
MECILLINAM	115
MECLOCYCLINE	115
MECLOFENAMATE	115
MECLOFENAMIC ACID	176
MECLOFENOXATE	115
MECLOQUALONE	257
MECLOZINE	51, 115, 343
MECOPROP	176, 220
MECOPROP-P	220
MEDAZEPAM	115, 343
MEDETOMIDINE	115
MEDICAL AND VETERINARY ADHESIVES	262
MEDICAL DEVICES	262
MEDIGOXIN (METHYLDIGOXIN)	115
MEDROXYPROGESTERONE	115
MEDRYSONE	115
MEFENAMIC ACID	52, 115, 323
MEFENOREX	115
MEFENPYR-DIETHYL	176
MEFLOQUINE	115
MEFLUIDIDE	220
MEFRUSIDE	115
MEGESTROL	115
MELAGATRAN	116
MELALEUCA OIL	28, 220, 293
MELATONIN	116
MELENGESTROL	116
MELENGESTROL ACETATE	221

MELIA AZEDARACH.....	277
MELOXICAM.....	116
MELPHALAN.....	116
MEMANTINE.....	116
MENAZON.....	221
MENINGOCOCCAL VACCINE.....	116
MENOTROPHIN.....	116
MEPACRINE.....	116
MEPENZOLATE.....	116
MEPHENESIN.....	116
MEPHENTERMINE.....	116
MEPINDOLOL.....	116
MEPIQUAT.....	176
MEPITIOSTANE.....	116
MEPIVACAINE.....	116
MEPROBAMATE.....	116, 343
MEPTAZINOL.....	116
MEPYRAMINE.....	52, 62, 116, 343
MEQUITAZINE.....	116
2-MERCAPTOETHANOL.....	221
MERCAPTOMERIN.....	116
MERCAPTOPURINE.....	116
MERCURIC CHLORIDE.....	245, 293
MERCURIC IODIDE.....	293
MERCURIC NITRATE.....	293
MERCURIC OXIDE.....	221, 293
MERCURIC POTASSIUM IODIDE.....	293
MERCURIC THIOCYANATE.....	293, 323
MERCUROCHROME.....	221, 293
MERCUROUS CHLORIDE.....	293
MERCURY.....	52, 116, 245, 247, 293, 332, 340
MERCURY, METALLIC.....	245, 293
MEROPENEM.....	117
MERSALYL.....	117
MESABOLONE.....	117
MESALAZINE.....	117
MESCALINE.....	256, 259
<i>See also</i> 3,4,5-TRIMETHOXY-PHENYLETHYLAMINE	
MESNA.....	117
MESOLSULFURON-METHYL.....	271
MESTANOLONE.....	117
MESTEROLONE.....	117
MESTRANOL.....	117
METACRESOLSULPHONIC ACID/FORMALDEHYDE CONDENSATION.....	221, 323
METAFLUMIZONE.....	176
METALAXYL.....	176, 221
METALDEHYDE.....	176, 221, 293
METANDIENONE.....	117
METARAMINOL.....	117
METARHIZIUM ANISOPLIAE.....	271, 272

METAZOCINE.....	257
METENOLONE.....	117
METERGOLINE.....	117
METFORMIN.....	117
METHABENZTHIAZURON.....	176
METHACHOLINE.....	117
METHACRIFOS.....	221, 245, 340
METHACYCLINE.....	117
METHADONE.....	251, 343
METHADONE INTERMEDIATE <i>See</i> 4-CYANO-2-DIMETHYLAMINO-4,4-DIPHENYLBUTANE	
METHALLENOESTRIL.....	117
METHAM.....	221
METHAM SODIUM <i>See</i> METHAM	
METHAMIDOPHOS.....	245
METHANDRIOL.....	117
METHANOL.....	4, 177, 221, 263, 293, 323
METHANTHELINIUM.....	117
METHAPYRILENE.....	245
METHAQUALONE.....	257
METHAZOLAMIDE.....	117
METHAZOLE.....	245
METHCATHINONE.....	257
METHDILAZINE.....	62, 117, 343
METHENOLONE.....	117
METHICILLIN.....	117
METHIDATHION.....	245
METHIMAZOLE.....	117
METHIOCARB.....	177, 221, 245
METHISAZONE.....	117
METHIXENE.....	118
METHOCARBAMOL.....	118, 343
METHOHEXITONE.....	118
METHOIN.....	118
METHOMYL.....	221, 245
METHOPRENE.....	272
METHOTREXATE.....	118
METHOTRIMEPRAZINE <i>See</i> LEVOMEPRMAZINE	
METHOXAMINE.....	52, 118, 323
METHOXSALEN.....	118
METHOXYCHLOR.....	177
METHOXYETHYLMERCURIC ACETATE.....	245, 340
METHOXYETHYLMERCURIC CHLORIDE.....	246, 340
METHOXYFENOZIDE.....	272
METHOXYFLURANE.....	118
5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE.....	257
4-METHOXY-METHYLPHENYLETHYLAMINE.....	257
METHOXYPHENAMINE.....	52, 259

METHOXYPHENETHYLAMINE.....	259
5-METHOXY-METHYLTRYPTAMINE	257
METHOXY-PHENYLETHYLAMINE	259
METHOXY POLYETHYENE GLYCOL-EPOETIN BETA <i>See</i> EPOETINS	
METHSUXIMIDE	118
METHYCLOTHIAZIDE	118
METHYL (2S, 4AR, 6AR, 7R, 9S, 10AS, 10BR)-9-ACETOXY-6A,10B-DIMETHYL-4,10- DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-C]PYRAN-7- CARBOXYLATE	257
N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE	257
N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE	257
2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (MORAMIDE INTERMEDIATE)	257
1-METHYL-4-PHENYLPYPERIDINE-4-CARBOXYLIC ACID (PETHIDINE INTERMEDIATE C)	252
METHYL ACETATE	272
METHYL AMINOLEVULINATE	118
4-METHYLAMINOREX.....	257
METHYLAMPHETAMINE	252
METHYLANDROSTANOLONE	118
METHYLATED SPIRIT(S).....	293
METHYL BENZOQUATE.....	272
METHYL BROMIDE	246, 340
METHYL CHLORIDE	323
METHYLCLOSTEBOL	118
METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL.....	221, 246
1-METHYLCYCLOPROPENE	272
METHYLDESORPHINE.....	257
METHYLDIHYDROMORPHINE	252
METHYLDOPA	118
4,4'-METHYLENEBIS[2-CHLOROANILINE] (MOCA)	246, 340
METHYLENE BISTHIOCYANATE	221, 323
METHYLENE BLUE	118, 177, 246
METHYLENE CHLORIDE.....	289, 318
<i>See also</i> DICHLOROMETHANE	
METHYLENE DIANILINE	241, 315, 339
<i>See also</i> 4,4-DIAMINODIPHENYLMETHANE	
3,4-METHYLENEDIOXYAMPHETAMINE	257
3,4-METHYLENEDIOXY-N,A-DIMETHYLPHENYLETHYLAMINE <i>See</i> N,A-DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE	
METHYLEPHEDRINE	52
METHYLERGOMETRINE.....	118
METHYL ETHYL KETONE.....	4, 177, 294, 323
METHYL ETHYL KETONE PEROXIDE	177, 294, 323
METHYLEUGENOL.....	221, 294, 323
3-METHYLFENTANYL	257
METHYL ISOAMYL KETONE	294
METHYL ISOBUTYL KETONE.....	294

METHYL ISOTHIOCYANATE.....	221, 323
METHYLMERCURY.....	118, 332
METHYL METHACRYLATE.....	222, 323
METHYL NEODECANAMIDE.....	222
METHYLNORBORNYPYRIDINE.....	222, 323
METHYL P-HYDROXYBENZOATE.....	272
METHYLPENTYNOL.....	118
METHYLPHENIDATE.....	252
METHYLPHENOBARBITONE.....	118, 343
<i>See also</i> BARBITURATE	
1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE.....	257
METHYLPREDNISOLONE.....	118
N-METHYL-2-PYRROLIDONE.....	4, 168, 177, 179, 222, 294
METHYL SALICYLATE.....	28, 118, 177, 210, 222, 294
1-(B-METHYL SULPHONAMIDOETHYL)-2-AMINO-3-N,N- DIETHYLAMINOBENZENE.....	323
METHYLTESTOSTERONE.....	118
4-METHYLTHIOAMPHETAMINE.....	258
3-METHYLTHIOFENTANYL.....	258
2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6- CYCLOPRROPYLAMINO-5- TRIAZINE.....	177
METHYLTHIOURACIL.....	119
METHYLTRIENOLONE.....	119
METHYPRYLONE.....	119
METHYSERGIDE.....	119
METIRAM.....	18, 178
METOCLOPRAMIDE.....	62, 119
METOLACHLOR.....	178
METOLAZONE.....	119
METOPON.....	258
METOPROLOL.....	119
METOSULAM.....	222
METRIBOLONE.....	119
METRIBUZIN.....	222
METRIFONATE.....	119
METRONIDAZOLE.....	119
METSULFURONMETHYL.....	272
METYRAPONE.....	119
MEVINPHOS.....	246
MEXILETINE.....	119
MEZLOCILLIN.....	119
MIANSERIN.....	119, 343
MIBEFRADIL.....	119
MIBOLERONE.....	119
MICONAZOLE.....	52, 62, 119, 222, 323, 334
MIDAZOLAM.....	119
MIDODRINE.....	119
MIGLITOL.....	119
MIGLUSTAT.....	119
MILBEMECTIN.....	178, 222

MILBEMYCIN OXIME	178
MILRINONE	120
MINERAL OIL	
<i>See</i> HYDROCARBONS, LIQUID	
MINERAL TURPENTINE	26
MINOCYCLINE	120
MINOXIDIL	52, 120
MIPAFOX	246
MIREX	246, 340
MIRTAZAPINE	120, 343
MISOPROSTOL	35, 120, 324
MITOBRONITOL	120
MITOMYCIN	120
MITOTANE	120
MITOXANTRONE	120
MITRAGYNA SPECIOSA	258
MITRAGYNINE	258
MITRATAPIDE	120
MIVACURIUM CHLORIDE	120
MMDA	
<i>See</i> 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE	
MOCA	
<i>See</i> 4,4'-METHYLENEBIS[2-CHLOROANILINE]	
MOCLOBEMIDE	120
MODAFINIL	120
MOLGRAMOSTIM	120
MOLINATE	246, 340
MOLINDONE	120
MOMETASONE	52, 120
MONENSIN	120, 178, 222
MONOBENZONE	48, 120
MONOCLONAL ANTIBODIES	120
MONOCROTOPHOS	246
MONOMALEATE	201
MONTELUKAST	121
MOPERONE	121
MORAMIDE	
<i>See</i> DEXTROMORAMIDE	
MORAMIDE INTERMEDIATE	
<i>See</i> 2-METHYL-3-MORPHOLINO-1,1-DIPHENYLPROPANE- CARBOXYLIC ACID (MORAMIDE INTERMEDIATE)	
MORANTEL	178, 222
MORAZONE	121
MORICIZINE	121
MORPHERIDINE	258
MORPHINE	252, 343
MORPHINE-N-OXIDE	252
MORPHINE METHOBROMIDE	252
MOTOR, HEATING AND FURNACE FUELS	263
MOTRAZEPAM	121

MOTRETINIDE.....	121
MOXIDECTIN.....	121, 178, 223, 246
MOXIFLOXACIN.....	121
MOXONIDINE.....	121
MPPP	
<i>See</i> 1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE	
MSMA.....	223, 246
MUMPS VACCINE.....	121
MUPIROCIN.....	121
MURAGLITAZAR.....	121
MUROMONAB.....	121
MUSCIMOL.....	258
MUSTINE.....	121
MYCLOBUTANIL.....	178
MYCOPHENOLATE MOFETIL.....	121
MYCOPHENOLIC ACID.....	121
MYRISTIC ACID.....	272
MYROPHINE.....	258
N	
NAA.....	178
NABILONE.....	252
NABUMETONE.....	121
NADOLOL.....	121
NADROPARIN.....	121
NAFARELIN.....	121
NAFTIDROFURYL.....	121
NALBUPHINE.....	121, 343
NALED.....	178, 223
NALIDIXIC ACID.....	121
NALORPHINE.....	121
NALOXONE.....	122
NALTREXONE.....	122
NAME AND ADDRESS.....	6
NANDROLONE.....	122
NAPHAZOLINE.....	52, 324
NAPHTHALENE.....	24, 30, 223, 294, 324, 332
NAPHTHALENEACETIC ACID	
<i>See</i> NAA	
NAPHTHALOPHOS.....	223, 246
NAPROPAMIDE.....	272
NAPROXEN.....	52, 122, 324
NAPTALAM.....	178
NAPHTHYL ACETAMIDE.....	272
NARASIN.....	122, 223
NARATRIPTAN.....	122
NATALIZUMAB.....	122
NATAMYCIN.....	122
NATEGLINIDE.....	122

NEBACUMAB	122
NEDOCROMIL	122
NEEM	275, 287, 312
NEFAZODONE	122
NEFOPAM	122
NELFINAVIR	122
NELFINAVIR MESYLATE	122
NEOMYCIN	122
NEOSTIGMINE	122
NERIUM OLEANDER	122, 332
<i>See also</i> OLEANDER	
NEROLI OIL	272
NESIRITIDE	122
NETILMICIN	122
NETOBIMIN	178, 223
NEVIRAPINE	122
NIALAMIDE	122
NICARBAZIN	272
NICARDIPINE	123
NICERGOLINE	123
NICKEL SULFATE	223
NICLOSAMIDE	52
NICOCODINE	258
NICODICODINE	258
NICOFURANOSE	123
NICOMORPHINE	258
NICORANDIL	123
NICOTINE	52, 123, 223, 246, 324, 340
NICOTINIC ACID	63, 123
NICOTINYL ALCOHOL	63
NICOUMALONE	123
NIFEDIPINE	123
NIFENAZONE	123
NIKETHAMIDE	123
NILUTAMIDE	123
NIMESULIDE	123
NIMIDANE	223, 246
NIMODIPINE	123
NIMORAZOLE	123
NIRIDAZOLE	123
NISIN	71, 272
NISOLDIPINE	123
NITENPYRAM	223
NITRAZEPAM	123, 343
NITRENDIPINE	124
NITRIC ACID	178, 223, 294, 324
NITRIC OXIDE	124
NITROBENZENE	223, 294, 324
NITROFEN	246, 341
NITROFURANTOIN	124

NITROFURAZONE.....	124
NITROGEN MUSTARD	121
NITROPHENOL	224, 294, 324
NITROPRUSSIDES.....	224, 246, 294, 324
NITROSCANATE	179
NITROUS OXIDE	124
NITROXOLINE	124
NITROXYNIL	224
NIZATIDINE	52, 124, 324
NOMIFENSINE.....	124
NON-ACCESS PACKAGING.....	6
NON-VOLATILE CONTENT.....	6
NONOXINOL 9.....	179, 224, 294
NORACYMETHADOL.....	258
NORADRENALINE.....	124, 324
19-NORANDROSTENEDIOL.....	124
19-NORANDROSTENEDIONE.....	124
NORANDROSTENOLONE.....	124
NORBOLETHONE.....	124
NORCLOSTEBOL.....	124
NORCODEINE.....	252
NORELGESTROMIN	124
NORETHANDROLONE.....	124
NORETHISTERONE.....	124
NORFLOXACIN	124
NORFLURAZON	272
NORGESTREL.....	124
NORLEVORPHANOL.....	258
NORMETHADONE.....	252, 343
NORMETHANDRONE.....	124
NORMORPHINE.....	258
NORPIANONE.....	258
NORTRIPTYLINE.....	124, 343
NOSCAPINE	52, 252, 343
NOVALURON.....	272
NOVOBIOCIN.....	124
NOXIPTYLINE	124
NUCLEAR POLYHEDROSIS VIRUS.....	272
NUTMEG OIL	28, 179, 294
NUTRITION REPLACEMENT PREPARATIONS.....	263
NUX VOMICA	
<i>See</i> STRYCHNINE	
NYSTATIN.....	52, 63, 124, 324, 334

O

OCTAMYLAMINE.....	125
OCTATROPINE	125
1-OCTEN-3-OL	224
OCTHILINONE.....	224, 294
<i>See also</i> 2-OCTYL-4-ISOTHIAZOLIN-3-ONE	

OCTREOTIDE.....	125
OCTYL ALCOHOLS	272
N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE	179
2-OCTYL-4-ISOTHIAZOLIN-3-ONE (OCTHILINONE).....	294
OCTYL NITRITE	125
N-(N-OCTYL)-2-PYRROLIDONE	179, 224, 294
OESTRADIOL	125, 179, 332
OESTRIOL.....	125
OESTROGENS	125
OESTRONE	125, 332
OFLOXACIN	125
OLANZAPINE.....	125, 343
OLAQUINDOX	224
OLEANDOMYCIN	125, 179
OLEANDRIN	125
OLEIC ACID	272
N-OLEYL-1,3-DIAMINOPROPANE	224
OLMESARTAN.....	125
OLOPATADINE.....	125
OLSALAZINE	125
OMALIZUMAB	125
OMEPRAZOLE	125
OMETHOATE	179, 224, 247
ONDANSETRON	125
OPIPRAMOL.....	125
OPIUM.....	252, 343
ORANGE OIL.....	180, 295
ORANGE OIL (BITTER).....	180, 324
ORANGE OIL, SWEET.....	272
ORBIFLOXACIN	125
ORCIPRENALINE	125, 324
ORGANOPHOSPHORUS COMPOUND.....	17, 126
ORGANO-TIN COMPOUNDS	
<i>See</i> TIN ORGANIC COMPOUNDS	
ORLISTAT	63, 126
ORNIDAZOLE	126
ORNIPRESSIN	126
ORPHENADRINE	126
ORTHOPTERIN	126
OSELTAMIVIR.....	126
OUABAIN	126
OVANDROTONE	126
OXABETRINIL	272
OXABOLONE	126
OXACILLIN	126
OXADIARGYL	180
OXADIAZON	224
OXADIXYL.....	180
OXALATES, METALLIC.....	324

OXALIC ACID	XI, 224, 295, 325
OXALIPLATIN	126
OXALONITRILE <i>See</i> CYANOGEN	
OXAMYL	247
OXANDROLONE	126
OXANTEL EMBONATE	180
OXAPROZIN	126
OXAZEPAM	126, 343
OXCARBAZEPINE	126
OXEDRINE	126
OXETACAINE	52, 126
OXETHAZAINE	52, 126
OXFENDAZOLE	180
OXIBENDAZOLE	180
OXICONAZOLE	63, 126
OXITROPIUM	127
OXOLAMINE	127
OXOLINIC ACID	127
OXPENTIFYLLINE	127
OXPRENOLOL	127
OXYBUPROCAINE	127
OXYBUTYNIN	127
OXYCARBOXIN	180
OXYCLOZANIDE	224
OXYCODONE	252, 344
OXYDEMETON METHYL	247
OXYFLUORFEN	272
OXYMESTERONE	127
OXYMETAZOLINE	52, 325
OXYMETHOLONE	127
OXYMORPHONE	252
OXYPHENBUTAZONE	127
OXYPHENCYCLIMINE	127
OXYPHENISATIN	277
OXYPHENONIUM	127
OXYTETRACYCLINE	127, 180
OXYTHIOQUINOX	180
OXYTOCIN	127, 332

P

PACLITAXEL	127
PACLOBUTRAZOL	180
PAECILOMYCES LILACINUS STRAIN 251	225
PAINT	6, 325
PALIFERMIN	127
PALIPERIDONE	127, 344
PALIVIZUMAB	127
PALMAROSA OIL	272

PALMITIC ACID	272
PALONOSETRON	127
PAMAQUIN	127
PAMIDRONIC ACID	127
PANCREATIC ENZYMES	127
PANCURONIUM	128
PANITUMUMAB	128
PANTOPRAZOLE	63, 128
PAPAVERETUM	344
PAPAVERINE	52, 128, 252, 343
PAPER	263
PARA-FLUOROFENTANYL	258
PARACETAMOL	53, 59, 72, 128, 140, 325
PARAFFIN OIL	
<i>See</i> HYDROCARBONS, LIQUID HYDROCARBONS, LIQUID	
PARAFORMALDEHYDE	53, 225, 278, 291, 295
PARAHEXYL	
<i>See</i> 3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-	
TRIMETHYL-6H-DIBENZO(B,D)PYRAN*(PARAHEXYL)	
PARALDEHYDE	128
PARAMETHADIONE	128
PARAMETHASONE	128
PARAQUAT	15, 33, 247
PARATHION	247
PARATHION-METHYL	225, 247
PARBENDAZOLE	225
PARECOXIB	128
PARICALCITOL	128
PAROMOMYCIN	128
PAROXETINE	128
PATCHOULI OIL	272
PCBS	
<i>See</i> POLYCHLORINATED BIPHENYLS	
PCE	
<i>See</i> ETICYCLIDINE	
PCP	
<i>See</i> PENTACHLOROPHENOL or <i>See</i> PHENCYCLIDINE	
PCPY	
<i>See</i> ROLICYCLIDINE	
PDB	
<i>See</i> para-DICHLOROBENZENE	
PEBULATE	225
PECAZINE	128
PECTINASE	272
PEFLOXACIN	128
PEGAPTANIB	128
PEGFILGRASTIM	128
PEGINTERFERON	128
PEGVISOMANT	129

PEMETREXED.....	129
PEMOLINE.....	129
PEMPIDINE.....	129
PENBUTOLOL.....	129
PENCICLOVIR.....	54, 129
PENCONAZOLE.....	180
PENCYCURON.....	272
PENDIMETHALIN.....	180
PENETHAMATE.....	129
PENICILLAMINE.....	129
PENNYROYAL OIL.....	29, 225, 295
PENTACHLORONITROBENZENE <i>See</i> QUINTOZENE	
PENTACHLOROPHENOL.....	226, 247, 325
PENTADECANOIC ACID.....	272
PENTAERYTHRITYL TETRANITRATE.....	129
PENTAGASTRIN.....	129
PENTAMETHONIUM.....	129
PENTAMIDINE.....	129
PENTAZOCINE.....	252, 344
PENTHIENATE.....	129
PENTOBARBITONE.....	129, 252, 344
PENTOLINIUM.....	129
PENTOSAN POLYSULFATE SODIUM.....	129
PENTOXIFYLLINE.....	127
PEPAP <i>See</i> 1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE	
PEPPERMINT OIL.....	272
PERACETIC ACID.....	180, 226, 295, 325
PERFLUIDONE.....	226
PERGOLIDE.....	129
PERHEXILINE.....	129
PERICYAZINE.....	129, 344
PERINDOPRIL.....	129
PERMANGANATES.....	226, 295, 325
PERMETHRIN.....	129, 181, 226
PERPHENAZINE.....	129, 344
PERTUSSIS ANTIGEN.....	129
PESTICIDE.....	7
PETASITES.....	278
PETHIDINE.....	252, 344
PETHIDINE INTERMEDIATE A <i>See</i> 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE	
PETHIDINE INTERMEDIATE B <i>See</i> 4-PHENYL-PIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER	
PETHIDINE INTERMEDIATE C <i>See</i> 1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID	
PETROL.....	26, 181, 239, 263, 295

PETROLEUM OILS

See HYDROCARBONS, LIQUID

PHEDRAZINE	54
PHENACEMIDE	130
PHENACETIN	130
PHENADOXONE	258
PHENAGLYCODOL	130
PHENAMPROMIDE	258
PHENAZOCINE	258
PHENAZONE	54, 130, 181
PHENAZOPYRIDINE	130
PHENCYCLIDINE	258
PHENDIMETRAZINE	252
PHENELZINE	130, 344
PHENETICILLIN	130
PHENFORMIN	130
PHENGLUTARIMIDE	130
PHENINDIONE	130
PHENIRAMINE	54, 63, 130, 344
PHENISATIN	130
PHENISOPHAM	181
PHENMEDIPHAM	272
PHENMETRAZINE	252
PHENOBARBITONE	130, 344
PHENOL	54, 130, 181, 226, 295, 325
PHENOLPHTHALEIN	130
PHENOMORPHAN	258
PHENOPERIDINE	252, 344
PHENOTHIAZINE	226
D-PHENOTHRIN	272
PHENOXYBENZAMINE	130
PHENOXYMETHYLPENICILLIN	130
PHENSUXIMIDE	130
PHENTERMINE	130, 280
PHENTHIMENTONIUM	130
PHENTOLAMINE	130
PHENYL BUTAZONE	130
PHENYL MERCURIC CHLORIDE	
<i>See</i> MERCURY	
PHENYLENEDIAMINES	226, 235, 278, 295, 325
PHENYLEPHRINE	54, 131, 325
1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE	258
PHENYLMERCURIC ACETATE	247, 341
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE- 2,6-DIMETHANAMINE	198, 295, 325
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE- 2,5-DIMETHANAMINE	197, 295, 325
PHENYL METHYL KETONE	4, 181, 295

ORTHO-PHENYLPHENOL.....	181, 296, 325
PHENYLPHENOL.....	325
4-PHENYLPYPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER	252
PHENYLPROPANOLAMINE	131, 325
PHENYLTOLOXAMINE.....	131, 344
PHENYTOIN	131, 326
PHOLCODINE	54, 131, 252, 344
PHORATE	247
PHOSALONE	227
PHOSFOLAN	247
PHOSMET	227
PHOSPHIDES, METALLIC.....	247, 341
PHOSPHINE.....	247, 341
PHOSPHONIC ACID	181, 296, 326
PHOSPHORIC ACID	181, 227, 296, 326
PHOSPHORUS.....	332
PHOSPHOROUS ACID	
<i>See</i> PHOSPHONIC ACID	
PHOSPHORUS (YELLOW).....	247, 326, 296
PHOTOGRAPHIC PAPER OR FILM.....	263
PHOXIM.....	227
PHP	
<i>See</i> ROLICYCLIDINE	
ORTHO-PHTHALALDEHYDE.....	181, 227, 296, 326
PHTHALALDEHYDE.....	326
PHTHALYLSULFATHIAZOLE.....	131
PHYSOSTIGMINE.....	131
PHYTASE.....	272
PICARIDIN.....	181
PICLORAM	272
PICOLINAFEN.....	273
PICRIC ACID	296, 326
<i>See also</i> TRINITROPHENOL	
PICROTOXIN.....	131
PIGEON POX VACCINE.....	153
PIGMENTS.....	263
PILOCARPINE.....	131
PIMECROLIMUS.....	131
PIMELIC ACID	273
PIMINODINE.....	258
PIMOBENDAN	131
PIMOZIDE.....	131, 344
PINACIDIL.....	131
PINDOLOL.....	131
PINDONE	227
PINE OIL	181, 227
PINOXADEN.....	182, 227
PIOGLITAZONE.....	131
PIPECURONIUM.....	131

PIPEMIDIC ACID	131
PIPENZOLATE	132
PIPERACILLIN	132
PIPERAZINE	55, 182
PIPERIDINE	132
PIPERIDOLATE	132
PIPER METHYSTICUM	132
PIPERONYL BUTOXIDE	273
PIPEROPHOS	227
PIPOBROMAN	132
PIPOTHIAZINE	132
PIPRADROL	132
PIRACETAM	132
PIRBUTEROL	132
PIRENOXINE	132
PIRENZEPINE	132
PIRETANIDE	132
PIRFENOXONE SODIUM	133
PIRIMICARB	182, 227
PIRIMIPHOS-ETHYL	228
PIRIMIPHOS-METHYL	228
PIRITRAMIDE	252
PIROXICAM	133
PIRPROFEN	133
PITUITARY	133
PIVAMPICILLIN	133
PIZOTIFEN	133, 344
PLICAMYCIN	133
PMA	
<i>See</i> 4-METHOXY-A-METHYLPHENYL-ETHYLAMINE	
PNEUMOCOCCAL VACCINE	133
PODOPHYLLIN	55, 133, 326, 332
PODOPHYLLOTOXIN	55, 63, 133, 326
PODOPHYLLUM EMODI	55, 63, 133
PODOPHYLLUM PELTATUM	55, 63, 133
PODOPHYLLUM RESIN	332
POISON	7, 279, 280, 281
POLIDEXIDE	133
POLIHEXANIDE	182, 326
POLIOMYELITIS VACCINE	133
POLIXETONIUM SALTS	182, 228
POLOXALENE	273
POLY (GNRF) OVALBUMIN	273
POLY(OXY-1,2-ETHANEDIYL)	182
POLY(OXY-1,2-ETHANEDIYL), A-[2-[(2-HYDROXYETHYL)AMINO]-2- OXOETHYL]-Ω-HYDROXY-, MONO-C13-15-ALKYL ETHERS	296, 327
POLYACRYLAMIDE	133
POLYDADMAC	273
POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE	273

POLYESTRADIOL	134
POLYETHANOXY	296
POLYETHANOXY (15) TALLOW AMINE	182, 327
POLYHEDROSIS VIRUS	273
POLYLACTIC ACID	134
POLYMYXIN	134
POLYSILICONE-15	
<i>See</i> DIMETHICODIETHYLBENZALMALONATE	
POLYSORBATE 20	273
POLYSULFATED GLYCOSAMINOGLYCANS	134
POLYTHIAZIDE	134
POPPY STRAW CONCENTRATE	
<i>See</i> CONCENTRATE OF POPPY STRAW	
PORACTANT	134
PORCELAIN	263
PORCINE SOMATOTROPHIN	273
POSACONAZOLE	134
POTASSIUM AZELOYL DIGLYCINATE	228
POTASSIUM BICARBONATE	273
POTASSIUM BROMATE	228, 296
POTASSIUM BROMIDE	134
POTASSIUM CARBONATE	
<i>See</i> ALKALINE SALTS	
POTASSIUM CHLORATE	55, 182, 296
POTASSIUM CHLORIDE	134
POTASSIUM CHROMATE	XI
POTASSIUM CYANATE	228, 296
POTASSIUM HYDROXIDE	29, 182, 228, 296, 327
POTASSIUM METABISULPHITE	182, 296, 327
POTASSIUM NITRITE	182, 228, 247, 296, 327
POTASSIUM PERCHLORATE	134
POTASSIUM PERMANGANATE	
<i>See</i> PERMANGANATES	
POTASSIUM PEROXOMONOSULFATE	297
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT	182, 228
POTASSIUM PERSULFATE	229, 297, 327
POTASSIUM PHOSPHATE	
<i>See</i> ALKALINE SALTS	
POTASSIUM SILICATE	
<i>See</i> ALKALINE SALTS	
POTASSIUM SORBATE	273
POTASSIUM SULFIDE	183, 297, 327
POULTRY VACCINES	153
PRACTOLOL	134
PRALIDOXIME	134
PRALLETHRIN	183, 229
PRAMIPEXOLE	134
PRAMOCAINE	134
PRAMPINE	134
PRASTERONE	134

PRAVASTATIN	134
PRAZEPAM.....	135, 344
PRAZIQUANTEL.....	135, 273
PRAZOSIN	135
PREDNISOLONE.....	135
PREDNISONONE	135
PREGABALIN.....	135, 344
PREGNENOLONE	135
PRENALTEROL.....	135
PRENYLAMINE	135
PRILOCAINE	55, 135
PRIMAQUINE.....	135
PRIMARY PACK	7
PRIMIDONE.....	135
PRINTING INKS	263, 337
PROBENECID.....	135
PROBUCOL.....	135
PROCAINAMIDE	135
PROCAINE	135
PROCAINE PENICILLIN.....	135, 229
PROCARBAZINE	135
PROCHLORAZ	229
PROCHLORPERAZINE.....	63, 135, 344
PROCYCLIDINE.....	55, 135
PROCYMIDONE.....	247
PROFENOFOS	229
PROFOXYDIM.....	183
PROGESTERONE.....	135, 183, 332
PROGESTOGENS.....	135
PROGLUMIDE.....	135
PROGUANIL.....	135
PROHEPTAZINE	258
PROHEXADIONE CALCIUM.....	183
PROLINTANE.....	136
PROMACYL.....	229
PROMAZINE.....	136, 344
PROMETHAZINE.....	55, 63, 136, 344
PROMETRYN	183
PROMOXOLANE	136
PROPACHLOR.....	229
PROPAFENONE	136
PROPAMIDINE.....	55, 136
PROPAMOCARB	183
PROPANIDID.....	136
PROPANIL	183
PROPANTHELINE	136
PROPAQUIZAFOP	183
PROPARGITE	229
PROPENTOFYLLINE.....	136
PROPERIDINE.....	259

PROPETAMPHOS	229
PROPETANDROL.....	136
PROPICONAZOLE	183, 229
PROPINEB.....	18, 229
<i>See also</i> DITHIOCARBAMATES	
PROPIONIBACTERIUM ACNES	136
PROPIONIC ACID	183, 229, 297, 327
PROPIRAM	253
PROPOFOL	136
PROPOXUR.....	183, 229
PROPRANOLOL.....	136, 332
PROPYL ACETATES	273
PROPYLENE GLYCOL.....	273
2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER.....	273
PROPYLENE OXIDE.....	247
PROPYLHEXEDRINE.....	136
PROPYLTHIOURACIL	136
PROPYPHENAZONE	136
PROPYZAMIDE.....	184
PROQUAZONE.....	136
PROSCILLARIDIN	136
PROSTAGLANDINS	136
PROSTIANOL	136
PROSULFOCARB.....	229
PROTAMINE.....	136
PROTHIOCONAZOLE	273
PROTHIOFOS	229
PROTHIONAMIDE.....	136
PROTHIPENDYL.....	136
PROTIRELIN.....	136
PROTOVERATRINES	137
PROTRIPTYLINE	137, 344
PROXYMETACAINE	137
PSEUDOEPHEDRINE	64, 137, 334
PSEUDOMONAS FLUORESCENS	273
PSILOCINE	255, 259
<i>See also</i> 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE	
PSILOCYBINE	259
PSILOTSIN	255, 259
<i>See also</i> 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE	
PTERIDIUM	278
D-PULEGONE.....	29, 229, 297
PULMONARIA	278
PYMETROZINE.....	184
PYRACLOFOS.....	230
PYRACLOSTROBIN	184
PYRAFLUFEN-ETHYL.....	184
PYRANTEL	55

PYRASULFOTOLE.....	184
PYRAZINAMIDE.....	137
PYRAZOPHOS.....	230
PYRETHRINS.....	55, 184
PYRIDABEN.....	184, 230
PYRIDALYL.....	230
PYRIDATE.....	230
PYRIDINOLCARBAMATE.....	137
PYRIDOSTIGMINE.....	137
PYRIDOXAL.....	137
PYRIDOXAMINE.....	137
PYRIDOXINE.....	137
PYRIFENOX.....	184
PYRIMETHAMINE.....	137
PYRIMETHANIL.....	273
PYRINURON.....	247, 341
PYRIPROLE.....	230
PYRIPROXYFEN.....	273
PYRITHIOBAC SODIUM.....	184
PYRITHIONE COPPER.....	230
PYRITHIONE ZINC.....	56, 184, 230, 297
PYROVALERONE.....	137
PYROXSULAM.....	230
PYRVINIUM.....	137

Q

QUASSIA.....	273
QUATERNARY AMMONIUM COMPOUNDS.....	17, 184, 230, 297
QUAZEPAM.....	137
QUETIAPINE.....	137, 344
QUINAGOLIDE.....	137
QUINALBARBITONE.....	253, 344
QUINAPRIL.....	137
QUINBOLONE.....	137
QUINCLORAC.....	184
QUINETHAZONE.....	137
QUINIDINE.....	137
QUININE.....	137, 184, 247
QUINISOCAINE.....	138
QUINOXYFEN.....	273
QUINTOZENE.....	184
QUINUPRISTIN.....	138
QUIZALOFOP-P-ETHYL.....	184, 231
QUIZALOFOP-P-TEFURYL.....	231
QUIZALOFOP ETHYL.....	231
QUIZALOFOP ETHYL (D + ISOMER) <i>See</i> QUIZALOFOP ETHYL	

R

RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN	
<i>See</i> IMMUNOGLOBULINS	
RABEPRAZOLE	138
RABIES VACCINE	138
RACEMETHORPHAN	259
RACEMORAMIDE	253
RACEMORPHAN	259
RACTOPAMINE	138, 185
RADIOGRAPHIC CONTRAST MEDIA	263
RADIOISOTOPES	263
RADIOPAQUES	
<i>See</i> RADIOGRAPHIC CONTRAST MEDIA	
RALOXIFENE	138
RALTEGRAVIR	138
RALTITREXED	138
RAMIPRIL	138
RANIBIZUMAB	138
RANITIDINE	56, 138, 327
RAPACURONIUM	138
RASAGILINE	138
RASBURICASE	138
RAUWOLFIA SERPENTINA	138
RAUWOLFIA VOMITORIA	138
RAZOXANE	138
REBOXETINE	138
REDUCERS	26
REMIFENTANIL	253
REMOXIPRIDE	138
REPAGLINIDE	138
REQUIRED ADVISORY STATEMENTS FOR MEDICINE LABELS	7
RESERPINE	138
RESMETHRIN	185, 231
RESTRICTED FLOW INSERT	7
RETEPLASE	139
RIBAVIRIN	139
RIFABUTIN	139
RIFAMPICIN	139
RIFAMYCIN	139
RIFAPENTINE	139
RILUZOLE	139
RIMEXOLONE	139
RIMITEROL	139
RIMONABANT	139
RIMSULFURON	185
RISEDRONIC ACID	139
RISPERIDONE	139, 344
RITODRINE	139
RITONAVIR	139

RITUXIMAB	139
RIVASTIGMINE	139
RIZATRIPTAN.....	139
ROBENIDINE.....	185
ROCURONIUM.....	139
ROFECOXIB	139
ROLICYCLIDINE	259
ROLITETRACYCLINE.....	139
ROMIFIDINE	139
ROMIPLOSTIM	139
RONIDAZOLE	139
ROPINIROLE	140
ROPIVACAINE.....	140
ROSEMARY OIL	273
<i>See also</i> CAMPHOR CINEOLE	
ROSIGLITAZONE	140
ROSOXACIN.....	140
ROSUVASTATIN	140
ROTENONE	231
ROTIGOTINE.....	140, 341, 344
ROXIBOLONE.....	140
ROXITHROMYCIN	140
RUBELLA VACCINE.....	140
RUBOXISTAURIN	140

S

SABADILLA	140
SAFROLE.....	231, 278, 297, 327
SAGE OIL.....	29, 160, 201, 231, 297
SAGE OIL (SPANISH).....	273
<i>See also</i> CAMPHOR	
SALBUTAMOL.....	64, 140, 327
SALCATONIN	140
SALICYLAMIDE	56, 72, 140, 327
SALICYLANILIDE.....	185
SALICYLIC ACID	64
SALINOMYCIN	140, 231
SALMETEROL.....	140
SALVIA DIVINORUM	259
SANTONIN	64
SAQUINAVIR	140
SASSAFRAS OIL	231, 297, 328
SAVIN.....	277
SCABBY MOUTH VACCINE.....	153
SCHOENOCALON OFFICINALE.....	140
SCHRADAN.....	247
SCOPOLIA CARNIOLICA	140
SEAWEED & UNFRACTIONED SEAWEED-EXTRACTS.....	273
SECBUTOBARBITONE	253, 344

SECOND SCHEDULE PAINT.....	7
SEEDS.....	263
SELAMECTIN.....	185
SELECTED CONTAINER.....	7
SELEGILINE.....	140
SELENIUM.....	56, 64, 141, 232, 248, 328, 333, 335
SELENIUM COMPOUNDS.....	297, 328
SEMDURAMICIN.....	232, 248
SENECIO.....	278
SERMORELIN.....	141
SERTINDOLE.....	141
SERTRALINE.....	141
SETHOXYDIM.....	185
SEVELAMER.....	141
SEVOFLURANE.....	141
SEX HORMONES.....	141
SHUI OIL <i>See</i> CAMPHOR	
SIBUTRAMINE.....	141
SIDURON.....	185
SILANDRONE.....	141
SILDENAFIL.....	141
SILICOFLUORIC ACID <i>See</i> HYDROSILICOFLUORIC ACID	
SILICOFLUORIDES.....	185, 232, 297, 320
SILICONES.....	141, 278
SILVER.....	328
SILVER NITRATE.....	232
SILVER SALTS.....	56, 297
SILVER SULFADIAZINE.....	141
SIMAZINE.....	273
SIMVASTATIN.....	141
SINBIOALLETHRIN.....	185, 233
SINGLE-USE TUBES.....	263
SIROLIMUS.....	141
SISOMICIN.....	142
SITAGLIPTIN.....	142
SITAXENTAN.....	142, 281
SLIMICIDES.....	261
SMELLING SALTS.....	311
SODIUM ALUMINATE.....	233, 297, 328
SODIUM BICARBONATE.....	273
SODIUM BROMATE.....	233, 297
SODIUM BROMIDE.....	142
SODIUM CARBONATE <i>See</i> ALKALINE SALTS	
SODIUM CELLULOSE PHOSPHATE.....	142
SODIUM CHLORATE.....	185, 298, 328
SODIUM CLODRONATE.....	85

SODIUM CROMOGLYCATE	56, 142
SODIUM DIACETATE	185, 298
SODIUM DICHLOROISOCYANURATE	298
SODIUM 2,2-DICHLOROPROPIONATE <i>See</i> 2,2-DPA	
SODIUM DODECYLBENZENE SULFONATE	185, 298, 328
SODIUM FLUORIDE	328
SODIUM HYDROGEN SULFATE	185, 298, 328
SODIUM HYDROSULFITE	185, 298, 328
SODIUM HYDROXIDE	29, 185, 233, 298, 328
SODIUM HYPOCHLORITE <i>See</i> CHLORINATING COMPOUNDS	
SODIUM LAURETH-6 CARBOXYLATE	186, 298, 328
SODIUM METABISULPHITE	186, 298, 328
SODIUM MORRHUATE	142
SODIUM NITRITE	56, 186, 233, 248, 298, 329
SODIUM NITROPRUSSIDE	142
SODIUM OXALATE	XI
SODIUM OXYBATE <i>See</i> 4-HYDROXYBUTANOIC ACID	
SODIUM PERCARBONATE	186, 233, 298
SODIUM PERSULFATE	233, 298, 329
SODIUM PHOSPHATE	64, 142
<i>See also</i> ALKALINE SALTS	
SODIUM PICOSULFATE	64
SODIUM POLYSTYRENE SULPHONATE	142, 186
SODIUM PROPIONATE	273
SODIUM SALICYLATE	142
SODIUM SILICATE(S) <i>See</i> ALKALINE SALTS	
SODIUM STANNATE	186, 298
SODIUM SULFIDE	186, 234, 298, 329
SODIUM TETRADECYLSULFATE	142
SODIUM TRICHLOROACETATE	298
SOLASODINE	142
SOLID	7
SOLIFENACIN	142
SOMATOSTATIN	142
SOMATOTROPIN, EQUINE	142
SOMATROPIN	142, 280
SONTOQUINE	142
SORAFENIB	142
SOTALOL	142
SPARFLOXACIN	142
SPARTEINE	142
SPECTINOMYCIN	142
SPINETORAM	186
SPINOSAD	186
SPIRAMYCIN	142

SPIRAPRIL	143
SPIRONOLACTONE	143
SPIROTETRAMAT	234
SPIROXAMINE	234
SQUILL	56
S,S,S-TRIBUTYLPHOSPHOROTRITHIOATE	
<i>See</i> TRIBUFOS	
STABAXOL	
<i>See</i> 2,2',6,6'-TETRAISOPROPYLDIPHENYLCARBODIIMIDE	
STANOLONE	143
STANOZOLOL	143
STAPHISAGRIA	43
STAR ANISE OIL	186
STAVUDINE	143
STENBOLONE	143
STERIC ACID	273
STEROID HORMONES	143
STILBOESTROL	143
STP	
<i>See</i> 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE	
STRAMONIUM	43, 88, 89
STREPTODORNASE	143
STREPTOKINASE	143
STREPTOMYCIN	143
STRONTIUM RANELATE	143
STROPHANTHINS	143
STROPHANTHUS	143, 333
STRYCHNINE	34, 143, 248, 298, 333, 341
STRYCHNOS SPP	143, 333
STYRAMATE	143
STYRENE	4, 187, 298, 329
SUCCINYLATED & ETHERIFIED STARCHES	261
SUCRALFATE	273
SUFENTANIL	253
SULBACTAM	143
SULCOFURON	248, 298, 341
SULCONAZOLE	56, 143
SULESOMAB	273
SULFACETAMIDE	64, 143, 187
<i>See also</i> SULFONAMIDES	
SULFADIAZINE	143, 187
SULFADIMETHOXINE	143
SULFADIMIDINE	143, 187
SULFADOXINE	144
SULFAFURAZOLE	144
SULFAGUANIDINE	144
SULFAMERAZINE	144
SULFAMETHIZOLE	144
SULFAMETHOXAZOLE	144

SULFAMETHOXYDIAZINE	144
SULFAMETHOXPYRIDAZINE.....	144
SULFAMETROLE.....	144
SULFAMIC ACID.....	187, 234, 299, 329
SULFAMONOMETHOXINE.....	144
SULFAMOXOLE	144
SULFAPHENAZOLE.....	144
SULFAPYRIDINE.....	144
SULFAQUINOXALINE.....	144, 187
SULFASALAZINE.....	144
SULFATHIAZOLE.....	144, 187
SULFATROXAZOLE	144
SULFENTRAZONE	248
SULFINPYRAZONE.....	144
SULFLURAMID.....	234
SULFOMETURON-METHYL.....	187
SULFOMYXIN.....	144
SULFONAL.....	144
SULFONAMIDES.....	144
SULFONMETHANE.....	144
SULFOSULFURON.....	274
SULFOTEP	248
SULFURIC ACID.....	234, 299, 329
SULFURYL FLUORIDE.....	234
SULINDAC.....	144
SULPHANILAMIDE	
<i>See</i> SULFONAMIDES	
SULPHATED POLYSACCHARIDES.....	274
SULPROFOS	234
SULTAMICILLIN	145
SULTHIAME.....	145
SUMATRIPTAN.....	145
SUNITINIB.....	145
SUPROFEN	145
SUTILAINS	145
SUXAMETHONIUM	145
SUXETHONIUM.....	145
SYMPHYTUM	187, 194, 278, 329

T

2,4,5-T.....	234
T-CELL RECEPTOR ANTIBODY	145
TACRINE.....	145
TACROLIMUS.....	145
TADALAFIL.....	145
TALLOW ALKYLAMINE ACETATES.....	234
N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE.....	234
TAMOXIFEN	145
TAMSULOSIN	145

TANACETUM VULGARE	145
TANNIC ACID	274
TANNIC ACID/BENZYL ALCOHOL-PRODUCT	274
TANSY OIL	145
TAR	
<i>See</i> PHENOL	
TAR ACIDS	234
TASONERMIN	145
TAZAROTENE	145, 329
TAZOBACTAM	145
2,3,6-TBA	187
TBTO	
<i>See</i> TRI-ALKYL TIN COMPOUNDS/SALTS	
TCMTB	234
TCP	
<i>See</i> TENOCYCLIDINE	
TDE (1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE)	187, 234
TEA-TREE OIL	
<i>See</i> MELALEUCA OIL	
TEBUCONAZOLE	187
TEBUFENOZIDE	187
TEBUFENPYRAD	234
TEBUTHIURON	234
TEFLUTHRIN	187, 248
TEGAFUR	145
TEGASEROD	145
TEICOPLANIN	145
TELBIVUDINE	145
TELITHROMYCIN	145
TELMISARTAN	146
TEMAZEPAM	146, 344
TEMEPHOS	187, 234
TEMOZOLOMIDE	146
TENECTEPLASE	146
TENIPOSIDE	146
TENOCYCLIDINE	259
TENOFOVIR	146
TENOXICAM	146
TEPOXALIN	146
TEPP	249
TEPRALOXYDIM	187
TERAZOSIN	146
TERBACIL	274
TERBINAFINE	56, 146
TERBUCONAZOLE	
<i>See</i> TEBUCONAZOLE	
TERBUFOS	249
TERBUTALINE	146, 329
TERBUTALINESALBUTAMOL	64
TERBUTHYLAZINE	234

TERBUTRYN	187
TERFENADINE	146, 329
TERIPARATIDE	146, 279
TERLIPRESSIN	146
TERMITE BARRIERS	264
TERODILINE	146
TEROPTERIN	146
TERPENES	299
TERPENES, CHLORINATED	234, 329
TESTOLACTONE	146
TESTOSTERONE	146, 234, 333
TETANUS ANTITOXIN	146
TETANUS TOXOID	146
TETRABENAZINE	147
TETRACHLOROETHANE	249, 299, 329, 341
TETRACHLOROETHYLENE	4, 56, 188, 235, 299, 329
TETRACHLORVINPHOS	188
TETRACONAZOLE	188, 235
TETRACOSACTRIN	147
TETRACYCLINE	147, 188
TETRADIFON	235
TETRAETHYLAMMONIUM	147
TETRAHYDROCANNABINOLS	259
TETRAHYDROZOLINE	56, 329
2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE	235, 249, 341
TETRAMETHRIN	188
TETRAMISOLE	235
TETRAPION <i>See</i> FLUPROPANATE	
TETROXOPRIM	147
THALIDOMIDE	35, 147, 279, 329
THALLIUM	34, 249, 341
THALLIUM SULFATE <i>See</i> THALLIUM	
THAUMATIN	274
THEBACON	253
THEBAINE	253
THENYLDIAMINE	56, 64, 147, 344
THEOPHYLLINE	147
THERAPEUTIC USE	8
THEVETIA PERUVIANA	147
THEVETIN	147
THIABENDAZOLE	56, 188
THIACETARSAMIDE	147
THIACLOPRID	235
THIAMBUTOSINE	147
THIAMETHOXAM	188, 235
THIAZAFLURON	235
THIAZOPYR	188
THIAZOSULFONE	147

THIDIAZURON	274
THIETHYLPERAZINE	147, 344
THIFENSULFURON	188
THINNERS	26
THIOACETAZONE	147
THIOBENCARB	188
THIOCARLIDE	147
2-(THIOCYANOMETHYLTHIO)BENZOTHAZOLE	
<i>See</i> TCMTB	
THIODICARB	188, 235
THIOFANOX	249
THIOFENTANYL	259
THIOGUANINE	147
THIOMESTERONE	147
THIOMETON	235
THIOPENTONE	147
THIOPROPAZATE	147, 344
THIOPROPERAZINE	147
THIORIDAZINE	147, 344
THIOSTREPTON	147
THIOTEPA	148
THIOTHIXENE	148, 344
THIOURACIL	148
THIOUREA	148, 235, 299, 329
THIRAM	18, 235
<i>See also</i> DITHIOCARBAMATES	
THIRD SCHEDULE PAINT	8
THUJONE	29, 235, 299
THYME OIL	29, 188, 299
THYMOXAMINE	148
THYROID	148
THYROID STIMULATING HORMONE	
<i>See</i> THYROTROPHIN	
THYROTROPHIN	148
THYROTROPHIN RELEASING FACTOR	
<i>See</i> PROTIRELIN	
THYROXINE	148
THYROXINE SODIUM	333
TIAGABINE	148
TIAMULIN	148
TIAPROFENIC ACID	148
TIARAMIDE	148
TIBOLONE	148
TICARCILLIN	148
TICLOPIDINE	148
TIEMONIUM	148
TIENILIC ACID	148
TIGECYCLINE	148
TIGLOIDINE	148
TILETAMINE	148

TILIDINE.....	253
TILMICOSIN.....	148
TILUDRONIC ACID.....	148
TIMBER.....	264
TIMOLOL.....	148
TINIDAZOLE.....	149
TIN ORGANIC COMPOUNDS.....	249
TINTER.....	8
TINZAPARIN.....	149
TIOCARBAZIL.....	189
TIOCONAZOLE.....	56, 64, 149
TIOMESTERONE.....	147
TIOTROPIUM.....	149
TIPEPIDINE.....	149
TIPRANAVIR.....	149
TIRILAZAD.....	149
TIROFIBAN.....	149
TMA <i>See</i> 3,4,5-TRIMETHOXY-A-METHYLPHENYLETHYLAMINE	
TOBRAMYCIN.....	149
TOCAINIDE.....	149
TOLAZAMIDE.....	149
TOLAZOLINE.....	149
TOLBUTAMIDE.....	149
TOLCAPONE.....	149
TOLCLOFOS-METHYL.....	189
TOLFENAMIC ACID.....	149
ORTHO-TOLIDINE.....	249, 299, 341
TOLMETIN.....	149
TOLONIUM.....	149
TOLPROPAMINE.....	149
TOLRESTAT.....	149
TOLTERODINE.....	149
TOLTRAZURIL.....	189
TOLUENE.....	26, 235, 237, 299, 329, 336
TOLUENEDIAMINE.....	278, 299, 329
TOLYLFLUANID.....	236
TOPICAL USE.....	8
TOPIRAMATE.....	149
TOPOTECAN.....	149
TORASEMIDE.....	150
TOREMIFENE.....	150
TOXOIDS.....	150
TOY.....	8
TOY FUELS.....	263
TRALKOXYDIM.....	189
TRAMADOL.....	150, 344
TRAMAZOLINE.....	57, 330
TRANDOLAPRIL.....	150
TRANEXAMIC ACID.....	150

TRANSDERMAL USE.....	8
TRANSFLUTHRIN	236
TRANLYCYPROMINE	150, 344
TRASTUZUMAB.....	150
TRAVOPROST.....	150
TRAZODONE.....	150
TRENBOLONE	150, 189
TREOSULPHAN.....	150
TREPROSTINIL.....	150
TRESTOLONE	150
TRETAMINE.....	150
TRETINOIN.....	35, 150, 280, 330
TRI-ALKYL TIN COMPOUNDS	249
TRI-ALLATE.....	18, 189
TRI-PHENYL TIN COMPOUNDS.....	249
TRIACETYLOLEANDOMYCIN.....	150
TRIADIMEFON	189, 236
TRIADIMENOL	189
TRIAMCINOLONE.....	57, 64, 150, 330
TRIAMIPHOS.....	249
TRIAMTERENE.....	150
TRIASULFURON.....	274
TRIAZBUTIL	249
TRIAZQUONE.....	150
TRIAZOLAM	150
TRIBENURON-METHYL	189
TRIBUFOS.....	249
TRICHLORFON	236
TRICHLORMETHIAZIDE.....	150
TRICHLOROACETATES, ALKALINE SALTS.....	189
TRICHLOROACETIC ACID	150, 189, 236, 299, 330
1,1,1-TRICHLOROETHANE	4, 158, 189, 278, 299, 330
TRICHLOROETHENE	
<i>See</i> TRICHLOROETHYLENE	
TRICHLOROETHYLENE	150, 236, 299, 330
TRICHLOROISOCYANURIC ACID	299, 341
<i>See also</i> CHLORINATING COMPOUNDS	
TRICHLOROPHENOL	236, 330
TRICHLORPHON	
<i>See</i> TRICHLORFON	
TRICHODERMA HARZIANUM.....	274
TRICHODESMA	278
TRICLABENDAZOLE.....	236
TRICLOFOS	151
TRICLOPYR.....	237
TRICOSENE.....	274
TRICYCLAMOL	151
TRIDEMORPH.....	237
TRIDIHEXETHYL	151
TRIDIPHANE.....	190

TRIENBOLONE	150
TRIENOLONE	150
TRIETAZINE	190
TRIETHANOLAMINE	190, 299, 330
TRIETHYLENE GLYCOL	274
TRIETHYLENE THIOPHOSPHORAMIDE	
<i>See</i> THIOTEPA	
TRIETHYL PHOSPHATE	237, 299, 330
TRIFLOXYSTROBIN	190
TRIFLOXYSULFURON	274
TRIFLUMIZOLE	190
TRIFLUMURON	190
TRIFLUOPERAZINE	151, 344
TRIFLUOROMETHANE	300
TRIFLUOROMETHANESULFONIC ACID	237, 330
1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE	259
TRIFLUPERIDOL	151
TRIFLUPROMAZINE	151
TRIFLURALIN	274
TRIFORINE	274
TRIIODOTHYRONINE	
<i>See</i> LIOTHYRONINE SODIUM	
TRISOPROPANOLAMINE LAURYL ETHER SULFATE	190, 300, 330
TRILOSTANE	151
TRIMEPERIDINE	259
TRIMEPRAZINE	57, 65, 151, 344
TRIMETAPHAN	151
TRIMETHOPRIM	151
3,4,5-TRIMETHOXY-METHYLPHENYLETHYLAMINE	259
3,4,5-TRIMETHOXYPHENETHYLAMINE	259
1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINO BUTANE	259
TRIMETHYL TIN CHLORIDE	
<i>See</i> TIN ORGANIC COMPOUNDS	
TRIMETHYL TIN COMPOUNDS	249
TRIMIPRAMINE	151, 344
TRIMUSTINE	151
TRINEXAPAC-ETHYL	190
TRINITROPHENOL	151, 237
3,6,9-TRIOXAUNDECANEDIOIC ACID	190, 330
TRIOXYSALEN	151
TRIPARANOL	278
TRIPELENNAMINE	151
TRIPLE ANTIGEN VACCINE	151
TRIPROLIDINE	57, 65, 151, 344
TRIPROPYL TIN COMPOUNDS	
<i>See</i> TIN ORGANIC COMPOUNDS	
TRIPTORELIN	151
TRISODIUM NITRILOTRIACETATE	237
TRITICONAZOLE	190
TROGLITAZONE	151

TROMETAMOL.....	151
TROPICAMIDE.....	151
TROPISETRON.....	151
TROVAFLOXACIN.....	152
TROXIDONE.....	152
TRYPTOPHAN.....	152
TSH	
<i>See</i> THYROTROPHIN	
TUAMINOHEPTANE.....	57
TUBOCURARINE.....	152
TULATHROMYCIN.....	152
TULO BUTEROL.....	152
TURPENTINE.....	300
TURPENTINE (MINERAL).....	171
TURPENTINE (VEGETABLE).....	29, 190
TURPENTINE OIL.....	300
TUSSILAGO.....	278
TYLOSIN.....	152, 191
TYMAZOLINE.....	57, 330
TYPHOID VACCINE.....	152
U	
ULOCLADIUM OUDEMANSII.....	274
UNICONAZOLE-P.....	202
UNOPROSTONE.....	152
URACIL.....	152
URAPIDIL.....	152
13C-UREA.....	274
UREA.....	274
URETHANE.....	152
UROFOLLITROPIN.....	152, 279
UROKINASE.....	152
URSODEOXYCHOLIC ACID.....	152
V	
VACCINES.....	152
VACCINES, VETERINARY LIVE VIRUS.....	153
VALACICLOVIR.....	153
VALDECOXIB.....	153
VALGANCICLOVIR.....	153
VALNOCTAMIDE.....	153
VALPROIC ACID.....	153
VALSARTAN.....	153
VAMIDOTHION.....	237
VANCOMYCIN.....	153
VARDENAFIL.....	153
VARENICLINE.....	153
VARICELLA VACCINE.....	153
VASOPRESSIN.....	153

VECURONIUM.....	153
VEDAPROFEN.....	153
VENLAFAXINE.....	153
VERAPAMIL.....	153
VERATRUM.....	153
VERNOLATE.....	191
VERTEPORFIN.....	153
VETIVER OIL.....	274
VIDARABINE.....	153
VIGABATRIN.....	153
VILDAGLIPTIN.....	154
VILOXAZINE.....	154
VINBLASTINE.....	154
VINCA ALKALOIDS	
<i>See</i> UNDER INDIVIDUAL ENTRIES	
VINCAMINE.....	154
VINCLOZOLIN.....	249, 330
VINCRISTINE.....	154
VINDESINE.....	154
VINORELBINE.....	154
VINYL CHLORIDE.....	249, 341
VINYL ETHER.....	154, 274
VIPRYNIUM	
<i>See</i> PYRVINIUM	
VIRGINIAMYCIN.....	154, 191
VISNADINE.....	154
VITAMIN A.....	154
VITAMIN D.....	154
VITAMIN K.....	274
VITREOUS ENAMELS.....	264
VORICONAZOLE.....	154
W	
WALLBOARD.....	264
WARFARIN.....	154, 191, 237
WHITE LEAD	
<i>See</i> BASIC LEAD CARBONATE	
WHITE PETROLEUM SPIRIT.....	26
<i>See also</i> HYDROCARBONS, LIQUID	
WHITE SPIRIT.....	300
<i>See also</i> HYDROCARBONS, LIQUID	
WRITING.....	8
WRITING CORRECTION FLUIDS.....	189
WRITING CORRECTION PENS.....	264
X	
XAMOTEROL.....	154
XANTHINOL NICOTINATE.....	154
XANTHOPHYLL.....	274

XIMELAGATRAN	154
XIPAMIDE	154
XYLANASE	274
XYLAZINE	154
XYLENE	26, 235, 237, 300, 330, 336
XYLENOLS	181, 226, 300

See also PHENOL

XYLOMETAZOLINE	57, 331
----------------------	---------

Y

YLANG YLANG OIL	274
YOHIMBINE	155

Z

ZAFIRLUKAST	155
ZALCITABINE	155
ZALEPLON	155
ZANAMIVIR	155
ZERANOL	155, 237
ZETA-CYPERMETHRIN	237, 249
ZIDOVUDINE	155
ZILPATEROL	155
ZIMELDINE	155
ZINC CHLORIDE	57, 237, 300, 331
ZINC COMPOUNDS	155
ZINC NAPHTHENATE	274
ZINC P-PHENOLSULFONATE	237
ZINC PHOSPHIDE	

See PHOSPHIDES, METALLIC

ZINC SULFATE	237, 300, 331
ZINEB	18, 191

See also DITHIOCARBAMATES

ZIPRASIDONE	155, 344
ZIRAM	18, 237

See also DITHIOCARBAMATES

ZOLAZEPAM	155
ZOLEDRONIC ACID	155
ZOLMITRIPTAN	155
ZOLPIDEM	155, 344
ZONISAMIDE	155, 344
ZOPICLONE	155, 344
ZOXAZOLAMINE	155
ZUCLOPENTHIXOL	155